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Improvements in the diagnosis and management of preeclampsia (PE) have 
contributed to a reduction in maternal mortality in parts of the world. However, 
current treatments still carry safety and efficacy issues, and perinatal morbidity 
and mortality remains prevalent. Research into the pathology of PE and new 
treatment strategies are therefore warranted. Gene therapy represents a 
potential treatment strategy since PE is now recognised as a complex genetic 
disorder. Despite the clinical progress of gene therapy in foetal growth 
restriction, less invasive and non-viral delivery systems targeting the placenta 
are required to mitigate safety concerns and extend research to other pregnancy 
disorders, such as PE. Identifying a therapeutic gene target in PE remains a 
challenge since a lack of replication in gene association studies suggests rare 
variants with small effect sizes likely contribute to the development of PE. 
Alternatively, a growing body of evidence suggests placental microRNAs 
(miRNAs) play a key role in the pathology of PE and may therefore represent 
therapeutic targets. Preclinical studies however remain limited, and 
inconsistencies between clinical studies make it difficult to discern placental 
miRNA profiles characteristic of PE. Therefore, in addition to investigating non-
invasive and non-viral delivery systems for gene therapy purposes in PE, there is 
a need for further preclinical and clinical studies to examine the role of 
placental miRNAs in PE and evaluate their therapeutic potential. 
Ultrasound-mediated gene delivery (UMGD) can be utilised for non-viral and non-
invasive gene transfer, a method in which ultrasound (US) stimulates vector 
uptake through its mechanical effects following interaction with US contrast 
agents known as microbubbles. Although the technique has been investigated in 
a variety of tissues, research into targeting the placenta is limited, with a single 
UMGD study in baboons published to date. Chapter 3 sought to develop and 
optimise an in vivo UMGD protocol in rodents that stimulates targeted transfer 
of a reporter gene to a surrogate organ which could then be applied to the 
placenta, given the difficulty in targeting a specific placenta in litter-bearing 
species. These optimisation studies allowed issues to be identified and logical 
modifications to be made to the protocol, including the type and size of vector 
employed, the plasmid DNA and MB dose, and the organ targeted. Through these 
7 
 
studies, a protocol was established showing evidence of gene transfer of a 
luciferase plasmid to mouse hearts, allowing progression to a proof-of-concept 
study. 
Chapter 4 sought to demonstrate proof-of-concept that UMGD can achieve 
tissue-specific transfer of an expression vector and is therefore suitable for 
targeting placenta. UMGD of a luciferase plasmid to mouse hearts showed 
luciferase activity was significantly greater in the ventricles compared to non-
target organs (liver, lungs, and spleen) (p<0.05), providing evidence of tissue-
specific transfer. Although there was a trend towards greater luciferase activity 
in the ventricles compared with the remaining non-target organs (skeletal 
muscle, left kidney, and right kidney), this was non-significant. Due to small n-
numbers, significance testing was not performed comparing tissue from the 
negative control mice with UMGD treatment mice. The protocol was 
subsequently applied to pregnant mice to target the placenta. Low levels of 
luciferase gene transfer were evident in the placenta positioned closest to the 
cervix on the targeted left uterine horn. Non-target tissues were not evaluated 
for gene transfer due to time constraints, meaning this aspect of safety could 
not be confirmed. Placental-specific delivery of an expression vector with UMGD 
therefore remains to be demonstrated in order to support the clinical 
translatability of this technique. 
Identifying a placental miRNA dysregulated in preeclamptic patients or a subset 
of patients remains essential to identifying miRNAs that represent a clinically 
relevant therapeutic target. Animal models on the other hand provide a means 
of exploring the role and therapeutic potential of miRNAs in PE. In Chapter 5, a 
literature review was conducted to collate evidence from patient studies and 
identify clinically relevant miRNAs of interest for therapeutic targeting. 
Subsequently, the expression of candidate miRNAs was evaluated in whole 
placental tissue and individual placental layers of a rat model of superimposed 
PE (SPE) previously established by our group. The literature review identified 
placental miRNAs consistently detected as significantly differentially expressed 
by miRNA expression profiling studies in third trimester preeclamptic patients. 
Clinical studies were either in agreement or discordant in the direction of 
expression of the miRNAs in PE. Evaluation of candidate miRNAs in the placenta 
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of the SPE rat model contributed to the growing body of evidence that placental 
miRNAs differ between PE subtypes and placental layers, also providing novel 
evidence of dysregulation of miRNAs within placental layers in rats, a finding 
previously only shown in humans. Furthermore, four miRNAs (miR-210-3p, miR-
223-3p, miR-181a-5p, and miR-363-3p) were identified as potential therapeutic 
targets given their consistent dysregulation in PE. 
MiRNA expression profiling allows identification of differentially expressed 
placental miRNAs in a hypothesis free manner. In Chapter 6, miRNA sequencing 
was performed to identify differentially expressed placental miRNAs in the rat 
model of SPE, representing the first study to conduct miRNA sequencing in the 
placenta of an animal model of PE. Furthermore, the dysregulation of select 
miRNAs and predicted gene targets was examined by RT-qPCR in placental tissue 
from the SPE rat model as well as preeclamptic patients to evaluate the clinical 
relevance of the findings. Expression of miR-210-3p and its predicted gene 
target, fibroblast growth factor receptor-like 1 (FGFRL1), demonstrated an 
inverse relationship in the placentas of the SPE rat model and preeclamptic 
patients as well as in a BeWo trophoblast cell line. This is in agreement with 
published data that show miR-210-3p is upregulated in PE and provides novel 
evidence of altered FGFRL1 expression in the placentas of preeclamptic 
patients. This adds to the existing literature that suggests miR-210-3p plays a 
pathological role in PE and is a promising therapeutic target. 
This thesis has provided information on a non-viral and non-invasive gene 
therapy technique for targeting the placenta as well as miRNAs dysregulated in 
the placenta in PE and potential therapeutic targets. The development of safe 
and efficient delivery systems that target the placenta and the identification of 
suitable targets represent key aspects to establishing placental gene therapy as 
a treatment strategy in PE. The work in this thesis has provided means to further 
investigate UMGD for targeting the placenta in pregnant mice, important 
preclinical models in pregnancy research. Furthermore, the work in this thesis 
has identified aspects of placental miRNAs that should be considered in future 
work seeking to investigate the role of and/or target placental miRNAs. Finally, 
the work in this thesis has identified several miRNAs that are potentially 
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1.1 Preeclampsia (PE) 
1.1.1 Definition of PE 
Preeclampsia (PE) is a multisystem hypertensive disorder of pregnancy defined 
as new-onset hypertension (systolic blood pressure ≥140 mmHg and/or diastolic 
blood pressure ≥90 mmHg) occurring at or after 20 weeks of gestation 
accompanied by proteinuria (spot urine protein/creatinine ≥30 mg/mmol or ≥300 
mg in 24 h or ≥ 1 g/L [‘2+’] on dipstick testing) or uteroplacental/maternal 
organ dysfunction, according to guidelines recently published by the 
International Society for the Study of Hypertension in Pregnancy (ISSHP) (Brown 
et al., 2018). Uteroplacental dysfunction encompasses complications, such as 
foetal growth restriction (FGR), abnormal umbilical artery Doppler waveform, 
and/or stillbirth. Maternal organ dysfunction includes acute kidney injury, liver 
involvement and/or haematological complications, most notably haemolysis, 
elevated liver enzyme levels, and low platelets (HELLP) syndrome, and 
neurological complications, such as seizures or ‘eclampsia’. The ISSH guidelines 
seek to address a shift in PE diagnosis, with revised criteria from international 
obstetric and gynaecological societies stating proteinuria may be absent from 
diagnosis if alongside hypertension an adverse or severe event is present (ACOG, 
2013, Magee et al., 2014, Lowe et al., 2015). The variable clinical 
manifestations of PE highlight the diverse nature of this multisystem disorder. 
1.1.2 Subtypes of PE 
The revised diagnostic criteria of PE were published by the ISSH to address a lack 
of consensus regarding the definition of PE; similar discordance exists in 
classifying PE into subtypes. Several classification systems have been proposed 
relating to the severity and timing of onset of symptoms: mild and severe 
(primarily determined by blood pressure levels and the presence/absence of 
proteinuria , HELLP syndrome, and eclampsia), early-onset (EO) and late-onset 
(LO) (generally referring to a diagnosis before or after 34 weeks of gestation), 
and preterm and term PE (occurring before or after 37 weeks of gestation) 
(Tranquilli et al., 2013). Although classifying preeclamptic patients with distinct 
profiles seeks to improve management, rapid changes to their condition can 
hinder the clinical utility of classifications. In turn, the ISSH recommends that PE 
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be classified as de novo or superimposed on chronic hypertension (high blood 
pressure prior to pregnancy or <20 weeks of gestation) with or without severe 
features (Brown et al., 2018). Superimposed PE (SPE) is defined as patients with 
chronic hypertension that develop new-onset proteinuria and/or maternal organ 
dysfunction at or after 20 weeks of gestation (Brown et al., 2018). The recent 
ISSH recommendations seek to support high-quality and collaborative research 
into hypertensive pregnancy disorders and promote good clinical practice. 
1.1.3 Epidemiology of PE 
In the most recent World Health Organisation (WHO) systematic review of global 
causes of maternal death, hypertensive disorders of pregnancy were the second 
leading cause of maternal mortality worldwide, accounting for 14% of maternal 
deaths during 2003-2009 (Say et al., 2014). On its own, PE complicates 
approximately 3-8% of pregnancies worldwide (Abalos et al., 2013). A systematic 
review of 74 studies across 40 countries estimated the incidence of PE and 
eclampsia at 4.6% and 1.4%, respectively (Abalos et al., 2013). PE and eclampsia 
increase the risk of maternal and perinatal death as well as serious adverse 
outcomes, representing a leading cause of maternal and perinatal morbidity and 
mortality worldwide (Vogel et al., 2014, Abalos et al., 2014). The incidence of 
PE and eclampsia and the risk of adverse outcomes shows disparity between 
countries. Regions with the highest rates of hypertensive disorders of pregnancy, 
PE, and eclampsia include Africa, Latin America, and the Caribbean, although 
substantial heterogeneity appears within regions (Say et al., 2014, Abalos et al., 
2013, Abalos et al., 2014). The extent to which environmental and genetic 
factors contribute to these variations remains inconclusive. However, reduced 
access to quality care has consistently shown to contribute to higher rates of 
eclampsia and maternal morbidity and mortality (Giordano et al., 2014, Vousden 
et al., 2019, Goldenberg et al., 2011). 
In the UK, the incidence of eclampsia dropped from 74.1/10000 in the 1930s to 
7.2/10000 in the 1980s, and maternal deaths from eclampsia decreased from 
15.1% to less than 1% over the same time period (Leitch et al., 1997). These 
reductions have been attributed to the introduction of anticonvulsants in the 
1950s and antihypertensives in the 1970s (Leitch et al., 1997) as well as 
improvements in the overall standard of maternal care in Britain since the mid-
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1930s (Loudon, 2000). Between 2012-2014 in the UK, only two women died from 
PE (MBRRACE-UK, 2018), and in 2013, PE and eclampsia incidence estimates 
were 2.5% and 0.0%, respectively (Abalos et al., 2013). Improvements in 
surveillance, diagnosis, and management, most notably implementation of 
magnesium sulphate (Altman et al., 2002, Knight and Ukoss, 2007) and routine 
blood pressure monitoring and treatment (Cantwell et al., 2011), further 
contribute to the low rates of adverse maternal outcomes in the UK since the 
turn of the 21st century. However, perinatal mortality rates in preeclamptic 
pregnancies remain largely unchanged in the UK (Knight and Ukoss, 2007). 
Although PE interventions have shown to reduce the risk of eclampsia and 
maternal death, it is less clear whether they have a beneficial effect on 
perinatal outcomes (Altman et al., 2002). 
An analysis of the WHO Multicountry Survey on Maternal and Newborn Health 
conducted in 2010/11 reported hypertensive disorders of pregnancy were a 
leading cause of late foetal and early neonatal deaths, and PE and eclampsia 
were associated with a significant increase in the risk of perinatal deaths (Vogel 
et al., 2014). PE and eclampsia are also associated with an increased risk of 
small for gestational age (SGA), stillbirth, and preterm birth, further 
contributing to perinatal morbidity and mortality (Abalos et al., 2014, Roberts et 
al., 2005, Ngoc et al., 2006). Preterm birth is the leading cause of newborn 
deaths and second leading cause of death in children under the age of 5 (Who, 
2012). It can cause severe morbidity, ranging from short-term complications to 
life-long impairments (Teune et al., 2011, D’onofrio et al., 2013, Ancel et al., 
2015, Stoll et al., 2015). The increased risk of preterm birth with PE reflects 
planned early deliveries, now a routine intervention implemented in PE 
management (Brown et al., 2018). Planned early deliveries are evaluated on a 
case-by-case basis since the condition of mother and child must be taken into 
consideration. 
The substantial reduction in PE-related maternal mortality in the UK has led to a 
description of maternal PE deaths as ‘avoidable’ (Shennan et al., 2017). 
However, epidemiological data demonstrating the prevalent perinatal morbidity 
and mortality arising from PE show management of the hypertensive disorder 
still requires improvement. 
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1.1.4 Management of PE 
Delivery of the foetus and placenta ultimately resolves the maternal 
complications of PE. However, preterm deliveries are associated with a higher 
risk of foetal morbidity and mortality (Teune et al., 2011, D’onofrio et al., 2013, 
Ancel et al., 2015, Stoll et al., 2015). Managing PE therefore represents a 
balance between inducing delivery to reduce maternal risks and prolonging 
pregnancy to reduce foetal risks. The gestational age of the mother and the 
severity of her symptoms dictate the course of treatment since the mother is 
considered the primary patient. 
In patients that develop PE at or after 37 weeks of gestation, delivery is 
recommended since this is a term pregnancy, which carries a low risk of adverse 
neonatal outcomes (Brown et al., 2018). In patients that develop PE before 37 
weeks of gestation, planned early deliveries are considered on an individual 
basis. A Cochrane review of hypertensive disorders reported planned early 
delivery from 34 weeks of gestation was associated with a significantly lower risk 
of maternal morbidity and mortality compared to expectant management 
(Cluver et al., 2017). Although a lack of evidence prevented the study from 
drawing any conclusions on infant morbidity and mortality, planned early 
delivery was associated with a greater risk of respiratory distress syndrome and 
neonatal intensive care unit (NICU) admissions (Cluver et al., 2017). Similarly, in 
a recent large randomised controlled trial (RCT) in late preterm PE patients, 
early planned delivery led to a significant reduction in maternal adverse 
outcomes but greater number of NICU admissions, primarily due to prematurity 
(Chappell et al., 2019). Prolonging pregnancy to 37 weeks is therefore currently 
recommended as it allows foetal maturation and improves perinatal outcomes 
(Brown et al., 2018). If maternal or foetal conditions worsen prior to 37 weeks of 
gestation, delivery is deemed necessary, and antenatal corticosteroids and 
magnesium sulphate are recommended to promote foetal lung maturation and 
neuroprotection, respectively (Brown et al., 2018). 
Managing maternal complications to delay delivery primarily involves the use of 
antihypertensives to control blood pressure levels at least below 160/85 mmHg 
(135/85 mmHg in the UK (NICE, 2019)) (Brown et al., 2018). A Cochrane review 
of mild to moderate hypertension in pregnancy showed that antihypertensives 
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approximately halve the risk of severe hypertension, although a lack of high-
quality large RCTs made it difficult to discern whether antihypertensives 
produce beneficial or harmful effects in other clinical outcomes (Abalos et al., 
2018). Inconclusive data is similarly evident when comparing antihypertensives, 
and thus the selection of antihypertensive agent is driven by side-effect profiles, 
clinician’s familiarity with the drug, and the woman’s preference (Duley et al., 
2013, Abalos et al., 2018). Reported side effects include: headache, flushing, 
light head, nausea, and palpitations (hydralazine); flushing, light head, 
palpitations, and scalp tingling (labetalol); flushing, nausea, and vomiting 
(nifedipine); and somnolence (methyldopa) (Duley et al., 2013). 
Alongside blood pressure monitoring and control, management includes routine 
assessments of whole blood counts, liver and renal function, and foetal status 
(Brown et al., 2018). During expectant management, magnesium sulphate may 
be recommended for the prophylaxis of eclampsia (Brown et al., 2018). A 
Cochrane review reported magnesium sulphate halves the risk of eclampsia and 
reduces risk of placental abruption, although no significant differences were 
seen in maternal morbidity and mortality as well as stillbirth and neonatal death 
(Duley et al., 2010). While toxicity was uncommon, magnesium sulphate 
increased the risk of any side-effect, including respiratory depression and most 
commonly flushing (Duley et al., 2010). 
At earlier stages of pregnancy, other prophylactic strategies are recommended. 
If PE occurs before 24 weeks of gestation, when the foetus is at the limits of 
viability, termination of pregnancy may be recommended to protect the mother 
(Brown et al., 2018). For mothers at high risk of developing PE, as determined by 
clinical risk factors, low dose aspirin is recommended (Brown et al., 2018). 
Systematic reviews have found aspirin reduces the risk of PE as well as adverse 
perinatal outcomes, including infant deaths, preterm birth, and SGA babies 
(Henderson et al., 2014, Duley et al., 2007). While this may prevent the risk of 
preterm PE, a separate systematic review found it does not reduce the risk of 
term PE (Roberge et al., 2018). 
Finally, management of PE extends to postpartum care. Although delivery 
ultimately resolves maternal complications, women are still at an increased risk 
of developing complications, such as eclampsia and hypertension, in the early 
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postpartum period (Kayem et al., 2011, Chames et al., 2002, Smith et al., 2013). 
Women who have had PE are also at an increased risk of kidney disease 
(Mcdonald et al., 2010, Dai et al., 2018) and cardiovascular conditions, including 
hypertension, venous thromboembolism, heart failure, coronary heart disease, 
stroke, and cardiovascular disease (CVD)-related death later in life (Wu et al., 
2017, Bellamy et al., 2007). Underlying cardiovascular risk factors have shown to 
predispose women to PE (Magnussen et al., 2007), and prepregnancy 
cardiovascular risk may contribute to the elevated risk post PE (Ghossein-Doha 
et al., 2017). In contrast, studies have demonstrated CVD risk persists in PE 
patients when adjusting for potential confounders, suggesting PE may also 
contribute to the development of CVDs (Berks et al., 2013, Wu et al., 2017). 
Children born to PE mothers also appear to be at an increased risk of CVD later 
in life, although it remains unclear the degree to which the intrauterine 
environment and genetic factors contribute to the heightened risk (Alsnes et al., 
2017, Vatten et al., 2003, Tenhola et al., 2006, Davis et al., 2012). 
While developments in the management of PE have contributed to fewer PE-
related maternal deaths, safety and efficacy issues still persist, particularly in 
relation to perinatal morbidity and mortality. In turn, different interventions for 
preventing and treating PE continue to be investigated (Grimes et al., 2019, 
Esteve-Valverde et al., 2018). Furthermore, due to the complications that can 
arise in preeclamptic mothers and their children later in life, research into the 
pathology and new treatments remains key to improve the management of PE. 
1.1.5 Pathology of PE 
1.1.5.1 Development of the human placenta 
The placenta is a maternofoetal organ that provides an interface for nutrient, 
blood gas, hormone, and waste exchange to support the developing foetus and 
ensure a healthy pregnancy. One of the initial steps of human pregnancy is 
implantation of the blastocyst to the mucosal lining of the uterus, known as the 
endometrium, which occurs 6-7 days post fertilisation (dpf) (Figure 1-1A) (Turco 
and Moffett, 2019). The blastocyst comprises of an inner layer, the inner cell 
mass from which the embryo develops, and an outer layer, the trophectoderm, 
which develops into the placenta. After initial attachment, the trophectoderm 
33 
 
fuses with the surface epithelium to form a multinucleated syncytium which 
invades into the endometrium (Figure 1-1B). During this process, the maternal 
endometrium is undergoing decidualization, which is characterised by the 
transformation of endometrial stromal cells to decidual cells. By around 14 dpf, 
the blastocyst is fully encapsulated within the decidua and the trophectoderm 
has differentiated into cytotrophoblasts that lie beneath the syncytium (Turco 
and Moffett, 2019) (Figure 1-1B). During the subsequent lacunar stage, the 
syncytium further embeds into the decidua, forming regions known as lacunae, 
which are initially filled with tissue fluids and uterine gland secretions and 
eventually become the intervillous space (Figure 1-1C). The next stage is the 
primary villous stage, in which proliferating cytotrophoblasts project through the 
syncytium to form primary villi, comprising of an inner cytotrophoblastic core 
and outer syncytiotrophoblastic lining (Figure 1-1D). By day 18 dpf, cells from 
the extraembryonic mesoderm have invaded the core of the villi to form 
secondary villi, and foetal capillaries have emerged in the core to form tertiary 
villi (Turco and Moffett, 2019). Cytotrophoblasts continue to proliferate and 
invade, forming a cytotrophoblastic shell that surrounds the villi and lies in 
contact with the decidua. At around 8 weeks of gestation, the cytotrophoblastic 
shell gives rise to extravillous trophoblasts (EVTs) that migrate through the 
decidua towards the maternal spiral arteries (interstitial EVTs) as well as down 
along the lumen of the maternal spiral arteries (endovascular EVTs) (Figure 1-2 
upper panel). Trophoblast invasion leads to the breakdown of trophoblast plugs 
and remodelling of maternal spiral arteries (Saghian et al., 2019, James et al., 
2018, Roberts et al., 2017), key events that enhance maternal blood flow into 
the intervillous space to accommodate the growing foetus (Figure 1-2 upper 
panel). This process is largely complete by 12 weeks of gestation and the 
fundamental structure and function of the placenta is established; significant 
increases in uterine artery diameter (Palmer et al., 1992), perfusion rate 
(Roberts et al., 2017), and oxygen tension (Jauniaux et al., 2000) reflect 
transformation of the arteries to high-capacitance low-resistance vessels, with 
flow steadily increasing and resistance steadily decreasing throughout pregnancy 
(Palmer et al., 1992, Gómez et al., 2008). To maintain adequate blood supply to 
the placenta and ensure the metabolic demands of both mother and foetus are 
met, the mother undergoes substantial cardiovascular adaptations during 
pregnancy. Blood volume and heart rate steadily rise throughout pregnancy, 
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reaching an approximate 45% and 25% increase respectively at term compared to 
prepregnancy levels (Sanghavi and Rutherford, 2014). Cardiac output and stroke 
volume also significantly increase until the second trimester, after which it 
remains unclear whether levels increase, decrease, or stabilise (Sanghavi and 
Rutherford, 2014). These elevations are mirrored by significant reductions in 
systemic vascular resistance and blood pressure, which slowly begin to rise again 
after the second trimester (Sanghavi and Rutherford, 2014). Overall, the 
development of the placenta is crucial to a successful pregnancy, as the 
maternofoetal interface enables the exchange of molecules to ensure the 
demands of mother and foetus are met. 
 
 
Figure 1-1 The early stages of human placental development. 
Diagram depicting the early steps in placenta formation following blastocyst implantation: (A, B) 
pre-lacunar stages, (C) lacunar stage, and (D) primary villous stage. 1° ys, primary yolk sac; ac, 
amniotic cavity; cs, cytotrophoblastic shell; eec, extra-embryonic coelom; exm, extra-embryonic 
mesoderm; GE, glandular epithelium; ICM, inner cell mass; lac, lacunae; LE, luminal epithelium; 
mn. tr, mononuclear trophoblast; pr. syn, primary syncytium; TE, trophectoderm; vs, blood vessels. 
Figure taken from (Turco and Moffett, 2019) under Creative Commons Attribution 4.0 International 




Figure 1-2 Placentation in a normal and preeclamptic placenta. 
Schematic of placental vascular remodelling in normal healthy placenta (upper panel) and 
preeclampsia (lower panel). (Upper panel) In normal placental development, invasive 
cytotrophoblasts of foetal origin invade the maternal spiral arteries, transforming them from small-
calibre resistance vessels to high-calibre capacitance vessels capable of providing placental 
perfusion adequate to sustain the growing foetus. (Lower panel) In preeclampsia, cytotrophoblasts 
fail to invade. Instead, invasion of the spiral arteries is shallow, and they remain small calibre, 
resistance vessels. This may result in placental ischemia. Figure taken from (Karumanchi et al., 




1.1.5.2 Placental origin of PE 
The placenta as the origin of PE was first introduced by Redman in 1991, coined 
the ‘Two Stage Model’ (Redman, 1991). The long-standing hypothesis states that 
poor placental perfusion (stage 1), characterised by maternal spiral artery 
defects, namely failed trophoblast invasion and acute atherosis, leads to the 
maternal syndrome (stage 2), the clinical symptoms characteristic of the 
disorder (Redman, 1991) (Figure 1-3). In 1992, Redman proposed that abnormal 
placentation in PE was immunologically mediated based on PE being more 
common in first pregnancies, new paternity increasing PE risk, and placentation 
involving a maternofoetal interaction (Redman, 1992). In 1993, systemic 
endothelial dysfunction due to the release of factors from the underperfused 
placenta was proposed as the link between stage 1 and 2 (Roberts and Redman, 
1993) (Figure 1-3). 
 
Figure 1-3 The Two Stage Model proposed by Redman and Roberts. 
In stage 1, poor placentation arising from maternal spiral artery defects leads to the release of 
placental factors into the maternal circulation. Circulating factors induce widespread endothelial 
dysfunction in the mother. This leads to the clinical stage 2. Stage 2 is characterised by the 









release of placental factors 
maternal systemic endothelial dysfunction
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Inadequate spiral artery remodelling in PE patients was first described in the 
1970s (Brosens et al., 1970, Brosens et al., 1972) (Figure 1-2 lower panel). Since 
then, studies of human placental explants have attributed this defect to limited 
endovascular rather than interstitial EVT invasion (Lyall et al., 2013), although 
studies have also shown limited interstitial EVT invasion (Kadyrov et al., 2003) 
(Figure 1-2 lower panel). Inadequate spiral artery remodelling contributes to 
impaired placental perfusion (Pijnenborg et al., 1991, Matijevic and Johnston, 
1999, Aardema et al., 2001). Placental ischaemia and hypoxia induce oxidative 
and endoplasmic reticulum stress, leading to the release of placental factors, 
including pro-inflammatory cytokines, anti-angiogenic factors, and trophoblast 
debris, into the maternal circulation (Burton et al., 2009). An imbalance in 
maternal circulating factors induces widespread endothelial dysfunction. 
Elevated levels of soluble fms-like tyrosine kinase-1 (sFlt-1) (a circulating 
antagonist of vascular endothelial growth factor (VEGF) and placental growth 
factor (PlGF)) and soluble endoglin (sEng) (a circulating antagonist of 
transforming growth factor β (TGF-β)) and reduced levels of PlGF have 
consistently been found in PE patients (Powers et al., 2010, Masuyama et al., 
2007, Aggarwal et al., 2012). Systematic reviews have shown the ratio of sFlt-
1:PlGF has some utility in predicting PE (Agrawal et al., 2018, Yusuf et al., 2018) 
and is currently recommended to help diagnose suspected PE (NICE, 2019). 
Endothelial dysfunction is characterised by an increase in vascular reactivity and 
resistance and loss of vascular integrity, which impacts the cardiovascular 
system and contributes to the symptoms of PE (Boeldt and Bird, 2017). 
However, several key findings do not fit in with the Two Stage Model and 
placental origin hypothesis. FGR does not occur in all cases of PE, and some 
infants are born large for gestational age (LGA) (Rasmussen and Irgens, 2003, 
Xiong et al., 2000, Powe et al., 2011). Impaired spiral artery remodelling and 
reduced uterine blood flow also do not occur in all cases of PE but can occur in 
other pregnancy disorders, including FGR, SGA, gestational hypertension (GH), 
and maternal anaemia, as well as normal pregnancies, although subtle 
differences in the extent of invasion may differentiate pathological events (Lyall 
et al., 2013, Aardema et al., 2001, Kadyrov et al., 2003, Olofsson et al., 1993). 
Lastly, changes in the levels in maternal circulating factors have been reported 
prior to 12 weeks of gestation, suggesting that pathological insults occur before 
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trophoblast invasion and establishment of maternal blood flow in the placenta 
(Akolekar et al., 2011, Salomon et al., 2017). 
Limitations of the model were acknowledged at the time, and the Two Stage 
Model has since been refined and expanded. In 1996, a maternal origin of PE was 
added to the model, which supported the concept that prepregnancy maternal 
disorders could contribute to systemic endothelial dysfunction and account for 
pathological and clinical heterogeneity (Ness and Roberts, 1996). More recently 
in 2019, the model has been extended to incorporate maternal and placental 
factors potentially contributing to the development of the disorder at both 
stages (Staff, 2019) (Figure 1-4). Furthermore, two distinct pathways (extrinsic 
and intrinsic) have been proposed that precede the development of stage 1 and 
stage 2 (Figure 1-4). In the extrinsic pathway, factors extrinsic to the placenta 
cause abnormal placentation, which is linked to an earlier onset of PE and more 
severe phenotype (Staff, 2019) (Figure 1-4). In the intrinsic pathway, 
placentation is normal; however, due to the placenta outgrowing the uterine 
capacity (an intrinsic placental problem), uteroplacental malperfusion occurs, 
leading to less severe and later onset PE (Staff, 2019) (Figure 1-4). 
However, the placental origin of PE remains a highly contested subject. A host of 
theories, notably abnormal differentiation of the trophoblast lineage (Huppertz, 
2008); poor maternal cardiac reserve (Thilaganathan and Kalafat, 2019); 
maternofoetal immune incompatibility (Moffett-King, 2002); a T-helper type 1 
(Th1)/T-helper type 2 (Th2) imbalance (Saito and Sakai, 2003); placental 
oxidative stress, maternal hypoxia, and abnormalities in oxygen sensing 
(Zamudio, 2007); dysregulation of the renin-angiotensin system (RAS) (Lumbers 
et al., 2019), and pathological effects of placenta derived extracellular vesicles 
(EVs) (Gilani et al., 2016), have been proposed that support the concept that PE 
can arise from foetal, placental, and/or maternal maladaptations and 
independent from impaired trophoblast invasion. Nonetheless, a common thread 
amongst theories is the placenta as a component to the pathogenesis of PE and 
abnormalities in circulating factors contributing to endothelial dysfunction. Most 
theories also support the concept that PE can be broadly divided into two 
subtypes: a more severe EO form with clear placental dysfunction and a more 




Figure 1-4 The revised Two Stage Model of PE. 
Preeclampsia can follow two pathways: the extrinsic (type A) and intrinsic (type B) pathway. Type 
A: In the extrinsic pathway, factors extrinsic to the placenta cause poor placentation. This occurs 
earlier in pregnancy and FGR is more common. This pathology leads to early-onset PE. Type B: In 
the intrinsic pathway, factors intrinsic to the placenta cause the placenta to outgrow its capacity, 
leading to poor placental perfusion. This occurs later in pregnancy and FGR is less common. This 
pathology leads to late-onset PE. Type A and Type B: Both pathways induce placental stress, 
causing the placenta to release of factors into the maternal circulation, which in turn leads to the 
maternal syndrome characterised by the clinical symptoms of PE. Maternal factors contribute to the 
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1.1.6 Animal models of PE 
Animal models are essential to our understanding of PE since the disorder is 
almost exclusive to humans, although several cases have been reported in non-
human primates (Thornton and Onwude, 1992, Palmer et al., 1979, Krugner-
Higby et al., 2009). The spontaneous development of PE is attributed to the 
distinct placentation of primates, which involves extensive trophoblast invasion 
and spiral artery remodelling (Pijnenborg et al., 2011b, Pijnenborg et al., 
2011a). However, trophoblast invasion is not unique to primates but rather a 
feature of haemochorial placentas. Haemochorial is used to describe placentas 
in which maternal blood is in direct contact with foetal chorionic villi, the type 
of placenta common to mammals such as primates, lagomorphs, and rodents. 
One of the distinguishing placental characteristics between species is the depth 
of trophoblast invasion, with most extensive invasion seen in humans followed by 
rabbits, guinea pigs, rats, and then mice (Swanson and David, 2015). The number 
of trophoblast layers also differs between species, with one layer present in 
primates and guinea pigs (haemomonochorial), two layers in rabbits 
(haemodichorial), and three layers in rats and mice (haemotrichorial) (Furukawa 
et al., 2014). Although placentation in rabbits and guinea pigs more closely 
mirrors that of humans, rats and mice are more commonly used as PE models 
due to their shorter gestation, larger litter size, and cheaper housing costs. 
1.1.6.1 Rodent models of PE 
Rodents are valuable models for studying the human placenta since they share 
commonalities in placental development, structure, function, and genetic make-
up (Rai and Cross, 2014, Georgiades et al., 2002, Soncin et al., 2018). Analogous 
layers consisting of varying portions of maternal and foetal tissue make 
comparisons between the placenta of rodents and humans possible (Rai and 
Cross, 2014). Rodent pregnancies also display cardiovascular adaptations similar 
to those seen in humans, including increased glomerular filtration rate and renal 
plasma flow (Conrad, 2004); impaired vascular response (Paller, 1984); 
decreased vascular tone and vasomotion (Meyer et al., 1993); and elevated 
cardiac output, stroke volume, and heart rate (Wong et al., 2002). Hence, 
rodent models of PE are vital to preclinical investigations since abnormal 
placental development and cardiovascular dysfunction are characteristic of PE. 
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However, key morphological differences persist that are important to consider 
and highlight the limitations of comparing the placenta.  
The rodent placenta is divided into the decidua, junctional zone, and labyrinth. 
Similarly, the human placenta is divided into the decidua, basal plate, and 
placenta villi (Figure 1-5). The decidua is the maternal layer of the placenta 
through which maternal blood passes via spiral arteries. In both rodents and 
primates, the decidua is derived from endometrial stromal cells (Rai and Cross, 
2014). In rodents, trophoblast giant cells (TGCs) line the decidua and maternal 
spiral arteries, while in humans, it is EVTs that invade maternal spiral arteries 
(Rai and Cross, 2014). Adjacent to the decidua, the junctional zone in rodents 
and basal plate in humans is the region in which maternal arteries are further 
lined by different foetal cells: spongiotrophoblasts, glycogen cells, and TGCs in 
rodents and cytotrophoblasts and syncytiotrophoblasts in humans (Rai and Cross, 
2014). Finally, the labyrinth in rodents and placenta villi in humans is the layer 
in which gas and nutrient exchange occurs, comprising of the maternal and 
foetal blood supplies. While in humans, foetal blood vessels lined by villous 
cytotrophoblasts and syncytiotrophoblasts bathe in maternal blood, in rodents, 
maternal vessels lined by TGCs and syncytiotrophoblasts form a branch-like 
structure that is in contact with foetal blood vessels (Rai and Cross, 2014) 
(Figure 1-5). Despite differences in cellular and structural features, similarities 
in the placenta and its anatomical layers make comparisons between rodent 
models of PE and patients with PE possible. 
Since rodents do not spontaneously develop PE, pharmacological, surgical, or 
genetic manipulation is required (Table 1-1). Recapitulating the disorder in 
rodents therefore carries limitations and extrapolating findings to humans must 
be carefully considered. In addition, depending on the research question being 
asked, certain models are more or less suitable and must therefore be 
appropriately selected (Table 1-1). Nonetheless, numerous rodent models 
exhibit the hallmark symptoms of PE, hypertension and proteinuria, and other 
PE-like symptoms, including endothelial dysfunction, placental abnormalities, 
and foetal demise/growth restriction. Given the ethical implications of 
conducting research in human pregnancy and the inadequacy of obtaining 
information from post-delivery examinations, rodents represent a valuable 
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model system for investigating the pathological mechanisms underlying PE and 
potential therapeutic interventions. 
 
 
Figure 1-5 Comparative anatomy of the placenta in the (A) mouse and (B) human. 
Figure taken from (Rai and Cross, 2014) with permission from Elsevier. 
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Table 1-1 Key examples of rodent models of PE and their advantages and disadvantages. 
Model Intervention Advantages Disadvantages References 
Surgical (RUPP) Clipping of aorta and ovarian 
arteries in Sprague Dawley rats on 
GD 14 / ovarian and/or uterine 
arteries in CD-1 mice on GD 14.5 
- Displays maternal and foetal symptoms 
- Can be used to study uteroplacental 
ischaemia 
- Consistently reproduced across studies 
- No impaired trophoblast invasion 
- Onset of symptoms late in pregnancy 
(1) (2) (3) (4) 
Genetic BPH/5 mice - Displays maternal and foetal symptoms 
- Onset of foetal symptoms early in 
pregnancy 
- No impaired trophoblast invasion 
- Mildly elevated blood pressure prepregnancy 
- Better model for GH or SPE 
(5) (6) 
 COMT -/- mice - Displays maternal symptoms 
- Onset of some symptoms mid-pregnancy 
- Displays some foetal symptoms 
- No impaired trophoblast invasion 
- No abnormal uterine artery blood flow 
- No evidence of endothelial dysfunction 
- Conflicting evidence of COMT in PE patients 
(7) (8) (9) 
 Ad-sFLT1 injection in Sprague 
Dawley rats mid-gestation / 
Lentiviral transduced blastocyst 
implanted in CD-1 mice 
- Displays maternal symptoms 
- Ability to modify dose – can be used to 
study more and less severe phenotypes 
- Displays some foetal symptoms 
- Non-pregnant rats also develop hypertension 
and proteinuria – onset of symptoms 
independent of pregnancy 
(10) (11) 
Pharmacological L-NAME infusion in Sprague 
Dawley rats mid-gestation 
- Displays maternal and foetal symptoms - No impaired trophoblast invasion 
- Conflicting evidence of NO in PE patients 
- Onset of symptoms late in pregnancy 
(12) (13) (14) (15) 
 AT1-AA infusion in Sprague Dawley 
rats mid-gestation / injection in 
C57BL/6J mice on GD13 
- Displays maternal symptoms - No impaired trophoblast invasion 
- Displays some foetal symptoms 
- Onset of symptoms late in pregnancy 
(16) (17) 
 Poly I:C injection in Sprague 
Dawley rats from GD 10 / in 
C57BL/6J mice from GD 13 
- Displays maternal symptoms - No impaired trophoblast invasion 
- Displays some foetal symptoms 
- Onset of symptoms late in pregnancy 
(18) (19) 
(1) (Alexander et al., 2001) (2) (Sholook et al., 2007) (3) (Banek et al., 2012) (4) (Fushima et al., 2016) (5) (Davisson et al., 2002) (6) (Dokras et al., 2006) (7) (Kanasaki et al., 2008) (8) (Stanley et 
al., 2012) (9) (Palmer et al., 2011) (10) (Maynard et al., 2003)(11) (Kumasawa et al., 2011)(12) (Molnár et al., 1994) (13) (Shu et al., 2018) (14) (Seligman et al., 1994) (15) (Smárason et al., 1997) 
(16) (Lamarca et al., 2009) (17) (Zhou et al., 2008) (18) (Tinsley et al., 2009) (19) (Chatterjee et al., 2012). RUPP, reduced uterine perfusion pressure; GD, gestational day; GH, gestational 
hypertension; SPE, superimposed preeclampsia; COMT, catechol-O-methyltransferase; PE, preeclampsia; Ad-sFLT1, adenovirus soluble fms-like tyrosine kinase-1; L-NAME, N(γ)-nitro-L-arginine 
methyl ester; NO, nitric oxide; AT1-AA, angiotensin II type 1-receptor autoantibody.
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1.1.7 Genetic and environmental factors in PE 
Publications in the 1960s were the first to report familial aggregation of PE, 
providing evidence of an underlying genetic basis (Chesley et al., 1968, Chelsey 
et al., 1962). However, elucidating the genetic component of PE has proven 
challenging, with studies from the 1980s and 1990s producing conflicting models 
concerning its mode of inheritance and magnitude of effects (Chesley and 
Cooper, 1986, Arngrimsson et al., 1990). This is due to the role of both maternal 
and foetal genotypes, which includes maternal and paternal genes and their 
independent and interactive effects not only with each other but also the 
environment in determining PE risk. Although some families exhibit a Mendelian 
pattern of inheritance (Chesley and Cooper, 1986), PE is now recognised as a 
complex disorder involving multiple genetic and environmental factors. 
Population-based twin studies from the early 2000s estimate genetic factors 
contribute approximately 50%, the majority of which is attributed to maternal 
genetic effects and to a lesser extent foetal (maternal and paternal) genetic 
effects (Cnattingius et al., 2004, Salonen Ros et al., 2000). PE is twice as likely 
in women whose mother had PE during their pregnancy and in women born to 
uncomplicated pregnancies but whose sibling (man or woman) had a child born 
to a preeclamptic pregnancy (Skjærven et al., 2005). Men born to pregnancies 
complicated by PE are also at an increased risk of fathering a preeclamptic 
pregnancy by approximately 1.5-fold (Skjærven et al., 2005). Maternal and 
paternal ethnicity have also shown to confer genetic susceptibility. Highest rates 
of PE have been reported in women from black ethnic groups (Bramham et al., 
2011, Caughey et al., 2005, Sibai et al., 1997) and lowest rates have been 
reported in women from Asian ethnic groups (Jian et al., 2012, Nakagawa et al., 
2016, Caughey et al., 2005, Anderson et al., 2012) as well as in pregnancies with 
Asian paternity (Caughey et al., 2005). In contrast, a UK-based study reported 
highest rates in women with Asian ethnicity (Bramham et al., 2011), and 
multiple studies show substantial variations between countries from the same 
region (Nakagawa et al., 2016, Bilano et al., 2014, Abalos et al., 2013), 
indicating ethnicity is not a strong predictive risk factor. Current research 
ascertains the involvement of both maternal, foetal, and in turn paternal 
genotypes as well as environmental factors in the development of PE. 
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1.1.7.1 Maternal risk factors 
Identifying genetic components that determine PE susceptibility remains a 
challenge. In addition to the involvement of two genotypes, PE presents as a 
heterogenous disorder, with distinct phenotypes likely corresponding to differing 
degrees of maternal and foetal contributions to the genetic influence on its 
pathology (Triche et al., 2014). Candidate gene studies in women with PE have 
implicated hundreds of genetic variants involved in various biological pathways 
related to PE, including thrombophilia, blood pressure control, fluid balance, 
endothelial function, inflammation, lipid metabolism, and oxidative stress 
(Staines-Urias et al., 2012, Buurma et al., 2013) (Table 1-2). A major issue is a 
lack of replication between studies due to small sample sizes and poor quality 
reporting (Staines-Urias et al., 2012). Despite these issues, two metanalyses of 
candidate gene studies identified genetic variants reproducibly and significantly 
associated with PE risk (Staines-Urias et al., 2012, Buurma et al., 2013) (Table 
1-2). However, a lack of replication is similarly observed with genome-wide 
linkage studies (GWLS) and genome-wide association studies (GWAS) (Williams 
and Broughton Pipkin, 2011). Three relatively small-scale GWAS in preeclamptic 
patients have been conducted to date (Johnson et al., 2012, Zhao et al., 2012, 
Zhao et al., 2013). Only one study identified single nucleotide polymorphisms 
(SNPs) that reached genome-wide significance: two SNPs (rs7579169, 
p = 3.58×10−7, odds ratio (OR) = 1.57 and rs12711941 p = 4.26×10−7, OR = 1.56) in 
the intergenic region downstream of the Inhibin, beta B (INHBB) gene on 
chromosome 2q14 (Johnson et al., 2012). They were found to be in linkage 
disequilibrium with one another but not any other genotyped SNP within 250 
kilobase pairs (kb), suggesting potential linkage with a rare risk variant (Zhao et 
al., 2013). The SNP associations were not replicated in case-control cohorts. 
Larger sample sizes with sufficient power to detect or replicate associations are 
needed. The heterogenous nature of PE may also contribute to a lack of 
significance in studies, with placental miRNA expression found to differ between 
timing of disease onset and delivery (Lykoudi et al., 2018, Weedon-Fekjær et 
al., 2014, Anton et al., 2015) as well as presenting symptoms (Pineles et al., 
2007, Awamleh et al., 2019). Although stratifying patients by subtype could 
address this issue, obtaining adequate sample sizes is of foremost importance. 
Overall, a lack of detection and replication amongst genetic studies supports the 
involvement of rare variants with effects in determining PE risk.
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Table 1-2 Results from two meta-analyses of genetic variants reproducibly and significantly associated with PE risk. 
Biological 
pathway 








OR (CI)* P 
value 
Study 
RAS ACE Angiotensin converting enzyme rs4646994 30 3101 5134 1.17 (0.99,1.40) 0.017 (1) 
 20 2855 4582 1.20 (1.08,1.34) Sig. (2) 
 AGT Angiotensinogen rs699 27 2329 4896 1.26 (1.00,1.59) 0.009 (1) 
    21 2104 4530 1.23 (0.98,1.54) Sig. (2) 
 AGTR1 Angiotensin II receptor type 1 rs5186 10 894 1379 1.22 (0.96,1.56) 0.036 (1) 
Inflammation CTLA4 Cytotoxic T-lymphocyte-associated 
protein 4 
rs231775 4 353 536 1.24 (1.01,1.52) Sig. (2) 
Lipid 
metabolism 
LPL Lipoprotein lipase rs268 3 395 579 2.27 (0.62,8.24) Sig. (2) 
Thrombophilia F5 Coagulation factor V  
(factor V Leiden) 
rs6025 41 4499 15188 1.74 (1.43,2.12) <0.001 (1) 
 40 4373 6446 1.95 (1.56,2.45 Sig. (2) 
   rs6020 2 266 336 1.94 (1.05,3.60) Sig. (2) 
 F2 Coagulation factor II 
(prothrombin) 
rs1799963 30 3546 11712 1.72 (1.31,2.26) <0.001 (1) 
 30 3329 4878 1.95 (1.43,2.66) Sig.  (2) 
 SERPINE1 Serpin peptidase inhibitor  
(plasminogen activator inhibitor type 1) 
rs1799889 11 1283 1661 1.17 (1.03,1.33) Sig. (2) 
*99% CI for (1) and 95% CI for (2). (1) (Staines-Urias et al., 2012) and (2) (Buurma et al., 2013). RAS, renin-angiotensin system; OR, odds ratio; CI, confidence interval. 
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In addition to specific genetic variants, several other maternal factors are 
associated with PE risk, although the proportion of environmental and genetic 
effects contributing to these factors as well as the biological mechanisms 
underpinning the relationship remain unclear. Women with a history of PE or GH 
(Nzelu et al., 2018, Duckitt and Harrington, 2005), advanced maternal age (35 
years or older) (Khalil et al., 2013, Ogawa et al., 2017), shorter stature (Lee and 
Magnus, 2018, Sohlberg et al., 2012), higher body mass index (BMI) (Giannakou 
et al., 2018, Duckitt and Harrington, 2005), and lighter weight or earlier 
gestational age at birth (Dempsey et al., 2003, Á Rogvi et al., 2012) are at an 
increased risk of developing PE. Multiple gestations (Laine et al., 2019, Duckitt 
and Harrington, 2005) and use of assisted reproductive technologies (Almasi-
Hashiani et al., 2019), particularly oocyte donation (Giannakou et al., 2018), 
also put women at an increased risk of PE. In addition, poor mental health (Kurki 
et al., 2000, Qiu et al., 2007), micro/macronutrient deficiency (Purswani et al., 
2017, Qiu et al., 2008), and pre-existing medical conditions (including diabetes, 
chronic hypertension, obesity, antiphospholipid antibody syndrome, and kidney 
disease) (Duckitt and Harrington, 2005, Giannakou et al., 2018) are associated 
with increased PE risk. Finally, several key environmental exposures during 
pregnancy have shown to influence PE risk. While smoking and physical activity 
are associated with a reduced risk of PE (England and Zhang, 2007, Aune et al., 
2014), high altitude and environmental contaminants are associated with an 
elevated risk of PE (Keyes et al., 2003, Palmer et al., 1999, Bailey et al., 2020, 
Rosen et al., 2018). These factors highlight the key role of environmental factors 
in contributing to the development of PE. 
1.1.7.2 Paternal and foetal risk factors 
The role of the father in contributing to the development of PE is further 
supported by a change in paternity altering the risk of PE (Robillard et al., 1993, 
Li and Wi, 2000) and greater vaginal exposure to paternal sperm reducing the 
risk of PE (Di Mascio et al., 2020, Wang et al., 2002). These findings support the 
immune maladaptation theory, which proposes that PE arises from dysregulation 
of the maternal immune response to ‘paternal antigens’, with research primarily 
focussing on the interaction between maternal uterine natural killer (uNK) cells 
and trophoblast cells expressing human leukocyte antigen (HLA)-C and HLA-G 
(Moffett-King, 2002). Two candidate gene studies found that paternally derived 
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HLA-G polymorphisms in the foetus significantly increased the risk of PE (Table 
1-3). Another candidate gene study reported that the combination of foetal HLA-
C2 and maternal killer cell immunoglobulin-like receptor (KIR) AA genotype was 
significantly associated with PE (Table 1-3). In contrast, a number of studies 
report no significant association between primipaternity and PE (Verwoerd et 
al., 2002, Trogstad et al., 2001), and a systematic review found no association 




Table 1-3 Candidate gene studies implicating paternal and foetal genotypes in PE risk. 
Biological pathway Gene Gene name Genotype Genetic variant OR (CI 95%) P 
value 
Study 
Vasoactive peptide END1 Endothelin 1 Paternal rs5370 0.42 (0.18,0.94) 0.034 (1) 
Oxidative stress SOD2 Superoxide dismutase 2 Paternal rs4880 2.77 (1.32,5.81) 0.007 (2) 
Immune tolerance HLA-G Human leukocyte antigen G Foetal G*0106 10.10 (2.20,6.80) 0.003 (3) 




9.60 (2.40,38.70) 0.001 (3) 
   Foetal Exon 8 +14 bp/+14 bp 
(transmitted from father)  





Human leukocyte antigen C 





Maternal KIR AA 
2.38 (1.45,3.90) 0.001 (5) 






Foetal ATCA haplotype (COMT) 
and rs1801133 (MTHFR) 
1.37 (1.05,1.79) 0.022 (6) 
Immune response and 
blood pressure control 
ERAP2 Endoplasmic reticulum 
aminopeptidase 2 
Foetal rs2549782 1.53 (1.10, 2.13) 0.012 (7) 
(1) (Galaviz-Hernandez et al., 2016) (2) (Luo et al., 2018) (3) (Tan et al., 2008) (4) (Hylenius et al., 2004) (5) (Hiby et al., 2004) (6) (Hill et al., 2011b) (7) (Hill et al., 
2011a). OR, odds ratio; CI, confidence interval. 
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Other paternal factors that have shown to increase the risk of PE include 
increased weight and advanced age (Harlap et al., 2002, Lee and Magnus, 2018), 
although it remains unclear whether weight- or age-related gene variants 
underlie this association. Nonetheless, several candidate gene studies examining 
genetic variants in foetal and paternal genotypes provide supporting evidence of 
paternal and foetal genetic effects in determining PE risk (Table 1-3). The first 
GWAS in offspring of PE patients, identified a SNP that reached genome-wide 
significance (rs4769613; P = 5.4 × 10−11) located within the enhancer region of 
the fms related receptor tyrosine kinase 1 (FLT1) gene on chromosome 13 
(Mcginnis et al., 2017). Further examination revealed no association between 
the foetal rs4769613 genotype and Flt-1 and sFlt-1 protein expression in the 
placenta and no association with maternal serum sFlt-1 levels (Mcginnis et al., 
2017). Hence, it remains to be seen whether the foetal rs4769613 genotype 
impacts FLT1 in a pathological manner. In a recent study, the association of the 
placental FLT1 variant with PE risk was replicated in a meta-analysis of two 
independent cohorts (rs4769613; P = 4 × 10−3) (Kikas et al., 2020). Furthermore, 
placental FLT1 gene expression and maternal serum sFlt-1 were significantly 
higher in PE patients with CC and CT genotypes versus controls, suggesting the C 
allele of rs4769613 may promote FLT1 expression and be directly involved in the 
pathology of PE (Kikas et al., 2020). These studies highlight the role of the 
placental genome in contributing to PE risk. 
1.1.7.3 Epigenetic risk factors 
Another component of genetic risk in PE involves epigenetic factors, namely DNA 
methylation, imprinting, and non-coding RNA. Previous candidate genes 
associated with PE risk have shown to exhibit altered methylation levels in PE 
(Kim et al., 2017, White et al., 2016). DNA methylation of polymorphisms 
associated with PE has also shown to alter the risk of developing PE (Harati-
Sadegh et al., 2019). Polymorphisms in the long non-coding imprinted gene H19 
have found to influence PE susceptibility (Harati-Sadegh et al., 2018), and 
polymorphisms in foetal imprinted genes have shown to be associated with 
maternal blood pressure (Petry et al., 2016). MicroRNAs (miRNAs), a form of 
non-coding RNA, have also been identified as risk factors in PE. Polymorphisms in 
miRNA biogenesis machinery (Rezaei et al., 2019, Eskandari et al., 2018), 
placental and maternal miR-146a (Salimi et al., 2019), and the maternal miR-26 
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gene influenced PE risk (Eskandari et al., 2019). Collectively, these studies 
further highlight the complexity of PE aetiology, as epigenetic factors in both 
the mother and foetus contribute to PE susceptibility. 
1.2 MicroRNAs (miRNAs) 
1.2.1 MiRNA biogenesis 
MiRNAs are a class of short, non-coding RNA molecules that regulate gene 
expression post-transcriptionally (Bartel, 2009). Since the discovery of miRNA in 
1993 (Lee et al., 1993), there are now approximately 2000 miRNAs annotated in 
the human genome (miRBase v22). It is estimated that 30-60% of protein coding 
genes may be subject to miRNA regulation (Lewis et al., 2005, Friedman et al., 
2009). In order to form functional mature miRNA, miRNAs undergo stepwise 
processing either via the canonical or non-canonical pathways (Figure 1-6). 
In the canonical pathway, miRNA genes are transcribed by RNA polymerase II 
binding to promoter elements of the gene to produce primary miRNA (pri-miRNA) 
stem loop structures (Lee et al., 2004). A microprocessor complex consisting of 
DGCR8 (an RNA binding protein) and Drosha (a nuclear RNase III enzyme) 
recognises and cleaves the pri-miRNA transcript at the base of the stem loop to 
release precursor miRNA (pre-miRNA), a hair-pin structure approximately 70 
nucleotides (nts) in length characterised by a ~2 nt 3′ overhang (Han et al., 2004, 
Lee et al., 2002). Pre-miRNA is transported out of the nucleus via exportin 5, a 
nucleocytoplasmic transport factor (Bohnsack et al., 2004). RanGTP binds to 
exportin 5 which recognises the ~2 nt 3′ overhang of pre-miRNA and the complex 
migrates through the nuclear pore complex (Wang et al., 2011). In the 
cytoplasm, pre-miRNA is released from the complex by hydrolysis of RanGTP to 
RanGDP. Free pre-miRNA is cleaved by Dicer (a cytoplasmic RNase III enzyme) in 
complex with transactivation response element RNA-binding protein (TRBP), 
leading to removal of the terminal loop and production of a ~22 nt miRNA duplex 
(Chendrimada et al., 2005). TRBP mediates loading of the duplex into an 
Argonaute (Ago) protein, a core component of the RNA-induced silencing 
complex (RISC) (Su et al., 2009). Ago proteins unwind the duplex, and a single 
strand is retained (the guide strand) while the other is degraded (the passenger 
strand) (Matranga et al., 2005), with selection favouring the strand that exhibits 
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lower thermostability of the 5’ end (Khvorova et al., 2003). Incorporation of the 
guide strand into an Ago protein forms a mature RISC and guides the miRNA-
induced silencing complex (miRISC) to target mRNA and inhibit gene expression 
(Kwak and Tomari, 2012). 
Non-canonical pathways refer to the biogenesis of miRNAs in the absence of 
components of the canonical pathway, generally grouped into Drosha/DGCR8-
independent and Dicer-independent pathways (Figure 1-6). Drosha/DGCR8-
independent pathways include mirtrons (pre-miRNAs generated from introns 
during mRNA splicing (Ruby et al., 2007)) and 7-methylguanosine (m7G) capped 
pre-miRNAs, pre-miRNAs generated directly by RNA polymerase II transcription 
(Xie et al., 2013). The dicer-independent pathway involves Drosha cleavage of 
transcripts that generate short pre-miRNAs cleaved directly by Ago proteins 
rather than Dicer due to the mature sequence spanning the pre-miRNA stem loop 
(Cheloufi et al., 2010). Despite processing differences, all pathways converge at 





Figure 1-6 Canonical and non-canonical miRNA biogenesis pathways. 
In the canonical pathway, miRNA genes are transcribed by RNA polymerase II binding to promoter 
elements of the gene to produce primary miRNA (pri-miRNA). A microprocessor complex 
consisting of DGCR8 and Drosha cleaves the pri-miRNA transcript at the base of the stem loop to 
release precursor miRNA (pre-miRNA). Pre-miRNA is transported out of the nucleus via exportin 5 
and RanGTP and released by hydrolysis of RanGTP to RanGDP. Free pre-miRNA is cleaved by 
Dicer in complex with transactivation response element RNA-binding protein (TRBP) to produce a 
miRNA duplex. The duplex is loaded into an Argonaute (Ago) protein, a core component of the 
RNA-induced silencing complex (RISC), which unwinds the duplex. A single strand is retained 
forming a mature RISC (miRNA-induced silencing complex (miRISC). In non-canonical pathways, 
miRNAs are processed in the absence of either Drosha/DGCR8 or Dicer. Drosha/DGCR8-
independent pathways include mirtrons (pre-miRNAs generated from spliceosomes) and m7G-
capped pre-miRNAs (exported via exportin 1). The dicer-independent pathway involves Drosha 
cleavage of small hairpin RNA (shRNA) cleaved directly by Ago proteins. All pathways converge at 
the miRISC to induce posttranscriptional silencing of target genes. Pri-miRNA, primary miRNA; pre-
miRNA, precursor miRNA; m7G, 7-methylguanosine; TRBP, transactivation response element 
RNA-binding protein, Ago, argonaute; RISC, RNA-induced silencing complex; miRISC, miRNA-
induced silencing complex; shRNA, small hairpin RNA. Figure adapted from (O'brien et al., 2018) 
under Creative Commons Attribution License (CC BY).  
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Besides the Drosha/DGCR8 complex and Dicer/TRBP complex, the involvement of 
other RNA binding proteins during biogenesis can further regulate miRNA 
maturation. For example, RNA binding protein Lin-28 was shown to bind to the 
loop region of pri-miRNA let-7 family members, and Lin-28 overexpression and 
knockdown repressed and stimulated miRNA expression respectively, 
demonstrating the inhibitory effects of Lin-28 prior to Drosha processing 
(Newman et al., 2008). In contrast, heterogeneous nuclear ribonucleoprotein 
complex A1 was found to bind to the stem region of pri-miR-18a and promote 
subsequent Drosha/DGCR8 processing (Guil and Cáceres, 2007). Other RNA 
binding proteins, such as KH-type splicing regulatory protein and TAR DNA-
binding protein-43, have shown to interact directly with Drosha and Dicer 
complexes and bind to the loop region of pri-miRNA and pre-miRNA to promote 
miRNA maturation (Trabucchi et al., 2009, Kawahara and Mieda-Sato, 2012). In 
addition to RNA binding proteins, a host of other accessory proteins, including 
enzymes, hormones, and cytokines, as well as non-protein factors have shown to 
regulate miRNA processing (reviewed by (Newman and Hammond, 2010, 
Kurzynska-Kokorniak et al., 2015). Although the biochemical basis and role of 
these interactions remains largely unclear, the vast regulatory network of miRNA 
biogenesis demonstrates how miRNA expression and in turn mRNA expression is a 
carefully regulated process. 
The spatial and temporal regulation of miRNA expression is also subject to 
modulation at both the transcriptional and posttranscriptional level. The basic 
mechanisms of transcriptional regulation of miRNA genes are comparable to that 
of protein-coding genes; transcriptional units consist of promoters, terminators, 
transcription factors, and other regulatory elements, and transcription is driven 
by RNA polymerase II (De Rie et al., 2017, Lee et al., 2004). Approximately half 
of miRNA genes are intergenic and transcribed by their own transcriptional unit 
(Lee et al., 2002, De Rie et al., 2017). The other half are intronic, where they 
can be transcribed from the same promoter as their host gene or transcription 
can also occur independently and involve RNA polymerase III (De Rie et al., 2017, 
Monteys et al., 2010). Transcriptional units determine the expression of miRNA 
in specific cells/tissues or in response to certain stimuli, thereby regulating their 
expression in both health and disease (Sweetman et al., 2008, Bhatt et al., 
2015). At the posttranscriptional level, cell-specific expression is primarily 
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mediated by the existence of alternative 3’ untranslated region (UTR) isoforms 
in mRNAs, which determine the presence or absence of miRNA binding sites 
(Nam et al., 2014). Besides molecules involved in the biogenesis pathways, 
transcriptional and posttranscriptional mediators further highlight how the 
expression and in turn function of miRNAs is subject to extensive regulation. 
1.2.2 MiRNA mechanism of action 
MiRNAs are responsible for the mRNA targeting specificity of the miRISC, and Ago 
proteins (Ago 1-4 in mammals) are essential to the mRNA silencing ability of the 
miRISC (Su et al., 2009). Single stranded mature miRNAs harbour a highly 
conserved sequence, known as the seed region, which consists of nts 2-8 at the 
5’ end (Lewis et al., 2005). Via full or partial complementary base pairing, the 
miRNA seed region binds to miRNA response elements primarily located within 
the 3’ UTR of target mRNA (Lewis et al., 2005). MiRNA:mRNA interaction 
efficiency is enhanced by positioning of the target site within close proximity to 
other target sites for coexpressed miRNAs, outside of the first 15 nts of the 3’ 
UTR, and near both ends of the 3’ UTR (Grimson et al., 2007). Recent studies 
have also predicted target sites exist outside of the 3’ UTR of mRNA, namely 
within the 5’ UTR and coding regions of mRNA, and shown miRNAs retain their 
ability to inhibit posttranscriptional gene expression at these sites (Xu et al., 
2014b, Lytle et al., 2007, Hausser et al., 2013). Furthermore, studies have 
identified sites outside the seed region at the 5’ end of miRNAs that enhance 
interaction efficiency, including base pairing at the 3’ end of miRNAs, base 
pairing at miRNA nts 13-16, and mRNA AU-rich nt composition near the target 
site (Grimson et al., 2007, Broughton et al., 2016, Zhang et al., 2018). These 
factors underpin the ability of miRNAs to target up to hundreds of genes and the 
ability of miRNAs with identical seed sequences to target different genes. 
In the presence of perfect complementary base pairing, the catalytically active 
Ago 2 can induce cleavage of target mRNA, leading to mRNA degradation and 
gene silencing (Jo et al., 2015). In contrast, Ago 1, 3, and 4 do not exhibit 
independent cleavage activity (Su et al., 2009). During partial complementary 
base pairing, Ago proteins therefore recruit additional proteins to mediate gene 
silencing. The GW182 protein family, which interacts with Ago proteins via an 
Ago-binding domain have been identified as an essential requirement for gene 
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silencing in animals (reviewed by (Jonas and Izaurralde, 2015)). They act as 
scaffolds, bridging the interaction between Ago proteins and downstream 
proteins required for gene silencing. Posttranscriptional gene silencing by 
miRNAs occurs via two key mechanisms: mRNA degradation, which includes 
deadenylation, 3’-to-5’ decay, decapping, and 5’-to-3’ decay, and translational 
repression (Jonas and Izaurralde, 2015) (Figure 1-7).  
Deadenylation refers to shortening or removal of the poly(A) tail of mRNA by 
poly(A)-specific 3′ exonucleases (deadenylases) (Charenton and Graille, 2018). 
PAN2-PAN3 and CCR4-NOT deadenylase complexes catalyse deadenylation 
(Figure 1-7). Deadenylated mRNAs can be directly degraded in a 3’-to-5’ 
direction by RNA exosome complexes or decapped (Charenton and Graille, 2018) 
(Figure 1-7). Decapping refers to removal of the 5′ m7G cap by the decapping 
enzyme, decapping protein 2 (Figure 1-7). Decapped mRNAs undergo 5’-to-3’ 
decay via exoribonuclease 1, leading to mRNA degradation (Charenton and 
Graille, 2018) (Figure 1-7). Translation is promoted by the poly(A) tail and 5’-cap 
structure of mRNA (Figure 1-7). The poly(A)-binding protein of the poly(A) tail 
and cap-binding protein, eukaryotic translation initiation factor 4E (eIF4E), of 
the 5’-cap structure interact via the scaffolding protein eIF4G, which together 
with eIF4E and eIF4A forms eIF4F complex (Jonas and Izaurralde, 2015). It is 
proposed that miRNAs interfere with the activity and/or assembly of the eIF4F 





Figure 1-7 Mechanism of action of miRNAs in posttranscriptional silencing of gene targets. 
Posttranscriptional gene silencing by miRNAs occurs via two key mechanisms: mRNA degradation (which includes deadenylation, 3’-to-5’ decay, decapping, and 5’-to-
3’ decay) and translational repression. In mRNA degradation, the miRNA-induced silencing complex (miRISC) binds to the 3’ UTR of target genes. PAN2-PAN3 and 
CCR4-NOT deadenylase complexes catalyse deadenylation, which leads to shortening or removal of the poly(A) tail of mRNA. Deadenylated mRNAs can be directly 
degraded in a 3’-to-5’ direction by RNA exosome complexes or decapped. In decapping, the 5′ cap of mRNA is removed by the decapping enzyme, decapping protein 
2 (DCPC2). Decapped mRNAs undergo 5’-to-3’ decay via exoribonuclease 1 (XRN1), leading to mRNA degradation. In translational repression, miRNA-induced 
silencing complex (miRISC) binds to the 3’ UTR of target genes during translation initiation. Translation is promoted by the poly(A)-binding protein (PABC) of the 
poly(A) tail and eukaryotic translation initiation factor 4E (eIF4E) of the 5’-cap structure interacting via the scaffolding protein eIF4G, which together with eIF4E and 
eIF4A forms eIF4F complex. MiRNAs interfere with the activity and/or assembly of the eIF4F complex to induce translational repression. ORF, open reading frame. 
miRISC, miRNA-induced silencing complex; DCP2, decapping protein 2; XRN1, exoribonuclease 1; eIF4, eukaryotic initiation factor 4; PABC, poly(A)-binding protein. 
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Besides mRNA degradation and translational repression, miRNAs have shown to 
exhibit alternative functions under certain conditions. For example, translational 
activation of mRNA has been observed when Ago 2 associates with fragile-X-
mental-retardation-related protein 1 rather than GW182 proteins (Truesdell et 
al., 2012) and when miRNA binds to the 5’ UTR rather than the 3’UTR of mRNA 
(Ørom et al., 2008). MiRNAs have also shown to act in the nucleus, where they 
can inhibit transcription via non-seed region binding (Benhamed et al., 2012, 
Miao et al., 2016). 
In addition to regulating intracellular gene targets, miRNAs can be released from 
cells and act in a paracrine and endocrine manner. Circulating miRNAs have 
been detected in various extracellular fluids, including plasma (Mitchell et al., 
2008), serum (Lawrie et al., 2008), urine (Weber et al., 2010), and saliva (Weber 
et al., 2010). MiRNAs are stable in biofluids as they are either found in EVs or 
bound to other proteins, most notably Ago 2, protecting them from RNA 
degradation and potentially trafficking them to specific cells (Gallo et al., 2012, 
Arroyo et al., 2011). Although it was initially thought miRNAs were passively 
released from dying or injured cells, evidence from profiling studies in numerous 
diseases and in vitro characterisation of circulating miRNAs suggests they exert 
biological and in turn pathological functions, acting as an intercellular 
communication network (reviewed by (Sohel, 2016)). 
1.2.3 MiRNAs in the placenta 
MiRNAs and their mRNA targets are well conserved across species (Friedman et 
al., 2009, Li et al., 2010), highlighting their involvement in critical cellular 
processes. The importance of miRNAs in prenatal development is demonstrated 
by knockout (KO) of Dicer and Ago 2 in mice inducing embryo lethal phenotypes 
(Bernstein et al., 2003, Liu et al., 2004). Embryo and perinatal lethality is also 
observed in mice with global targeted deletion of several miRNAs, including miR-
106b~25 and miR-17~92 (Ventura et al., 2008), miR-1-2 (Zhao et al., 2007), miR-
290~295 (Medeiros et al., 2011), miR-126 (Wang et al., 2008), and miR-205 
(Wang et al., 2013). In addition to the essential role of miRNAs in embryonic 
development, knockdown of Ago 2 in mice induces placental and embryo 
malformation, demonstrating the critical role miRNAs play in placental 
development (Cheloufi et al., 2010). In ex vivo placental explants, primary 
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trophoblasts, and trophoblast cell lines, knockdown of Dicer has shown to impair 
the proliferation, invasion, and angiogenic properties of trophoblasts (Forbes et 
al., 2012, Tang et al., 2020). Moreover, polymorphisms in placental DROSHA and 
DICER have found to be associated with an increased risk of pregnancy-related 
disorders such as PE (Rezaei et al., 2019, Eskandari et al., 2018). Collectively, 
these preclinical and clinical studies support the crucial role of miRNAs in the 
development of the placenta. 
Barad et al. were the first to detect miRNA expression in the human placenta, 
identifying several miRNAs, miR-141, miR-23A, and miR-136, that were highly 
enriched in the placenta compared to other tissues (Barad et al., 2004). 
Subsequently, a miRNA cluster located on chromosome 19 (C19MC) was 
identified and found to be conserved across primate genomes (Bentwich et al., 
2005). The C19MC is preferentially expressed in the placenta, where it has been 
detected as early as 5 weeks of pregnancy, and comprises of 46 miRNA genes 
that encode 58 mature miRNAs (Donker et al., 2012). The cluster is imprinted in 
the placenta, with only the paternally inherited allele being expressed (Noguer-
Dance et al., 2010). Similar imprinted miRNA clusters expressed almost 
exclusively in the placenta have been detected specific to rodents, a paternally 
expressed chromosome 2 miRNA cluster (C2MC), and to eutherians, a maternally 
expressed chromosome 14 miRNA cluster (C14MC) (Malnou et al., 2018). KO 
studies in mice highlight the critical function of these miRNA clusters in the 
placenta. KO of the C2MC in mice induced severe impaired placental 
development, embryolethality, and foetal defects (Inoue et al., 2017). KO of one 
or more miRNAs from the C14MC in mice led to placentomegaly with severe 
abnormalities in the labyrinth zone and neonatal lethality (Ito et al., 2015, 
Yoichi et al., 2008). In-vitro studies further support their essential role in the 
placenta, with evidence demonstrating their involvement in trophoblast and 
endothelial cell development and function as well as cell-to-cell communication 
(reviewed by (Malnou et al., 2018)). In trophoblast cell lines, overexpression of 
several members, including miR-520c-3p, miR-520g, and miR-519d-3p, inhibited 
migration and invasion (Takahashi et al., 2017, Jiang et al., 2017, Ding et al., 
2015). Another group showed exosomes isolated from primary human 
trophoblasts conferred antiviral effects on a range of recipient cells, including 
human umbilical vein endothelial cells (HUVECs), human uterine microvascular 
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endothelial cells, and human placental fibroblasts (Delorme-Axford et al., 2013). 
This effect was attributed to the C19MC since overexpression in cells not 
naturally expressing the cluster similarly displayed resistance to viral infection 
(Delorme-Axford et al., 2013). Characterisation of the C19MC in primary 
trophoblasts and four trophoblast cells lines showed that the cluster accounted 
for the majority of miRNAs expressed in term trophoblasts as well as in exosomal 
fractions (Donker et al., 2012). In vitro differentiation and hypoxia largely had 
no effect on the expression of C19MC miRNAs, suggesting the cluster may exert 
their effects regardless of differentiation status but unlikely modulate the 
trophoblast response to hypoxic conditions (Donker et al., 2012). Nonetheless, 
their robust expression and involvement in other pathways support a key role for 
the cluster in aspects of placentation. 
MiRNAs conserved across species have also shown to regulate placental 
development and function, with the majority of research into their role in 
trophoblasts. Morales-Prieto et al. conducted microarray expression profiling in 
first trimester and term primary human trophoblasts as well as four trophoblast 
cell lines (Morales-Prieto et al., 2012). Of the 762 miRNAs screened, 
approximately 50% were detected in any of the cell types, demonstrating the 
vast number of miRNAs potentially involved in mediating trophoblast 
development and function (Morales-Prieto et al., 2012). In addition to changes in 
miRNAs from conserved clusters, 27 miRNAs were differentially expressed more 
than 100-fold between first and third trimester trophoblasts, indicating miRNAs 
exhibit temporal regulation across pregnancy (Morales-Prieto et al., 2012). This 
is further supported by a study that examined miRNA expression profiles in 
villous tissue from the first and third trimester and identified 191 significantly 
differentially expressed miRNAs between trimesters (Gu et al., 2013). MiRNAs 
associated with oncogenic and immunosuppressive properties showed higher 
expression in the first trimester while miRNAs associated with differentiation 
and tumour suppressive characteristics exhibited higher expression in the third 
trimester, reflecting the dynamic changes occurring in the placenta (Gu et al., 
2013). Placental miRNAs have shown to be altered in response to stimuli 
characteristic of the intrauterine environment. In trophoblasts exposed to 
hypoxia and oxidative stress, miRNAs and their gene targets were found to be 
differentially expressed (Mouillet et al., 2010, Cross et al., 2015). In addition to 
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impacting gene expression, candidate studies have shown miRNAs modulate an 
array of trophoblast properties, including migration, invasion, proliferation, 
differentiation, mitochondrial function, survival, and signalling (Luo et al., 2012, 
Liu et al., 2019a, Dai et al., 2012, Brkic et al., 2018, Wang et al., 2018a, Gysler 
et al., 2016, Ospina-Prieto et al., 2016). 
In addition to trophoblasts, in vitro and in vivo studies have examined the intra- 
and extracellular roles of miRNAs in other placental cell types. In decidua 
derived mesenchymal stem cells (dMSCs), overexpression of miR-136 inhibited 
cell viability and proliferation and promoted apoptosis (Ji et al., 2017) and 
overexpression of miR-494 inhibited cell growth (Chen et al., 2015), with the 
miRNAs exerting their effects in part via inhibiting VEGF. Both studies collected 
supernatants from the dMSCs overexpressing the miRNAs and found that co-
culture incubation inhibited HUVEC capillary formation and trophoblast invasion 
and migration (Ji et al., 2017, Chen et al., 2015) . Hence, in addition to 
regulating dMSCs properties, miRNAs expressed in dMSCs may regulate the 
angiogenic and invasive properties of other placental cell types. Another study 
reported supernatant from miR-494-overexpressed dMSCs inhibited macrophage 
polarisation toward the immunosuppressive M2 macrophages and favoured the 
formation of proinflammatory M1 macrophages, indicating a further regulatory 
mechanism of dMSC miRNAs in immune cells (Zhao et al., 2016). MiRNAs have 
also shown to modulate the properties of placental immune cells directly. For 
example, in decidual NK cells, suppressing miR-30e promoted cytotoxicity while 
overexpressing miR-30e inhibited cytotoxicity via targeting perforin 1 (PRF1) 
(Huang et al., 2019). Elevating miR-30e and in turn suppressing PRF1 led to 
downregulation of the Th1 proinflammatory cytokines, interferon γ (IFN-γ) and 
tumour necrosis factor α (TNF-α), and upregulation of the Th2 cytokines 
(interleukin (IL)-4 and IL-10) and angiogenic factors (VEGF, angiotensin II (Ang 
II), and PlGF) suggesting miR-30e in NK cells may be involved in the 
maternofoetal immune response and placental angiogenic signalling (Huang et 
al., 2019). Several miRNAs have also been implicated in regulating endothelial 
cell function in the placenta. KO of miR-126 in mice, a miRNA abundantly 
expressed in endothelial cells, led to embryolethality in approximately 40% of 
cases and surviving embryos showed severe systemic oedema, multifocal 
haemorrhages, and ruptured blood vessels due to impaired angiogenesis of 
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endothelial cells (Wang et al., 2008). A separate group showed miR-126 
stimulated endothelial progenitor cell proliferation, differentiation, and 
migration in vitro and subsequently examined the effects of altering placental 
miR-126 expression in pregnant rats by intraplacental administration of 
chemically modified oligonucleotides specific to miR-126 (Yan et al., 2013). 
Agomir-126 administration significantly increased placental microvessel density 
and the size and weight of placentas and foetuses, while antagomir-126 induced 
the opposite effects, demonstrating a key role of the miRNA in endothelial cells 
and in turn placental development and function (Yan et al., 2013). MiR-203 and 
miR-31-5p have also been implicated in regulating endothelial cell function in 
the placenta. Examination of placental miR-203 expression in early, term, and 
late-term human placentas, showed expression decreased with higher 
gestational age alongside an increase in VEGFA and VEGF receptor 2 expression 
(Liu et al., 2018a). In HUVECS, overexpression of miR-203 inhibited proliferation, 
migration, invasion, and tube formation via modulating VEGF levels (Liu et al., 
2018b). In an ex vivo model of human placenta arteries, miR-31-5p induced 
endothelial dysfunction by impairing angiogenesis, trophoblast invasion, and 
vasorelaxation (Kim et al., 2018). Finally, several miRNAs have also shown to be 
involved in the decidualization of endometrial stromal cells (Qian et al., 2009, 
Sirohi et al., 2019, Zhang et al., 2015c). For example, miR-145 overexpression 
inhibited the decidualization of stromal cells and suppressed the migration and 
invasion of HUVECs (Sirohi et al., 2019). The altered expression of a miRNA in 
different placental cell types can also produce concerted effects. MiR-15b, miR-
155, and miR-320a have shown to inhibit the invasive properties of trophoblasts 
and angiogenic properties of endothelial cells, demonstrating the involvement of 
miRNAs in coordinating cellular responses in the placenta during pregnancy (Dai 
et al., 2012, Yang et al., 2016b, Cheng et al., 2011, Liu et al., 2018c).  
MiRNAs may also regulate placentation as cargo of EVs, a heterogenous group of 
lipid bilayer particles that are released from cells and contain various proteins, 
nucleic acid, and lipids (Tannetta et al., 2017a) (Figure 1-8). The number of 
placenta derived EVs, including exosomes, microvesicles, and apoptotic bodies, 
increase throughout pregnancy and have found to be dysregulated in pregnancy 
disorders (Tannetta et al., 2017a, Sarker et al., 2014, Redman et al., 2012). EVs 
derived from the placenta are released into the maternal circulation, where 
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they can transfer cargo into recipient cells (Figure 1-8). MiRNAs from placenta 
derived EVs have shown to regulate systemic endothelial function and immune 
responses by transfer into maternal cells, such as endothelial cells (Cronqvist et 
al., 2017, Wei et al., 2017) and peripheral blood mononuclear cells (Holder et 
al., 2012). Locally derived EVs have also shown to exhibit paracrine 
communication between cell types of the placenta via miRNAs. Exosomal miR-
520c-3p derived from chorionic villous trophoblasts inhibited the invasion of 
EVTs in vitro (Takahashi et al., 2017). Exosomal miR-146a-5p and miR-548e-5p 
derived from amniotic fluid MSCs reduced trophoblast migration and invasion 
(Yang et al., 2019a). EVs therefore represent another mechanism by which 




Figure 1-8 Schematic of extracellular miRNAs derived from human trophoblasts.  
MiRNAs can be released from trophoblasts in microvesicles, protein-bound, exosomes, and 




1.2.4 MiRNAs in pregnancy disorders 
In 2007, Pineles et al. were the first to report miRNAs were significantly 
differentially expressed in the placentas of preeclamptic patients with and 
without SGA infants (Pineles et al., 2007). Since then, studies have found 
significantly differentially expressed placental miRNAs in a number of other 
pathological pregnancy conditions, including GH (Hromadnikova et al., 2015a), 
FGR (Higashijima et al., 2013), SGA and LGA infants (Thamotharan et al., 2017, 
Guo et al., 2018), gestational diabetes mellitus (Li et al., 2015b), gestational 
obesity (Carreras-Badosa et al., 2017), placenta accreta (Umemura et al., 2013), 
and preterm birth (Mayor-Lynn et al., 2011). Studies examining placental miRNA 
expression across multiple pregnancy disorders have found that disorders show 
unique as well as overlapping dysregulated miRNA profiles (Hromadnikova et al., 
2015a, Mayor-Lynn et al., 2011, Hromadnikova et al., 2015b). Hromadnikova et 
al. reported four members of the C19MC (miR-517-5p, miR-519d, miR-520a-5p, 
and miR-525) were downregulated in placental tissue across pregnancies 
complicated by GH, FGR, and PE, a further two members (miR-518f-5p and miR-
519a) were downregulated in both FGR and PE, and an additional five members 
were downregulated only in PE (miR-515-5p, miR-518b, miR-520h, miR-524-5p, 
and miR-526a) compared to normal pregnancies (Hromadnikova et al., 2015b). 
Whether the shared differences in miRNA expression reflect pathological 
processes common amongst pregnancy disorders remains unclear. Furthermore, 
it remains a challenge to elucidate whether dysregulated placental miRNAs 
represent a cause or consequence of pathological processes. Due to ethical 
reasons, clinical studies are generally limited to placental tissue collected at the 
time of delivery, preventing investigations at earlier time points in pregnancy. 
None of the significantly differentially expressed C19 members were associated 
with abnormal blood flow parameters present in the complicated pregnancies 
(Hromadnikova et al., 2015b). In addition, more miRNAs were significantly 
downregulated in complicated pregnancies with later delivery dates 
(Hromadnikova et al., 2015b). These findings suggest differential expression of 
these placental miRNAs may be a consequence rather than a cause of pathology. 
In a separate study, Hromadnikova et al. evaluated the expression of non-
clustered miRNAs previously implicated in cardiovascular and cerebrovascular 
diseases in placental tissue from GH, FGR, and PE pregnancies (Hromadnikova et 
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al., 2015a). Besides identifying overlapping (miR-499a-5p in GH, FGR, and PE) 
and unique (miR-122-5p, miR-125b-5p, and miR-195-5p in FGR) miRNAs, three 
miRNAs (miR-26a-5p, miR-103a-3p, and miR-145-5p) were found to be 
significantly downregulated in PE and FGR in cases where delivery occurred prior 
to 34 weeks of pregnancy (Hromadnikova et al., 2015a). In vitro studies 
demonstrate the involvement of the three miRNAs in trophoblast and endothelial 
cell proliferation and migration, providing evidence that dysregulated placental 
miRNAs may drive pathological processes (Brooks and Fry, 2017, Lv et al., 2019, 
Wu et al., 2020, Huang et al., 2016). In vitro studies provide a means of 
investigating the impact of altered miRNA expression on target gene expression 
and functional properties of cells. However, a major issue in deciphering the 
role of placental miRNAs in pregnancy disorders lies in the inconsistent findings 
between clinical studies regarding the direction of miRNA expression (Hu and 
Zhang, 2019, Frazier et al., 2020). The discordance between studies in part 
arises from placental miRNA expression being influenced by disease severity, 
presenting symptoms, gestational age, and labour status (Pineles et al., 2007, 
Hromadnikova et al., 2015a, Hromadnikova et al., 2015b, Mayor-Lynn et al., 
2011). Placental miRNA signatures are therefore more likely to be present in a 
subset of patients rather than characteristic of a pregnancy disorder as a whole. 
In addition, it should be noted that methodological aspects of study design, such 
as sample size, confounding variables, sampling technique, and platform-
dependent sensitivity and specificity, likely contribute to inconsistencies 
between studies as well. 
Differences in miRNA expression in serum (Ura et al., 2014), plasma (Fallen et 
al., 2018), and urine (Gan et al., 2017) have also been reported in pregnancy 
disorders. In turn, numerous studies have explored the utility of circulating 
miRNAs as non-invasive biomarkers for adverse pregnancy outcomes 
(Tsochandaridis et al., 2015). Placenta derived miRNAs are detectable as early 
as 6 weeks of pregnancy and have shown to act as markers of placental function 
(Sarker et al., 2014, Whitehead et al., 2013, Hromadnikova et al., 2015a). 
Biomarkers have the potential to facilitate earlier diagnosis and improve 
management by predicting maternal and foetal outcomes. Given that maternal 
history and risk factors alone are generally poor predictors of adverse pregnancy 
outcomes, biomarkers are important tools for monitoring pregnancies (Kane et 
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al., 2014). However, there are only a limited number of blood-based biomarkers 
routinely used in clinical practice due to a lack of sensitivity and/or specificity 
(Kane et al., 2014). It remains to be seen whether circulating miRNAs can 
achieve adequate sensitivity and specificity for pregnancy-related disorders in 
order to be adopted clinically. In patients with macrosomia, one study found 
miR-376a had a sensitivity of 96.7% and specificity of 40.0% (Hu et al., 2014), 
and another reported the miR-17-92 cluster had a sensitivity of 82.61% and 
specificity of 69.57% (Li et al., 2015a). In preterm birth, the predictive 
performance of miR-150-5p (as measured by area under the curve (AUC)) 
increased from 0.87 to 0.91 when combined with six other miRNAs (Cook et al., 
2019). Similarly, a combination of C19MC miRNAs had a stronger predictive 
performance then individual C19MC miRNAs in GH (66.1% sensitivity for miR-
520a-5p and miR-525-5p versus 48.2% sensitivity for miR-517-5p alone) and PE 
(44.19% sensitivity for miR-517-5p, miR-520a-5p, and miR-525-5p versus 27.9%, 
41.9%, and 39.5% for each miRNA alone respectively) (Hromadnikova et al., 
2019). Hence, a combination of circulating miRNAs rather than an individual 
miRNA may show to be a more accurate biomarker. However, findings to date 
should be interpreted with caution due to the relatively small sample sizes of 
studies. Validation in larger cohorts is particularly important given the 
inconsistencies in circulating miRNA expression between studies. Nonetheless, 
investigations into differentially expressed circulating miRNAs provides a means 
of investigating the role of miRNAs at an earlier timepoint in pregnancy 
disorders. Furthermore, with some miRNAs displaying a correlation between 
placental and circulating levels in healthy and complicated pregnancies, 
circulating miRNAs can provide a unique way to explore the role of placental 
miRNAs in humans (Xu et al., 2014a, Williams et al., 2013). 
1.2.5 MiRNAs in PE 
MiRNA expression profiling and candidate studies in cells and tissues from the 
placenta and blood of preeclamptic patients have identified hundreds of miRNAs 
dysregulated in PE (Sheikh et al., 2016). A change in the concentration, 
composition, and bioactivity of placenta and non-placental derived EVs has been 
reported as early as the first trimester in preeclamptic pregnancies (Truong et 
al., 2017, Salomon et al., 2017). Besides the involvement in placental 
dysfunction, studies have implicated EVs in promoting the systemic inflammatory 
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response, endothelial dysfunction, and hypercoagulation in PE through their 
interaction with immune cells, endothelial cells, and platelets (reviewed by 
(Tannetta et al., 2017b)). Both clustered miRNAs, such as members from the 
C19MC, and non-clustered miRNAs in EVs have found to be differentially 
expressed across the different trimesters of preeclamptic pregnancies, 
prompting studies to investigate their potential as biomarkers (Hromadnikova et 
al., 2019, Devor et al., 2020). A systematic review pooled the results from three 
articles, estimating circulating miRNAs had a sensitivity of 0.61% and specificity 
of 0.78% for predicting PE (Yin et al., 2020). Studies have shown differences in 
the concentration and miRNA content of EVs between PE subtypes (Pillay et al., 
2016, Pillay et al., 2019), suggesting stratifying preeclamptic patients into 
subtypes may improve the predictive power of circulating miRNAs as biomarkers. 
Distinct miRNA profiles in PE subtypes have similarly been reported in the 
placenta (Lykoudi et al., 2018, Zhu et al., 2009), lending weight to the concept 
that subtypes show unique miRNA signatures. This may in turn account for the 
inconsistencies between clinical studies in terms of the direction of expression 
of dysregulated placental miRNAs, although other patient characteristics (such 
as ethnicity, age, and the timing of delivery) and study design parameters 
(sample size, sampling technique, and experimental methodology) also likely 
contribute.  
Characterisation of differentially expressed placental miRNAs has been 
conducted in an array of placental cell types, such as trophoblasts (Lee et al., 
2011, Muralimanoharan et al., 2012, Luo et al., 2012, Wang et al., 2017, Xiao et 
al., 2017, Wang et al., 2018c, Yang et al., 2019c, Liu et al., 2018a, Zhang et al., 
2019, Wang et al., 2019a, Yang and Guo, 2019), immune cells (Wang et al., 
2019b), endothelial cells (Cheng et al., 2011, Zhou et al., 2017), MSCs (Liu et 
al., 2012, Wang et al., 2012c, Hu et al., 2015), and co-cultures of these cells 
(Chen et al., 2015, Zhao et al., 2016, Ji et al., 2017). In vitro characterisation 
by corroborating gene targets and conducting functional assays supports the 
involvement of miRNAs in regulating key pathological processes associated with 
PE, namely impaired trophoblast and endothelial function, angiogenesis, and 
immune tolerance. The role of differentially expressed miRNAs has been studied 
most extensively in trophoblasts since placental dysfunction is one of the main 
pathological features of PE. Figure 1-9 presents miRNAs for which studies have 
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evaluated the expression of the miRNA and gene target in preeclamptic patients, 
validated the gene as a target through reporter constructs in vitro, and 
demonstrated overexpression/knockdown of the miRNA impairs trophoblast 
function. 
 
Figure 1-9 MiRNAs and validated gene targets dysregulated in PE implicated in impairing 
trophoblast function. 
MiRNAs for which studies have found dysregulation of the miRNA and gene target in preeclamptic 
patients, validated the gene as a target through reporter constructs in vitro, and demonstrated 
overexpression/knockdown of the miRNA impairs trophoblast function. (1) (Yang et al., 2019c) (2) 
(Xiao et al., 2017) (3) (Wang et al., 2018c) (4) (Liu et al., 2018a) (5) (Yang and Guo, 2019) (6) 
(Wang et al., 2014b) (7) (Lu et al., 2017) (8) (Gao et al., 2018) (9) (Liu et al., 2019a) (10) (Xue et 
al., 2019) (11) (Zhang et al., 2012) (12) (Lee et al., 2011) (13) (Muralimanoharan et al., 2012) and 
(14) (Wang et al., 2018a). THBS2, thrombospondin-2; PTEN, phosphatase and tensin homolog; 
PAX3, paired box gene 3; VEGFA, vascular endothelial growth factor A; PDGFRA, platelet-derived 
growth factor receptor α; FOXA1, forkhead box protein A1; ERRα, oestrogen-related receptor α; 
HDAC2, histone deacetylase 2; TGF‑β1, transforming growth factor‑β1; SMAD4, Smad family 
member 4; HOXA9, homeobox-A9; EFNA3, ephrin-A3; ISCU, iron-sulphur cluster scaffold; 
FOXRED1, FAD-dependent oxidoreductase domain-containing 1; PDPR, pyruvate dehydrogenase 
phosphatase regulatory subunit. Figure was created using images from Servier Medical Art under 
Attribution 3.0 Unported (CC BY 3.0).  
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In addition to altering trophoblast function, significantly upregulated placental 
miRNAs have shown to inhibit the expression of various angiogenic factors that 
are downregulated in PE, such as VEGFA and endothelial nitric oxide synthase 
(eNOS), indicating their role in contributing to the imbalance in angiogenic 
signalling in PE (Li et al., 2013, Jiang et al., 2015). As an example, in 
trophoblasts, miR-155 inhibited cysteine-rich angiogenic inducer 61 (CYR61), an 
extracellular matrix-associated signalling protein, and eNOS, key enzyme 
involved in production of nitric oxide (NO), matching the observed upregulation 
of the miRNA and downregulation of CYR61 and eNOS in preeclamptic placentas 
(Zhang et al., 2010, Li et al., 2014). Besides trophoblasts, dysregulation of 
miRNAs in other cell types in PE has further shown to impair angiogenic 
signalling. In HUVECs isolated from preeclamptic patients, miR-155 expression 
was decreased and its gene target Ang II type 1 receptor was increased, leading 
to excessive Ang II-induced signalling (Cheng et al., 2011). MiR-29a/c-3p were 
downregulated in HUVECs isolated from preeclamptic patients, and knockdown 
of the miRNAs in HUVECs from normotensive pregnancies blocked VEGFA- and 
fibroblast growth factor 2-stimulated endothelial cell migration (Zhou et al., 
2017). Overexpression of miR-15b in HUVECs reduced cell proliferation and tube 
formation via targeting AGO2, in line with the increased expression of miR-15b 
and decreased expression of AGO2 in preeclamptic placentas (Yang et al., 
2016b). In MSCs isolated from patients with PE, miR-136, miR-495, and miR-16 
were upregulated and inhibited cell growth and promoted apoptosis (Ji et al., 
2017, Li et al., 2017, Wang et al., 2012c). Moreover, supernatants collected 
from the preeclamptic MSCs overexpressing the miRNAs inhibited trophoblast 
invasion and HUVEC tube formation by targeting VEGF and BMI1 (Ji et al., 2017, 
Li et al., 2017, Wang et al., 2012c). The involvement of miRNAs in endothelial 
dysfunction has also been shown through investigations into maternal blood and 
vessels. In plasma from preeclamptic patients, elevated sFlt-1 levels showed a 
positive correlation with circulating miR-195-5p expression (Sandrim et al., 
2016a). In a separate study, incubating HUVECs with plasma from preeclamptic 
patients stimulated miR-195-5p and reduced VEGF expression (Sandrim et al., 
2016b). In maternal vessel endothelium from subcutaneous fat tissue from 
preeclamptic patients, miR-203 was increased and its predicted gene target, 
suppressor of cytokine signalling 3, was decreased (Wang et al., 2016). 
Overexpression of miR-203 in HUVECs promoted the expression and production of 
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IL-6 and IL-8, and intercellular adhesion molecule 1, suggesting involvement of 
the miRNA in the endothelial inflammatory response (Wang et al., 2016). Other 
miRNAs dysregulated in the placentas of preeclamptic patients, namely, miR-
520c-3p, miR-125b, and miR-181a, have also shown to stimulate the production 
of inflammatory cytokines in trophoblasts and MSCs, further supporting the role 
of miRNAs in modulating the immune response in a range of cell types in PE (Liu 
et al., 2019b, Yang et al., 2016c, Liu et al., 2012). MiRNAs may also be involved 
in modulating maternofoetal immune compatibility. MiRNAs previously reported 
as upregulated in PE, miR-152 (Zhu et al., 2009) and miR-365 (Zhou et al., 2016), 
inhibited HLA-G expression in trophoblasts (Zhu et al., 2010, Mori et al., 2016). 
Moreover, overexpression of miR-152 increased trophoblast susceptibility to NK 
cell-mediated cytolysis, providing functional evidence of the consequences of 
dysregulated miRNAs and their gene targets in immune processes in PE. 
In contrast to the extensive in vitro experiments, only a handful of studies 
investigating dysregulated miRNAs have been conducted in animal models of PE 
(Kopriva et al., 2013, Yan et al., 2014, Yang et al., 2016a, Wang et al., 2020c). 
In poly I:C induced PE mice, miR-210 was significantly upregulated in the 
placenta compared to wild type (WT) mice (Kopriva et al., 2013). This finding is 
in line with the 22 studies that have reported its upregulation in the placenta 
and blood of preeclamptic patients (Frazier et al., 2020), although one study to 
date reported it was significantly downregulated in patients with mild PE (Zhu et 
al., 2009). MiR-210 has been described as the master ‘hypoxamir’ (a hypoxia-
inducible miRNA) (Chan et al., 2012), and multiple in vitro studies have shown 
involvement of miR-210 in mediating trophoblast function (Muralimanoharan et 
al., 2012, Wang et al., 2019a, Li et al., 2019). In the poly I:C induced PE mice, 
hypoxia-inducible factor 1 α (HIF-1 α) was significantly upregulated in the 
placenta, providing supporting evidence of miR-210 as a key mediator of the 
hypoxia response (Kopriva et al., 2013). In addition, the miR-210 gene target 
signal transducer and activator of transcription 6 (STAT6) and IL-4, both 
mediators of the anti-inflammatory Th2 cytokines, were found significantly 
downregulated, suggesting miR-210 may also play a role in mediating the 
immune response in PE (Kopriva et al., 2013). In N(γ)-nitro-L-arginine methyl 
ester (L-NAME) induced PE rats, miR-148a and miR-152 (members of the miR-
148/152 family) were upregulated in the placenta, coinciding with a 
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downregulation of DNA methyl‐transferase 1 (DNMT1), a gene target of miR-
148/152, and fatty acid-binding protein 4 (FABP4), a gene target of DNMT1 (Yang 
et al., 2016a). Through altering the expression of the methylation enzyme, 
DNMT1, miR-148/152 may in turn modulate methylation patterns of various 
genes and pathways, such as FABP4 which mediates inflammatory and metabolic 
pathways. In vitro studies have also shown miR-152 inhibits HLA-G expression in 
trophoblasts, suggesting miR-148/152 may be involved in immune tolerance in PE 
(Zhu et al., 2010). While three studies in preeclamptic patients have reported 
upregulation of miR-148/152 members (Zhou et al., 2016, Zhu et al., 2009, Jiang 
et al., 2015), one study found miR-148a was downregulated (Zhao et al., 2014) 
highlighting a discordance between clinical studies regarding the direction of 
miRNA expression as seen with miR-210 (Frazier et al., 2020). In another study of 
L-NAME induced PE rats, miR-576-5p was decreased and its gene target, 
transcription factor AP‐2α, was increased in placenta (Wang et al., 2020c). 
Investigations in HTR8/SVneo trophoblasts showed inhibition of miR-576-5p 
suppressed cell proliferation and invasion (Wang et al., 2020c). No published 
clinical study in preeclamptic patients could be identified that examined or 
detected differential miR-576-5p expression. Finally, following investigations in 
pregnant rats, where intraplacental administration of chemically modified 
oligonucleotides specific to miR-126 altered placental microvessel density and 
the size and weight of placentas and foetuses (Yan et al., 2013), Yan et al. 
evaluated the effects of intraplacental agomir-126 administration in L-NAME 
induced PE rats (Yan et al., 2014). Elevating placental miR-126 expression led to 
greater placental and foetal weight, enhanced microvessel density, and a higher 
proportion of live pups (Yan et al., 2014). While increasing placental miR-126 
expression may therefore represent a therapeutic strategy in PE, clinical studies 
provide conflicting results as to the direction of miR-126 expression in the 
placenta in preeclamptic patients. Three clinical studies have reported 
decreased miR-126 expression in preeclamptic placentas (Yan et al., 2013, Hong 
et al., 2014, Jiang et al., 2015), while two have reported increased expression 
(Yang et al., 2015, Hu et al., 2009). Nonetheless, this study is the first to 
provide evidence that altering placental miRNA expression may represent a 
therapeutic strategy in PE. Since animal models provide the opportunity to study 
the role and therapeutic potential of miRNAs in PE in an in vivo setting, 
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preclinical investigations are essential to our understanding of how miRNAs are 
involved in a pregnancy disorder almost unique to humans. 
1.2.6 MiRNAs as a therapeutic strategy 
As research into the role of miRNAs in diseases and disorders has expanded so 
has the field of miRNA-based therapeutics, with phase I and phase II clinical 
trials currently underway (Chakraborty et al., 2017). Their use is being explored 
in a range of conditions, such as cancer, viral infections, and neurological, 
metabolic, inflammatory, and cardiovascular disorders (Chakraborty et al., 
2017). MiRNAs (in the absence of EVs or binding proteins) are unstable in the 
circulation and unable to penetrate cell membranes. Therapeutic targeting of 
miRNAs therefore traditionally involves utilizing chemically synthesized 
oligonucleotides that either inhibit (antagomirs) or mimic (agomirs) the miRNA 
of interest. Antagomirs are complementary to the target miRNA to inhibit it, 
while agomirs are double-stranded RNA molecules that mimic the sequence and 
in turn function of miRNAs. Due to low intestinal absorption following oral 
administration, antagomirs and agomirs are typically administered by 
intravenous or subcutaneous injections (Chakraborty et al., 2017). However, 
these agents are still susceptible to nuclease degradation, off-target binding, 
and low cellular membrane permeability (Ling, 2016). Various alternatives, such 
as miRNA expression vectors and miR sponges, as well as delivery systems, most 
commonly lipid nanoparticles, have in turn been developed to protect against 
nuclease degradation, promote targeted delivery, and avoid immune responses 
(Ling, 2016). Results from early clinical trials have provided mixed results in 
terms of safety and efficacy. While some therapeutics have shown to be safe and 
improve disease-related measures (Janssen et al., 2013), other therapeutics 
have shown limited clinical activity and been discontinued due to safety reasons 
(Hong et al., 2020). One of the major advantages of miRNA-based therapeutics is 
the ability of miRNAs to target more than one gene, potentially modulating 
multiple components of a single biological pathway or multiple biological 
pathways. For example, in a rat model of heart failure, subcutaneous delivery of 
MGN-9103 (an inhibitor of miR-208a) prevented pathological cardiac remodelling 
and improved cardiac function, overall health, and survival (Montgomery et al., 
2011). Subsequent microarray analysis of heart tissue revealed that 131 genes 
were differentially expressed of which 31 were predicted gene targets, and the 
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expression of 28 of these was increased corresponding with decreased expression 
of miR-203 (Montgomery et al., 2011) . These findings highlight the pleiotropic 
nature of miRNAs. While this may confer therapeutic benefit, off-target effects 
due to inhibition of multiple genes is a potential safety issue with miRNA-based 
therapeutics. In addition to identifying suitable miRNAs to target, developing 
efficient and safe delivery systems remains key to ensuring the translational 
success of miRNA-based therapeutics. 
1.3 Gene therapy 
Gene therapy is the introduction of foreign genetic material (DNA or RNA) into 
host cells to prevent, treat, or cure a disease. It can be divided into two main 
categories: somatic and germline. Somatic gene therapy involves transfer of 
genetic material into non-reproductive or ‘somatic’ cells. Introduction into 
somatic cells means any genetic changes occur only in the patient and cannot be 
inherited by their offspring. In germline gene therapy, genetic material is 
transferred into germline cells (sperm or egg cells) and can therefore be passed 
down to subsequent generations. Germline gene therapy remains largely banned 
or restricted (Araki and Ishii, 2014). Conventional approaches to somatic gene 
therapy include introducing genetic material to confer therapeutic benefit or to 
compensate for a missing or defective gene. A fundamental requirement of gene 
therapy is delivery of foreign genetic material into the cell nucleus. This can be 
achieved in vivo, in which gene transfer occurs inside the body, or ex vivo, in 
which cells from a patient are removed, genetically modified, and reintroduced 
back into the patient. Its successful application also requires transfer in target 
cells, with the genetic material expressed at therapeutic levels for a clinically 
relevant length of time. To address these conditions and due to the rapid 
degradation of genetic material in vivo, different viral and non-viral gene 
carriers or ‘vectors’ have been developed, each harbouring advantages and 
disadvantages (Nayerossadat et al., 2012). 
1.3.1 Viral gene therapy 
Viral systems take advantage of the innate ability of viruses to infect host cells 
and access the nucleus. Viruses are genetically modified by deleting components 
of their genome, which alters their ability to replicate and suppresses their 
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virulence while maintaining their ability to infect host cells (Nayerossadat et al., 
2012). Viral vectors exhibit high transgene efficiency and expression, 
contributing to their popular use as vectors in more than two thirds of gene 
therapy clinical trials (Ginn et al., 2018). However, attenuated viruses still carry 
a risk of immunogenicity, insertional mutagenesis, and toxicity (Nayerossadat et 
al., 2012). In addition, they have limits in their transgene packaging capacity 
and can be difficult to manufacture (Van Der Loo and Wright, 2016). Despite 
their limitations, viruses have shown to be suitable in certain diseases, 
dependent on their tissue and cell tropism, transgene capacity, integration 
profile, duration of transgene expression, and immune profile (Table 1-4).
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• Cancer (brain, pancreatic, ovarian, prostate, breast, skin, liver, bladder, 
eye, blood, lungs, colorectal, oral, neck) 
• Cardiovascular diseases (CAD, CHD, CHF) 
• Rare inherited disorders (cystic fibrosis) 










5 kb Stable Low Common Dividing 
and non-
dividing 
• Cancer (neck, gastric) 
• Blood clotting disorders (haemophilia A/B) 
• Vision disorders (LHON, LCA, macular degeneration, achromatopsia, 
choroideremia) 
• Neurodegenerative disorders (NCL, AD, PD, HD) 
• Neuromuscular disorders (MD, x-linked myotubular myopathy, SMA) 
• Inflammatory disorders (arthritis) 
• Other rare inherited disorders (Danon disease, Pompe disease, AAT 
deficiency, phenylketonuria, AADC deficiency, mucopolysaccharidosis, 
OTC deficiency, Crigler-Najjar syndrome, glycogen storage type 






Episomal 50 kb Transient High Common Dividing 
and non-
dividing 
• Skin disease (TGM-1 related ARCI, dystrophic epidermolysis bullosa) 
• Cancer (brain, liver, skin) 
• Cancer pain 
Retrovirus Broad Chromosomal 8 kb Stable Low Uncommon Dividing • Cancer (brain, CNS, breast, skin, eye, vaginal, cervical, anal, penile, 
oral, neck, kidney, blood) 
• Immune conditions (HIV, X-linked lymphoproliferative disease, EBV 
infection, hemophagocytic lymphohistiocytosis, arthritis, SCID, Wiskott-
Aldrich syndrome, CGD) 
• Other rare inherited conditions (Gaucher’s disease, Fabry’s disease, 
Fanconi anaemia, mucopolysaccharidosis, junctional epidermolysis 
bullosa, gyrate atrophy) 
Lentivirus Broad Chromosomal 8 kb Stable Low Uncommon Dividing 
and non-
dividing 
• Immune conditions (HIV, AIDS-related lymphoma, severe combined 
immunodeficiency, Wiskott-Aldrich syndrome, CGD) 
• Blood conditions (haemophilia A, Beta-thalassemia, sickle cell disease, 
Fanconi anaemia) 
• Other rare inherited conditions (X-linked adrenoleukodystrophy, 
Fabry’s disease, mucopolysaccharidosis, metachromatic 
leukodystrophy, cystinosis) 
*denotes third generation vectors. CAD, coronary artery disease; CHD, coronary heart disease; CHF, congestive heart failure; LHON, Leber's hereditary optic neuropathy; LCA, Leber congenital amaurosis; 
NCL, neuronal ceroid lipofuscinosis; AD, Alzheimer’s disease; PD, Parkinson’s disease; HD, Huntington’s disease; MD, muscular dystrophy; SMA, spinal muscular atrophy; AAT, alpha-1-antitrypsin; AADC, 
aromatic l-amino acid decarboxylase; OTC, ornithine transcarbamylase; LPL, lipoprotein lipase; ARCI, autosomal recessive congenital ichthyosis; CNS, central nervous system; HIV, human immunodeficiency 
virus; EBV, Epstein-barr virus; SCID, severe combined immunodeficiency; CGD, chronic granulomatous disease; AIDS, acquired immunodeficiency. Table was created using the ClinicalTrial.gov database and 
adapted from (Lundstrom, 2018) under the Creative Commons Attribution 4.0 International (CC BY 4.0).
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1.3.2 Non-viral gene therapy 
Non-viral systems encompass all methods used to transfer genetic material into 
host cells that do not employ viral vectors. Although generally less efficient than 
viral systems, their favourable safety profile, transgene capacity, and ease and 
cost-effectiveness of production support their continued development 
(Nayerossadat et al., 2012). ‘Naked’ plasmid DNA is the third most popular 
vector used in gene therapy clinical trials (Ginn et al., 2018). It has shown to be 
a safe and effective method for achieving therapeutic transgene expression in 
multiple conditions, including cancer (Lavie et al., 2017, Mahvi et al., 2007), 
cardiovascular diseases (Penn et al., 2013, Kukuła et al., 2019, Deev et al., 
2018, Gu et al., 2019), diabetic neuropathy (Ajroud-Driss et al., 2013, Ropper et 
al., 2009), and amyotrophic lateral sclerosis (Sufit et al., 2017). However, 
several clinical trials have failed to show lack of a therapeutic effect (Belch et 
al., 2011, Stewart et al., 2009, Shishehbor et al., 2019, Chung et al., 2015). To 
promote targeted and efficient gene expression, naked RNA or DNA is routinely 
delivered in conjunction with chemical and/or physical methods in preclinical 
studies. The main chemical methods are cationic lipids, cationic polymers, 
and/or nanoparticles, and physical methods include gene gun, electroporation, 
hydroporation, magnetofection, and sonoporation.  
1.3.2.1 Chemical methods 
Chemical methods involve carriers, namely cationic lipids, cationic polymers 
and/or nanoparticles, that protect genetic material against degradation and 
deliver genetic material into target cells via endocytosis. The major advantages 
of chemical methods are low immunogenicity and toxicity, while low transfer 
efficiency persists as the main disadvantage (Nayerossadat et al., 2012). As a 
result, targeting moieties, such as proteins (Wolschek et al., 2002), antibodies 
(Meissner et al., 2015), and peptides (Ren et al., 2015), have shown to promote 
higher transgene expression levels in preclinical models in vivo to achieve 
therapeutically relevant levels. Clinical trials have demonstrated the feasibility 
of chemical methods for gene therapy in several diseases, including cancer 
(Siefker-Radtke et al., 2016, Thaker et al., 2017, Lu et al., 2012), cystic fibrosis 
(Alton et al., 2015), and coronary artery disease (Hedman et al., 2009). Several 
clinical trials have however reported lack of a therapeutic effect and low 
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transfer efficiencies (Grossman et al., 2007, Alvarez et al., 2014). In turn, 
chemical methods have been employed in conjunction with physical methods, 
which has shown to achieve safe and effective gene delivery in several 
preclinical and clinical studies (Lin et al., 2018, Devulapally et al., 2018, Nicol 
et al., 2002). 
1.3.2.2 Physical methods 
In the gene gun approach, biocompatible heavy metal particles coated with 
plasmid DNA are propelled at high velocity via discharge from a ‘gun’ to induce 
gene transfer (Figure 1-10). Early preclinical studies demonstrated feasibility of 
the non-invasive and targeted gene therapy technique for superficial organs (Sun 
et al., 1995, Rakhmilevich et al., 2000, Lu et al., 2002). However, low transfer 
efficiency, transient transgene expression, restricted treatment area in terms of 
depth and surface, and the requirement of invasive procedures for non-
superficial organs have limited the development of the tool for gene therapy 
purposes in humans (Kitagawa et al., 2003, Sato et al., 2000, Chuang et al., 
2003). Rather, research has focused on the utility of the device for gene transfer 
in plants (Acanda et al., 2019) and DNA vaccinations in humans (Hopkins, 2016). 
With electroporation, electrodes are placed on either side of the target tissue, 
and electrical pulses are delivered generating an electric field that leads to 
reversible breakdown of the cell membrane, permitting transfer of genetic 
material (Figure 1-10). Efficient delivery of therapeutic genes to skeletal muscle 
and tumours in preclinical studies has led to application of electroporation in 
clinical trials (Lucas and Heller, 2003, Ugen et al., 2006, Guha et al., 2019). In a 
clinical trial, intramuscular electrotransfer of an antiangiogenic plasmid to 
patients with solid tumours caused local pain and oedema and systemic toxicity 
in some patients (Spanggaard et al., 2017). Furthermore, low and transient 
transgene expression coincided with no clinical response (Spanggaard et al., 
2017). In contrast, clinical trials of intratumoural plasmid IL-12 electrotransfer 
to patients with subcutaneous or cutaneous melanoma have shown to produce 
long-term clinical benefit without systemic toxicity, although local pain was 
listed as the main side-effect (Daud et al., 2008, Greaney et al., 2020, Daud et 
al., 2015). While local pain and tissue damage remain a concern, electroporation 
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as a non-invasive and non-viral gene therapy technique holds potential for 
targeting superficial organs. 
Hydrodynamic gene therapy involves rapid intravenous administration of a large 
volume to induce gene delivery via pressure, a process known as hydroporation 
(Figure 1-10). The method is primarily used for targeting the liver since transfer 
occurs almost exclusively in organs linked within close proximity to the inferior 
vena cava. Preclinical studies have demonstrated the ability of the technique to 
produce stable and therapeutic levels of transgene expression in the liver and in 
turn circulating factors in various diseases, including diabetes (He et al., 2004), 
growth hormone deficiency (Sondergaard et al., 2003), liver fibrosis (Kobayashi 
et al., 2016), haemophilia (Ye et al., 2003), metabolic diseases (Meyer-Kovac et 
al., 2017, Holm et al., 2003), and rare inherited conditions (Grisch-Chan et al., 
2017, Zhang et al., 2000, Aliño et al., 2003). While hydroporation research has 
extended to large animal studies and a clinical trial (Kumbhari et al., 2018, 
Khorsandi et al., 2008), low transfer efficiency and cardiovascular safety 
concerns due to volume overload have hindered its translational progress 
(Sawyer et al., 2008, Sawyer et al., 2007). However, advancements in the 
delivery method, such as computer-assisted devices (Suda et al., 2008) and 
image-guided techniques (Kumbhari et al., 2018, Khorsandi et al., 2008), may 
help the development of hydrodynamic gene therapy as a safe and effective 
delivery system. 
In magnetofection, a magnetic field is applied to target tissue which attracts 
magnetic nanoparticles coated with genetic material, and the particles are 
taken up by non-specific endocytosis (Figure 1-10). The gene delivery system has 
been primarily investigated in vitro for transfection in cell culture experiments, 
cell models (Krötz et al., 2003, Lee et al., 2017, Buerli et al., 2007), and stem 
cell therapy (Park et al., 2012, Pickard et al., 2017, Fernandes and Chari, 2016). 
In turn, magnetofection in vivo as a gene therapy method remains in the proof-
of-concept stage, with reporter gene transfer demonstrated in superficial 
targets, namely the skin (Holzbach et al., 2010), spinal cord (Song et al., 2010), 
and brain (Soto-Sánchez et al., 2015). Although safety analyses were not 
performed in these proof-of-concept studies, in an oncological veterinary study 
delivering a granulocyte‐macrophage colony‐stimulating factor plasmid with 
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magnetofection to cats with fibrosarcoma, low doses were well-tolerated, with 
only mild adverse events and no major toxicity reported (Hüttinger et al., 2008). 
Further investigations are required to evaluate the safety and efficacy of 
magnetofection as a gene therapy strategy for targeting superficial organs. 
Ultrasound-mediated gene delivery (UMGD) represents a physical method for 
enhancing gene transfer via sonoporation (Figure 1-10). In UMGD, viral or non-
viral vectors are co-administered with microbubbles (MBs) (systemically or 
locally) followed by exposure of the target tissue to ultrasound (US). This 
stimulates uptake of the genetic material in the insonified region via the 
generation of transient pores (Newman and Bettinger, 2007). This method can 
augment transgene expression and improve spatial targeting, leading to more 
efficient delivery of genetic material with both viral (Müller et al., 2008) and 
non-viral vectors (Lan et al., 2003). Preclinical studies have provided evidence 
of site-specific gene transfer in a variety of tissue, including the heart (Chen et 
al., 2003), kidneys (Ishida et al., 2016), liver (Anderson et al., 2013), pancreas 
(Chen et al., 2006), brain (Thévenot et al., 2012), eyes (Sonoda et al., 2006), 
skeletal muscle (Pislaru et al., 2003), and tumours (Howard et al., 2006). In 
addition, safe and efficient transfer of genetic material has been demonstrated 
in preclinical studies for numerous conditions, such as cancer (Carson et al., 
2011), CVD (Yuan et al., 2012), blood clotting disorders (Ye et al., 2003), renal 
disease (Wu et al., 2014), and neurodegenerative disease (Wang et al., 2014a). 
With the ability to theoretically target any organ in a non-invasive manner, 
UMGD represents a promising gene therapy technique, supported by its recent 
clinical application to deliver therapeutic drugs in cancer patients (Dimcevski et 




Figure 1-10 Diagram of mechanisms of common physical methods (gene gun, electroporation, hydroporation, magnetofection, and sonoporation) for 
enhancing transfer of genetic material. 





























1.3.3 History of gene therapy 
In 1990, the first in-human gene therapy trial demonstrated the feasibility and 
safety of the technique (Rosenberg et al., 1990). In the trial, tumour-infiltrating 
lymphocytes were genetically modified ex vivo utilizing a retroviral vector and 
reintroduced into patients with metastatic cancer. The therapy conferred anti-
tumour effects in some patients and was well-tolerated by all patients; no side-
effects relating to the viral vector were reported (Rosenberg et al., 1990). These 
results prompted initiation of gene therapy clinical trials, including a 
lymphocyte-directed gene therapy trial for adenosine deaminase severe 
combined immunodeficiency (ADA-SCID), a monogenic disorder that if left 
untreated can be fatal within the first 2 years of life (Blaese et al., 1995). In 
1990, a 4-year-old child who lacked a lymphocyte antigen-matched related 
donor and did not sufficiently respond to traditional treatment entered the trial, 
receiving lymphocytes transduced ex vivo with a retroviral vector containing the 
ADA gene (Blaese et al., 1995). To date, she requires low-dose enzyme 
replacement therapy, which has left some questioning the effectiveness of the 
gene therapy, but she has lived to become a healthy adult and is often described 
as the first patient cured by gene therapy (Philippidis, 2016). Despite some of 
the early successes of gene therapy, fatal outcomes in subsequent gene therapy 
trials highlight the consequences of scientific developments outpacing human 
understanding, mirrored by concerns expressed in a seminal paper published in 
1972 (Friedmann and Roblin, 1972): 
‘For the foreseeable future, however, we oppose any further attempts 
at gene therapy in human patients because (i) our understanding of 
such basic processes as gene regulation and genetic recombination in 
human cells is inadequate; (ii) our understanding of the details of the 
relation between the molecular defect and the disease state is 
rudimentary for essentially all genetic diseases; and (iii) we have no 
information on the short-range and long-term side effects of gene 
therapy.’ 
In 1999, 18-year-old Jesse Gelsinger, who suffered from ornithine 
transcarbamylase deficiency, was the first person to die in a gene therapy trial 
(Raper et al., 2003). Administration of an adenoviral vector triggered activation 
of his innate immune system; systemic inflammation and multiple organ system 
failure led to his death (Raper et al., 2003). The Food and Drug Administration 
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(FDA) halted the trial, and the principle investigator was charged with violating 
federal regulations pertaining to clinical trials, including failure to conduct the 
trial in accordance with the protocol; failure to protect the rights, safety, and 
welfare of subjects; failure to submit accurate safety reports; failure to identify 
changes to research activity; and failure to obtain informed consent (Baker, 
2020). In recognition of insufficient monitoring, the FDA and National Institutes 
of Health (NIH) established the Gene Therapy Clinical Trial Monitoring Plan and 
the Gene Transfer Safety Symposia the following year (Sibbald, 2001). Although 
a lack of oversight contributed to the fatal event, the trial demonstrated for the 
first time the life-threatening capability of viral vectors. Another theoretical 
safety risk of viral vectors was subsequently confirmed in an ex vivo retrovirus-
mediated gene therapy trial for X-linked SCID (Hacein-Bey-Abina et al., 2002). 
Several years after treatment, four out of ten children developed leukaemia due 
to insertional mutagenesis of the vector near proto-oncogenes (Hacein-Bey-Abina 
et al., 2008, Hacein-Bey-Abina et al., 2003). In response, the FDA as well as 
regulatory authorities in France, Germany, and Italy halted clinical trials 
investigating retroviral vectors in order for new guidelines relating to risk 
assessment and informed consent to be published (ESGT, 2003). Consensus at the 
European Society of Gene Therapy (ESGT) was that delays in the development of 
effective treatment be avoided and gene therapy clinical trials be resumed in a 
timely manner (ESGT, 2003). Serious adverse events underpinned the relatively 
lengthy period between the first in-human trial in 1990 and the first gene 
therapy approved in the Western world in 2012 (Ylä-Herttuala, 2012): Glybera, 
an adeno-associated virus-based gene therapy to treat the rare inherited 
disorder lipoprotein lipase deficiency. However, Glybera’s approval has since 
been withdrawn due to its high cost, with treatment averaging at $1 million 
making it one of the world’s most expensive therapies (Senior, 2017). As a 
potentially one-off curative treatment, high price tags are expected for gene 
therapies, particularly for rare diseases with small patient populations. Drug 
companies have further defended high costs citing the lifelong expenses of 
alternative treatments as well as payment plans and insurance covers available 
(Stein, 2019). Despite the withdrawal of Glybera, the number of clinical trials 
and approved therapies has since been steadily increasing (Ginn et al., 2018). 
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There are currently five gene therapies approved by the FDA and seven approved 
by the European Medicines Agency (EMA), all utilizing viral vectors (Table 1-5). 
While more than two thirds of gene therapy clinical trials in 2017 used viral 
vectors, ‘naked’ or plasmid DNA was the third most popular vector in 
development (Ginn et al., 2018). The majority of completed trials in 2017 were 
phase I or I/II, although the proportion of late-phase clinical trials has been 
increasing (Ginn et al., 2018). With more than a dozen near-term approvals and 
filings for approvals in 2019, the number of gene therapies approved across the 
US and Europe is anticipated to double within one to two years (ARM, 2020). 
Approximately three quarters of gene therapy trials are investigating its 
application in monogenic disorders and cancer (Ginn et al., 2018), mirroring the 
diseases for which gene therapies are currently approved (Table 1-5). Its 
applicability in other polygenic diseases, such as neurological, infectious, and 
cardiovascular disease, is also under investigation in clinical trials (Ginn et al., 
2018). In addition to a growing understanding of the genetic basis of diseases, 
continuous development of non-viral and viral systems to improve the safety and 
efficacy of treatments underpins recent advances in the field. The rising 
potential of gene therapy is reflected by its considerable financing, which 
reached US$7.6 billion in 2019 (ARM, 2020). The substantial clinical benefit of 
gene therapy and its recent successes have also received considerable media 
attention, and public acceptability for somatic gene therapy has steadily been 
rising over the past ten years (Delhove et al., 2020). Despite these 
advancements, patient deaths in gene therapy clinical trials have still occurred 
recently, highlighting the risks of gene therapy persist (AACR, 2017, Holles and 
Conner, 2020). Nonetheless, authorities continue to voice their support; the FDA 
published six new guidelines relating to gene therapy manufacturing and clinical 
development at the start of 2020 (FDA, 2020). With the field expanding, 
developing safe and effective gene delivery systems remains cornerstone to 
make gene therapy a therapeutic reality for patients.
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Table 1-5 Gene therapies approved by the FDA and EMA. 
Name  Indications 
Approval 
(year) 
General description Vector Approach Warnings 
Imlygic (Talimogene 
laherparepvec) 
Melanoma EMA (’15) 
FDA (’15) 




In vivo Herpetic infection; cellulitis at the injection site; 
impaired healing at the injection site; immune-
mediated events; plasmacytoma at injection site; 
obstructive airway disorder  
Strimvelis 
(Autologous CD34+ 
cells encoding ADA) 
ADA-SCID EMA (’16) Genetically modified autologous 
CD34+ cells transduced to 
express ADA from HSC/HPC 
(CD34+)  
Retroviral vector 
encoding ADA from 
HSC/HPC (CD34+) 





Lymphoma EMA (’17) 
FDA (’17) 
CD19-directed genetically 





Ex vivo Cytokine release syndrome*; neurologic 
toxicities*; hypersensitivity reactions; serious 
infections; prolonged cytopenias; febrile 
neutropenia; hypogammaglobulinemia; 
secondary malignancies; HBV reactivation; 
tumour lysis syndrome 
Kymriah 
(Tisagenlecleucel) 
Lymphoma EMA (’18) 
FDA (’17) 
CD19-directed genetically 





Ex vivo  Cytokine release syndrome*; neurologic 
toxicities*; hypersensitivity reactions; serious 
infections; prolonged cytopenias; febrile 
neutropenia; hypogammaglobulinemia; 








AAV vector-based gene therapy rAAV2 vector 
encoding hRPE65 
In vivo Eye inflammation; permanent decline in visual 
acuity; retinal abnormalities; increased 
intraocular pressure; expansion of intraocular air 









AAV vector-based gene therapy rAAV9 vector 
encoding SMN 
In vivo Acute serious liver injury*; thrombocytopenia; 
elevated troponin-i; immunogenicity; hepatic 
injury 
Zynteglo (Autologous 
CD34+ cells encoding 
β A-T87Q-globin 
gene) 
β-thalassaemia EMA (‘19) Genetically modified autologous 
CD34+ cells that contains HSCs 





Ex vivo Risk of insertional oncogenesis; engraftment 
failure; delayed platelet engraftment 
*black box warning (include full list of abbreviations). Table was created using EMA and FDA ‘Product Information’ reports. EMA, European Medicines Agency; FDA, Food and Drug Administration; ADA, 
adenosine deaminase; ADA-SCID, Adenosine deaminase severe combined immunodeficiency; HSV, herpes simplex virus; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSC, haematopoietic 
stem cells; HPC, haematopoietic progenitor cells; CAR, chimeric antigen receptor; RPE65, retinal pigment epithelium-specific 65 kDa; AAV, adeno-associated virus; SMN1, survival motor neuron 1. 
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1.4 Ultrasound-mediated gene delivery (UMGD) 
1.4.1 Ultrasound (US) 
US is a biomedical imaging tool routinely used in a range of clinical applications 
for diagnostic purposes, with a safety record spanning decades (Torloni et al., 
2009). As one of the most commonly used imaging modalities worldwide, its 
widespread availability and utilisation provides a basis for its acceptance by 
clinicians and patients alike. In physics, US refers to acoustic waves with a 
frequency higher than human hearing, i.e. above 20 kHz. For medical diagnostic 
applications, US waves typically lie in the frequency range of 1-20 MHz. 
Conventional diagnostic US broadly encompasses obstetric and neonatal scanning 
as well as adult and paediatric transcranial, abdominal, peripheral vascular, and 
ocular US. Alongside its diagnostic applications, US has developed as a 
therapeutic modality, which dates back to the 1950s where low frequencies 
were employed in physiotherapy for musculoskeletal disorders (Gam and 
Johannsen, 1995). Although current evidence questions the effectiveness of 
therapeutic US in physiotherapy (Ebadi et al., 2014, Van Den Bekerom et al., 
2011), it has expanded to a range of applications, with therapeutic US now 
approved for cancer treatment, tissue ablation, lithotripsy, thrombus 
dissolution, and bone fracture healing, owing to the biological effects or 
‘bioeffects’ of US (Miller et al., 2012). 
In US imaging, an US probe or ‘transducer’ emits soundwaves which propagate 
through the human body. When these mechanical waves encounter a medium, 
they can either be reflected back to the transducer, scattered in other 
directions, absorbed by the medium, or transmitted on through the medium 
(Figure 1-11). Energy absorbed by the medium can lead to biological effects 
divided into thermal and non-thermal effects. Thermal effects arise from the 
absorption of energy and its conversion to heat, leading to an increase in 
temperature. Non-thermal or ‘mechanical’ effects are further subdivided into 
cavitational and non-cavitational effects. Cavitation refers to the activation of 
gas bodies in an US field and their expansion and contraction in response to 
pressure changes induced by US waves. Non-cavitational effects include acoustic 
radiation force, the force exerted by the momentum of the US waves, and 




Figure 1-11 Diagram illustrating interaction of US with a medium. 
In US imaging, a transducer emits soundwaves which can either be reflected back, scattered in 
other directions, absorbed by the medium, or transmitted through the medium (peach area). 
Due to the potential safety risks associated with thermal and mechanical 
effects, conventional US machines display indices relating to these bioeffects, 
namely the thermal index (TI) and mechanical index (MI), respectively. The TI is 
a ratio of the acoustic power to the power required to increase the temperature 
by 1ºC, a measure of relative risk of temperature rise. The MI is a ratio of the 
peak negative pressure derated by 0.3 dB/cm/MHz (to account for energy loss) 
to the square root of the frequency, a measure that indicates the relative 
potential for cavitation. For diagnostic US, safety standards are maintained by 
limits to the acoustic output of US machines (derated spatial peak temporal 
average intensity (ISPTA) ≤720 mW/cm2 and either MI ≤1.9 or derated spatial peak 
pulse average intensity (ISPPA) ≤190 W/cm2) as well as stringent guidelines 
relating to the TI, MI, and exposure time to promote the principle ‘as low as 
reasonably possible’ (FDA, 2019, BMUS, 2019). Although conventional diagnostic 
US machines can still be used for certain therapeutic purposes, novel US 
machines and probes have arisen alongside the growing field of therapeutic US 
(Song et al., 2012, Wong et al., 2019, Yonetsuji et al., 2013). In addition, 
conventional diagnostic US has undergone its own advancements, such as the 
development of contrast agents, which since their discovery have also emerged 
as therapeutic tools. 
reflection scattering absorption transmission
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1.4.2 Microbubbles (MB) 
The term ‘contrast echocardiography’ arose from the works of Dr Raymond 
Gramiak and Dr Pravin Shah, who reported in 1968 that ‘ultrasonic contrast 
injections’ of indocyanine green and saline produced enhanced echo signals 
during echocardiographic examinations (Gramiak and Shah, 1968), confirming 
observations described by Dr Claude Joyner at the First International Course on 
Diagnostic Ultrasound (Shah, 1993). In 1970, an ex vivo study investigating the 
mechanisms of the US contrast effect attributed the enhanced echo signals to 
the formation of miniature bubbles (Kremkau et al., 1970). Over a decade later, 
research into methods producing small, uniform, and stable MBs was underway 
to develop contrast agents that could be injected intravenously and pass through 
the pulmonary circulation to achieve non-invasive contrast echocardiography 
(Feinstein et al., 1984). Such investigations led to the approval of the first 
commercially available contrast agents: air-filled MBs composed of an albumin 
shell, Albunex, or polymer shell, Levovist and Echovist. Although safe and well-
tolerated (Feinstein et al., 1990, Ries, 1997), all first-generation agents were 
eventually withdrawn, as the air-filled MBs were replaced with more stable MBs. 
There are currently four commercially available MBs approved for diagnostic 
purposes (Table 1-6). MBs are gas-filled spheres encapsulated by a stabilising 
shell, typically consisting of lipids, albumin, or polymers and generally 0.5-10 µm 
in size (Sirsi and Borden, 2009). The core of ‘second generation agents’ comprise 
of a high molecular weight gas, either sulphur hexafluoride or perfluorocarbon, 
making them more resistant to pressure changes and less soluble in blood (Table 
1-6). When exposed to US, MBs expand and contract due to changes in pressure 
as the mechanical sound waves propagate through a medium, which enhances 
their acoustic backscattering. MBs exhibit high echogenicity due to scattering 
from their cross-section and large impedance mismatch between the oscillating 
gas-filled bubbles and the surrounding fluid. This improves the signal to noise 
ratio, and MBs are used clinically in echocardiography and ultrasonography to 
assess blood flow characteristics and delineate tissue borders for improved 
diagnosis in CVD, cancer, and urinary tract conditions (Table 1-6). Alongside a 
growing understanding of the diagnostic value of MBs and their acoustic 
behaviour in an US field, preclinical and clinical research is investigating the 
therapeutic ability of MBs to facilitate drug and gene delivery.
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Table 1-6 MBs currently approved worldwide. 














Phospholipid Perflutren  
(C3F8) 




Ultrasonography of cerebral, extracranial 
carotid, and peripheral arteries and portal veins 
Ultrasonography of liver and breast lesions 

















1.5-2.5 1.5-5.6 x 108 
Optison Echocardiography EU 
Norway 
USA 
Albumin Perflutren  
(C3F8) 
2.5-4.5 5-8 x 108 







2.6 1.2 x 109 
Table was created using the ‘Global Contrast-Enhanced Ultrasound Map’ from icus-society.org and ‘Product Information’ reports. 
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1.4.3 Mechanisms of UMGD 
At the turn of the 20th century, in vitro studies demonstrated the ability of US 
to stimulate plasmid DNA transfection in mammalian cells (Kim et al., 1996, 
Fechheimer et al., 1987). Simultaneously, lithotripsy shock waves were found to 
induce transfection in eukaryotic cells via increasing cell permeability attributed 
to acoustic cavitation (Lauer et al., 1997). Subsequent in vitro UMGD studies 
showed addition of Albunex MBs substantially increased transfection, providing 
evidence that acoustic cavitation and resulting sonoporation were the 
mechanisms underlying UMGD (Bao et al., 1997, Greenleaf et al., 1998). 
Acoustic cavitation is the formation, growth, oscillation, and collapse of bubbles 
in an acoustic field. MBs are referred to as artificial cavitation nuclei as they 
expand and contract in an US field in response to pressure changes known as 
rarefaction and compression, respectively. Stable cavitation refers to the 
oscillation of bubbles around a resonant diameter, which has shown to exert 
pushing and pulling, microstreaming, and shear stress on adjacent cell 
membranes (Van Wamel et al., 2006, Nejad et al., 2016, Meng et al., 2019) 
(Figure 1-12A). Transient or ‘inertial’ cavitation occurs at higher intensities 
whereby bubbles rapidly expand during rarefaction and eventually collapse in 
the compression phase due to the inertia of the surrounding fluid, which has 
shown to produce shockwaves, shear stress, microjets, and free radicals 
(Helfield et al., 2016, Adhikari et al., 2015, Postema et al., 2004, Lawrie et al., 
2000) (Figure 1-12B). 
Stable and inertial cavitation underlie the transient formation of pores in cell 
membranes, a process known as sonoporation. Estimates of pore sizes range 
from several nanometres to micrometres (Yang et al., 2008, Kudo et al., 2009, 
Schlicher et al., 2006). Sonoporation pores display bidirectional transport (Van 
Wamel et al., 2006, Schlicher et al., 2006, Meijering et al., 2009, Fan et al., 
2012) and reseal within seconds (Kudo et al., 2009, Van Wamel et al., 2006), 
attributed to the native wound healing response of cell membranes (Schlicher et 
al., 2006), Ca2+-dependent and -independent mechanisms (Kudo et al., 2009, Fan 
et al., 2012), and lysosomal-exocytosis (Yang et al., 2008). Enhanced membrane 
permeabilization has been implicated as a key mechanism facilitating cellular 
uptake of exogenous agents of varying sizes and structures and has been shown 
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with nanospheres (Mehier-Humbert et al., 2005), fluorescent dyes (Schlicher et 
al., 2006), propidium iodide (Van Wamel et al., 2006), dextrans (Mehier-
Humbert et al., 2005), proteins (Schlicher et al., 2006), and plasmid DNA 
(Duvshani-Eshet et al., 2006), highlighting a prominent role for cavitation in 
intracellular drug and gene delivery. Several other mechanisms arising from US 
and MB bioeffects implicated in the cellular delivery of foreign molecules 
include rearrangement of the cytoskeleton (Juffermans et al., 2009, Wang et al., 
2018b), stimulation of endocytic pathways (Meijering et al., 2009), and 
disruption of the endothelial monolayer integrity (Juffermans et al., 2009), 
which have also been proposed to contribute to nuclear and intercellular 
transport. Although an understanding of the mechanisms governing UMGD 
remains incomplete, preclinical research underpins the potential of this delivery 
system as a strategy in gene therapy. 
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Figure 1-12 Diagram of proposed mechanisms of cell membrane sonoporation induced by 
(A) stable cavitation and (B) inertial cavitation.  
MBs expand and contract in an US field due to rarefaction and compression of the medium through 
which US waves propagate. (A) Stable cavitation: MBs oscillate around a resonant diameter 
producing pulling/pushing mechanisms, shear stress, and microstreaming. (B) Inertial cavitation: 
MBs rapidly grow and then collapse during compression due to the inertial energy of surrounding 
fluid producing shock waves, shear stress, microjets, and sonochemical effects.   
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1.4.4 UMGD in development 
Due to the safety risks associated with viral-based systems, research efforts have 
primarily focused on employing non-viral vectors in UMGD. Several in vivo 
studies have reported comparable transfer efficiencies between plasmid-based 
UMGD and other non-viral gene therapy methods, such as HVJ liposomes (Koike 
et al., 2005), lipofection (Pislaru et al., 2003), and electroporation (Sheyn et al., 
2008). Although viral gene therapies have shown greater transfer efficiencies 
compared with non-viral UMGD, viral vectors exhibit less specificity due to 
transgene expression in the liver (Pislaru et al., 2003, Chen et al., 2003). 
Another advantage of UMGD when utilised in conjunction with non-viral vectors 
is a low risk of toxicity, which has consistently been demonstrated by a lack of 
adverse events in preclinical studies investigating different tissues, MBs, and US 
parameters (Newman and Bettinger, 2007). Several UMGD studies that reported 
abnormalities in functional, histological, and biochemical parameters found 
these were transient in nature (Guo et al., 2004, Tsunoda et al., 2005, Wang et 
al., 2014a). Other studies reporting local histological damage, such as 
inflammation, haemorrhage, and necrosis, found these side-effects were related 
to MB concentration (Koike et al., 2005), US exposure time (Ishida et al., 2016), 
and acoustic output (Ishida et al., 2016, Miao et al., 2005), which could be 
prevented by modulating these factors while still maintaining significant gene 
transfer. The growing potential of UMGD as a non-viral and non-invasive delivery 
system is further supported by application of the method to large animals. 
Proof-of-concept studies have demonstrated non-viral reporter gene transfer 
with minimal tissue damage in porcine and canine livers (Tran et al., 2019, 
Noble-Vranish et al., 2018, Noble et al., 2013) and hearts (Liu et al., 2015). 
Moreover, UMGD of therapeutic genes has been shown in the hearts of canine 
models of myocardial infarction (Yuan et al., 2012, Cui et al., 2017), in 
pancreatic islets of a baboon model of diabetes (Chen et al., 2014), and in the 
placenta of a baboon model of insufficient uterine artery remodelling 
(Babischkin et al., 2019). Nonetheless, proof-of-concept studies remain 
cornerstone experiments for demonstrating safety and specificity to support 
development of UMGD as an effective and clinically translatable gene therapy 
system.  
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1.5 Hypotheses and aims 
1.5.1 Hypotheses 
• UMGD stimulates tissue-specific gene transfer in vivo, representing a non-
viral and non-invasive gene delivery system for targeting the placenta.  
• Specific miRNAs are consistently dysregulated in placentas of patients 
with PE and show the same pattern of expression in a rat model of SPE.  
• Dysregulated placental miRNAs in PE impact gene expression and 
functional properties of trophoblast cells, therefore representing 
potential therapeutic targets for gene therapy applications. 
1.5.2 Aims 
• To optimise an in vivo UMGD protocol to demonstrate tissue-specific gene 
transfer of a reporter gene in a surrogate organ in rodents. 
• To apply the in vivo UMGD protocol to pregnant rodents to demonstrate 
placental-specific gene transfer of an expression vector. 
• To identify dysregulated placental miRNAs that are consistently 
dysregulated in patients with PE as well as placental miRNAs differentially 
expressed in a rat model of SPE and compare their expression patterns.  
• To Investigate the relationship between a candidate dysregulated 
placental miRNA and its predicted gene targets and functional effects in 




Chapter 2 General materials and methods 
This chapter details the general materials and methods utilised in subsequent 
results chapters. Any chapter-specific materials and methods and/or any 





2.1 General laboratory techniques 
2.1.1 Luria-Bertani medium 
For Luria-Bertani (LB) medium, 10 g tryptone, 5 g yeast extract, and 10 g of NaCl 
were dissolved in 950 mL dH2O. For low-salt LB medium, 10 g tryptone, 5 g yeast 
extract, and 5 g of NaCl were dissolved in 950 mL dH2O. The pH was adjusted to 
8 with 1 M NaOH, and the volume was adjusted to 1 L with dH2O. LB medium was 
sterilized by autoclaving. 
2.1.2 Plasmid DNA purification 
2.1.2.1 Transformation of plasmid DNA into competent bacteria 
Plasmid DNA was transformed into MAX Efficiency™ DH5α™ Competent Cells 
(ThermoFisher, Paisley, UK). Competent cells were thawed on wet ice, and 50 
µL were aliquoted into chilled 1.5 mL microcentrifuge tubes. Plasmid DNA (50 
pg) was added to the competent cells, and the tubes were gently tapped to mix. 
The transformation mixture was incubated on ice for 30 min, heat-shocked for 
45 s in a 42ºC water bath, and then placed on ice for 2 min. Room temperature 
S.O.C. Medium (450 µL) was added to the mixture, and the mixture was placed 
in a shaking incubator for 20 min at 37 ºC with shaking at 225 RPM. Transformed 
cells (100 µL) were spread on 90 mm plates containing Luria Agar (Formedium, 
Norfolk, UK) with 100 µg/mL ampicillin or Hygromycin B (Invivogen, San Diego, 
USA), and plates were incubated overnight at 37 ºC. The following morning, a 
single colony was used to inoculate a 10 mL overnight starter culture, from 
which a glycerol stock was prepared. 
2.1.2.2 Glycerol stocks  
Glycerol stocks of transformed bacterial culture were prepared as a long-term 
stock. To obtain 50% glycerol, 100% glycerol was diluted 1:1 with dH2O and then 
sterilised by autoclaving. In a cryovial, 1 mL of overnight starter culture was 
added to 1 mL 50% glycerol and gently mixed by pipetting up and down. Glycerol 
stocks were stored at -80 ºC and replenished every 12 months. 
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2.1.2.3 Large-scale plasmid DNA purification by centrifugation 
A single bacterial colony or swab from a glycerol stock of pVIVO2-GFP/LacZ was 
used to inoculate a 10 mL LB medium starter culture with 100 µg/mL Hygromycin 
B. Starter culture was incubated overnight at 37C with shaking at 200 RPM. The 
following morning, starter culture was diluted 1:1000 into 1 L or 800 mL 
selective LB medium culture, which was incubated for 12 h at 37C with shaking 
at 200 RPM. pVIVO2-GFP/LacZ was purified using QIAGEN Plasmid Mega Kit 
(QIAGEN, Hilden, Germany), according to the April 2012 QIAGEN Plasmid 
Purification Handbook. Bacterial cells in selective LB medium culture were 
harvested by centrifugation at 5000 RPM for 15 min at 4C and supernatant was 
discarded. Bacterial cells were resuspended in 50 mL Buffer P1, containing 100 
g/mL RNase A and Lyse Blue diluted 1:1000. For alkaline lysis, 50 mL Buffer P2 
was added and mixed by inverting the lysate 6 times, and the cell suspension 
was incubated at room temperature for 5 min. For precipitation of plasmid DNA, 
50 mL prechilled Buffer P3 was added and mixed by inverting 6 times, and the 
cell suspension was incubated on ice for 30 min. To collect plasmid DNA, the 
suspension was centrifuged at 10000 RPM for 30 min at 4C, and the supernatant 
was collected in a 250 mL polypropylene centrifuge tube. The supernatant was 
centrifuged at 10000 RPM for 15 min at 4C, and the supernatant was collected 
in a clean 250 mL centrifuge tube. An optional 120 µL sample of cleared lysate 
was collected saved for an analytical gel to assess growth and lysis conditions. A 
QIAGEN-tip 2500 was equilibrated by adding 35 mL Buffer QBT to the column, 
which was allowed to empty by gravity flow. The supernatant was loaded onto 
the QIAGEN-tip 2500 and passed through the column by gravity flow. An optional 
120 µL sample of the flow-through fraction was collected and saved for an 
analytical gel to assess efficiency of column loading. To remove any 
contaminants, the QIAGEN-tip 2500 was washed with 200 mL Buffer QC. Two 
optional 120 µL samples from the first and second half of the wash fractions 
were collected and saved for an analytical gel to assess plasmid DNA binding and 
removal of RNA. Plasmid DNA was eluted from the column by adding 35 mL 
Buffer QF to the QIAGEN-tip 2500. An optional 22 µL sample of the elute was 
collected and saved for an analytical gel to assess contamination. Eluted plasmid 
DNA was precipitated by adding 0.7 times the volume of room temperature 
isopropanol (Sigma Aldrich, Steinheim, Germany) and centrifuging at 14000 RPM 
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for 30 min at 4C, and supernatant was discarded. The plasmid DNA pellet was 
washed with 7 mL room temperature 70% ETOH (Sigma Aldrich, Steinheim, 
Germany) and centrifuged at 14000 RPM for 10 min, and supernatant was 
discarded. The plasmid DNA pellet was air-dried for 10-20 min and resuspended 
in 320 µL nuclease free water (NFW). Plasmid DNA quality and concentration 
were measured using NanoDrop ND-1000 Spectrophotometer (ThermoFisher, 
Paisley, UK), with an A260/A280 ratio of ~1.8 accepted as ‘pure’ DNA. Plasmid 
DNA concentration was adjusted to 4 µg/µL with NFW for in vivo use. 
2.1.2.4 Large-scale plasmid DNA purification by filtration 
A single bacterial colony or swab from a glycerol stock of luciferase plasmid 
vector (pGL3 or pGL4.13) was used to inoculate a 10 mL LB medium starter 
culture with 100 µg/mL ampicillin. Starter culture was incubated overnight at 
37C with shaking at 200 RPM. The following morning, starter culture was diluted 
1:1000 into 1 L selective LB medium culture, which was incubated for 12 h at 
37C with shaking at 200 RPM.  
pGL3 was purified using QIAfilter Plasmid Mega Kit (QIAGEN, Hilden, Germany), 
according to the April 2012 QIAGEN Plasmid Purification Handbook. Bacterial 
cells in selective LB medium culture were harvested by centrifugation at 5000 
RPM for 15 min at 4C and supernatant was discarded. Bacterial cells were 
resuspended in 50 mL Buffer P1, containing 100 µg/mL RNase A and Lyse Blue 
diluted 1:1000. For alkaline lysis, 50 mL Buffer P2 was added and mixed by 
inverting the lysate 6 times. The lysate was poured onto the QIAfilter Mega-Giga 
Catridge and incubated at room temperature for 10 min to allow a precipitate 
containing proteins, genomic DNA, and detergent to form. The lysate was then 
pulled through by a vacuum source. Buffer FWB2 (50 mL) was added to the 
QIAfilter Mega-Giga Catridge, and the precipitate was gently stirred with a 
sterile spatula. The remaining lysate was then pulled through by a vacuum 
source. An optional 120 µL sample of cleared lysate was collected saved for an 
analytical gel to assess growth and lysis conditions. A QIAGEN-tip 2500 was 
equilibrated by adding 35 mL Buffer QBT to the column, which was allowed to 
empty by gravity flow. The cleared lysate was loaded onto the QIAGEN-tip 2500 
and passed through the column by gravity flow. An optional 120 µL sample of the 
flow-through fraction was collected and saved for an analytical gel to asses 
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efficiency of column loading. To remove any contaminants, the QIAGEN-tip 2500 
was washed with 200 mL Buffer QC. An optional 120 µL sample of the wash 
fraction was collected and saved for an analytical gel to assess plasmid DNA 
binding and removal of RNA. Plasmid DNA was eluted from the column by adding 
35 mL Buffer QF to the QIAGEN-tip 2500. An optional 22 µL sample of the elute 
was collected and saved for an analytical gel to assess contamination. Eluted 
plasmid DNA was precipitated by adding 0.7 times the volume of room 
temperature isopropanol (Sigma Aldrich, Steinheim, Germany) and centrifuging 
at 14000 RPM for 30 min at 4C, and supernatant was discarded. The plasmid 
DNA pellet was washed with 7 mL room temperature 70% ETOH (Sigma Aldrich, 
Steinheim, Germany) and centrifuged at 14000 RPM for 10 min, and supernatant 
was discarded. The plasmid DNA pellet was air-dried for 10-20 min and 
resuspended in 320 µL NFW. 
pGL4.13 was purified using Invitrogen™ PureLink™ HiPure Expi Plasmid Megaprep 
Kit (ThermoFisher, Vilnus, Lithuania), according to the Revision A.0 User Guide. 
Bacterial cells were resuspended in 50 mL Resuspension Buffer containing 100 
µg/mL RNase A. For alkaline lysis, 50 mL Lysis Buffer was added and mixed by 
inverting the lysate 6 times, and the suspension was incubated for 5 min at room 
temperature. For precipitation of plasmid DNA, 50 mL Precipitation Buffer was 
added and mixed by inverting 6 times. The lysate was poured onto the Megaprep 
Lysate Filtration Cartridge and incubated at room temperature for 2 min to 
allow precipitate to float. The lysate was then pulled through by a vacuum 
source. Wash buffer (50 mL) was added to the Megaprep Lysate Filtration 
Cartridge, and the precipitate was gently stirred with a sterile spatula. The 
remaining lysate was then pulled through by a vacuum source. An optional 100 
µL sample of cleared lysate was collected saved for an analytical gel to assess 
growth and lysis conditions. The Megaprep DNA Binding Cartridge was 
equilibrated by adding 100 mL Equilibration Buffer, which was pulled through by 
a vacuum source and discarded. The cleared lysate was loaded onto the 
Megaprep DNA Binding Cartridge, which was pulled through by a vacuum source. 
An optional 100 µL sample of the flow-through fraction was collected and saved 
for an analytical gel to assess efficiency of column loading. To remove any 
contaminants, the cartridge was washed twice with 175 mL wash buffer by 
pulling through the liquid with a vacuum source. An optional 100 µL sample of 
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the final wash fraction was collected and saved for an analytical gel to assess 
plasmid DNA binding and removal of RNA. The Megaprep DNA Binding Cartridge 
was attached to onto a clean, sterile Stericup Receiver flask (Merck, Dorset, 
UK). Plasmid DNA was eluted by adding 50 mL Elution Buffer and applying a soft 
vacuum (-200 to -300 mbar) for 30 s. After letting the cartridge stand for 1 min 
without agitation, the remaining plasmid DNA was eluted. An optional 100 µL 
sample of the elute was collected and saved for an analytical gel to assess 
contamination. Eluted plasmid DNA was precipitated by adding 0.7 times the 
volume of room temperature isopropanol (Sigma Aldrich, Steinheim, Germany) 
and centrifuging at 13000 RPM for 30 min at 4C, and supernatant was discarded. 
The plasmid DNA pellet was washed with 20 mL room temperature 70% ETOH 
(Sigma Aldrich, Steinheim, Germany) and centrifuged at 13000 RPM for 10 min, 
and supernatant was discarded. The plasmid DNA pellet was air-dried for 10-20 
min and resuspended in 320 µL 1X Tris-EDTA (TE) buffer. 
2.1.2.5 Precipitation of samples from plasmid DNA purification 
Samples from stages of the plasmid DNA purification procedure, including 
cleared lysates, flow-through fractions, wash fractions, and elutes, were 
collected to assess efficiency of the purification procedure. An equal volume of 
isopropanol (Sigma Aldrich, Steinheim, Germany) was added to samples. Samples 
were centrifuged for 30 min at 16 RPM at 4°C, and supernatant was discarded. 
Samples were washed with 500 µL of 70% ETOH (Sigma Aldrich, Steinheim, 
Germany) and centrifuged for 10 min at 16 RPM at 4°C, and supernatant was 
discarded. After air-drying for 10 min, samples were resuspended in 10 µL 1X TE 
buffer. 
2.1.2.6 Restriction digest 
Restriction digest of plasmid DNA was performed with XhoI (New England 
Biolabs, Dublin, Ireland) and BglII (New England Biolabs, Dublin, Ireland) 
restriction enzymes in a 30 μL reaction, using 250 ng of plasmid DNA. Reagents 
were incubated for 1 h and 30 min in a 37°C water bath, pulsed for several s, 
and incubated on ice prior to gel loading. Products were run on a 0.8% agarose 
gel at 110 mV. The reagents and volumes used in the reaction were as following: 
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Reagent Volume (µL) 
Plasmid DNA (500 ng/µL) 0.5 
10X NE Buffer 3.0 
XhoI (20000 U/mL) 2.0 
NFW 24.5 
 
Reagent Volume (µL) 
Plasmid DNA (500 ng/µL) 0.5 
10X NE Buffer 3.0 
BglII (10000 U/mL) 1.0 
NFW 25.5 
 
2.1.2.7 Plasmid DNA quality and concentration 
Plasmid DNA quality and concentration were measured using NanoDrop ND-
1000 Spectrophotometer (ThermoFisher, Paisley, UK), with an A260/A280 ratio 
of ~1.8 accepted as ‘pure’ DNA. Plasmid DNA concentration was adjusted to 4 
µg/µL with NFW or 1X TE when prepared for in vivo use. 
2.1.3 Agarose gel electrophoresis 
Visualisation and sizing of DNA/RNA molecules were performed on 0.8-1.5% 
agarose gels. Agarose (Invitrogen, Carlsbad, USA) was dissolved in 100 mL 1X 
Tris-Borate EDTA (TBE) by heating in microwave for 3-5 min and then left to cool 
for 15 min. Once the agarose was molten, 1.5 µL of 10 mg/mL ethidium bromide 
solution (Sigma, Dorset, UK) was added, and molten agarose was poured into a 
gel tray and left for 30 min to solidify with a well comb in place. Gels were 
placed in a BioRad electrophoresis tank (BioRad, Hampstead, UK) containing 1X 
TBE. Samples were loaded with 6X blue/orange loading dye (Promega, Madison, 
USA). 1 kb DNA ladder (Promega, Madison, USA) and 100 bp DNA ladder (New 
England Biolabs, Massachusetts, USA) were used to size samples. Gels were run 
at 110 mV (BioRad Powerpac 300, Hamsptead, UK) and visualized by 




2.1.4 RNA extraction 
Total RNA was extracted from tissue and cells using the miRNeasy Mini Kit 
(QIAGEN, Manchester, UK). Placental samples from the SPE rat model (50 mg) 
were homogenised in 700 µL QIAzol Lysis Reagent four times for 30 s at 25 kHz 
using Polytron PT2100 Benchtop Homogeniser (KINEMATICA, Luzern, Switzerland) 
with 3 mm dispersing aggregate. The dispersing aggregate was cleaned between 
each tissue sample by washing the aggregate three times in NFW for 30 s. All 
other tissue samples (50 mg) were homogenised in 700 µL QIAzol Lysis Reagent 
four times for 30 s at 25 kHz using TissueLyser (QIAGEN, Haan, Germany) with 
stainless steel beads. Cells were lysed directly in cell-culture dishes by adding 
700 µL QIAzol Lysis Reagent. The lysate was transferred to a microcentrifuge 
tube and vortexed for 1 min. Tissue and cell homogenates were either stored at 
-80ºC, or RNA extractions were immediately performed. 
Homogenates were placed at room temperature for 5 min. Chloroform (140 µL) 
was added and tubes were shaken vigorously for 15 s. Tubes were placed for a 
further 2-3 min at room temperature. Samples were centrifuged at 12000 x g for 
15 min at 4ºC. All subsequent centrifuges were performed at 20ºC. The upper 
aqueous phase containing RNA (350 µL) was transferred to a tube containing 525 
µL 100% ETOH. The sample was mixed thoroughly by pipetting up and down 
several times, and 700 µL was pipetted into a RNeasy Mini Spin Column in a 2 mL 
collection tube. Samples were centrifuged at 11000 x g for 15 s and flow-through 
was discarded; this was repeated using the remainder of the sample. An optional 
on-column DNase digestion was performed, or extractions were performed as 
following. Buffer RWT (700 µL) was added to the RNeasy Mini Spin Column to 
wash the column. Samples were centrifuged at 11000 x g for 15 s, and flow-
through was discarded. Buffer RPE (500 µL) was added to the RNeasy Mini Spin 
Column to wash the column. Samples were centrifuged at 11000 x g for 15 s, and 
flow-through was discarded. Another 500 µL of Buffer RPE was added to dry the 
column, and samples were centrifuged at 11000 x g for 2 min. The RNeasy Mini 
Spin Column was placed in a new 2 mL collection tube and 40 µL of NFW was 
added. To elute the RNA, the samples were centrifuged at 11000 x g for 1 min. 
RNA yield was measured using NanoDrop ND-1000 Spectrophotometer 
(ThermoFisher, Paisley, UK) as detailed in section 2.1.4.1. If the yield was >30 
µg, a further 40 µL of NFW was added to the RNeasy Mini Spin Column. Samples 
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were centrifuged again at 11000 x g for 1 min to collect the elute in the same 
collection tube. Samples were stored at -80ºC until use. 
2.1.4.1 Nucleic acid concentration and quality 
RNA quality and concentration were measured using NanoDrop ND-1000 
Spectrophotometer (ThermoFisher, Paisley, UK), with an A260/A280 ratio of ~2.0 
accepted as ‘pure’ RNA.  
2.1.4.2 Agilent Bioanalyzer 
RNA quality and concentration were measured by an external quality control 
service offered by Glasgow Polyomics using the Agilent 2100 Bioanalyzer. 
Samples were analysed using the Eukaryote Total RNA Nano assay, providing the 
concentration of RNA and an objective measurement of RNA quality known as 
the RNA integrity number (RIN). Following electrophoretic separation of RNA 
samples, RNA integrity was determined by analysing the entire electrophoretic 
trace and ratio of the 18S and 28S ribosomal RNA. The RIN scale ranges from 1 
(degraded RNA) to 10 (intact RNA). All RNA samples with a RIN >8 were 
accepted. 
2.2 SYBR and TaqMan RT-qPCR 
2.2.1 Reverse transcription 
Reverse transcription was performed for synthesis of cDNA, the first step in two-
step RT-qPCR. TaqMan™ Reverse Transcription was performed for detection and 
quantification of mRNA expression with SYBR and TaqMan qPCR and TaqMan™ 
MicroRNA Reverse Transcription was performed for detection and quantification 
of miRNA expression with TaqMan qPCR. 
2.2.1.1 TaqMan reverse transcription 
cDNA synthesis for SYBR and TaqMan RT-qPCR was performed with Applied 
Biosystems™ TaqMan™ Reverse Transcription Reagents (ThermoFisher, Carlsbad, 
USA) by reverse transcription of RNA templates. Reverse transcription reactions 
were set-up as 20 μL reactions with 1000 ng of RNA template in 96-well PCR 
plates (Starlab, Milton Keynes, UK) on ice. Controls included no template 
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controls (NFW only and mastermix (MM) only) to monitor false positive results 
and no reverse transcriptase (RT) controls (no MultiScribe™ Reverse 
Transcriptase) to monitor genomic DNA contamination. Plates were covered with 
adhesive PCR plate seals (ThermoFisher, Paisley, UK) and centrifuged for 1 min 
at 1000 x g. Thermal cycling for reverse transcription was performed on MJ 
research Tetrad PTC-225 Thermal Cycler (MJ research, Ramsey, USA). The 
reagents used and reaction conditions were as following: 
Template Volume (µL) (SYBR) Volume (µL) (TaqMan) 
RNA up to 1000 ng   
NFW adjust to 7.7 adjust to 9.6 
 
Mastermix reagents Volume (µL) (SYBR) Volume (µL) (TaqMan) 
10X RT Buffer 2.0 2.0 
MgCl2 (25 mM) 4.4 1.4 
dNTPs (2.5 mM each) 4.0 4.0 
Random Hexamers (50 µM) 1.0 1.0 
RNase Inhibitor (20 U/µL)  0.4 1.0 
MultiScribe™ Reverse 
Transcriptase (50 U/µL) 
0.5 1.0 
 
Thermocycling conditions   
25°C for 10 min   
48°C for 30 min (SYBR) and 37°C for 30 min (TaqMan)   
95°C for 5 min   
 
2.2.1.2 TaqMan miRNA reverse transcription 
cDNA synthesis for detection and quantification of miRNA expression with 
TaqMan RT-qPCR was performed with Applied Biosystems™ TaqMan™ MicroRNA 
Reverse Transcription Reagents (ThermoFisher, Vilnius, Lithuania) by reverse 
transcription of RNA templates. Up to 10 ng of miRNA was reverse transcribed 
using 5X miRNA-specific stem-loop primers supplied with Applied Biosystems™ 
TaqMan™ MicroRNA Assays in a Tetrad PTC-225 Thermal Cycler (MJ research, 
Ramsey, USA). Reverse transcription reactions were set-up as 15 μL reactions in 
96-well PCR plates (Starlab, Milton Keynes, UK) on ice. A no template control 
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was included for every mastermix with a 5X miRNA-specific stem-loop primer to 
monitor contamination. Plates were covered with adhesive PCR plate seals 
(ThermoFisher, Paisley, UK) and centrifuged for 1 min at 1000 x g. Thermal 
cycling for reverse transcription was performed on MJ research Tetrad PTC-225 
Thermal Cycler (MJ research, Ramsey, USA). The reagents used and reaction 
conditions were as following: 
Template Volume (µL)  
RNA up to 10 ng   
NFW adjust to 5.00  
 
Mastermix reagents Volume (µL) 
10X RT Buffer 1.50 
100 mM dNTPs 0.15 
RNase Inhibitor (20 U/ µL)  0.19 
MultiScribe™ Reverse 
Transcriptase (50 U/ µL) 
1.00 
5X RT primer 3.00 
 
Thermocycling conditions   
16°C for 30 min   
42°C for 30 min   
85°C for 5 min   
 
2.2.2 qPCR 
2.2.2.1 SYBR qPCR for mRNA expression 
Amplification of cDNA template was performed with Power SYBR™ Green PCR 
Master Mix (ThermoFisher, Warrington, UK). All PCR reactions were run in 
singleplex and used custom designed PCR primers (Eurofins Genomics, 
Ebersberg, Germany) to determine mRNA expression of the β-actin housekeeping 
gene and gene of interest (GOI). All PCR reactions were set-up as 12.5 μL 
reactions in MicroAmp™ Optical 384-well reaction plates (ThermoFisher, Paisley, 
UK) on ice and were performed in triplicate. Controls included controls from the 
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cDNA plate and no-template controls (NFW only and MM only). Plates were 
covered with MicroAmp™ Optical Adhesive Film (ThermoFisher, Paisley, UK) and 
centrifuged for 1 min at 1000 x g. Thermal cycling for qRT-PCR was performed 
with QuantStudio 12K Flex Real-Time PCR System using standard SYBR qRT-PCR 
cycling conditions. A melt curve stage was performed to detect non-specific 
amplification. The reagents used and reaction conditions were as following: 
Mastermix reagents Volume (µL) 
2X Power SYBR™ Green PCR Master Mix 6.35 
Forward primer (500 nM) 0.50 
Reverse primer (500 nM)  0.50 
NFW  2.65 
cDNA template  2.50 
 
Thermocycling conditions   
Hold stage:   
50°C for 2 min    
95°C for 10 min   
PCR stage:    
95°C for 15 s and 60°C for 1 min (40 cycles)   
Melt curve stage:   
95°C for 15 s   
60°C for 1 min   
95°C for 15 s   
 
2.2.2.2 TaqMan qPCR for mRNA expression 
Amplification of cDNA template was performed with TaqMan™ Universal Master 
Mix II, No UNG (ThermoFisher, Carlsbad, USA). All PCR reactions were run in 
duplex (VIC-labelled housekeeping and FAM-labelled GOI probe) and used 
Applied Biosystems™ 20X gene expression assays to determine mRNA expression. 
All PCR reactions were set-up as 5 μL reactions in MicroAmp™ Optical 384-well 
reaction plates (ThermoFisher, Paisley, UK) on ice and were performed in 
triplicate. Controls included controls from the cDNA plate and no-template 
controls (NFW only and MM only). Plates were covered with MicroAmp™ Optical 
Adhesive Film (ThermoFisher, Paisley, UK) and centrifuged for 1 min at 1000 x g. 
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Thermal cycling for TaqMan RT-qPCR was performed with QuantStudio 12K Flex 
Real-Time PCR System using standard TaqMan RT-qPCR thermal cycling 
conditions. The reagents used and reactions conditions were as following: 
Mastermix reagents Volume (µL) 
2X TaqMan Universal Master Mix 2.00 
20X GOI expression assay 0.25 
20x housekeeper expression assay  0.25 
cDNA template  2.00 
 
2.2.2.3 TaqMan qPCR for miRNA expression 
Amplification of cDNA template was performed with TaqMan™ Universal Master 
Mix II, No UNG (ThermoFisher, Carlsbad, USA). All PCR reactions were run in 
singleplex and used 20X TM probes supplied with Applied Biosystems™ TaqMan™ 
MicroRNA Assays. All PCR reactions were set-up as 10 μL reactions in MicroAmp™ 
Optical 384-well reaction plates (ThermoFisher, Paisley, UK) on ice and were 
performed in triplicate. Controls included controls from the cDNA plate and no-
template controls (NFW only and MM only). Plates were covered with MicroAmp™ 
Optical Adhesive Film (ThermoFisher, Paisley, UK) and centrifuged for 1 min at 
1000 x g. Thermal cycling for TaqMan qPCR was performed with QuantStudio 12K 
Flex Real-Time PCR System using standard TaqMan qPCR thermal cycling 
conditions. The reagents used and reactions conditions were as following: 
Mastermix reagents Volume (µL) 
2X TaqMan Universal Master Mix 5.00 
20X TM probe 0.50 
NFW  3.84 
cDNA template  0.66 
 
2.2.3 Analysis of RT-qPCR 
Gene expression was analysed using cycle threshold (Ct). Ct is the cycle number 
at which fluorescence from amplification of a PCR product crosses a threshold, 
indicating detection of fluorescence greater than background signal. Ct is 
therefore a relative measure of concentration of a PCR product. Ct values were 
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compared between samples and controls, after normalizing Ct values of a GOI to 
a housekeeping gene. Ct values from the GOI and housekeeping gene from 
samples and controls were extrapolated from the Real-Time PCR system and 
exported into Microsoft Excel for data analysis. For both samples and controls, 
the GOI was normalised to the housekeeping gene to obtain Ct as follows: 
Ct = Ct(GOI) – Ct(housekeeping) 
For each experiment performed in triplicate, the average Ct was calculated for 
samples and controls. For statistical analysis, the average Ct of samples was 
compared to controls.  
2.3 In vivo procedures 
All animal work was performed at the University of Glasgow in accordance with 
the United Kingdom Animals (Scientific Procedures) Act 1986, with all 
procedures approved by the Home Office under the Project Licence 70/9021 
held by Dr Delyth Graham. All procedures were performed at the in vivo facility 
at the BHF Glasgow Cardiovascular Research Centre between 0900 and 1700 h 
i.e., during ‘lights on’ period. Stroke-prone spontaneously hypertensive (SHRSP) 
and Wistar Kyoto (WKY) rats used came from established inbred colonies at the 
University of Glasgow, maintained in-house since 1991 by strain-specific brother-
sister mating. ICR (CD-1) outbred mice used were purchased from Envigo. All 
animals purchased externally were given a one-week acclimatisation period prior 
to any procedure. All rats and mice were housed in a temperature-controlled 
environment (21°C±3°C) and controlled 12-h light/dark conditions, with access 
to water and standard diet (rat and mouse No.1 maintenance diet, Special Diet 
Services). Rats and mice from the same strain and sex were housed together in 
individually ventilated cages with a maximum of five animals per cage. Corn cob 
bedding and sizzle nests were used as bedding. Non-aversive handling techniques 
were used when transferring animals between cages or equipment e.g., use of 
handling tubes. Animals were monitored daily for general welfare indicators, 
namely appearance, body functions (food and water intake) and behaviour 
(posture, social interaction and gait). 
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2.3.1 Plasmid DNA and MB suspension 
UMGD studies utilised the commercially available contrast agent, SonoVue 
(Bracco International B.V., Amsterdam, Netherlands). A new kit of SonoVue, 
sulphur hexafluoride MBs stabilised by a phospholipid shell, was prepared 
immediately prior to commencing a UMGD study. The MB dispersion was 
prepared at double the concentration by discarding half the volume (2.5 mL) of 
NaCl 0.9% w/v (saline) solution. The remaining half was injected into the vial to 
reconstitute the lyophilised powder content by vigorously shaking the MB 
dispersion. A plasmid DNA and MB suspension was prepared on an individual basis 
for each animal. Prior to preparing the suspension for each animal, the MB 
dispersion was reconstituted by inverting the vial several times until cloudy. MB 
dispersion (500 µL) was collected with a 19 G needle (Terumo, Leuven, Belgium) 
in a 1 mL syringe and injected into a sterile microcentrifuge tube. The required 
volume of MB dispersion was then pipetted in a clean, sterile microcentrifuge 
tube. The required volume of 4 µg/µL plasmid DNA was added, making up the 
injectable plasmid DNA and MB suspension for one animal. 
2.3.2 Anaesthetic procedure 
All animals were anaesthetised prior to in vivo procedures in an induction 
chamber filled with 5% isoflurane and supplied with 1.5 L/min medical oxygen 
flow. Once anaesthesia was confirmed in animals by tail pinch, their nose and 
mouth were positioned in an anaesthetic mask. Animals were maintained on 
1.5% isoflurane on a homeothermic mat, with adjustments made when required. 
At the end of all in vivo procedures, animals were monitored until they regained 
consciousness. 
2.3.3 UMGD procedure 
UMGD treatment animals underwent the same principal in vivo gene delivery 
procedure. For each UMGD study, protocol amendments and details of the 




2.3.3.1 Hair removal 
For UMGD to the left kidney, rodents were placed in a supine position and hair 
was removed by shaving and depilatory cream across an area (~4 cm x 4.5 cm for 
rats or ~2 cm x 2.5 cm for mice) over the left upper quadrant below the ribcage, 
marking the area overlying the left kidney (Figure 2-1). An area of 1.5 cm x 2.5 
cm over the left inguinal region was also shaved, marking the area overlying the 
left femoral vein (Figure 2-1). For UMGD to the heart, rodents were placed in a 
lateral recumbent position, and hair was removed by shaving and depilatory 
cream across an area of ~2 cm x 2.5 cm over the chest, marking the area 
overlying the heart (Figure 2-1). For UMGD to the placenta, mice were placed in 
a supine position, and hair was removed by shaving and depilatory cream across 
an area of ~4 cm x 4.5 cm over the left middle and lower quadrant and pubic 
region, marking the area overlying the left uterine horn (Figure 2-1). For UMGD 
to the heart and placenta, a glove filled with warm water was placed on the tail 
to dilate the tail vein. 
2.3.3.2 UMGD treatment 
The ACUSON Sequoia 512 ultrasound system (Siemens, Surrey, UK) and 15L8 
linear array ultrasound transducer was used for all US scans. B-mode output was 
used for organ location, with an input frequency of 14 MHz, MI of 0.6, and focal 
depth of 10 mm. The transducer was placed on the shaved area overlying the 
target organ to obtain a longitudinal view of the left kidney, parasternal long 
axis view of the heart, or view of the foetoplacental unit (Figure 2-1). Once the 
organ was located and the appropriate view obtained, several images of the 
organ were taken using the image store function. The probe was then held in a 
fixed position, and output was set to harmonic imaging, with an input frequency 
of 7 MHz (H14 MHz), MI of 1.8, and focal depth of 10 mm. The output was either 
maintained (kept on) or frozen using the freeze function. 
For UMGD to the left kidney in rats, a superficial incision was made to expose 
the left femoral vein prior to administer the plasmid DNA and MB suspension. In 
all UMGD studies, the plasmid DNA and MB suspension was stirred with a 25 G 
needle (Terumo, Leuven, Belgium) and drawn into a 1 mL syringe. For UMGD 
studies targeting the left kidney, the suspension was slowly administered over a 
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period of 5-60 s via the left femoral vein. For UMGD studies targeting the heart 
and placenta, the suspension was slowly administered over a period of 5-60 s via 
the tail vein. Once the suspension was fully administered, US was applied for a 
further 2 min utilising the harmonic imaging parameters set prior to the 
injection. The probe was then removed, and if a superficial incision was made it 




Figure 2-1 Diagram illustrating set-up of UMGD treatment to target organs and representative US images once appropriate view was obtained. 
(A) Set-up of UMGD treatment target the left kidney (longitudinal view) with plasmid DNA and MB delivery via the left femoral artery. (B) Set-up of UMGD treatment to 
target the heart (parasternal long axis view) with plasmid DNA and MB delivery via the tail vein. (C) Set-up of UMGD treatment to target the placenta (view of the 











2.3.3.3 Negative and positive control animals 
Control animals from the same species as UMGD treatment animals were used in 
each study, and procedures were carried out on the same day as UMGD 
treatment animals. Control animals were anesthetised prior to any procedures as 
detailed in section 2.3.2. Negative control animals underwent the same hair 
removal procedure as detailed in section 2.3.3.1 and UMGD treatment as 
detailed in section 2.3.3.2 as treatment animals except, in place of the plasmid 
DNA and MB suspension, 1X phosphate buffered saline (PBS) (Gibco™, 
ThermoFisher, Paisley, UK) or a PBS and MB suspension was administered. For 
positive control animals, an area overlying the left gracilis muscle was shaved, 
and plasmid DNA or a plasmid DNA and MB suspension was administered into the 
gracilis muscle by multiple intramuscular (IM) injections. 
2.3.4 Euthanasia 
All animals were euthanised 3 d after UMGD procedures. Animals were 
anaesthetised as detailed in section 2.3.2. prior to euthanasia. Once anaesthesia 
was confirmed by tail pinch, animals were placed in a supine position with their 
nose and mouth positioned in an anaesthetic mask. Animals were maintained on 
5% isoflurane while euthanised by exsanguination. Midline and quarterline 
thoracic incisions were made, followed by a blunt dissection at the sternum and 
transverse cuts along the bottom of the ribcage to open the thoracic cavity. 
Longitudinal cuts up the ribcage were made to expose the heart. In rats, 
perfusion was carried out with heparinised saline (5000 IU/mL) from the aortic 
arch, and the right atrium was cut to allow drainage to ensure rats were dead 
prior to continuing with tissue harvest. In mice, once the heart was exposed, the 
right atrium was cut to ensure mice were dead prior to harvesting tissue. 
2.3.5 Tissue harvest 
Tissues were dissected, cleaned and fixed in 10% (v/v) neutral buffered formalin 
(CellPath, Powys, UK), embedded in optimum cutting temperature (OCT) 
compound (VWR international, Leuven, Belgium), and/or snap frozen in liquid 
nitrogen. When required for multiple types of tissue processing, tissues were cut 
into pieces as following. Kidneys and hearts were cut longitudinally when two 
tissue pieces were required or longitudinally and transversely when three pieces 
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were required. The full gracilis muscle was dissected as far as possible and cut 
transversely when two pieces were required or transversely and longitudinally 
when three pieces were required. For the liver, a section from the left lateral 
lobe and right medial lobe were cut when two pieces were required and an 
additional section from the right lateral lobe was cut when three pieces were 
required. For the lungs, random sections from the right and left lungs were cut 
and for the spleen, random sections were cut. When tissue was only snap frozen, 
whole tissue samples of the heart (or separated atria and ventricles), left 
kidney, right kidney, skeletal muscle (gracilis muscle), liver, lungs, spleen, 
placenta, and foetuses were collected. 
2.4 Histology 
2.4.1 Formalin-fixed paraffin-embedded tissue processing 
Tissues were fixed in 10% (v/v) neutral buffered formalin for 24 h. Tissues were 
washed three times for 10 min in 1X PBS and placed in 70% ETOH prior to tissue 
processing. Tissues were processed through a series of alcohol gradients to Histo-
Clear (Fisher Scientific, Loughborough, UK) to paraffin wax in a Citadel 1000 
processor (ThermoFisher, Loughborough, UK) in the following conditions: 
Processing conditions   
70% alcohol for 30 min   
95% alcohol for 30 min   
100% alcohol for 30 min (2x)   
100% alcohol for 45 min (2x   
100% alcohol for 60 min   
Histo-Clear for 30 min (5x)   
Paraffin wax for 30 min (2x)   
Paraffin wax for 45 min (2x)   
 
Tissues were then embedded in paraffin wax, with kidney sections positioned 
longitudinally, and tissue blocks were stored at 4ºC overnight prior to sectioning. 
Paraffin tissue blocks were sectioned at 5 µm using the Leica RM2235 Microtome 
(Leica biosystems, Milton Keynes, UK). Sections were mounted onto silane 
coated slides (Smith Scientific, Edenbridge UK), and dried in a 50ºC oven 
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overnight. Prior to staining, tissue sections were dewaxed and then rehydrated 
by placing slides through a series of alcohol gradients followed by a final wash as 
following: 
Rehydration   
Histo-Clear for 5 min (3x)   
100% alcohol for 5 min (2x)   
90% alcohol for 5 min   
70% alcohol for 5 min   
50% alcohol for 5 min   
dH2O for 5 min   
 
2.4.2 Frozen tissue processing 
Tissue embedded in OCT was transferred onto a tissue holder, which was placed 
on a freezing temperature bar in the microtome cryostat (Leica, Milton Keynes, 
UK). Frozen blocks were cryosectioned at 10 µm and mounted onto silane 
treated slides (Smith Scientific, Edenbridge UK). Sections were allowed to air dry 
for 3-5 h and stored at -20ºC. 
2.5 Luminescence and colorimetric assays 
2.5.1 Protein extraction 
Mortar and pestle were used for tissue disruption, and tissue was homogenised in 
1:20 (w/v) tissue protein extraction reagent (ThermoFisher, Loughborough, UK). 
Samples were homogenised either by gentle agitation on a shaker on ice for 30 
min or by bead milling four times for 30 s at 30 kHz with the TissueLyser 
(QIAGEN, Haan, Germany) followed by three freeze-thaw cycles. Samples were 
centrifuged at 10000 x g for 5 min, and supernatant was collected. 
2.5.2 Protein assay 
Protein concentration of tissue samples was measured using the Pierce BCA 
protein assay (ThermoFisher, Loughborough, UK). Protein standards of bovine 
serum albumin (BSA) (ThermoFisher, Loughborough, UK) were prepared at 
concentrations ranging from 25-2000 μg/mL by dilution in 1X PBS. 1X PBS (0 
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μg/mL BSA) was used as a blank. Samples were diluted between 1:5 to 1:20 with 
1X PBS to place values within the range of the standard curve. Samples and 
controls (25 μL) were pipetted into a clear flat bottom 96-well plate (Greiner, 
Dorset, UK) in duplicate or triplicate. Working reagent was prepared with BCA 
Reagent A and BCA Reagent B at a ratio of 50:1, of which 200 μL was added to 
each reaction well. The plate was incubated for 30 min at 37°C. Absorbance was 
measured at 562 nm with PerkinElmir 2030 plate reader (Perkin Elmer, 
Singapore, Singapore). The blank absorbance value was subtracted from all 
readings, and a standard curve was constructed from the known standard 
concentrations. Protein concentrations of samples were extrapolated from the 
standard curve. 
2.5.3 Luciferase assay 
Luciferase activity was measured using the luciferase assay reporter system 
(Promega, Southampton, UK). Luciferase assays were set-up on a white flat 
bottom 96-well plate (Greiner, Dorset, UK). Room temperature luciferase assay 
reagent (100 μL) (Promega, Southampton, UK) and 20 μL of sample supernatant 
or TPER (blank) were added to each well. Luciferase activity was measured in 
counts per second (CPS) for a period of 10 s using the PerkinElmir 2030 plate 
reader (Perkin Elmer, Singapore, Singapore). The blank absorbance value was 
subtracted from all readings prior to normalising luciferase activity to protein 
content. 
2.6 Literature review 
2.6.1 Literature search 
Literature searches were conducted using PubMed database. Truncation 
searching was performed by assigning the wildcard character (*) to each term to 
capture entries that contain terms with the same word stem. Abstracts were 
initially screened to identify full-text research articles available in English. 
Thereafter, abstracts and/or full-text articles were screened for eligibility 
and/or relevance. For all studies included in the literature reviews, the full text 
was assessed for eligibility and/or relevance. 
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2.7 Statistical analysis 
GraphPad Prism 9 was used to analyse data sets. Luciferase activity data are 
shown as mean counts per second (CPS)/µg of protein ± standard deviation (SD) 
or standard error of mean (SEM). Luciferase activity data were analysed by 
Friedman’s test followed by Dunn’s post-hoc multiple comparisons test. TaqMan 
data are shown as mean Ct ± SEM. TaqMan data were analysed using Ct values 
and groups were compared by unpaired t-test (with Welch’s correction as 
appropriate) when comparing two groups or one-way ANOVA followed by Tukey’s 
post-hoc multiple comparisons test when comparing three or more groups. 
Parametric tests were used since Ct values have shown to be normally 
distributed (Guo et al., 2010). Clinical characteristics are presented as mean ± 
standard deviation (SD) or median (range). All normally distributed variables 
were compared by unpaired t-test (with Welch’s correction as appropriate) and 
non-normally/discrete variables were compared by Mann-Whitney U test. MTT 
assay data were expressed as median cell viability % (IQR). This was calculated 
from absorbance ratios of treatment values normalised to ‘cells only’ values set 
to 100% and analysed by Kruskal-Wallis test followed by Dunn’s post-hoc multiple 





Chapter 3 Optimisation of an in vivo UMGD 
protocol in rodents 
3.1 Introduction 
Gene therapy represents a promising form of treatment for pregnancy-related 
disorders with an underlying genetic basis, such as FGR and PE. Recent 
developments in gene therapy for FGR pave the way for translational research. 
However, new gene delivery methods remain essential to extending research to 
other disorders, including PE. EVERREST marks the first-in-human trial to 
administer placental gene therapy during pregnancy (Spencer et al., 2017). 
Currently underway, the landmark study is evaluating the safety and efficacy of 
adenoviral delivery of a VEGF isoform, VEGF-DΔNΔC, to uterine arteries as a 
therapy for severe early-onset FGR. Preclinical studies in guinea pig and sheep 
models of FGR demonstrated therapeutic benefit following a single 
administration of adenoviral VEGF (Ad-VEGF), evidenced by increased foetal 
weight and growth pre- and postnatally (Carr et al., 2014, Swanson et al., 2016, 
Carr et al., 2016). Assessment of histological, biochemical, and haematological 
parameters supported its safety profile, and evaluation of maternal and foetal 
tissue demonstrated limited off-target expression (Swanson et al., 2016). In 
accordance with regulatory requirements for transitioning the research into 
clinical trials, a study utilising in vitro and ex vivo human placental model 
systems showed placental integrity and function were largely maintained 
following Ad-VEGF-DΔNΔC infusion on the maternal side (Desforges et al., 2018). 
With all legal and ethical requirements meeting regulatory standards, the 
clinical trial was approved. Nonetheless, possible safety and efficacy issues 
associated with the adenoviral vector and its delivery method underpin the need 
for non-viral and non-invasive gene delivery systems targeting the placenta. 
Local delivery of adenoviral vectors remains essential to mitigating potentially 
harmful systemic off-target effects. The ex vivo placental perfusion study found 
low levels of viral vector transfer across the placenta, demonstrating the risk of 
foetal gene transfer (Desforges et al., 2018). The majority of preclinical studies 
reported Ad-VEGF was not detected in any maternal or foetal tissue besides 
maternal uterine arteries (David et al., 2008, Mehta et al., 2012, Mehta et al., 
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2014). Conversely, one of the final preclinical studies preceding the clinical trial 
detected the vector in a maternal ovary, highlighting the risk of off-target 
expression (Swanson et al., 2016). A phase II clinical trial utilising the same first-
generation replication-deficient adenovirus demonstrated intracoronary delivery 
was safe and well tolerated in patients with coronary heart disease (Hedman et 
al., 2003). However, temporary fever and elevations in C-reactive protein (CRP) 
and lactate dehydrogenase (LDH) levels, markers of inflammation and cell injury 
respectively, were seen in several patients administered the gene therapy, 
potentially indicative of systemic inflammatory reactions. Similarly, a minor rise 
in LDH release was observed in the aforementioned ex vivo placental perfusion 
study, leading to an approximate 25-fold lower dose administered to patients in 
the EVERREST trial (Desforges et al., 2018). In a more recent phase I/IIa clinical 
trial in refractory angina patients, local intramyocardial delivery of Ad-VEGF-
DΔNΔC was also safe and well tolerated (Hartikainen et al., 2017). Although 
transient changes were noted in plasma CRP, haemoglobin, and thrombin, there 
were no significant differences in adverse events and clinical parameters of 
safety from 14 d until 1-year follow-up. Preclinical and clinical studies employing 
the adenoviral vector support limited safety issues. A risk of off-target 
expression however still persists, a particular concern when targeting the 
placenta as both maternal and foetal safety must be considered. 
In attempt to address maternal and foetal risks, preventative measures have 
been taken to ensure localised gene transfer. Preclinical studies optimised the 
gene delivery protocol to ensure gene transfer was restricted to the uterine 
arteries through reconstitution of the virus in pluronic gel in guinea pigs (Mehta 
et al., 2016) and occlusion of uterine arteries following laparotomy surgery in 
sheep (Carr et al., 2015). In the ongoing clinical trial, balloon occlusion 
catheters are being used for intravascular delivery of the virus to uterine 
arteries, which may interrupt uterine blood flow for up to 5 min (Desforges et 
al., 2018). This method is employed in clinical practice for controlling 
intraoperative bleeding in several pregnancy conditions, including abnormal 
placentation (Peng et al., 2019, Sun et al., 2018), elective caesarean section 
(Fuller et al., 2006), and uterine arteriovenous fistula (Yamamoto et al., 2015). 
Multiple studies have reported a lack of benefit and complications arising from 
balloon catheter placement (Bodner et al., 2006, Salim et al., 2015, Shrivastava 
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et al., 2007), and its routine use is therefore not recommended (ACOG, 2020). 
Less invasive and non-viral strategies for targeting the placenta therefore remain 
critical to extend research to other pregnancy disorders arising from abnormal 
placental development, such as PE. 
UMGD in conjunction with a plasmid vector represents a non-viral and non-
invasive method of gene transfer. Research into targeting the placenta remains 
limited, with a single in vivo UMGD study published to date (Babischkin et al., 
2019). The study demonstrated therapeutic benefit of delivering VEGF to uterine 
arteries to restore remodelling capabilities (Babischkin et al., 2019). However, 
tissue-specific expression was not examined, a critical step in demonstrating the 
clinical translatability of UMGD to the placenta. 
This chapter encompasses optimisation studies to develop an in vivo protocol for 
UMGD of a reporter gene to a more easily accessible organ in rodents, which 
could then be applied to the placenta. Rodents were chosen as suitable models 
to re-establish a previous successful method which targeted the heart in mice 
(Browning et al., 2011). Furthermore, with future investigations into targeting 
the placenta planned in rats due to availability of a rat model of PE (Morgan et 
al., 2018), rodents were selected for optimisation studies. Targeting rodent 
placentas with UMGD presents a unique challenge due to their relatively large 
litter size corresponding to a large number of placentas. Although the left and 
right uterine horns can help distinguish foetuses positioned along each horn, 
identifying a specific foetus and/or placenta in utero remains difficult. 
Optimisation studies were therefore conducted in non-pregnant rodents, utilising 
the kidney and heart as surrogate organs, which akin to the placenta are highly 
vascularised. In initial studies, the kidney was selected since the location of the 
organ is similar to that of the placenta and since the paired organ provides a 
comparable target and control in the same animal under same experimental 
conditions. Subsequently, the heart was targeted in optimisation studies to more 
closely recapitulate a previous UMGD study demonstrating tissue-specific gene 




3.2 Hypothesis and aim 
3.2.1 Hypothesis 
UMGD stimulates targeted gene transfer with a non-viral vector in vivo. 
3.2.2 Aim 
• To conduct optimisation studies in rodents to develop an in vivo UMGD 





All animal work was performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 under the authority of Home Office Licence 
70/9021. All animals were housed and maintained as detailed in section 2.3. 
UMGD optimisation studies were conducted in adult SHRSP and WKY rats and 
adult female CD-1 mice, utilising the left kidney and subsequently heart as 
target surrogate organs. The strain, sex, age, and weight of every animal and 
the total n-number of animals in each study is listed in Table 3-1. An n=3 was 
selected for the treatment group to minimise the number of animals used for 
initial research into the feasibility of the technique. An n=1 for the negative and 
positive control groups was chosen as the minimum number required to interpret 
the results from the treatment group. All animals were included in the study 
analysis. Formal randomisation and blinding were not performed; the order of 
experimental groups was decided prior to experiments, (negative control, UMGD, 
and then positive control group) to avoid contamination in negative control 
animals. No a prior criteria were used when randomly selecting animals from the 
cage. Rodents were sacrificed 3 d after UMGD, and target and non-target organs 
were either fixed or frozen for evaluation of reporter gene transfer by analysis 
of histology, gene expression, and/or enzymatic activity. 
3.3.1 Plasmid DNA preparation for in vivo use  
3.3.1.1 Plasmid DNA purification 
Plasmid DNA was transformed into competent MAX Efficiency™ DH5α™ 
Competent Cells as detailed in section 2.1.2.1. Glycerol stocks were prepared as 
a long-term stock as detailed in section 2.1.2.2. pVIVO2-GFP/LacZ was purified 
by centrifugation using the QIAGEN Plasmid Mega Kit (QIAGEN, Hilden, Germany) 
as detailed in section 2.1.2.3. A starter culture was initially diluted 1:1000 into 1 
L selective LB medium culture. In subsequent experiments, starter culture was 
diluted 1:1000 into 800 mL selective LB medium culture. pGL3 was purified by 
filtration using the QIAfilter Plasmid Mega Kit (QIAGEN, Hilden, Germany) as 
detailed in section 2.1.2.4. pGL4.13 was purified by filtration using the 
Invitrogen™ PureLink™ HiPure Expi Plasmid Megaprep Kit (ThermoFisher, Vilnus, 
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Lithuania) as detailed in section 2.1.2.4. Plasmid DNA with an A260/A280 ratio 
of ~1.8 was accepted as ‘pure’ DNA as detailed in section 2.1.2.7. 
3.3.1.2 Analytical gel of samples from plasmid DNA purification 
Samples from stages of the plasmid DNA purification were precipitated as 
detailed in section 2.1.2.5. Samples were run on a 1% agarose gel as detailed in 
section 2.1.3 to assess efficiency of the purification procedure, namely: growth 
and lysis conditions, efficiency of column loading, plasmid DNA binding, removal 
of RNA, and contamination. Purified plasmid DNA was run on the same gel to 
confirm isolation of plasmid DNA, lack of contamination in the final product, and 
conformation of the plasmid. If contamination was suspected, restriction digest 
was performed as detailed in section 2.1.2.6. Only plasmid DNA considered 
‘pure’ and confirmed as uncontaminated was used for in vivo procedures. 
3.3.2 Plasmid DNA and MB suspension 
The plasmid DNA and MB suspension was prepared on an individual basis for each 
animal in UMGD studies as detailed in section 2.3.1. The volume of plasmid DNA 
and MBs administered is listed in Table 3-1. 
3.3.3 UMGD studies 
3.3.3.1 UMGD 
UMGD was conducted as detailed in section 2.3.3. For each UMGD study, details 
of the type of plasmid; target organ; probe hold/output; animal strain, sex, age, 
weight, treatment, and n-numbers; injection site; and volumes administered are 
listed in Table 3-1. 
3.3.3.2 Negative and positive control animals 
In the first study, a kidney obtained from a control SHRSP rat (sacrificed as part 
of an unrelated study due to a surplus of requirements) was used as a negative 
control. In subsequent studies, negative control animals underwent a similar 
procedure as UMGD treatment animals as detailed in section 2.3.3.3, with 
modifications listed in Table 3-1. Positive control animals underwent the same 
procedure as detailed in section 2.3.3.3, with modifications listed in Table 3-1. 
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1 pVIVO2 left kidney stationary / 
frozen 
SHRSP (4) F 14 155-174 UMGD (3) left femoral vein 20 60 - 
   M 20 - NC (1) - - - - 
2 pVIVO2 left kidney stationary / 
frozen 
WKY (5) F 17-19 195-201 UMGD (3) left femoral vein 45 135 - 
   F 17 214 NC (1) left femoral vein - - 200 
    F 17 211 PC (1) gracilis muscle 50 150 - 
3 pGL4.13 left kidney sweeping /  
on 
WKY (5) F 13 193-196 UMGD (3) left femoral vein 125 375 - 
   F 13 172 NC (1) left femoral vein - - 500 
    F 13 186 PC (1) gracilis muscle 200 - - 
4 pGL3 left kidney sweeping /  
on 
CD-1 (5) F 6-8 25-32 UMGD (3) left femoral vein 50 150 - 
   F 6-8 30 NC (1) left femoral vein - - 200 
    F 6-8 28 PC (1) gracilis muscle 50 - - 
5 pGL3 heart stationary /  
on 
CD-1 (5) F 6-8 31- 35 UMGD (3) tail vein 50 150 - 
   F 6-8 33 NC (1) tail vein - - 200 
    F 6-8 29 PC (1) gracilis muscle 50 - - 
6 pGL3 heart stationary /  
on 
CD-1 (5) F 6-8 32- 45 UMGD (3) tail vein 50 150 - 
   F 6-8 39 NC (1) tail vein - 40 160 
    F 6-8 40 PC (1) gracilis muscle 17 33 - 
All values (strain, sex, weight, and treatment parameters) for animals were collected and/or noted prior to treatment. SHRSP, stroke-prone 
spontaneously hypertensive rats; WKY, Wistar Kyoto; F, female; M, male; wk, weeks; UMGD, ultrasound-mediated gene delivery; NC, negative control, 
PC, positive control; MB, microbubble; PBS, phosphate-buffered saline. 
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3.3.3.3 Sacrifice and tissue processing 
Animals were euthanised 3 d after UMGD procedures as detailed in section 2.3.4. 
Tissues were harvested and processed as detailed in section 2.3.5. 
3.3.4 RNA extraction and quality control 
RNA was extracted from tissue samples as detailed in section 2.1.4. Rat tissue 
was homogenised using Polytron PT2100 Benchtop Homogeniser (KINEMATICA, 
Luzern, Switzerland) and mouse tissue was homogenised using TissueLyser 
(QIAGEN, Haan, Germany). An optional on-column DNase digestion was 
performed. Buffer RWT (350 μL) was added to the RNeasy Mini Spin Column to 
wash the column. Samples were centrifuged at 11000 x g for 15 s, and flow-
through was discarded. DNase I incubation mix (10 μL DNase I stock solution and 
70 μL Buffer RDD) was added to the RNeasy Mini Spin Column and placed at room 
temperature for 15 or 30 min. Buffer RWT (350 μL) was added to the RNeasy Mini 
Spin Column to wash the column. Samples were centrifuged at 11000 x g for 15 
s, and flow-through was discarded. The RNA extraction protocol was then 
followed as detailed in section 2.1.4. RNA quality and concentration were 
assessed as detailed in section 2.1.4.1. 
3.3.5 SYBR and TaqMan RT-qPCR 
SYBR RT-qPCR was performed as detailed in section 2.2, using custom designed 
primers (LGP1, LGFP2, and LacZ) listed in Table 3-2. TaqMan RT-qPCR was 
performed as detailed in section 2.2, using the TaqMan® Gene Expression Assay 
for Actb (assay ID Mm01205647_g1) and Luc (assay ID Mr03987587_mr) and 
custom TaqMan® Gene Expression Assay for Luc2 (Table 3-2). Data were 
analysed as detailed in section 2.2.3, with Ct values normalised to housekeeper 
(β-actin). 
Table 3-2 Custom designed primers for SYBR and TaqMan RT-qPCR 
Primer (gene) Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
LGFP1 (LGFP) CACTATCTCCGCACTCAATC CTGCTGCTGTCACAAACTC 
LGFP2 (LGFP) GACCCTAATGAGAAAAGAGACC CATCCATTCCCAGAGTAATTCC 
LacZ (LacZ) CTCTCAATGGAGAGTGGAGG ATGCATCTGCCAGTTGCTGG 
Luc2 (LUC2) GCGCAGCTTGCAAGACTATAAG TTGTCGATGAGAGTGCTCTTAGC 
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3.3.6 PCR purification 
SYBR RT-qPCR products were purified for sequencing using the QIAquick® PCR 
purification Kit (QIAGEN, Hilden, Germany). Five volumes of Buffer PB were 
added to 1 volume of PCR product. The sample was added to a QIAquick column 
and centrifuged for 60 s at 17900 x g, and flow-through was discarded. Buffer PE 
(750 μL) was added to the QIAquick column and centrifuged for 60 s at 17900 x 
g, and flow through was discarded. Residual wash buffer was removed by 
centrifuging the QIAquick column for another 60 s at 17900 x g. To elute purified 
PCR product, 30 μL of NFW was added to the QIAquick column and centrifuged 
for 60 s at 17900 x g. 
3.3.7 Sequencing 
Sequencing of SYBR RT-qPCR products was outsourced to GATC Biotech. 
Sequences were analyzed using CLC Sequence Viewer. Sequences were aligned 
to known template sequences of primer pairs, LGFP1 and LGFP2. 
3.3.8 Fluorescence immunohistochemistry 
Tissue sections were dewaxed and rehydrated as detailed in 2.4.1. Sections were 
subject to antigen retrieval by incubating slides in heated citrate buffer (pH 6) 
for 20 min. Sections were blocked with 100 µL blocking agent (Tris-buffered 
saline and 0.05% Tween20 (TBST) (Sigma, Darmstadt, Germany) with 15% goat 
serum (Vector Laboratories Ltd., Peterborough, UK)) for 1 h. Sections were 
incubated with 100 µL primary antibody (1:100 (study 1) dilution of mouse anti-
GFP antibody [STJ97030] (St John’s Laboratory, London, UK), 1:100 (study 1) and 
in 1:500 (study 2) dilution of rabbit anti-GFP antibody [ab6556] (Abcam, 
Cambridge, UK) and 1:300 (study 2) dilution of rabbit IgG fraction to β-
galactosidase (β-gal) [ICN559762] (Fisher Scientific, Loughborough, UK)) or a 
negative IgG control (mouse IgG (Agilent Dako, Glostrup, Denmark) or rabbit IgG 
(ThermoFisher, Loughborough, UK) respectively) for 1 h at room temperature or 
overnight at 4°C. After washing three times with TBST, sections were incubated 
in 100 µL of secondary antibody (1:500 dilution of goat anti-mouse (H+L) highly 
cross-adsorbed Alexa Fluor 555 (ThermoFisher, Paisley, UK) or 1:500 dilution of 
goat anti-rabbit (H+L) highly cross-adsorbed Alexa Fluor 555 (ThermoFisher, 
Paisley, UK)). Sections were washed three times in TBS, mounted with ProLong 
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Diamond Antifade Mountant (ThermoFisher, Paisley, UK), sealed with coverslips 
(Smith Scientific, Edenbridge, UK), and allowed to cure overnight at room 
temperature. In study 2, sections were treated with Sudan Black B 0.1% for 5 
min at room temperature prior to mounting. Fluorescence microscopy was 
performed with AxioObserver Z1 (Zeiss, Cambridge, UK), and images were 
analysed using Zen Pro software with display setting parameters kept constant. 
Images of kidney cross-sections were taken at 4X magnification and kidney 
sections were taken at 20X magnification. Medullary and cortical regions were 
distinguished by absence or presence of renal corpuscles, respectively. All 
fluorescence images were manipulated to the same level (brightness: +40% and 
contrast: -40%). 
3.3.9 X-gal staining 
Frozen OCT tissue blocks were cryosectioned at 10 µm, mounted onto silane 
treated slides (Smith Scientific, Edenbridge UK), and allowed to dry for 3-5 h as 
detailed in 2.4.2. Sections were fixed in 0.2% glutaraldehyde for 10 min at 4°C. 
Slides were washed three times for 5 min with LacZ wash buffer (1.5 mL 1M 
MgCl2, 7.5 mL 1% NaDC, 7.5 mL 2% Nonidet-P40, and 733.5 mL 1X PBS). Slides 
were incubated in LacZ stain (72 mL LacZ wash buffer, 3 mL 25 mg/mL X-Gal, 
0.159 g K-ferrocyanide, and 0.123 g k-ferricyanide) at 37°C overnight and 
washed twice with 1X PBS. Slides were dehydrated through a gradient of ETOH 
concentrations to Histo-Clear and mounted with cover slips. Images were taken 
with Olympus BX41 Microscope (Olympus, Essex, UK) at 20X magnification. 
3.3.10 Luciferase activity 
Luciferase activity was measured as detailed in section 2.5.3 and normalised to 
protein content, which was extracted by gentle agitation as detailed in section 
2.5.1 and measured as detailed in section 2.5.2 
3.3.11 Statistical analysis 
GraphPad Prism 9 was used to summarise the data using descriptive statistics. 




3.4.1 UMGD optimisation studies delivering pVIVO2-GFP/LacZ to 
the left kidney in rats 
3.4.1.1 Purification of pVIVO2-GFP/LacZ 
The pVIVO2-GFP/LacZ plasmid, a 9620 bp dual reporter vector, was selected for 
initial in vivo UMGD optimisation studies targeting the left kidney as a surrogate 
organ. To assess efficiency of purification and pVIVO2-GFP/LacZ plasmid 
conformation, samples from stages of the purification procedure were run on an 
agarose gel. A band above 10000 bp (lane L) demonstrates denatured proteins, 
bacterial chromosomal DNA, and cell debris were removed, and the cleared 
lysate was enriched for plasmid DNA (Figure 3-1). A band above 10000 bp (lane 
F) indicates plasmid DNA was present in the flow-through fraction, and the 
column was overloaded (Figure 3-1). No band/s in the final wash fraction (lane 
W2) shows plasmid DNA was bound to the column and degraded RNA was 
removed (Figure 3-1). In the elute (lane E), a single band above 10000 bp 
demonstrates plasmid DNA was purified from E. coli and present in an open-






Figure 3-1 Representative agarose gel image of samples from stages of purification of 
pVIVO2-GFP/LacZ plasmid mega preps. 
pVIVO2-GFP/LacZ plasmid was isolated from E. coli mega preps during which samples were 
collected to assess the stages of the purification procedure and confirm isolation of plasmid DNA. 
Up to 10 µL of the sample or 250 ng of DNA was loaded per lane and sized on a 1% agarose gel, 
using a 1 kb DNA ladder; sizes indicated in bp. Lane L: cleared lysate, lane F: flow-through 




3.4.1.2 In vivo UMGD of pVIVO2-GFP/LacZ to the left kidney in rats 
Two in vivo UMGD optimisation studies targeting the left kidney in rats utilised 
the pVIVO2-GFP/LacZ plasmid. Specifically designed for in vivo use, the plasmid 
encodes two chemically synthesised reporter genes, LGFP and LacZ-∆CpG, each 
with CpG motifs removed and their own promoter and polyadenylation signals to 
promote sustained expression (Invivogen, 2016). 
3.4.1.2.1 Study 1 
Fluorescence IHC and X-Gal staining were used to assess gene transfer by 
detection of protein expression of GFP and LacZ, respectively. Examination of 
GFP with IHC, using a mouse anti-GFP primary antibody, showed fluorescence in 
both the left and right kidneys of all three UMGD treatment rats (Figure 3-2). 
Fluorescence was observed in the medullary region in the left and right kidneys 
of UMGD treatment rats and a negative control rat (Figure 3-3), indicating non-
specific antibody binding. Evaluation of GFP in the medullary and cortical 
regions of the left and right kidneys of UMGD treatment rats following incubation 
with a rabbit anti-GFP primary antibody showed low levels of fluorescence 
similar to incubation with an IgG control, providing evidence of a lack of gene 
transfer (Figure 3-4). Higher levels of fluorescence by qualitative assessment 
were seen in the medullary and cortical regions in the kidney of a negative 
control rat (Figure 3-5) compared to kidneys from UMGD treatment rats (Figure 
3-4), further indicating failure of GFP transfer to the left kidney. X-Gal staining 
revealed presence of β-gal (evidenced by blue staining) in the medulla and 
cortex in both the left and right kidneys of a UMGD treatment rat, representing 
detection of endogenous LacZ expression rather than LacZ gene transfer (Figure 
3-6). There was no evidence of β-gal in negative control organs: heart, liver, and 
skeletal muscle (Figure 3-6). 
In this study, MBs were reconstituted for 20 min rather than 20 s due to human 
error. In all future studies, MBs were reconstituted for 20 s as described in the 
‘Summary of Product Characteristics’(EMA, 2008b). In addition, 40% of the 
intended plasmid DNA and MB dose (previously published dose successfully used 
in mice (Browning et al., 2011)) was administered due to loss of volume from 
unaccounted for dead space in the syringe. In all future studies, 100 µL dead 
space volume was accounted for when preparing the plasmid DNA and MBs.  
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Figure 3-2 Representative images of visualisation of GFP with fluorescence IHC (mouse 
anti-GFP primary antibody) in cross-sections of left and right kidneys from UMGD treatment 
rats from study 1. 
(A) UMGD treatment rat 1, (B) UMGD treatment rat 2, and (C) UMGD treatment rat 3 kidneys were 
incubated with mouse anti-GFP primary antibody (top panels) or mouse IgG (bottom panels) and 
goat anti-mouse Alexa Flour 555 secondary antibody to visualise GFP in the left kidneys (left 
panel) and right kidneys (right panel). All images were taken at 4x magnification. Scale bar 



































Figure 3-3 Representative images of visualisation of GFP with fluorescence IHC (mouse 
anti-GFP primary antibody) in medullary and cortical regions of kidneys from a UMGD 
treatment rat and the negative control rat from study 1. 
(A) Left kidney of UMGD treatment rat, (B) right kidney of UMGD treatment rat, and (C) kidney of 
negative control rat were incubated with mouse anti-GFP primary antibody (top panels) or mouse 
IgG (bottom panels) and goat anti-mouse Alexa Flour 555 secondary antibody to visualise GFP. 
Representative images were taken from the medullary (left panel) and cortical (right panel) regions 
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Figure 3-4 Representative images of visualisation of GFP with fluorescence IHC (rabbit anti-
GFP primary antibody) in medullary and cortical regions of left and right kidneys from 
UMGD treatment rats from study 1. 
(A) UMGD treatment rat 1, (B) UMGD treatment rat 2, and (C) UMGD treatment rat 3 kidneys were 
incubated with rabbit anti-GFP primary antibody (top panels) or rabbit IgG (bottom panels) and goat 
anti-rabbit Alexa Flour 555 secondary antibody to visualise GFP in the medullary and cortical 
regions of the left kidneys (left panel) and right kidneys (right panel). All images were taken at 20x 












Figure 3-5 Representative images of visualisation of GFP with fluorescence IHC (rabbit anti-
GFP primary antibody) in medullary and cortical regions of a kidney from the negative 
control rat from study 1. 
Kidney sections were incubated with rabbit anti-GFP primary antibody (top panels) or rabbit IgG 
(bottom panels) and goat anti-rabbit Alexa Flour 555 secondary antibody to visualise GFP in the 
medullary (left panel) and cortical (right panel) regions. All images were taken at 20x magnification. 

































Figure 3-6 Representative images of visualisation of LacZ by X-Gal staining of β-gal in 
tissues from a UMGD treatment rat from study 1. 
Tissue sections were incubated with X-Gal stain overnight. All images were taken at 20x 




3.4.1.2.2 Study 2 
Although loss of volume from dead space was accounted for, 90% of the intended 
plasmid DNA and MB dose (previously published dose successfully used in mice 
(Browning et al., 2011)) was administered due to loss of volume unaccounted for 
by air bubble removal. Fluorescence IHC was used to examine GFP and LacZ 
protein expression and SYBR qPCR was used to examine GFP mRNA expression. 
Evaluation of GFP in the medullary and cortical regions of the left and right 
kidneys of UMGD treatment rats following incubation with a rabbit anti-GFP 
primary antibody revealed low levels of fluorescence similar to incubation with 
an IgG control, providing evidence of unsuccessful GFP gene transfer (Figure 
3-7). Non-targeted negative control kidneys from the positive control rat and 
negative control rat showed no detection of GFP (Figure 3-8). Unsuccessful gene 
transfer was further supported by lack of fluorescence in left and right kidneys 
of a UMGD treatment rat and control rats following addition of Sudan Black B to 
the IHC protocol to quench tissue auto fluorescence (Figure 3-9). Evaluation of 
LacZ gene transfer by examining β-gal protein expression with IHC using a rabbit 
anti-β-gal primary antibody showed similar levels of fluorescence with IgG 
controls and between both kidneys in a UMGD treatment rat and the negative 
control rat (Figure 3-10), suggesting lack of gene transfer. 
Two custom GFP primer pairs were designed to detect mRNA expression of LGFP, 
a chemically synthesised allele of GFP expressed by the plasmid. Amplification 
with LGFP1 and LGFP2 showed detection of GFP in the right and left kidney of 
all three UMGD treatment rats (Appendix Table 8-1). LGFP1 was not detected in 
the kidneys of the negative control rat and plasmid only sample, while LGFP2 
was detected in both the left and right kidney of the negative control rat and 
plasmid only sample (Appendix Table 8-1), indicating detection of 
contamination. The housekeeper β-actin was stably expressed across both 
kidneys from all rats (Appendix Table 8-2). 
SYBR qPCR products were sized on an agarose gel. No clear bands were visible in 
samples amplified with the LGFP1 primer pair, where the expected fragment 
size was 88 bp (Figure 3-11). Faint bands ~100 bp were visible in samples 
amplified with the LGFP2 primer pair, matching the expected fragment size of 
76 bp (Figure 3-11). SYBR qPCR product sequences aligned to the LGFP1 and 
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LGFP2 template sequences (Figure 3-12). This demonstrates presence of GFP in 
SYBR qPCR products from the right kidney of a UMGD treatment rat and the left 
kidney of the negative control rat, providing evidence of contamination during 
tissue processing. 
Given the issues with analysing reporter gene expression of pVIVO2-GFP/LacZ, 
future in vivo UMGD studies employed luciferase plasmid vectors, routinely used 
in UMGD studies (Browning et al., 2011, Browning et al., 2012, Shen et al., 2008, 
Song et al., 2011). Also, in all future studies, loss of volume from the plasmid 
DNA and MB suspension arising from both dead space and removal of air bubbles 
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Figure 3-7 Representative images of visualisation of GFP with fluorescence IHC (rabbit anti-
GFP primary antibody) in medullary and cortical regions of left and right kidneys from 
UMGD treatment rats from study 2. 
(A) UMGD treatment rat 1, (B) UMGD treatment rat 2, and (C) UMGD treatment rat 3 kidneys were 
incubated with rabbit anti-GFP primary antibody (top panels) or rabbit IgG (bottom panels) and goat 
anti-rabbit Alexa Flour 555 secondary antibody to visualise GFP in the medullary and cortical 
regions of the left kidneys (left panel) and right kidneys (right panel). All images were taken at 20x 
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Figure 3-8 Representative images of visualisation of GFP with fluorescence IHC (rabbit anti-
GFP primary antibody) in medullary and cortical regions of left and right kidneys from 
control rats from study 2. 
(A) Negative control rat and (B) positive control rat kidneys were incubated with rabbit anti-GFP 
primary antibody (top panels) or rabbit IgG (bottom panels) and goat anti-rabbit Alexa Flour 555 
secondary antibody to visualise GFP in the medullary and cortical regions of the left kidneys (left 
panel) and right kidneys (right panel). All images were taken at 20x magnification. Scale bars 
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Figure 3-9 Representative images of visualisation of GFP with fluorescence IHC (rabbit anti-
GFP primary antibody and 0.1% Sudan Black B) in medullary and cortical regions of left and 
right kidneys from UMGD treatment rats from study 2. 
(A) UMGD treatment rat, (B) negative control rat, and (C) positive control rat kidneys were 
incubated with rabbit anti-GFP primary antibody (top panels) or rabbit IgG (bottom panels) and goat 
anti-rabbit Alexa Flour 555 secondary antibody followed by Sudan Black B treatment to visualise 
GFP in the medullary and cortical regions of the left kidneys (left panel) and right kidneys (right 
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Figure 3-10 Representative images from visualisation of β-gal (LacZ) with fluorescence IHC 
(rabbit anti-β-gal primary antibody) in medullary and cortical regions of left and right 
kidneys from a UMGD treatment rat and the negative control rat from study 2. 
(A) UMGD treatment rat and (B) negative control rat kidneys were incubated with rabbit anti-β-gal 
primary antibody (top panels) or rabbit IgG (bottom panels) and goat anti-rabbit Alexa Flour 555 
secondary antibody to visualise β-gal (LacZ) in the medullary and cortical regions of the left 
kidneys (left panel) and right kidneys (right panel). All images were taken at 20x magnification. 





Figure 3-11 SYBR RT-qPCR products amplified with LGFP1 and LGFP2 primer pairs 
visualised on an agarose gel.  
cDNA from SYBR RT-qPCR products of samples amplified with LGFP1 and LGFP2 was loaded at 
100 ng per lane and sized on a 1.5% agarose gel, using a 100 bp DNA ladder; sizes indicated in 
bp. Samples from UMGD treatment rat 1 (R1) right kidney (RK) and left kidney (LK) amplified with 
LGFP1 (lane 1 and 2) and LGFP2 (lane 3 and 4), the negative control rat (NC) right kidney (RK) 
and left kidney (LK) amplified with LGFP2 (lane 5 and 6), and pVIVO2-GFP/LacZ plasmid (P) 





Figure 3-12 Chromatogram of sequences of SYBR RT-qPCR products aligned to LGFP1 and 
LGFP2 template sequences. 
After PCR purification, SYBR RT-qPCR products were sequenced by GATC Biotech and aligned to 
LGFP1 and LGFP2 template sequence using CLC Sequence Viewer. Highlighted in yellow: LGFP1 
and sequences of the forward and reverse primer and highlighted in green: LGFP2 and sequence 
of the forward primer. Blue arrows indicate orientation of primers. Samples from UMGD treatment 
rat 1 right kidney amplified with LGFP1 and LGFP2 and the negative control rat left kidney 




3.4.2 UMGD optimisation studies delivering luciferase plasmids 
to the left kidney in rats and mice 
3.4.2.1 Purification of pGL4.13  
pGL4.13, a 4641 bp vector expressing luc2 (modified Photinus Pyralis luciferase 
gene) was selected for in vivo UMGD targeting of the left kidney in rats. In order 
to assess the efficiency of the purification of pGL4.13 and plasmid conformation 
of isolated pGL4.13, samples from stages of the purification procedure and the 
final plasmid product were run on an agarose gel. In the cleared lysate (lane L), 
a band ~5000 bp indicates plasmid DNA was enriched in the lysate (Figure 3-13). 
No bands in the flow-through fraction (lane F) and final wash fraction (lane W2) 
demonstrates plasmid DNA efficiently bound to the column and degraded RNA 
was removed (Figure 3-13). Finally, presence of a band ~5000 bp in the elute 
(lane E) and plasmid only samples (lane P1 and P2) shows supercoiled plasmid 





Figure 3-13 Representative agarose gel image of samples from stages of purification of 
pGL4.13 plasmid mega preps. 
pGL4.13 plasmid was isolated from E. coli mega preps during which samples were collected to 
assess the stages of the purification procedure and confirm isolation of plasmid DNA. Up to 10 µL 
of the sample or 250 ng of DNA was loaded per lane and sized on a 1% agarose gel, using a 1 kb 
DNA ladder; sizes indicated in bp. Lane L: cleared lysate, lane F: flow-through fraction, lanes W1 
and W2: wash fractions, lane E: elute, lane P1: pGL3 plasmid from prep1, lane P2: pGL3 plasmid 




3.4.2.2 In vivo UMGD of pGL4.13 to the left kidney in rats 
3.4.2.2.1 Study 3 
In the previous UMGD studies, volumes of plasmid DNA and MBs administered 
were based on doses previously administered to mice (Browning et al., 2011). In 
this study, to account for a ~6-fold greater total blood volume in rats compared 
with mice (JHU, 2020), the plasmid DNA and MB suspension volume was 
increased by 2.5-fold, restricted by the maximum 500 µL volume of an IV bolus 
dose in rats. Luciferase and protein assays were used to examine luciferase 
activity and TaqMan qPCR was used to assess luciferase mRNA expression. 
Luciferase activity greater than background activity was not detected in the 
target left kidney of any of the three UMGD treatment rats, indicating lack of 
luciferase gene transfer to the target organ (Figure 3-14). Luciferase activity was 
detected in the skeletal muscle of the positive control rat (156.39±22.38 CPS/µg 
of protein), demonstrating naked pGL4.13 plasmid delivery to skeletal muscle by 
IM injection (Figure 3-14). 
Evaluation of luciferase mRNA expression with TaqMan qPCR was not possible. 
Although luciferase Ct values were undetermined in multiple negative controls 
(NFW and MM controls), luciferase was detected in the no RT negative control 
(Appendix Table 8-3). Ct values of β-actin in the same no RT wells were 
undetermined (Appendix Table 8-3), suggesting plasmid DNA contamination. RNA 
extraction was repeated with prolonged DNase treatment to promote digestion 
of plasmid DNA and remove contamination. Luciferase was still detected across 
all negative controls while β-actin was undetected (Appendix Table 8-4), 
suggesting plasmid DNA contamination from a source external to the samples. 
Due to contamination issues with custom qPCR probes, the pGL3 plasmid was 
selected for subsequent studies since the standard TaqMan® Gene Expression 
Assay for luciferase maps to luc+, the modified luciferase gene encoded by the 
vector, permitting evaluation of reporter gene mRNA expression. 
Given the volume restrictions of an intravenous (IV) bolus dose in rats, all 
subsequent in vivo UMGD studies were conducted in mice in order to administer 
the same doses of plasmid DNA and MBs which had been shown to be successful 




Figure 3-14 Luciferase activity in left and right kidneys and skeletal muscle of three UMGD 
treatment rats and the positive and negative control rats from study 3. 
Luciferase activity in tissues from UMGD treatment and control rats three days after in vivo gene 
delivery experiment. UMGD treatment rats were administered an IV injection of pGL4.13 and MB 
suspension followed by 2 min of US exposure to the left kidney. The positive control rat received an 
IM injection of pGL4.13 and MB suspension. The negative control rat received an IV injection of 
PBS followed by 2 min of US exposure to the left kidney. Luciferase activity was measured in 
counts per second (CPS) and normalised to protein content. Data are shown as mean CPS/µg of 


























































3.4.2.3 Purification of pGL3  
pGL3, a 5256 bp vector expressing a modified Photinus Pyralis luciferase gene 
luc+, was selected for in vivo UMGD targeting the left kidney in mice. To assess 
efficiency of purification and isolated pGL3 plasmid conformation, samples from 
stages of the purification procedure and the final plasmid product were run on 
an agarose gel. Although no bands are visible in the cleared lysate (lane L), flow-
through fraction (lane F), and wash fraction (lane W), two distinct bands in the 
elute (lane E) and final plasmid samples (lane P1 and P2) provide evidence that 
pGL3 was isolated (Figure 3-15). The lower band ~6000 bp suggests linear 
plasmid DNA was purified (Figure 3-15). To determine whether the upper band 
present above the DNA ladder represented bacterial chromosomal DNA 
contamination or open-circular plasmid DNA detection (Figure 3-15), restriction 
digest was performed. Digestion of pGL3 plasmid prep 1 with a single restriction 
enzyme, XhoI or BglII, produced a band ~6000 bp, indicating presence of 
linearised pGL3 plasmid rather than bacterial chromosomal DNA contamination 
(Figure 3-16). pGL3 plasmid prep 2 did not digest to completion (Figure 3-16). 
Presence of multiple bands and a light smear suggested potential chromosomal 





Figure 3-15 Representative agarose gel image of samples from stages of purification of 
pGL3 plasmid mega preps. 
pGL3 plasmid was isolated from E. coli mega preps during which samples were collected to assess 
the stages of the purification procedure and confirm isolation of plasmid DNA. Up to 10 µL of the 
sample or 250 ng of DNA was loaded per lane and sized on a 1% agarose gel, using a 1 kb DNA 
ladder; sizes indicated in bp. Lane L: cleared lysate, lane F: flow-through fraction, lane W: wash 





Figure 3-16 Restriction digest of pGL3 plasmid preps with XhoI and BglII restriction 
enzymes. 
Single digested pGL3 plasmid DNA from two separate plasmid mega preps. DNA was loaded at 
250 ng per lane and sized on a 0.8% agarose gel, using a 1kb DNA ladder; sizes indicated in bp 




3.4.2.4 In vivo UMGD of pGL3 to the left kidney in mice 
3.4.2.4.1 Study 4 
In contrast to all previous in vivo UMGD studies in this chapter, this study was 
conducted in mice, using the same doses of plasmid DNA and MBs administered 
to mice in a past study (Browning et al., 2011). Gene transfer of luciferase was 
assessed by measuring luciferase activity with luciferase and protein assays and 
mRNA expression with TaqMan qPCR. 
A low level of luciferase activity was detected in the target left kidney of UMGD 
treatment mouse 1 (1.07±0.53 CPS/µg of protein), higher than background 
luciferase activity in the negative control mouse left kidney (0.19±0.18 CPS/µg 
of protein) and right kidney (0.74±0.71 CPS/µg of protein), suggesting low levels 
of gene transfer (Figure 3-17). The highest level of luciferase activity was seen 
in the skeletal muscle of the positive control mouse (241.39±10.56 CPS/µg of 
protein) (Figure 3-17). 
Evaluation of luciferase mRNA expression with TaqMan qPCR showed luciferase 
Ct values were undetermined across all samples (Appendix Table 8-5). This 
suggests low levels of luciferase activity in the target left kidney of a treatment 
mouse may have reflected detection of background activity rather than gene 
transfer. β-actin was stably expressed, and both luciferase and β-actin were 
undetected in all negative controls (Appendix Table 8-6). 
Given the lack of gene transfer when targeting the left kidney, it was decided 
that subsequent studies would utilise the heart as a surrogate organ. The heart 
was selected since this was the organ successfully targeted in the past study 
(Browning et al., 2011) which formed the basis of the in vivo protocols 





Figure 3-17 Luciferase activity in left and right kidneys and skeletal muscle of three UMGD 
treatment mice and the positive and negative control mice from study 4. 
Luciferase activity in tissues from UMGD treatment and control mice three days after in vivo gene 
delivery experiment. UMGD treatment mice were administered an IV injection of pGL3 and MB 
suspension followed by 2 min of US exposure to the left kidney. The positive control mouse 
received an IM injection of pGL3. The negative control mouse received an IV injection of PBS 
followed by 2 min of US exposure to the left kidney. Luciferase activity was measured in counts per 
second (CPS) and normalised to protein content. Data are shown as mean CPS/µg of proteinSD, 


























































3.4.3 UMGD optimisation studies delivering luciferase plasmids 
to mouse hearts 
3.4.3.1 In vivo UMGD of pGL3 to mouse hearts 
The same UMGD protocol previously established in mice (Browning et al., 2011) 
was utilised in the following two studies (Study 5 and Study 6) in terms of target 
organ, injection site, and dose of plasmid DNA and MBs. However, pGL3 was 
utilised in place of pGL4.13 to permit evaluation of luciferase mRNA expression 
with a standard TaqMan® Gene Expression Assay. Gene transfer of luciferase was 
also assessed by luciferase and protein assays which measure luciferase activity. 
3.4.3.1.1 Study 5 
Evaluation of luciferase mRNA expression with TaqMan qPCR was not possible 
due to background noise. Although the β-actin housekeeper was stably expressed 
across samples and Ct values were undetermined in negative controls (Appendix 
Table 8-8), luciferase detected in the heart samples from the three UMGD 
treatment mice and skeletal muscle of the positive control mouse was 
comparable to non-target tissue (Appendix Table 8-7). TaqMan qPCR was 
subsequently run in singleplex and duplex to assess if primer interactions may 
have contributed to noise, but similar results were obtained (Appendix Table 
8-9). In all future in vivo UMGD studies, evaluation of gene transfer at the mRNA 
level was not conducted. 
Low levels of luciferase activity were detected in the heart of UMGD treatment 
mouse 1 (2.56±1.95 CPS/μg of protein), mouse 2 (0.66±0.73 CPS/μg of protein), 
and mouse 3 (2.05±2.08 CPS/μg of protein), compared to background luciferase 
activity in the heart of the positive control mouse (0.56±0.85 CPS/μg of protein) 
and negative control mouse (0.53±0.57 CPS/μg of protein) (Figure 3-18). Highest 
luciferase activity was detected in the skeletal muscle of the positive control 
mouse (21.2±5.90 CPS/μg of protein) (Figure 3-18). However, luciferase activity 
in the skeletal muscle of treatment mouse 1 (1.86±1.05 CPS/μg of protein) and 
mouse 3 (1.42±0.36 CPS/μg of protein) was higher than background activity in 
the skeletal muscle of the negative control mouse (0.57±0.70 CPS/μg of protein) 
(Figure 3-18), suggesting low levels detected in the hearts of UMGD treatment 
mice perhaps reflecting background luciferase activity rather than providing 
evidence of gene transfer. 
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Due to the large variation in expression levels between samples from a single 
tissue, tissue samples (representing technical replicates) were analysed 
ungrouped i.e., the mean and SD of individual tissue samples were summarised 
rather than the mean and SD of tissue samples when grouped. Analysis of heart 
tissue samples ungrouped revealed samples one and two of UMGD treatment 
mouse 1 (4.37±1.05 and 2.81±0.34 CPS/μg of protein, respectively) and sample 
three of UMGD treatment mouse 3 (4.45±0.29 CPS/μg of protein) had luciferase 
activity higher than background levels in the heart samples of the negative 
control mouse, with highest background activity in heart sample one of the 
negative control mouse (1.19±0.52 CPS/μg of protein) (Figure 3-19A), suggesting 
a low level of gene transfer in several heart samples. Heart tissue samples one 
and two of UMGD treatment mouse 1 and sample three of UMGD treatment 
mouse 3 also had luciferase activity higher than the non-targeted skeletal 
muscle of these UMGD mice, with highest background activity in skeletal muscle 
sample one of UMGD treatment mouse 1 and 3 (2.65±0.82 and 1.72±0.78 CPS/μg 
of protein, respectively) (Figure 3-19B), further suggesting a low level of gene 
transfer in these heart tissue samples. Due to large variations between heart 
tissue samples and gene transfer potentially detected in only several samples, 
hearts were dissected into atria and ventricles when analysing the tissue in 




Figure 3-18 Luciferase activity in hearts and skeletal muscle of three UMGD treatment mice 
and the positive and negative control mice from study 5. 
Luciferase activity in tissues from UMGD treatment and control mice three days after in vivo gene 
delivery experiment. UMGD treatment mice were administered an IV injection of pGL3 and MB 
suspension followed by 2 min of US exposure to the heart. The positive control mouse received an 
IM injection of pGL3. The negative control mouse received an IV injection of PBS followed by 2 min 
of US exposure to the heart. Luciferase activity was measured in counts per second (CPS) and 
normalised to protein content. Data are shown as mean CPS/µg of proteinSD, n=3 tissue samples 

























































Figure 3-19 Luciferase activity in ungrouped samples of hearts and skeletal muscle of three 
UMGD treatment mice and the positive and negative control mice from study 5. 
(A) Heart and (B) skeletal muscle samples ungrouped from UMGD treatment and control mice 
three days after in vivo gene delivery experiment. UMGD treatment mice were administered an IV 
injection of pGL3 and MB suspension followed by 2 min of US exposure to the heart. The positive 
control mouse received an IM injection of pGL3. The negative control mouse received an IV 
injection of PBS followed by 2 min of US exposure to the heart. Luciferase activity was measured in 
counts per second (CPS) and normalised to protein content. Data are shown as mean CPS/µg of 
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3.4.3.1.2 Study 6 
A high level of luciferase activity was evident in the atria of UMGD treatment 
mouse 2 (14.6±19.5 CPS/μg of protein), greater than luciferase activity in the 
skeletal muscle of the positive control mouse (6.17±4.51 CPS/μg of protein) and 
background activity in the atria of the negative control mouse (7.77±2.79 
CPS/μg) (Figure 3-20), providing evidence of gene transfer. Luciferase activity in 
the ventricles of UMGD treatment mouse 1 (1.04±0.20 CPS/μg of protein) and 
mouse 3 (6.43±5.84 CPS/μg of protein) was higher than background activity in 
the ventricles (0.49±0.05 CPS/μg of protein) but lower than background activity 
the atria (7.77±2.79 CPS/μg) of the negative control mouse (Figure 3-20), 
suggesting detection of background luciferase activity rather than gene transfer. 
Low levels of luciferase activity were detected in the skeletal muscle of 
treatment mouse 1 (1.03±0.13 CPS/μg of protein), higher than background 
luciferase in the negative control mouse skeletal muscle (0.88±0.13 CPS/μg of 
protein) but notably lower than luciferase activity in the positive control mouse 
skeletal muscle (6.17±4.51 CPS/μg of protein) (Figure 3-20).  
Due to large variability in the atria, ventricles, and skeletal muscle, tissue 
samples (representing technical replicates) were analysed ungrouped. Analysis of 
ventricle samples ungrouped, showed that luciferase activity in sample two of 
UMGD treatment mouse 3 (19.9±0.66 CPS/μg of protein) was higher than any of 
atria or ventricle samples of the negative control mouse (Figure 3-21A), 
providing evidence of gene transfer. Analysis of atria samples ungrouped showed 
that sample three of UMGD treatment mouse 2 (55.2±28.2 CPS/μg of protein) 
had more than 3-fold higher luciferase activity than any of the four atria samples 
of the negative control mouse (5.48±0.70, 6.10±1.44, 14.4±1.14, and 5.05±4.33 
CPS/μg of protein), suggesting gene transfer (Figure 3-21B). The remaining atria 
samples from UMGD treatment mouse 2 showed lower luciferase activity than 
any of the atria samples from the negative control mouse (Figure 3-21B).  
With evidence of gene transfer to the heart, the subsequent proof-of-concept 
study employed the in vivo UMGD protocol used in these studies. However, 
despite analysing the ventricles and atria separately, variability within the tissue 
was still evident. Hence, the tissue protein extraction protocol was optimised for 




Figure 3-20 Luciferase activity in ventricles, atria, and skeletal muscle of three UMGD 
treatment mice and the positive and negative control mice from study 6. 
Luciferase activity in tissues from UMGD treatment and control mice three days after in vivo gene 
delivery experiment. UMGD treatment mice were administered an IV injection of pGL3 and MB 
suspension followed by 2 min of US exposure to the heart. The positive control mouse received an 
IM injection of pGL3 and MB suspension. The negative control mouse received an IV injection of 
PBS and MBs followed by 2 min of US exposure to the heart. Luciferase activity was measured in 
counts per second (CPS) and normalised to protein content. Data are shown as mean CPS/µg of 


























































Figure 3-21 Luciferase activity in ungrouped samples of ventricles, atria, and skeletal 
muscle of three UMGD treatment mice and the positive and negative control mice from 
study 6. 
(A) Ventricles, (B) atria, and (C) skeletal muscle samples ungrouped from UMGD treatment and 
control mice three days after in vivo gene delivery experiment. UMGD treatment mice were 
administered an IV injection of pGL3 and MB suspension followed by 2 min of US exposure to the 
heart. The positive control mouse received an IM injection of pGL3 and MB suspension. The 
negative control mouse received an IV injection of PBS and MBs followed by 2 min of US exposure 
to the heart. Luciferase activity was measured in counts per second (CPS) and normalised to 





In this chapter, optimisation studies led to development of an in vivo UMGD 
protocol demonstrating evidence of luciferase gene transfer to mouse hearts, 
which can be subsequently utilised to demonstrate proof-of-concept. These 
optimisation studies provided unique insights into specific aspects that can be 
amended in future UMGD studies to further enhance gene transfer. 
UMGD optimisation studies utilising pVIVO2-GFP/LacZ failed to provide evidence 
of gene transfer. Despite being designed for in vivo use, several features of the 
plasmid hindered its utility and may have contributed to a lack of gene transfer. 
pVIVO2-GFP/LacZ was consistently purified in an open-circular conformation, 
indicating damage to the plasmid (Schleef and Schmidt, 2004). If damage 
occurred within transcriptional units, this may have reduced its efficiency. In 
addition, its relatively large size compared to luciferase reporter vectors may 
have hindered its ability to enter cells. Previous in vitro studies investigating 
UMGD mechanisms show pore size plays a role in cellular uptake of plasmid DNA 
(Fan et al., 2013) and other molecules (Mehier-Humbert et al., 2005), with 
larger molecules showing poorer uptake. In terms of analysing reporter gene 
expression, consistent contamination in RT-qPCR experiments hindered use of 
the method to evaluate mRNA expression. Fluorescence IHC to examine protein 
expression also presented several limitations, with non-specific antibody binding 
and tissue autofluorescence producing high background signals. Skeletal muscle 
was selected as a positive control due to ease of and past experience with IM 
delivery of plasmid DNA; however, its use as a positive control hindered 
evaluation of different antibodies, antibody dilutions, and blocking conditions 
since IHC requires organ specific optimisation. Furthermore, evaluating gene 
transfer in tissue sections reduced the likelihood of detecting reporter genes 
since only a planar section of the kidney was targeted. This was due to 
stationary positioning of the 15L8 linear array probe, which emits a planar beam 
profile. Finally, endogenous LacZ in rat kidneys (Bolon, 2008) potentially masked 
evidence of gene transfer. These optimisation studies highlight the importance 
of considering the size of the plasmid and types of reporter genes and their 
required analysis for future UMGD studies. 
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UMGD optimisation study 3 employing the pGL4.13 plasmid to target the left 
kidney in rats also failed to demonstrate gene transfer. This may have arisen 
partially due to the footprint size of the 15L8 probe. A past study in canines 
reported significantly greater gene transfection with a planar unfocused 
transducer with a beam diameter of 52 mm compared to a focused transducer 
with a 13 mm diameter (Noble et al., 2013). Although a sweeping motion was 
performed to target a larger area as described in previous studies (Song et al., 
2011, Tran et al., 2019), the size of the 15L8 probe and its beam profile may not 
be sufficient to trigger UMGD in rat organs compared to smaller mouse organs 
when utilising similar parameters (Browning et al., 2011). Unfocused transducers 
can exhibit larger US fields than focused transducers, in turn corresponding with 
greater UMGD treatment areas when held stationary. Nonetheless, studies 
comparing unfocused and focused transducers keeping US, plasmid DNA, and MB 
conditions closely matched have found no significant difference in gene transfer 
levels (Song et al., 2011, Tran et al., 2019). Moreover, large animal studies have 
demonstrated successful gene transfer utilising commercial US probes with 
focused transducers (Babischkin et al., 2019, Bez et al., 2018). Hence, the 15L8 
probe may induce UMGD in rats but this requires adapting protocol parameters. 
Another factor that may have contributed to a lack of gene transfer was the 
dose administered, which was lower than the dose previously administered to 
mice (Browning et al., 2011). Due to the volume restrictions of an IV bolus dose, 
translating the protocol between species may therefore not only require 
optimising the dose but also administration method. 
UMGD optimisation study 4 targeting the left kidney in mice showed evidence of 
gene transfer at low levels close to background in contrast to the distinctly 
higher levels in mouse hearts seen in a previously published study on which the 
protocol was based (Browning et al., 2011). Several key differences in the 
protocol may have contributed to low levels observed, including targeting the 
kidney rather than the heart. SonoVue is a transpulmonary contrast agent rapidly 
cleared through the lungs. In humans administered the maximum clinical dose, 
more than 80% of SonoVue was exhaled within 2 min (EMA, 2008b), and, in rats 
administered SonoVue via the femoral vein, non-enhanced imaging was observed 
after 70 s (Liu et al., 2013). Thus, UMGD to the kidney may be less efficient than 
delivery to the heart due to involvement of the pulmonary first-pass effect with 
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venous administration of the plasmid and MB suspension. This is further 
corroborated by findings from a previous study that examined different 
administration routes for UMGD to the kidney reporting significantly greater 
gene transfer when administering plasmid and MBs via the renal artery in 
comparison with the tail vein (Chen et al., 2012a). In UMGD studies, improved 
transfection efficiencies with arterial rather than venous administration have 
further been shown in the heart (Liu et al., 2015) and skeletal muscle 
(Christiansen et al., 2003), indicating arterial administration is potentially a 
superior method in terms of gene transfer efficiency. However, arterial 
administration has shown to cause more tissue damage in part arising from 
entrapment of larger MBs not cleared by the pulmonary circulation in arterioles 
and capillary networks (Lindner et al., 2002). In addition, cannulation of mouse 
and rat arteries normally requires temporary inhibition of blood flow and is 
therefore more invasive. With non-invasive venous administration therefore 
persisting as the preferred route of administration, future studies should account 
for loss of MB dose due to the first-pass effect. 
There was evidence of transfer of the luciferase reporter gene with UMGD to 
mouse hearts, reflecting gene transfer seen in previous studies utilising similar 
protocol parameters (Browning et al., 2011, Browning et al., 2012). Although 
transfer levels were higher than the levels observed in UMGD optimisation 
studies targeting the kidney, large variability was evident in gene transfer 
levels. A key source of variability was the administration route, namely the tail 
vein injections. Although the tail was warmed prior to injections, IV placement 
was challenging, particularly given the relatively large size of needle gauge 
employed. A 25 G needle was utilised based on a previous study showing a 25 G 
needle significantly improved gene transfer compared to needles with a larger 
gauge (i.e. smaller internal diameter) due to a lower pressure gradient and less 
shear stress in needles with a larger diameter (Browning et al., 2011). In 
addition, viscosity of the suspension due to the plasmid concentration often 
caused the vein to collapse resulting in blanching of the tail. When multiple 
attempts were required, this led to loss of volume and visible alteration in MB 
characteristics due to the additional time required to administer the suspension. 
Challenges with tail vein injections hindered the reproducibility of the 
technique, supported by evidence of gene transfer seen in two of the three 
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UMGD treatment mice in this study. In turn, for the proof-of-concept study, only 
animals in which a full volume was administered without requiring multiple 
attempts were included.  
In this chapter, although optimisation studies largely produced negative results, 
they were important for the progression to a proof-of-concept study. Initial 
optimisation studies allowed issues to be identified and logical modifications to 
be made to the protocol. The in vivo protocol developed in this chapter was 
applied to a minimum of n=3 UMGD treatment animals to demonstrate proof-of-









Safe and effective delivery systems targeting the placenta remain central to the 
development of placental gene therapy for pregnancy-related disorders. Despite 
the translational progress of adenoviral-mediated delivery of VEGF for the 
treatment of FGR (Spencer et al., 2017), its invasive nature and safety concerns 
highlight the need for alternative strategies. Investigations by other research 
groups seeking to target the placenta with adenoviral vectors also highlight the 
safety issues associated with viral vectors. In pregnant rabbits, intraplacental 
injection of Ad-LacZ led to high transgene expression in the labyrinth zone of the 
placenta without histological changes (Keswani et al., 2015). While there was no 
evidence of gene transfer in the heart, ovary, or lung, off-target gene transfer 
was detected in the liver and spleen (Keswani et al., 2015). In the same study, 
although adenoviral insulin-like growth factor-1 (IGF-1) therapy restored foetal 
weight in a rabbit model of placental insufficiency, administration of the vector 
required invasive laparotomy surgery (Keswani et al., 2015). A separate group 
investigated distribution of a mutant adenoviral vector containing the Arg-Gly-
Asp (RGD) peptide sequence (Ad-RGD), a sequence shown to promote cell entry 
(Mizuguchi et al., 2001), following tail vein administration in pregnant C57BL/6J 
mice (Katayama et al., 2011). In comparison to the WT vector, Ad-RGD induced 
significant and sustained transgene expression in the placenta (Katayama et al., 
2011). Ad-RGD transduced foetal placental cells, and no transgene expression 
was found in the embryo. However, off-target gene transfer was evident in the 
liver, spleen, kidney, lung, heart, and colon of pregnant mothers (Katayama et 
al., 2011). While the high transfer efficiency of adenoviral vectors underpins 
their common use in preclinical investigations, the concern for off-target 
expression supports the development of non-viral strategies for targeting the 
placenta. 
Two in vivo studies have investigated intraplacental injections of non-viral 
vectors as a strategy for placental gene therapy. It has been postulated that 
intraplacental injections could be safely conducted in humans with US guidance 
(Krishnan and David, 2017). In comparison with viral vectors, where 
intraplacental administration can induce foetal gene transfer (Woo et al., 1997, 
Türkay et al., 1999), studies have shown naked plasmid DNA does not cross the 
placenta unless delivered as part of a complex (Gaensler et al., 1999, Efremov 
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et al., 2010). In contrast, a study in a mouse model of surgically induced FGR 
showed complexes consisting of a polymer and plasmid DNA expressing human 
IGF-1 under the control of trophoblast-specific promoters (Cyp19a or PLAC1) 
achieved targeted placenta delivery (Ellah et al., 2015). IGF-1 appeared to be 
localised to the placenta, with no expression detected in control placentas from 
the opposite uterine horn as well as foetal liver samples, although other 
maternal tissue was not evaluated (Ellah et al., 2015). Furthermore, there was 
no evidence of inflammation or immune infiltration with intraplacental delivery 
of PLAC1-hIGF-1 complexes, which promoted a significant increase in pup 
birthweight similar to that of healthy controls (Ellah et al., 2015). A study in L-
NAME induced PE-like rats showed intraplacental injection of agomir-126 caused 
a significant increase in miR-126 expression in treatment rats compared with 
non-treated PE rats (Yan et al., 2014). Expression of the miRNA in non-targeted 
tissue and foetuses was not evaluated, making it unknown whether placenta-
specific and in turn foetal gene transfer occurs with intraplacental delivery of 
chemically modified oligonucleotides. Nonetheless, miR-126 treatment led to 
significantly greater foetal and placental weights, placental microvessel density, 
and proportion of live pups (Yan et al., 2014). However, blood pressure was not 
significantly influenced, and urinary protein data were not shown, indicating 
maternal complications were not resolved. While this study highlights the 
potential of modulating placental miRNAs as a gene therapy strategy in PE, 
further investigations are warranted due to lack of a therapeutic benefit in the 
mother. Overall, the risk of foetal gene transfer and invasive nature of 
intraplacental injections limits the utility of this technique for clinical 
translation. A non-invasive and non-viral delivery system which specifically 
targets the placenta would be the ideal method. 
To address the need for placental-specific delivery, King et al. evaluated the 
ability of tumour-homing peptides (CGKRK or CRGDKGPDC) to target the 
placenta (King et al., 2016). FAM-labelled peptides administered via the tail vein 
to pregnant BALB/c mice accumulated in the labyrinth and decidual spiral 
arteries (King et al., 2016). Although the peptides were not seen in the heart, 
brain, liver, spleen, or lungs of dams, they were detected in the kidney (King et 
al., 2016). Liposomes were subsequently decorated with the peptides and 
administered via the tail vein to pregnant C57BL/6J mice (King et al., 2016). 
166 
 
Peptide-decorated liposomes were seen in the labyrinth and spiral arteries as 
well as maternal clearance organs (liver, spleen, and kidney) but notably absent 
from the maternal brain, heart, and lung as well as foetal tissue (King et al., 
2016). In a subsequent study, the therapeutic potential of placental homing 
peptide-miRNA inhibitor conjugates was evaluated (Beards et al., 2017). First, 
an unconjugated scramble miRNA inhibitor was administered intravenously to 
pregnant C57BL/6J mice; the inhibitor was present in the placenta (labyrinth, 
junctional zone, and decidua) and in maternal tissue (heart, liver, kidney, and 
uterus) but absent from foetal organs (Beards et al., 2017). It had no significant 
effect on median foetal or placental weights, foetal-placental weight ratio, 
litter size, and the number of resorptions, suggesting it was well-tolerated 
(Beards et al., 2017). A miR-145 inhibitor and miR-675 inhibitor were then 
separately conjugated to a CGKRK peptide and administered intravenously to 
pregnant C57BL/6J mice; miR-145 and miR-675 have previously shown to alter 
trophoblast properties in vitro and found to be dysregulated in patients with PE 
and FGR (Gao et al., 2012, Hromadnikova et al., 2015a, Farrokhnia et al., 2014). 
While the miR-675 inhibitor conjugate significantly reduced placental miR-675 
expression and significantly increased median placental weight compared to 
controls, the miR-145 inhibitor conjugate had no significant effect on placental 
miR-145 expression and median placental weight (Beards et al., 2017). Both 
conjugates had no significant effect on litter size or foetal resorptions, 
suggesting they were well-tolerated in the pregnant mice (Beards et al., 2017). 
However, off-target expression seen with the peptide-decorated liposomes and 
unconjugated scramble miRNA inhibitor demonstrates the difficulty in achieving 
targeted placental delivery with non-invasive gene therapy strategies. 
UMGD in conjunction with a plasmid vector represents a non-viral and non-
invasive method for targeted gene transfer. To date, a single published study has 
employed UMGD for targeting the placenta, with investigations conducted in a 
baboon model of impaired uterine artery remodelling to assess the role of VEGF 
in mediating the process (Babischkin et al., 2019). At multiple time points 
throughout gestation, cationic MBs conjugated to a plasmid encoding a VEGF 
isoform and GFP were administered for 10 min via a saphenous vein infusion 
during which the placental basal plate was exposed to US via a 2-6 MHz 6C2 
transducer (B-mode output, 5-second burst pulses, and 1.9 MI) (Babischkin et al., 
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2019). UMGD restored VEGF levels in EVTs (distal anchoring villi, 
cytotrophoblastic shell, and uterine arteries) and normalised the extent of 
remodelling in uterine arteries to that seen in healthy pregnant baboons 
(Babischkin et al., 2019). While the study demonstrates VEGF plays a key role in 
regulating trophoblast invasion and uterine artery remodelling in a non-human 
primate pregnancy, non-targeted maternal and foetal tissue were not analysed 
for transgene expression. Site-specific gene transfer with UMGD therefore 
remains essential for ensuring safety in the clinical translation of this research. 
In this chapter, a proof-of-concept study was conducted in non-pregnant mice 
utilising the heart as a surrogate organ to demonstrate tissue-specific gene 
transfer. The in vivo UMGD protocol developed in Chapter 3 (study 6) was 
utilised for the proof-of-concept heart study; however, pGL4.13 was used in 
place of pGL3 since pGL4 vectors harbour a synthetically engineered luciferase 
gene, luc2, that displays greater luciferase expression compared to pGL3 vectors 
(Promega, 2015). Subsequently, the UMGD protocol was applied to target the 
placenta of pregnant mice.  
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4.2 Hypothesis and aims 
4.2.1 Hypothesis 
UMGD induces tissue-specific gene transfer in vivo, representing a potentially 
non-viral and non-invasive gene delivery system for targeting the placenta. 
4.2.2 Aims 
• To show the in vivo UMGD protocol induces tissue-specific gene transfer of 
a reporter gene in a surrogate organ in a proof-of-concept study through 
hypothesis testing. 
• To apply the in vivo UMGD protocol to pregnant rodents in an exploratory 






All animal work was performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 under the authority of Home Office Licence 
70/9021. All animals were housed and maintained as detailed in section 2.3. The 
proof-of-concept UMGD study was conducted in CD-1 mice targeting the heart. 
The UMGD protocol was then applied to pregnant CD-1 mice to target the 
placenta. Virgin CD-1 females were mated with C57BL/6J stud males, with two 
females housed with one male per cage for 3 d. Females were examined for 
coital plug and also examined by US on gestational day (GD) 12.5-14.5 to confirm 
pregnancy. The number of mice recruited and those excluded and included in 
the proof-of-concept heart study and placenta study are shown in Figure 4-1 and 
Figure 4-2, respectively. Only mice in which the full volume of injection 
suspension was administered without requiring multiple attempts were included 
in the study analysis. A minimum of n=3 was selected for the treatment group in 
the proof-of-concept heart study to enable inferential analysis for hypothesis 
testing. A minimum of n=1 was selected for the treatment group in the placenta 
study due to the exploratory nature of the research; however, n=12 females 
were time mated to account for lack of breeding. Non-pregnant mice were 
excluded from the placenta study, and in turn, used in the proof-of-concept 
heart study (Figure 4-1 and Figure 4-2). An n=1 for the negative control and 
positive control groups was chosen in both studies as this represents the 
minimum number required to interpret the results from the treatment groups in 
each study. Formal randomisation and blinding were not performed; the order of 
experimental groups was decided prior to experiments, (negative control, UMGD, 
and then positive control group) to avoid contamination in negative control 
animals. No a prior criteria were used when randomly selecting animals from the 
cage. Mice were sacrificed 3 d after UMGD (GD 15.5-17.5), and target and non-
target organs were snap frozen for evaluation of reporter gene transfer by 
analysis of enzymatic activity. 
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4.3.1 Plasmid DNA preparation for in vivo use  
4.3.1.1 Plasmid DNA purification 
Plasmid DNA was transformed into competent MAX Efficiency™ DH5α™ 
Competent Cells as detailed in section 2.1.2.1. Glycerol stocks were prepared as 
a long-term stock as detailed in section 2.1.2.2. pGL4.13 was purified by 
filtration using the Invitrogen™ PureLink™ HiPure Expi Plasmid Megaprep Kit 
(ThermoFisher, Vilnus, Lithuania) as detailed in section Plasmid DNA with an 
A260/A280 ratio of ~1.8 was accepted as ‘pure’ DNA as detailed in section 
2.1.2.7. 
4.3.1.2 Analytical gel of samples from plasmid DNA purification 
Samples from stages of the plasmid DNA purification were precipitated as 
detailed in section 2.1.2.5. Samples were run on a 1% agarose gel as detailed in 
section 2.1.3 to assess efficiency of the purification procedure, specifically: 
growth and lysis conditions, efficiency of column loading, plasmid DNA binding, 
removal of RNA, and contamination. Purified plasmid DNA was run on the same 
analytical gel to confirm isolation of plasmid DNA, lack of contamination in the 
final product, and conformation of the plasmid. Only plasmid DNA considered 





Figure 4-1 Flow diagram illustrating number of mice recruited, excluded, and included in 
each experiment for the UMGD proof-of-concept study targeting mouse hearts. 
Mice in each cohort underwent procedures on the same day, but procedures between cohorts were 
performed on separate days. Mice were excluded if the tail vein injection was unsuccessful or 
required multiple attempts. POC, proof-of-concept; UMGD, ultrasound-mediated gene delivery; PC, 
positive control; NC, negative control. 
 
Figure 4-2 Flow diagram illustrating number of mice recruited, excluded, and included in the 
UMGD study targeting the placenta. 
Pregnant mice were excluded if the tail vein injection was unsuccessful. *Non-pregnant mice were 
excluded to use in experiment 4 for the UMGD proof-of-concept study in the heart. POC, proof-of-
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4.3.2 Plasmid DNA and MB suspension 
The plasmid DNA and MB suspension was prepared on an individual basis for each 
animal in UMGD studies as detailed in section 2.3.1. The volume of plasmid DNA 
and MBs administered is listed in Table 4-1. 
4.3.3 UMGD studies 
4.3.3.1 UMGD 
UMGD was conducted as detailed in section 2.3.3. For each UMGD study, details 
of the type of plasmid; target organ; probe hold/output; animal strain, sex, age, 
weight, and treatment; total and group n-numbers of animals; injection site; 
and volumes administered are listed in Table 4-1. 
4.3.3.2 Negative and positive control animals 
For all studies, negative control animals underwent a similar procedure as UMGD 
treatment animals as detailed in section 2.3.3.3, with all modifications listed in 
Table 4-1. Positive control animals underwent the same procedure as detailed in 
section 2.3.3.3, with all modifications listed in Table 4-1. 
4.3.3.3 Sacrifice and tissue processing 
Animals were euthanised 3 d after UMGD procedures as detailed in section 2.3.4. 
Tissues were harvested and processed as detailed in section 2.3.5. The position 
and number of foetoplacental units in each uterine horn was recorded as shown 




























POC heart pGL4.13 heart stationary / 
on 
CD-1 (11) F 6-8 25-33 UMGD (5) tail vein 50 150 - 
   F 6-8 28, 30 NC (2) tail vein - - 200 
    F 6-8 26-32 PC (4) gracilis muscle 50 - - 
Placenta pGL4.13 placenta stationary / 
on 
CD-1 (5) F 6-8 37-49 UMGD (3) tail vein 50 150 - 
   F 6-8 49 NC (1) tail vein - - 200 
    F 6-8 29 PC (1) gracilis muscle 50 - - 
All values (strain, sex, weight, and treatment parameters) for animals were collected and/or noted prior to treatment. POC, proof-of-concept; F, female; M, male; wks, 





Figure 4-3 Diagram to show an example of the numbering system of foetoplacental units in 
the uterine horns. 
Foetoplacental units (indicated by the black box) were numbered according to their positioning 





4.3.4 RNA extraction and quality control 
RNA was extracted from tissue samples as detailed in section 2.1.4. Mouse tissue 
was homogenised using TissueLyser (QIAGEN, Haan, Germany). RNA quality and 
concentration were assessed as detailed in section 2.1.4.1. 
4.3.5 Luciferase activity 
Luciferase activity was measured as detailed in section 2.5.3 and normalised to 
protein content, which was extracted by bead-milling as detailed in section 
2.5.1 and measured as detailed in section 2.5.2. 
4.3.6 Statistical analysis 
GraphPad Prism 9 was used to analyse all data sets. Luciferase activity data are 
shown as mean CPS/µg of protein ± SEM. Luciferase activity data in tissue from 
UMGD treatment mice were analysed by Friedman’s test followed by Dunn’s 






4.4.1 UMGD proof-of-concept study delivering luciferase plasmid 
to mouse hearts 
4.4.1.1 Purification of pGL4.13 
pGL4.13, a 4641 bp vector expressing luc2 (modified Photinus Pyralis luciferase 
gene) was selected to demonstrate proof-of-concept since pGL4 vectors harbour 
a synthetically engineered luciferase gene, luc2, that displays greater luciferase 
expression compared to pGL3 vectors (Promega, 2015). In order to assess 
efficiency of the purification of pGL4.13 and plasmid conformation of isolated 
pGL4.13, samples from stages of the purification procedure and the final plasmid 
product were run on an agarose gel. In the cleared lysate (lane L) and elute 
(lane E), a band ~6000 bp indicates plasmid DNA was enriched in the samples 
(Figure 4-4). No bands in the flow-through fraction (lane F) and wash fraction 
(lane W) demonstrates plasmid DNA was bound to the column and degraded RNA 
was removed (Figure 4-4). Finally, a band ~5000 bp and faint band above the 
DNA ladder in the plasmid only samples (lane P1 and P2) shows plasmid DNA was 





Figure 4-4 Representative agarose gel image of samples from stages of purification of 
pGL4.13 plasmid mega preps. 
pGL4.13 plasmid was isolated from E. coli mega preps during which samples were collected to 
assess the stages of the purification procedure and confirm isolation of plasmid DNA. Up to 10 μL 
of the sample or 250 ng of DNA was loaded per lane and sized on a 1% agarose gel, using a 1 kb 
DNA ladder; sizes indicated in bp. Lane L: cleared lysate, lane F: flow-through fraction, lane W: 





4.4.1.2 In vivo UMGD of pGL4.13 to mouse hearts 
The UMGD protocol established in the previous chapter (Chapter 3) was utilised 
to demonstrate proof-of-concept UMGD of pGL4.13 to mouse hearts.  
Luciferase activity in the ventricles and atria of UMGD treatment mice 
(12.28±17.04 and 1.11±1.42 CPS/μg of protein, respectively) was higher than 
background luciferase activity in the ventricles, atria, skeletal muscle, left 
kidney, right kidney, liver, lungs, and spleen of the negative control mouse 
(0.17±0.17, 0.92±0.80, 0.64±0.21, 0.04±0.04, 0.00±0.01, 0.04±0.06, 0.07±0.06, 
and 0.00±0.00 CPS/μg of protein, respectively) (Figure 4-5A), suggesting UMGD 
of pGL4.13 to the heart. Luciferase activity was highest in the skeletal muscle of 
the positive control mouse (382.26±632.70 CPS/μg of protein) (Figure 4-5A). In 
UMGD treatment mice, luciferase activity was significantly greater in the 
ventricles (12.28±17.04 CPS/μg of protein, p<0.01) compared to the non-target 
organs liver, lungs, and spleen (0.05±0.07, 0.05±0.1, and 0.01±0.03 CPS/μg of 
protein, respectively) (Figure 4-5B), providing evidence of tissue specific UMGD 
of pGL4.13 to mouse hearts. There was no significant difference between any 
other tissue of the UMGD treatment mice. 
With this proof-of-concept study demonstrating tissue-specific UMGD in mice, 




Figure 4-5 Luciferase activity in ventricles, atria, skeletal muscle, and other non-target 
organs of UMGD treatment mice and positive and negative control mice. 
Luciferase activity in tissues from (A) UMGD treatment and control mice and (B) only UMGD 
treatment mice three days after in vivo gene delivery experiment. UMGD treatment mice were 
administered an IV injection of pGL4.13 and MB suspension followed by 2 min of US exposure to 
the heart. The positive control mice received an IM injection of pGL4.13. The negative control mice 
received an IV injection of PBS followed by 2 min of US exposure to the heart. Line at y=0.92 
designates highest mean value from negative control mice tissue, indicating values below are 
background luciferase activity. Luciferase activity was measured in counts per second (CPS) and 
normalised to protein content. Data are shown as mean CPS/μg of proteinSEM, n=2 negative 
control mice, n=4 positive control mice, and n=5 UMGD treatment mice. **p<0.01 and ***p<0.001, 
n=5 UMGD treatment mice, analysed by Friedman’s test followed by Dunn’s post-hoc multiple 
comparisons test.  
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4.4.2 UMGD of pGL4.13 to the placenta in pregnant mice 
The in vivo UMGD protocol utilised in the previous proof-of-concept study 
demonstrating tissue-specific gene transfer of pGL4.13 to mouse hearts was 
applied to pregnant mice to target the placenta. The total number of 
foetoplacental units in the targeted left uterine horn and non-targeted right 
uterine horn as well as the number of resorptions is shown in Table 4-2. In turn, 
in UMGD treatment mouse 1, 2, and 3, a total of 6, 7, and 7 placentas were 
potentially targeted. 
Low levels of luciferase activity were detected in placenta 1 from UMGD 
treatment mice 1, 2, and 3 (0.80±0.18, 0.50±0.22, and 0.59±0.04 CPS/μg of 
protein, respectively), which were higher than the highest background activity 
detected in placenta 1 from the negative control mouse (0.29±0.14 CPS/μg of 
protein) (Figure 4-6), providing evidence of gene transfer to the placenta. 
However, only two samples from placenta 1 from UMGD treatment mouse 1 (1.12 
and 0.76 CPS/μg of protein) and one sample from placenta 1 from UMGD 
treatment mouse 2 (0.92 CPS/μg of protein) were higher than the highest 
background activity detected in a placenta sample (placenta 2) from the 
negative control mouse (0.72 CPS/μg of protein) (Figure 4-6). In all other 
placentas from the UMGD treatment mice, luciferase activity was lower than the 
background activity in placenta 1 from the negative control mouse (Figure 4-6). 
Highest luciferase activity was detected in skeletal muscle from the positive 




Table 4-2 Pregnancy outcomes in mice included in the UMGD study targeting placentas in 
the left uterine horn.  
Mouse Number of foetoplacental units Number of resorptions 
 left uterine horn right uterine horn  
UMGD treatment mouse 1 6 4 0 
UMGD treatment mouse 2 7 3 1* 
UMGD treatment mouse 3 7 6 0 
Negative control mouse 7 6 0 
Positive control mouse N/A N/A N/A 





Figure 4-6 Luciferase activity in the placenta of UMGD treatment mice and the negative control mouse and in skeletal muscle of the positive control mouse. 
Luciferase activity in tissues from UMGD treatment and control mice three days after in vivo gene delivery experiment. UMGD treatment mice were administered an IV 
injection of pGL4.13 and MB suspension followed by 2 min of US exposure to placenta in the left uterine horn. The positive control mouse received an IM injection of 
pGL4.13. The negative control mouse received an IV injection of PBS followed by 2 min of US exposure to placenta in the left uterine horn. Luciferase activity was not 
measured in skeletal muscle from the UMGD treatment mice and negative control mouse. A non-pregnant mouse was used as a positive control, so no placental tissue 
was available to measure. Line at y=0.29 designates highest mean value from negative control mice tissue, indicating values below are background luciferase activity. 
Luciferase activity was measured in counts per second (CPS) and normalised to protein content. Data are shown as mean CPS/μg of proteinSEM, n=3 tissue 







































UMGD may act as a non-viral and non-invasive method for targeting the 
placenta, representing a potentially new form of treatment for disorders arising 
from abnormal placental development, such as PE. In this chapter, an in vivo 
UMGD protocol was developed, demonstrating proof-of-concept of tissue-specific 
gene transfer of a luciferase plasmid to mouse hearts. When applied to pregnant 
mice to target the placenta, low levels of gene transfer were evident. Although 
expression in non-target tissue was not evaluated due to time constraints, this 
study provides a basic protocol for future UMGD studies seeking to target the 
placenta. 
Tissue-specific gene transfer was demonstrated in the proof-of-concept UMGD 
study targeting mouse hearts. Transfer levels were higher than UMGD 
optimisation studies in the previous chapter (Chapter 3), demonstrating the 
importance of administering the full volume of the plasmid DNA and MB 
suspension in a single attempt. Due to small n-numbers, significance testing was 
not performed comparing tissue from the negative control mice with UMGD 
treatment mice. However, statistical analysis of target and non-target tissue 
from the UMGD treatment mice showed significantly greater luciferase activity 
was evident in the ventricles compared to some non-target organs (liver, lungs, 
and spleen), providing evidence of targeted gene transfer to the heart. Although 
there was a trend towards greater luciferase activity in the ventricles compared 
with the remaining non-target organs (skeletal muscle, left kidney, and right 
kidney), this was non-significant. Large variability was evident between both 
biological and technical replicates. Time constraints however meant that 
additional animals could not be included. In addition to biological variability 
arising from small n-numbers, several other sources likely contributed to 
variability in reporter gene activity as discussed in the following section. 
In the proof-of-concept study targeting the heart, higher reporter gene activity 
was seen in the ventricles compared with the atria. This was expected since the 
left ventricle makes up the majority of the parasternal long axis view, with only 
a portion of the right atrium and left atrium in view. This degree of spatial 
targeting is supported by previous UMGD studies evaluating gene transfer across 
the heart. In a UMGD study in pigs seeking to target the left ventricular anterior 
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wall, positioning the probe in a parasternal long axis view and mid short axis 
view led to significantly increased transgene expression in the left ventricular 
anterior versus posterior wall (Schlegel et al., 2016). A study in rats found 
keeping the probe stationary (parasternal short axis view) or in motion (cranio-
caudal direction) led to differing efficiencies between the anterior and posterior 
ventricles, apex, and atria, with lowest levels in the atria (Geis et al., 2009). In 
the proof-of-concept study, despite dividing the heart into atrial and ventricular 
samples to account for varying transfer levels across regions, high variability was 
still evident within samples. Moreover, adapting the tissue protein extraction 
protocol with the intent of achieving greater uniformity between samples from 
the same tissue did not reduce variability within samples. This highlights several 
factors that may be optimised in future experiments. Firstly, dividing tissue into 
further sections may help reduce variability in luciferase readings. Human 
technical variability in US imaging also likely contributed to differences in 
treatment area targeted. Rigs or platforms to position and control transducers 
may help reduce human variability but are more relevant to studies in which 
spatial specificity is crucial. The probe was held stationary in the proof-of-
concept study to minimise the risk of misaligning the transducer focal point with 
the heart due to the beating motion of the heart. However, previous studies 
show performing a sweeping motion with the probe across the target organ leads 
to more uniform gene transfer across a larger region (Shen et al., 2008, Geis et 
al., 2009). This may represent a suitable strategy in stationary organs or to 
reduce variability if specificity is not a priority, particularly in larger organs or 
animals where there is a reduced risk of misaligning the probe beam with the 
target organ. Finally, whole animal bioluminescence could be used as an 
alternative to evaluate luciferase activity in intact target and non-target organs. 
Gene transfer levels in the heart were lower compared with positive control 
levels in skeletal muscle following IM delivery of plasmid DNA. A previous UMGD 
study in rats similarly found IM injection of naked plasmid DNA into hindlimb 
skeletal muscle resulted in higher gene transfer levels than IV UMGD to the heart 
when using the same dose of plasmid DNA (Christiansen et al., 2003). Despite 
the apparent advantage of greater gene transfer seen with IM delivery of naked 
plasmid DNA, UMGD has consistently shown to induce significantly greater gene 
transfer than injection of naked plasmid DNA when targeting the same organ, 
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including in skeletal muscle (Wang et al., 2005), the liver (Shen et al., 2008), 
and the heart (Kondo et al., 2004). Comparing gene transfer levels between 
delivery methods to different organs rather than the same organ may therefore 
not accurately reflect transfer efficiency. Nonetheless, the positive control 
provided means of ascertaining that signals represented reporter gene transfer 
rather than an artefact and confirmed that the reporter gene was active and 
measurable. 
In the study targeting the placenta, there was evidence of low levels of gene 
transfer, with mean luciferase activity higher in a single placenta in each UMGD 
treatment mice than the highest mean background luciferase activity detected 
in a placenta from the negative control mouse. However, only three 
experimental samples of placentas from UMGD treatment mice were higher than 
the highest background activity detected in an experimental placenta sample 
from the negative control mouse. These findings highlight gene transfer was 
inconsistent between samples and that reproducibility remains an issue with this 
technique. In addition to the factors previously discussed in the heart that likely 
contributed to variability and the strategies that could be adopted to reduce 
technical and biological variability, several factors may have contributed to a 
lack of reproducibility in the placenta and findings from the placenta offer 
insight into parameters that could be optimised in future UMGD studies to 
enhance gene transfer as discussed in the following section. 
For every pregnant mouse subject to UMGD treatment, low levels of gene 
transfer were evident in the placenta positioned closest to the cervix on the 
targeted left uterine horn. In rodents, evidence suggests arteries supplying the 
placenta exhibit bidirectional inflow, in that they simultaneously receive blood 
from ovarian and uterine arteries, with the common iliac arteries at the cervical 
end acting as the predominant source (Raz et al., 2012, Ko et al., 2018). This 
physiological mechanism offers an explanation for evidence of gene transfer 
restricted to the placentas located closest to the cervix. However, these results 
may instead reflect coincidental targeting of the placenta located in this 
position in all treatment mice. Identifying the placenta targeted by UMGD 
remains difficult due to the inability to identify the positioning of placentas 
along a uterine horn in utero and the presence of multiple placentas on the US 
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display during imaging. Although irrelevant to nulliparous animals, this has 
important implications for preclinical UMGD studies targeting the placenta in 
litter-bearing animals. Additional studies are therefore required to further 
investigate whether gene transfer to the placenta positioned closest to the 
cervix occurred as a result of physiological or experimental factors. Micro-
ultrasound is a type of US that operates at higher frequencies and therefore has 
higher a resolution than conventional diagnostic US. Studies in mice have shown 
micro-ultrasound can be used to examine embryonic and placental development 
due to its ability to identify specific foetoplacental units in utero (Foster et al., 
2002, Mu et al., 2008). Hence, the system could be used to further investigate 
gene transfer to the placenta closest to the cervix, although this would require 
access to specialised US equipment. 
Low levels close to background in the placenta of pregnant mice subject to 
UMGD, similar to those seen when targeting the kidney in optimisation studies 
(Chapter 3), highlight the need for future studies to adjust plasmid DNA and MB 
doses to account for the first pass-effect. Studies have shown greater gene 
delivery with increasing concentrations of a variety of MBs (Song et al., 2011, 
Panje et al., 2012, Shapiro et al., 2016), although highest efficiency was noted 
at sub-maximal concentrations. A larger number of MBs increases the probability 
of cavitation-induced mechanisms required for gene transfer, but transfer could 
be limited by the availability of plasmid. Another proposed mechanism for 
optimal gene transfer seen with sub-maximal MB concentrations is that cellular 
damage arising from higher MB concentrations limits gene transfer, supported by 
in vitro (Zhou et al., 2012, Nomikou et al., 2012, Rahim et al., 2006) and in vivo 
studies (Koike et al., 2005). Potential safety issues arising from higher MB 
concentrations and volume restrictions of injections may limit the ability to 
adjust the MB dose to account for the first-pass effect. Optimisation of other 
parameters may therefore be required to improve gene transfer efficiency. 
Previous UMGD studies have shown plasmid dose-related increases in gene 
delivery (Pislaru et al., 2003, Panje et al., 2012, Shapiro et al., 2016). Similar to 
MB concentration, greatest gene delivery was evident at sub-maximal plasmid 
doses, suggesting involvement of other factors limiting gene transfer efficiency. 
While raising plasmid DNA concentration increases the amount of genetic 
material available for gene transfer, it remains to be seen whether further 
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elevations would correspond with greater gene transfer. Moreover, it is 
important to consider that obtaining the required volume of plasmid DNA at 
higher concentrations may be technically challenging and the resulting more 
viscous plasmid DNA suspensions may further complicate tail vein injections. 
In support of cavitation exerting a dominant influence over gene transfer levels, 
an in vivo study evaluating UMGD parameters for targeting cardiac tissue found 
significantly greater gene transfer at a higher MI and lower frequency (Chen et 
al., 2003). Furthermore, multiple in vivo studies targeting different organs and 
utilising different plasmids, MBs, and US parameters show a proportional 
relationship between peak negative pressure (PNP) and gene transfer (Miao et 
al., 2005, Song et al., 2011, Xie et al., 2012), with increases in acoustic pressure 
determining the extent of tissue damage. In the current study, an MI of 1.8 and 
frequency of 7 MHz were utilised corresponding to a PNP of 4.76 MPa. These 
settings were selected to enhance cavitation-related bioeffects compared to 
those achieved with 6 MHz and 1.6 MI, parameters utilised by the previous study 
on which the protocol was based (Browning et al., 2011). The parameters 
selected therefore represent the upper limits of the probe, with 1.9 the MI limit 
of diagnostic US systems. Future studies could further increase the MI from 1.8 
to 1.9 by setting the probe output to contrast pulsed sequencing (Anderson et 
al., 2010, Steinl et al., 2016). In support, in vivo studies examining acoustic 
output have shown triggered US produces significantly greater gene transfer 
compared to continuous wave output (Chen et al., 2003, Pislaru et al., 2003). 
This is assumed to arise from replenishment of MBs between pulsing intervals. 
However, optimising output parameters to further stimulate cavitation increases 
the risk of tissue damage. UMGD studies evaluating differing acoustic pressures 
showed tissue damage arising at levels greater than 2 MPa (Miao et al., 2005, 
Song et al., 2011, Xie et al., 2012), notably lower than the PNP of 4.76 MPa 
utilised in the current study. Although safety assessments were not conducted, 
measurements provided by clinical US machines often display overestimated 
parameter values as a safety measure. Experimental validation of the US output 
of the 15L8 probe with a hydrophone and water bath set-up found that at H14 
MHz (7 MHz output) the measured MI was 0.71 and MPa was 1.73, notably lower 
than the value displayed on the US machine (MI of 1.8) (Alete, 2008). Hence, 
optimising the MI, frequency, and/or PNP to increase the likelihood of cavitation 
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may not lead to the expected tissue damage based on the values displayed on 
the US machine, although this requires evaluation with safety assessments. 
Other parameters that have been examined in vivo, including duty cycle (Chen 
et al., 2011), pulse duration (Miao et al., 2005, Shen et al., 2008), and pulse 
length (Shen et al., 2008), were found to have no significant effect on gene 
transfer. Multiple studies also report extending treatment time beyond 2 min has 
no significant effect on transfer efficiency (Koike et al., 2005, Shen et al., 2008, 
Chen et al., 2011, Shapiro et al., 2016). This coincides with the short half-life of 
naked plasmid DNA and MBs under 10 min. Studies show trends towards higher 
intensities promoting gene transfer, but this parameter is not amenable on 
clinical diagnostic US machines (Chen et al., 2011, Sonoda et al., 2006, Liu et 
al., 2015). An alternative to adjusting output settings of the 15L8 probe is to 
evaluate other clinical transducers. Given the consistent use of frequencies ~1 
MHz, a probe with lower frequencies may be desirable. 
Another fundamental change that could be made is the type of MB employed. A 
UMGD study targeting skeletal muscle following IM plasmid DNA and MB 
administration found significantly greater gene transfer with SonoVue compared 
with Optison or Levovist (Wang et al., 2005). In contrast, a UMGD study targeting 
the heart following systemic administration of the plasmid DNA and MB 
suspension found Optison and Sonazoid induced significantly greater gene 
transfer (Alter et al., 2009). Further investigations found that the increased 
stability, rather than differences in the size and shell, account for the improved 
results with Optison and Sonazoid (Alter et al., 2009). Other studies have shown 
that MB size and shell composition significantly influence gene transfer (Liao et 
al., 2014, Browning et al., 2012). This highlights the uncertainty as to which MB 
most efficiently mediates gene delivery, likely dependent on multiple factors, 
including US parameters, target organ, and method of administration. 
Nonetheless, the negatively charged phospholipid shell of SonoVue does not bind 
negatively charged plasmid DNA, making the plasmid susceptible to degradation 
by nucleases in the blood. In turn, loading plasmid DNA into or onto MBs has 
shown to improve transfer efficiency. Multiple studies have shown greater gene 
transfer with positively charged cationic versus neutral MBs (Panje et al., 2012, 
Wang et al., 2012a) and MB-DNA complexes versus MBs alone (Chen et al., 2011, 
Burke et al., 2012). Introducing targeting moieties onto MBs has also shown to 
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enhance gene transfer (Xie et al., 2012). With SonoVue selected due to its 
availability and ease of preparation, future studies should take into 
consideration the convenience and feasibility of using other types of MBs. 
Targeting the placenta with UMGD remains a potential form of non-viral and 
non-invasive gene therapy for disorders characterised by placental dysfunction. 
Although low levels of placental gene transfer were observed, plasmid DNA 
and/or MB volume and US parameters (MI or frequency) could be optimised in 
the protocol. Further changes including the type of probe and MB employed 
could also be incorporated. While this chapter provides a protocol for UMGD to 
the placenta, evaluation of safety parameters and demonstration of site-specific 
gene transfer through examination of non-target organs with the technique is 
still warranted for development of UMGD as a safe and effective method for 
targeting the placenta. 
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Chapter 5 Literature review of differentially 
expressed miRNAs in patients with PE and 
evaluation of candidate miRNAs in a rat model 






Since the discovery that placental miRNAs are dysregulated in patients with PE 
(Pineles et al., 2007), preclinical and clinical studies have sought to elucidate 
the role of placental miRNAs in the pathology of PE. In 2016, a systematic review 
of 24 expression profiling studies, of which 19 were conducted in placental 
tissue, identified 241 unique miRNAs differentially expressed in patients with PE 
(Sheikh et al., 2016). MiR-223, miR-210, and miR-126 were amongst the top 10 
most frequently detected differentially expressed miRNAs in the placenta 
(Sheikh et al., 2016). Through examination of candidate and preclinical studies, 
the review found the miRNAs were implicated in key pathological processes of 
PE, namely immunity, ischaemia/hypoxia, and angiogenesis/vasculogenesis, 
respectively (Sheikh et al., 2016). Despite these studies providing evidence for a 
pathological role of these miRNAs in PE, a caveat lies in their reported direction 
of expression. Clinical studies show conflicting findings as to whether the 
miRNAs are up- or downregulated in preeclamptic placentas (Frazier et al., 
2020). Besides methodological factors, these conflicting findings may be 
attributed to various biological factors, with placental miRNA expression found 
to differ between PE subtypes (Lykoudi et al., 2018, Weedon-Fekjær et al., 
2014), presenting symptoms (Pineles et al., 2007, Awamleh et al., 2019), 
gestational age (Hromadnikova et al., 2015a, Anton et al., 2015, Yang et al., 
2019b), and placental layers (Zhang et al., 2015a, Xu et al., 2014a). 
Identifying a placental miRNA signature characteristic of PE or a subset of 
patients remains essential to identifying miRNAs that represent a clinically 
relevant therapeutic target. As PE is a disease almost exclusive to humans, 
clinical studies provide information essential to our understanding of placental 
miRNAs in PE. Animal models on the other hand provide a means of exploring the 
role and therapeutic potential of miRNAs in PE. Despite the unique insights and 
translational research that animal models offer, a limited number of studies 
have investigated placental miRNAs in animal models of PE (Kopriva et al., 2013, 
Yan et al., 2014, Yang et al., 2016a, Wang et al., 2020c). 
Our research group previously established a novel model of SPE using Ang II at 
500 ng/kg/min or 1000 ng/kg/min infusion from GD 10.5 in pregnant SHRSP rats 
(Morgan et al., 2018). On top of pre-existing hypertension, the 1000 ng/kg/min 
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treatment group displayed significantly elevated systolic and diastolic blood 
pressure compared to vehicle controls (Morgan et al., 2018). The 
albumin:creatinine ratio was also significantly increased in SPE rats compared to 
pre-Ang II levels and vehicle controls (Morgan et al., 2018). These findings 
highlight the animal model mirrors the clinical manifestations of a rise in blood 
pressure and new-onset proteinuria often characteristic of SPE in patients 
(Giannubilo et al., 2006, Townsend et al., 2016). SPE can also be diagnosed in 
the absence of a rise in blood pressure or new-onset proteinuria if maternal 
organ dysfunction develops (Brown et al., 2018). In SPE rats, histological 
examination of kidneys revealed morphological abnormalities, with evidence of 
Bowman capsule defects and reductions in the space between the visceral and 
parietal layers (Morgan et al., 2018). SPE rats treated with 1000 ng/kg/min also 
showed significant reductions in foetal and placental weight and uterine artery 
diameter and cross-sectional area, reflecting perinatal and maternal features 
seen in patients with SPE (Giannubilo et al., 2006). By exhibiting the 
haemodynamic and urinary profiles as well as multiorgan dysfunction of SPE in 
patients, our novel rat model of SPE provides a means of studying the role of 
placental miRNAs in a subtype of PE. 
This chapter initially conducted a literature review to collate evidence from 
patient studies and identify clinically relevant miRNAs of potential interest for 
therapeutic targeting. Subsequently, the expression of candidate miRNAs was 
evaluated in our rat model of SPE, marking the first study to investigate 
placental miRNAs in an animal model of a PE subtype. To explore the biological 
factors that may contribute to differences in the reported direction of miRNA 
expression in clinical studies, miRNA expression was evaluated in whole 
placental tissue as well as individual placental layers. Examining placental 
miRNA expression in preclinical models is crucial to driving forward research 
investigating the therapeutic potential of targeting placental miRNAs.  
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5.2 Hypotheses and aims 
5.2.1 Hypotheses 
• Specific miRNAs are consistently dysregulated in placentas of patients 
with PE. 
• Similar patterns of differentially regulated miRNAs are observed in the 
placenta of a preclinical model of PE when compared to human data in 
the literature. 
5.2.2 Aims 
• To identify significantly differentially expressed miRNAs detected by 
three or more miRNA expression profiling studies conducted in third 
trimester placentas of patients with PE through a literature review. 
• To select candidate miRNAs for evaluation in a rat model of SPE through a 
literature review. 
• To examine the expression of candidate miRNAs in whole placental tissue 





5.3.1 Literature review of miRNA expression profiling studies 
5.3.1.1 Database search 
A literature search was conducted using PubMed database for records published 
between the period January 1990 to March 2018 with the following search terms: 
(pre-eclamp OR preeclamp) AND (miR OR microRNA) (Figure 5-1). The search 
strategy was to identify miRNA expression profiling studies investigating 
differentially expressed miRNAs in third trimester placentas of patients with PE 
compared to normotensive controls without PE. The overall aim was to identify 
significantly differentially expressed placental miRNAs detected by three or 





Figure 5-1 Flow diagram of number of records identified and screened, full-text articles 
excluded, and studies included in the literature review. 
The search strategy was to identify miRNA expression profiling studies investigating differentially 
expressed miRNAs in third trimester placentas of patients with PE compared to normotensive 
controls without PE.   
Records identified through database search





Full-text articles excluded, 
with reasons
(n =   )
Records excluded
(n=63)
Abstract: full-text article not available (n=4)
Lecture: record is a lecture (n=1)
Comment: record is a comment (n=2)
Review: record is a review (n=53)
Language: record is not in English (n=3)
Full-text research articles 
assessed for eligibility
(n = 183)
Studies included in 
literature review
(n = 15)
Full-text research articles excluded
(n=168)
Candidate: article was a candidate study (n=126)
Bioinformatics: article used bioinformatics only (n=6)
Miscellaneous: article examined histology or 
methodology (n=3)
Study design: samples collected not from patients 
with PE, not human placenta, before 3rd trimester, or 
miRNAs not examined (n=25)
Comorbidities: case and/or controls with 
comorbidities (n=2)




5.3.1.2 Study selection 
Records were initially screened by screening abstracts to identify full-text 
research articles available in English. Thereafter, abstracts or full texts were 
assessed for eligibility according to the study selection criteria: 
1. The study has conducted a miRNA expression profiling experiment (i.e. 
microarray or sequencing) to investigate differentially expressed 
placental miRNAs in patients with PE. 
2. The study has examined third trimester placentas, with the time of tissue 
collection stated, comparing individuals diagnosed with PE to 
normotensive controls. 
3. The study has provided data of some or all miRNAs detected as 
significantly differentially expressed by the miRNA expression profiling 
experiment. 
For all studies included in the literature review, the full text was assessed for 
eligibility. Studies were included regardless of the type of PE investigated (i.e. 
diagnosed, mild, severe, EO, LO, and/or superimposed). 
5.3.1.3 Data collection 
From the studies included in the literature review, data were collected of all 
miRNAs reported as significantly differentially expressed between cases and 
controls, with significance defined by the study (e.g. p-value and fold change). 
Further information collected included type of study (i.e. microarray and/or 
sequencing), type of PE (i.e. diagnosed, mild, severe, EO, LO, and/or 
superimposed), sample size, type of delivery (preterm or term), and sampling 
area within the placenta. 
5.3.1.4 Data analysis 
Data of significantly differentially expressed placental miRNAs from individual 
studies was collated to identify miRNAs detected by three or more miRNA 
expression profiling studies. 
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5.3.2 Literature review for selection of candidate miRNAs 
A literature review was conducted of the miRNAs identified as significantly 
differentially expressed in three or more miRNA expression profiling studies in 
third trimester placentas of patients with PE in order to select candidate miRNAs 
for evaluation in a rat model of SPE. 
5.3.2.1 Criteria for candidate miRNAs 
MiRNAs detected by three or more miRNA expression profiling studies were 
selected as candidates if they met all of the following three criteria: 
1. Presence of a rat ortholog identical to the human miRNA sequence. 
2. In vitro evidence supporting a role for the miRNA in the pathology of PE. 
3. Validation of the miRNA in a fully and/or partially independent cohort. 
5.3.2.2 MiRBase sequence alignment 
The mature human miRNA sequence was imputed into the miRBase search 
engine. From the sequence search results, presence of a rat ortholog was 
identified by searching for the species-specific three-letter prefix for rats ‘rno’. 
If present, ‘align’ was selected for the given rat miRNA ID, and sequence 
alignment between the human and rat miRNA was evaluated for full identicality. 
5.3.2.3 Literature search 
A literature search was conducted to identify studies providing in vitro evidence 
supporting a role for the miRNA in the pathology of PE and/or evidence of 
validation of the miRNA in an independent cohort. PubMed database was 
searched using the following terms: (mir-x OR hsa-mir-x oR microRNA x OR mir x) 
AND (preeclamp* OR pre-eclamp*) – with x designating the respective miRNA 
under enquiry. Abstracts were initially screened for relevance, after which 
selected full-text articles were assessed for in vitro and/or validation evidence. 
MiRNA expression profiling studies identified by the previous literature search 




5.3.3 Evaluation of candidate miRNAs in a rat model of SPE 
5.3.3.1 SPE rat model placental tissue 
Placental tissue was obtained from a rat model of SPE previously established by 
our group (Morgan et al., 2018). In brief, the model was established as follows: 
once pregnancy was confirmed, 12-week-old SHRSP rats were randomly assigned 
to 0.9% saline vehicle (control) or Ang II at 1000 ng/kg/min (SPE) via ALZET® 
2002 osmotic minipumps (Charles River, Kent, UK) implanted subcutaneously on 
GD 10.5. Dams were euthanised on GD 18.5 for collection of placental tissue. 
From each litter, whole placentas were excised, of which several were dissected 
into individual placental layers (decidua (dec), junctional zone (jx), and 
labyrinth (lab)), snap frozen in liquid nitrogen, and stored at -80C (Figure 5-2). 
Whole placentas from n=4 SPE rats and n=4 control rats (total n= 8 rats) and 
individual placental layers from n=3 SPE rats and n=4 control rats (total n=7 rats) 




Figure 5-2 Diagram illustrating a cross-section of rat placental tissue showing the location 
and size of the placental layers. 
Whole placental tissue and individual placental layers (decidua (dec), junctional zone (jx), and 
labyrinth (lab)) from the rat model of SPE were available for investigation. Dec, decidua; jx, 









5.3.3.2 RNA extraction and quality control 
Total RNA was extracted from 50 mg of placental tissue using the miRNeasy Mini 
Kit (QIAGEN, Manchester, UK) as detailed in section 2.1.4. Once tissues were 
homogenised in QIAzol, RNA extractions were immediately carried out or tissues 
were stored at -80C until RNA extractions were performed. RNA extracted from 
whole placental tissue was analysed using the Agilent BioAnalyzer 2100 as 
detailed in section 2.1.4.2. RNA extracted from individual placental layers was 
analysed using NanoDrop ND-1000 Spectrophotometer as detailed in section 
2.1.4.1. All tissues passed the respective quality control checks. 
5.3.3.3 Evaluation of candidate miRNAs with TaqMan RT-qPCR 
TaqMan RT-qPCR was performed as detailed in section 2.2 using the primers 
listed in Table 5-1. Data were analysed as detailed in section 2.2.3, with Ct 
values normalised to housekeeper (U87). 
Table 5-1 Primer sequences of Applied Biosystems™ TaqMan™ microRNA Assays. 
Assay name Assay ID Mature miRNA sequence 
Hsa-miR-210 000512  CUGUGCGUGUGACAGCGGCUGA 
Hsa-miR-223 000526  UGUCAGUUUGUCAAAUACCCC 
Hsa-miR-195 000494 UAGCAGCACAGAAAUAUUGGC 
Hsa-miR-16 000391 UAGCAGCACGUAAAUAUUGGCG 
Hsa-miR-29b 000413 UAGCACCAUUUGAAAUCAGUGUU 
Hsa-miR-30a-5p 000417 UGUAAACAUCCUCGACUGGAAG 
Hsa-miR-181a 000480 AACAUUCAACGCUGUCGGUGAGU 
Rno-miR-363 001355 AAUUGCACGGUAUCCAUCUGU 
U87 001712  ACAATGATGACTTATGTTTTTGCCGTTTACCCAGCTGAG
GGTTTCTTTGAAGAGAGAATCTTAAGACTGAGC 
 
5.3.3.4 Statistical analysis 
GraphPad Prism 9 was used to analyse all data sets. TaqMan data are shown as 
mean Ct ± SEM. TaqMan data were analysed using Ct values and the SPE model 
group (Ang II treated) and control group (vehicle treated) were compared by 
unpaired t-test (with Welch’s correction as appropriate). For all statistical tests, 




5.4.1 Literature review of miRNA expression profiling studies 
A total of fifteen studies were identified by the literature review which met the 
study selection criteria whereby data were presented showing significantly 
differentially expressed miRNAs in third trimester placentas of patients with PE 
compared to normotensive controls by conducting a miRNA expression profiling 
experiment (Table 5-2). The most common measure for defining statistical 
significance was inclusion of both a p-value and fold change cut-off, employed 
by a total of seven studies (Table 5-2). All subtypes of PE (i.e. mild, severe, EO, 
LO, and superimposed) were represented by at least one study; only one study 
involved patients with SPE (Table 5-2). Two of the fifteen studies had groups 
with sample sizes >20 (Table 5-2). In the majority of studies (eleven out of 
fifteen), preeclamptic pateints delivered preterm (Table 5-2). A significant 
difference in gestational age at delivery, and therefore at placental tissue 
collection, was noted in six studies (Table 5-2). The sampling area varied 
between studies, with sampling from maternal and/or foetal sites across the 
placenta, including the decidua, basal plate, placental villi, and chorionic plate 
(Table 5-2). 
After collating the data from the fifteen miRNA expression profiling studies, a 
total of 22 significantly differentially expressed placental miRNAs were 
identified that were detected by three or more miRNA expression profiling 
studies in preeclamptic patients (Table 5-3). For ten of the miRNAs, studies 
concurred in the direction of miRNA expression, while for the remaining twelve 




Table 5-2 MiRNA expression profiling studies conducted in third trimester placentas of patients with PE included in the literature review. 
*statistically significant gestational age. FC, fold change; FDR, false discovery rate; PE, preeclampsia, EO, early onset; LO, late onset; SPE, superimposed PE, dMSCs, decidua-derived mesenchymal stem cells.
Study Type of study Significance Type of PE Sample size (n) Type of delivery  Sampling area 
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8 foetal sites 
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with central portion 
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8 foetal sites 

















Table 5-3 MiRNAs significantly differentially expressed in three or more miRNA expression 
profiling studies in third trimester placentas of patients with PE. 
miRNA Studies reporting significant difference in miRNA expression 
 Up Down Direction not reported 
210-3p (Enquobahrie et al., 2011) 
(Betoni et al., 2013) 
(Xu et al., 2014a) 
(Weedon-Fekjær et al., 2014) 
(Zhang et al., 2015a) 
(Zhou et al., 2016) 
(Vashukova et al., 2016) 
None None 
223-3p None (Betoni et al., 2013) 
(Xu et al., 2014a) 
(Weedon-Fekjær et al., 2014) 
(Zhao et al., 2014) 
(Vashukova et al., 2016) 
None 
16-5p (Hu et al., 2009) 
(Wang et al., 2012c) 
(Zhao et al., 2014) 
(Zhang et al., 2015a) 
None None 
193b-3p (Betoni et al., 2013) 
(Xu et al., 2014a) 
(Zhou et al., 2016) 
(Vashukova et al., 2016) 
None None 
31-5p (Xu et al., 2014a) 
(Zhou et al., 2016) 
(Vashukova et al., 2016) 
(Zhao et al., 2014) None 
584-5p (Xu et al., 2014a) (Enquobahrie et al., 2011) 
(Zhang et al., 2015a) 
(Zhou et al., 2016) 
None 
29b-3p (Hu et al., 2009) 
(Wang et al., 2012c) 
(Zhao et al., 2014) 
 None None 
181a-5p (Hu et al., 2009) 
(Xu et al., 2014a) 
(Zhang et al., 2015a) 
None None 
524-3p (Wang et al., 2012b) 
(Xu et al., 2014a) 
(Vashukova et al., 2016) 
None None 
214-3p None (Hu et al., 2009) 
(Xu et al., 2014a) 
(Zhao et al., 2014) 
None 
363-3p None (Betoni et al., 2013) 
(Xu et al., 2014a) 
(Zhang et al., 2015a) 
None 
542-3p None (Betoni et al., 2013) 
(Xu et al., 2014a) 
(Lykoudi et al., 2018) 
None 
1-3p (Zhang et al., 2015a) (Enquobahrie et al., 2011) 
(Vashukova et al., 2016) 
None 
let-7f-5p (Hu et al., 2009) (Betoni et al., 2013) 
(Vashukova et al., 2016) 
None 
10b-5p (Zhao et al., 2014) 
(Zhou et al., 2016) 
None (Wang et al., 2012c) 
30a-5p (Wang et al., 2012c) 
(Zhao et al., 2014) 
(Lykoudi et al., 2018)  None 
140-5p (Zhao et al., 2014) (Betoni et al., 2013) (Wang et al., 2012c) 
151-3p (Xu et al., 2014a) 
(Zhou et al., 2016) 
(Wang et al., 2012b) None 
192-5p (Zhou et al., 2016) (Wang et al., 2012b) 
(Betoni et al., 2013) 
None 
195-5p (Hu et al., 2009) (Xu et al., 2014a) 
(Vashukova et al., 2016) 
None 
224-5p (Yang et al., 2015) (Betoni et al., 2013) 
(Weedon-Fekjær et al., 2014) 
None 
301a-3p (Zhao et al., 2014) 
(Yang et al., 2015) 




5.4.2 Literature review for selection of candidate miRNAs 
Of the 22 miRNAs detected by three or more miRNA expression profiling studies, 
eight miRNAs met all three literature review criteria of presence of a conserved 
rat ortholog identical to the human sequence, in vitro evidence supporting a 
role for the miRNA in pathology of PE, and validation of the miRNA in a fully 
and/or partially independent cohort (Table 5-4). These miRNAs (miR-210-3p, 
miR-223-3p, miR-16-5p, miR-29b-3p, miR-181a-5p, miR-363-3p, miR-30a-5p, and 
miR-195-5p) were selected as candidates for evaluation in the placenta of a rat 
model of SPE.  
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Table 5-4 Selection of candidate miRNAs for evaluation in a rat model of SPE. 
miRNA Rat ortholog Role in PE 
Validated in 
independent cohort 
210-3p Yes (rno-miR-210-3p) Yes1,2,3,4 Yes
3,21,22,23 
223-3p Yes (rno-miR-223-3p) Yes5 Yes
24 
16-5p Yes (rno-miR-16-5p) Yes6,7,8 Yes
25,26,27 
29b-3p Yes (rno-miR-29b-3p) Yes9,10 Yes
25,26,27 
181a-5p Yes (rno-miR-181a-5p) Yes11,12,13 Yes
27,28 
363-3p Yes (rno-miR-363-3p Yes14 Yes
29 
30a-5p Yes (rno-miR-30a-5p) Yes15,16 Yes
24,25,26 
195-5p Yes (rno-miR-195-5p) Yes17,18,19 Yes
24,27 
1-3p Yes (rno-miR-1b) No No 
31-5p Yes (rno-miR-31a-5p) No No 
214-3p Yes (rno-miR-214-3p) No No 
542-3p Yes (rno-miR-542-3p) No No 
let-7f-5p Yes (rno-let-7f-5p) No No 
140-5p Yes (rno-miR-140-5p) No No 
192-5p Yes (rno-miR-192-5p) No No 
301a-3p Yes (rno-miR-301a-3p) No No 
193b-3p No No Yes
24,30 
584-5p No Yes20 Yes
20 
524-3p No No Yes
24 
10b-5p No No No 
151a-3p No No No 
224-5p No No No 
(1) (Lee et al., 2011) (2) (Zhang et al., 2012) (3) (Luo et al., 2014) (4) (Luo et al., 2016) (5) (Meng 
et al., 2017) (6) (Wang et al., 2012c) (7) (Zhao et al., 2014) (8) (Zhu et al., 2016) (9) (Li et al., 2013) 
(10) (Gu et al., 2016) (11) (Wu et al., 2018) (12) (Liu et al., 2012) (13) (Zhang et al., 2015c) (14) 
(Thamotharan et al., 2017) (15) (Hu et al., 2015) (16) (Niu et al., 2018) (17) (Bai et al., 2012) (18) 
(Wu et al., 2016) (19) (Wang et al., 2018a) (20) (Jiang et al., 2015) (21) (Muralimanoharan et al., 
2012) (22) (Lalevée et al., 2014) (23) (Adel et al., 2017) (24) (Xu et al., 2014a) (25) (Wang et al., 
2012c) (26) (Zhao et al., 2014) (27) (Hu et al., 2009) (28) (Wang et al., 2018c) (29) (Zhang et al., 




5.4.3 Evaluation of candidate miRNAs in a rat model of SPE 
The expression of eight candidate miRNAs was evaluated by RT-qPCR to 
determine if they were significantly differentially expressed in a rat model of 
SPE compared to control rats. MiR-223-3p was significantly upregulated 
(3.26±0.12 vs 3.80±0.14 Ct, p<0.05) and miR-181a-5p was significantly 
downregulated (5.63±0.09 vs 5.32±0.05 Ct, p<0.05) in whole placental tissue of 
a rat model of SPE compared to controls (Figure 5-3A and B). MiR-210-3p was 
significantly downregulated in the decidual layer (1.43±0.03 vs 0.41±0.29 Ct, 
p<0.05) and significantly upregulated in the labyrinth layer (3.04±0.05 vs 
3.60±0.12 Ct, p<0.05) of a rat model of SPE compared to controls (Figure 5-4C), 
while no significant difference was seen in whole placental tissue (Figure 5-3C). 
MiR-363-3p was significantly downregulated in the decidual layer (9.37±0.33 vs 
8.06±0.24 Ct, p<0.05) and miR-195-5p was significantly upregulated in the 
decidual layer (1.14±0.03 vs 1.32±0.04 Ct, p<0.05) of a rat model of SPE 
compared to controls (Figure 5-4F and H), while no significant difference in miR-
363-3p or miR-195-5p was seen in whole placental tissue (Figure 5-3F and H). 
The remaining candidate miRNAs (miR-16-5p, miR-29b-3p, and miR-30a-5p) were 
not significantly differentially expressed in whole placental tissue or individual 
placental layers of a rat model of SPE compared to controls (Figure 5-3D, E, and 





Figure 5-3 Evaluation of candidate miRNAs in whole placentas of a rat model of SPE by 
TaqMan RT-qPCR. 
(A) MiR-223-3p was significantly upregulated in whole placental tissue of a rat model of SPE. (B) 
MiR-181a-5p was significantly downregulated in whole placental tissue of a rat model of SPE. (C) 
MiR-210-3p, (D) miR-16-5p, (E) miR-29b-3p, (F) miR-363-3p, (G) miR-30a-5p, and (H) miR-195-5p 
were not significantly differentially expressed in whole placental tissue of a rat model of SPE. Data 
are shown as mean Ct  SEM. Ct values were normalised to housekeeper U87, *p<0.05, n=4 per 





Figure 5-4 Evaluation of candidate miRNAs in individual placental layers (decidua, 
junctional zone, and labyrinth) of a rat model of SPE by TaqMan RT-qPCR. 
(A) MiR-223-3p and (B) miR-181a-5p were not significantly differentially expressed in individual 
placental layers of a rat model of SPE. (C) MiR-210-3p was significantly downregulated in the 
decidua and significantly upregulated in the labyrinth of a rat model of SPE. (D) MiR-16-5p and (E) 
miR-29b-3p were not significantly differentially expressed in individual placental layers of a rat 
model of SPE. (F) MiR-363-3p was significantly downregulated in the decidua of a rat model of 
SPE. (G) MiR-30a-5p was not significantly differentially expressed in individual placental layers of a 
rat model of SPE. (H) MiR-195-5p was significantly upregulated in the decidua of a rat model of 
SPE. Data are shown as mean Ct  SEM. Ct values were normalised to housekeeper U87, 
*p<0.05, n=3 in SPE group and n=4 in control group, analysed using Ct values by unpaired t-test 





In this chapter, a literature review identified placental miRNAs repeatedly 
detected as significantly differentially expressed by miRNA expression profiling 
studies in third trimester preeclamptic patients. Clinical studies were either in 
agreement or discordant in the direction of expression of the miRNAs in PE. 
Several candidate miRNAs were confirmed as significantly differentially 
expressed in whole placental tissue or individual placental layers of a rat model 
of SPE, providing novel evidence of dysregulation of miRNAs within placental 
layers in rats, a finding previously only shown in humans. Due to inconsistencies 
in the reported direction of expression of miRNAs, comparing findings from 
clinical and preclinical studies remains essential to elucidating the role of 
placental miRNAs in PE and their potential as therapeutic targets. 
The incongruity between clinical studies in the direction of placental miRNA 
expression in PE may in part be attributed to methodological factors of 
expression profiling studies. Microarrays and sequencing offer the benefit of a 
hypothesis-free approach to quantitively profile miRNA content. However, 
sample preparation and processing as well as the sensitivity and specificity of a 
platform contribute to detection bias and, in turn, differences in reported 
miRNA expression levels (Willenbrock et al., 2009, Git et al., 2010). Features of 
miRNAs themselves can also impact their detection by profiling platforms due to 
the short length of miRNAs, sequence similarity between miRNA family 
members, and presence of miRNA isoforms (isomiRs) (Leshkowitz et al., 2013). A 
next generation sequencing study examining isomiRs in placental tissue from 
mild and severe PE patients reported differences in the types of isomiRs and 
their expression patterns between normal and disease samples as well as 
between PE subtypes (Guo et al., 2011). This further supports that isomiRs may 
contribute to differences in miRNAs detected and their reported direction of 
expression in preeclamptic patients. Another methodological factor that may 
account for a lack of replication between clinical studies is the utilisation of 
arbitrary fold change cut-offs in addition to p-values to designate significance. 
Although typically employed to identify miRNAs deemed biologically relevant, 
fold change cut-off values can exclude smaller RNA expression changes that are 
statistically significant by hypothesis testing. Various fold change threshold 
values utilised by studies in the literature review may contribute to differences 
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in miRNAs detected. Finally, expression profiling studies in the literature review 
had relatively small sample sizes and in turn lower statistical power to detect 
significant differences. Overall, studies with larger sample sizes are needed to 
add weighting to the findings. Despite the limitations of expression profiling 
studies, their unbiased approach compared to candidate studies highlights their 
utility in examining differentially expressed placental miRNAs in PE. 
The inconsistencies between clinical studies in the literature review may also 
arise from biological factors, such as the type of PE examined. Studies in severe 
LOPE patients reported a significant upregulation of miR-let-7f-5p (Hu et al., 
2009), miR-140-5p (Zhao et al., 2014), miR-192-5p (Zhou et al., 2016), and miR-
195-5p (Hu et al., 2009), while studies in patients with diagnosed, superimposed, 
and severe PE found a significant downregulation of these miRNAs (Betoni et al., 
2013, Vashukova et al., 2016, Wang et al., 2012b, Xu et al., 2014a). This 
suggests that a subset of miRNAs may show differential expression patterns 
unique to patients with severe LOPE. Similarly, a significant upregulation of miR-
1-3p was identified in a study in patients with severe PE (Zhang et al., 2015a), 
while it was detected as downregulated by studies examining patients diagnosed 
with PE and SPE (Enquobahrie et al., 2011). Collating data from multiple 
expression profiling studies can therefore help to identify miRNAs that may show 
differential expression patterns between subtypes. In contrast, miR-584-5p and 
miR-151-3p were reported as both up- and downregulated in studies of patients 
with severe PE (Wang et al., 2012b, Xu et al., 2014a, Zhang et al., 2015a). This 
highlights certain placental miRNAs also exhibit differences in the direction of 
expression within a subtype of PE, supporting the involvement of other factors in 
governing placental miRNA expression. 
Spatial and temporal regulation of placental miRNAs may also contribute to the 
diverging findings from clinical studies in the literature review. The study 
reporting a significant upregulation of miR-151-3p in patients with severe PE 
sampled random sites across the placenta (Xu et al., 2014a) in contrast to the 
study reporting a significant downregulation in severe PE patients which 
examined placental villous tissue free of decidua (Wang et al., 2012b). The 
former study reporting an increase in miR-151-3p went on to validate expression 
of the miRNA within placental layers, noting a significant decrease in the basal 
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plate and no significant difference in the chorionic plate (Xu et al., 2014a). 
Findings of an opposing direction of expression may therefore reflect layer-
specific differences. Placental miRNAs have also shown to differ in expression 
across gestation between the trimesters (Morales-Prieto et al., 2012, Gu et al., 
2013), with differences noted in PE patients as early as the first trimester (Singh 
et al., 2017). All studies included in the literature review examined third 
trimester placenta collected at the time of delivery, accounting for trimester-
dependent changes. However, placental miRNA differences between term and 
preterm deliveries (Mayor-Lynn et al., 2011, Hromadnikova et al., 2017) as well 
as term and preterm PE (Anton et al., 2015, Yang et al., 2019b) indicate 
gestational age at delivery even within the third trimester may influence 
expression patterns. With significant differences in gestational age noted 
between PE and control groups as well as inclusion of both term and preterm 
deliveries, these factors may have further contributed to contrasting findings 
between clinical studies. In addition, other factors, including foetal weight 
(Awamleh et al., 2019, Pineles et al., 2007, Weedon-Fekjær et al., 2014), foetal 
sex (Muralimanoharan et al., 2015), maternal diet (Baker et al., 2017), 
pollutants (Li et al., 2015c), BMI (Tsamou et al., 2017), and smoking status 
(Maccani et al., 2010), have shown to alter placental miRNA expression. Despite 
the numerous variables potentially influencing placental miRNA expression, 
several miRNAs were consistently detected as significantly differentially 
expressed in the same direction of expression across multiple clinical studies. To 
gain further insight into factors such as PE subtype and placental region in 
regulating placental miRNAs, candidate miRNAs detected as significantly 
differentially expressed by multiple expression profiling studies were examined 
in a preclinical model of SPE. 
MiR-223-3p was significantly upregulated in the rat model of SPE, while reported 
as significantly downregulated across expression profiling studies (Betoni et al., 
2013, Xu et al., 2014a, Weedon-Fekjær et al., 2014, Zhao et al., 2014), 
including in a study of patients with SPE (Vashukova et al., 2016). Hence, 
upregulation in the rat model of SPE does not reflect miRNA changes distinct to 
SPE. These contrasting findings are also unlikely to reflect layer-specific 
differences since there was no significant difference in miR-223-3p expression 
within individual placental layers in the rat model of SPE. Furthermore, one 
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clinical study validated miR-223-3p as downregulated in both the chorionic and 
basal plate of PE patients (Xu et al., 2014a). The opposing findings may 
therefore reflect processes specific to the preclinical model. In vitro, miR-223-
3p has shown to promote trophoblast survival, proliferation, and invasion by 
inhibiting signal transducer and activator of transcription 3 (STAT3) (Meng et al., 
2017). Thus, lower miR-223-3p expression levels reported in PE patients may 
reflect loss of its physiological role in mediating trophoblast function in 
placental development, with studies reporting elevated expression and 
activation of STAT3 in placentas of PE patients (Meng et al., 2017, Xu et al., 
2017). However, multiple studies have found reduced placental expression and 
activation of STAT3 in PE (Qu et al., 2018, Chen et al., 2018, Weber et al., 2012, 
Zhang et al., 2015d), suggesting other factors modulate STAT3. Additional in 
vitro studies examining functional properties and gene targets of miR-223-3p are 
required to gain a greater understanding of the role of the miRNA in 
trophoblasts. Furthermore, investigations into the role of miR-223-3p in other 
placental cell types remain to be conducted, with evidence suggesting miR-223-
3p plays an important role in regulating immune cells and their responses. In 
bone marrow derived macrophages from miR-223-3p KO or WT mice, higher miR-
223-3p expression shifted macrophage polarisation towards an anti-inflammatory 
M2 phenotype (Zhuang et al., 2012). In a separate study in mouse macrophages, 
downregulation of miR-223-3p in response to inflammatory stimuli activated 
STAT3 and, in turn, increased the production of pro-inflammatory cytokines 
(Chen et al., 2012b). With clinical studies repeatedly showing dysregulation of 
foetal and maternal macrophages in preeclamptic placentas and evidence of a 
shift towards an M1 phenotype in PE (Williams et al., 2009, Yang et al., 2017a, 
Milosevic-Stevanovic et al., 2016, Schonkeren et al., 2011, Ma et al., 2019), a 
reduction in miR-223-3p expression may correspond with loss of its anti-
inflammatory properties. MiR-223-3p has also been identified as one of the 
miRNAs preferentially expressed in regulatory T cells (T reg cells) compared to 
naïve T cells (Cobb et al., 2006) and of the most substantially downregulated 
miRNAs in activated NK cells (Fehniger et al., 2010). Dysregulation of these cell 
types has been reported in preeclamptic placentas (Toldi et al., 2008, Milosevic-
Stevanovic et al., 2016) and foetal and maternal macrophages, placental T reg 
cells, and uNK cells play a key role in inadequate spiral artery remodelling 
(reviewed by (Geldenhuys et al., 2018)). It remains to be explored whether miR-
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223-3p expression may be altered in these cell types in PE, and in turn involved 
in mediating immune responses within the placenta in PE. Evaluation of miR-223-
3p in different cell types as well as other animal models of PE may also provide 
insight into the cause of the contrasting increased expression in the SPE rat 
model, its role in the pathology of PE, and in turn its suitability as a therapeutic 
target. The consistent downregulation of miR-223-3p across clinical studies 
makes it a potential miRNA of interest to target therapeutically. 
In the rat model of SPE, miR-181a-5p was significantly downregulated in whole 
placental tissue contrasting with the reported upregulation of miR-181a-5p in 
three expression profiling studies, conducted in patients with severe LOPE (Hu et 
al., 2009, Xu et al., 2014a) and severe PE (Zhang et al., 2015a). Candidate 
studies in patients with severe PE (Wang et al., 2018c) and diagnosed PE (Khaliq 
et al., 2018, Liu et al., 2012, Wu et al., 2018) have similarly found a significant 
upregulation of miR-181a-5p in third trimester placentas. Findings from the 
preclinical model may therefore suggest an increase in miR-181a-5p expression is 
unique to SPE. However, the expression profiling study in SPE patients did not 
detect miR-181a-5p as significantly differentially expressed, and miR-181a-5p 
expression has found to be increased in placentas complicated by gestational 
hypertension (Khaliq et al., 2018). Downregulation of miR-181a-5p in the rat 
model of SPE may therefore reflect a response to the Ang II infusion. In vascular 
smooth muscle cells derived from rat aorta, Ang II incubation inhibited miR-
181a-5p expression by approximately 50% (Remus et al., 2013). In contrast, miR-
181a-5p expression was not altered in HUVECs treated with Ang II (Lin et al., 
2017). Whether circulating levels of Ang II in the rat model of SPE influenced 
miR-181-5p expression in certain placental cells remains unclear. However, miR-
181a-5p has also been implicated in regulating the RAS in the kidney in 
neurogenic hypertension (Biancardi and Sharma, 2020) and in the placenta 
during pregnancy (Wang et al., 2018e), raising the possibility that a relationship 
between miR-181a-5p and Ang II exists. In kidneys of hypertensive patients, a 
decrease in miR-181a-5p and increase in renin was reported (Marques et al., 
2011). In a mouse model of hypertension, targeted renal delivery of a miR-181a-
5p mimic and bilateral renal denervation led to increased renal miR-181a-5p 
expression and decreased renal renin mRNA levels and blood pressure (overview 
by (Biancardi and Sharma, 2020)). Overexpression of miR-181a-5p in trophoblast 
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cells was associated with a reduction in renin mRNA and prorenin protein release 
(Wang et al., 2018e). These findings suggest miR-181a-5p in the kidney and 
placenta may exhibit the ability to suppress blood pressure via downregulating 
renin, a key enzyme of the RAS pathway. However, further experiments are 
required, and it remains speculative that elevated circulating levels of Ang II in 
the SPE rat model may contribute to downregulation of placental miR-181a-5p 
expression. In vitro studies show miR-181a-5p may be involved in modulating 
several aspects of placental development through a variety cell types. MiR-181a-
5p has been shown to inhibit migration and invasion of trophoblasts in part by 
suppressing insulin-like growth factor 2 mRNA-binding protein 2, which exhibited 
significantly reduced protein levels in preeclamptic placentas (Wu et al., 2018), 
supporting the idea that an upregulation of miR-181a-5p may contribute to the 
pathological processes underlying PE. A separate in vitro study showed miR-
181a-5p inhibited MSC proliferation and stimulated T cell proliferation and T cell 
IFN‐γ production in co-cultures (Liu et al., 2012). In a latter in vivo study 
examining MSC-based therapy, the same group showed MSC proliferation and 
suppression of T cell proliferation were attributed to alleviating PE-like 
symptoms in a Th1 cell induced PE mouse model (Liu et al., 2014), suggesting 
overexpression of miR-181a-5p may modulate properties of MSCs that contribute 
to the development of PE. On the other hand, stimulating miR-181a-5p 
expression in human endometrial stromal cells promoted their decidualization 
via inhibiting Krüppel-like factor 12 (Zhang et al., 2015c), suggesting the miRNA 
may play an important physiological role in earlier stages of placental 
development. In vitro studies support a multifunctional role for the miRNA in 
different cell types, with its dysregulation in turn contributing to PE. Despite the 
conflicting results between the preclinical model of SPE and clinical studies, the 
consistently reported upregulation of miR-181a-5p in preeclamptic patients 
makes it an intriguing potential therapeutic target in PE. 
MiR-210-3p exhibited a significant difference in expression in opposing directions 
in placental layers of the rat model of SPE. Although previous clinical studies 
have shown that a miRNA can be significantly differentially expressed in one 
placental layer and not another, no published study to date has reported an 
opposite direction of expression in different layers (i.e., upregulation in one 
layer and downregulation in another layer). This finding lends weight to the 
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concept that discrepancies between clinical studies may reflect layer-specific 
differences, although this novel finding in rats remains to be validated in human 
placental layers. Furthermore, an opposing direction of expression between 
placental layers may underpin a lack of significance in whole placental tissue, 
highlighting the importance of examining miRNAs within placental layers. The 
significant upregulation of miR-210-3p in the labyrinth of a rat model of SPE is in 
line with its consistently reported upregulation in expression profiling studies 
(Enquobahrie et al., 2011, Betoni et al., 2013, Xu et al., 2014a, Weedon-Fekjær 
et al., 2014, Zhang et al., 2015a, Zhou et al., 2016, Vashukova et al., 2016) and 
candidate studies (Muralimanoharan et al., 2012, Zhang et al., 2012, Lalevée et 
al., 2014, Luo et al., 2014, Wang et al., 2019a, Biro et al., 2019) in third 
trimester placentas from patients with PE. An increase in miR-210-3p has also 
been reported in blood samples from preeclamptic patients (Zhang et al., 2012, 
Ura et al., 2014, Xu et al., 2014a, Anton et al., 2013) as well as in pregnant 
women with chronic hypertension and gestational hypertension (Biró et al., 
2017). A separate preclinical study also found significantly higher miR-210-3p 
expression in placentas of a poly I:C induced PE mouse model compared to WT 
controls (Kopriva et al., 2013). Finally, elevated levels of miR-210-3p have been 
reported in the uterine arteries of pregnant sheep residing at high altitude (Hu 
et al., 2017) and in human placentas from high-altitude pregnancies (Colleoni et 
al., 2013). These findings contribute to the growing body of evidence that an 
increase in placental miR-210-3p expression in PE may in part be driven by 
hypoxia, with hypoxia shown to induce miR-210-3p across primary cells and cell 
lines (Chan and Loscalzo, 2010), including HUVECS (Fasanaro et al., 2008), 
trophoblast cell lines (Ishibashi et al., 2012), primary trophoblasts (Zhang et al., 
2012), and ex vivo uterine arteries (Hu et al., 2017). Studies reporting a 
significant downregulation of miR-210-3p in the placenta, namely in mild PE 
patients (Zhu et al., 2009) and pregnant mice exposed to moderate hypoxia 
levels (Krawczynski et al., 2016), suggest miR-210 expression may only be 
induced in more severe hypoxic conditions. An in vitro study showed miR-210-3p 
was only significantly increased in hypoxic conditions below 5% O2, with no 
significant difference in cells exposed to 10% O2, further supporting miR-210-3p 
may in part be regulated by a hypoxic gradient (Li et al., 2019). Evidence from 
in vitro studies in trophoblasts support an increase in miR-210-3p expression 
leading to pathological changes in the placenta, with its increased expression 
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shown to inhibit trophoblast invasion (Luo et al., 2016, Luo et al., 2014, Zhang 
et al., 2012, Anton et al., 2013, Wang et al., 2019a, Awamleh and Han, 2020, Li 
et al., 2019), migration (Zhang et al., 2012, Wang et al., 2019a, Awamleh and 
Han, 2020), proliferation (Li et al., 2019, Wang et al., 2019a), syncytialization 
(Wang et al., 2020b), tube-like formation (Wang et al., 2019a), and 
mitochondrial respiration (Muralimanoharan et al., 2015, Muralimanoharan et 
al., 2012, Anton et al., 2019). In contrast, in HUVECs, miR-210-3p has shown to 
stimulate formation of capillary-like structures, VEGF-mediated migration, and 
endothelial cell survival (Fasanaro et al., 2008). Hence, downregulation in the 
decidua in the SPE rat model may represent a loss of physiological function in 
other cell types. In addition, other factors, such as poly I:C (Kopriva et al., 2013) 
and TNF- α (Muralimanoharan et al., 2013, Luo et al., 2014) by stimulating 
nuclear factor-κB (NF-κB) have been shown to drive miR-210-3p expression, 
indicating hypoxia-independent mechanisms can regulate miR-210-3p expression. 
The causes and/or consequences of a significant downregulation of miR-210-3p 
in the decidua of the SPE rat model remain unknown but could reflect 
dysregulation in cell types other than trophoblasts or involvement of other 
mechanisms besides hypoxia regulating its expression as a protective 
mechanism. Of note, no published clinical study has yet validated miR-210-3p 
expression in the decidua of PE patients, which would provide insight into the 
potential layer- and/or cell specific expression of miR-210-3p. Further 
investigations in a variety of cell types and evaluation of hypoxia-independent 
stimuli could shed light on its role in the placenta and, in turn, PE. Given its 
consistently reported upregulation in PE, inhibiting miR-210-3p in the placenta 
represents a potential therapeutic strategy in PE. 
There was no difference in miR-363-3p expression in whole placental tissue of 
the SPE rat model, but a significant downregulation was seen in the decidua. 
This is in agreement with the three expression profiling studies in patients 
diagnosed with PE (Betoni et al., 2013) and with severe PE (Xu et al., 2014a, 
Zhang et al., 2015a) as well as a candidate study in patients with severe PE (Zhu 
et al., 2009). An expression profiling study went on to validate miR-363-3p as 
downregulated in both the chorionic and basal plate (Zhang et al., 2015a). 
Altogether, evidence from studies to date suggests miR-363-3p is downregulated 
across the placenta in a range of PE subtypes. In contrast to its significant 
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differential expression in the SPE rat model, miR-363-3p was not detected as 
significantly differentially expressed in the expression profiling study conducted 
in SPE patients. Since a lack of significance may have arisen from methodological 
factors, additional studies are required to ascertain that miR-363-3p expression 
is decreased in SPE as supported by findings from the SPE rat model. In 
trophoblasts, nutrient restriction reduced miR-363-3p expression, which 
coincided with upregulation of its target genes sodium-coupled neutral amino 
acid transporters, SNAT1 and SNAT2 (Thamotharan et al., 2017). A previous 
study reported SNAT2 was downregulated in third trimester placentas from PE 
patients (Huang et al., 2018), while another study found no significant 
difference in the expression of the amino acid transporters in PE (Malina et al., 
2005). Although investigations into the role of miR-363-3p in the placenta and PE 
remain limited, its consistent downregulation seen across preclinical and clinical 
studies highlight its potential as a therapeutic target in PE. 
MiR-195-5p was significantly upregulated in the decidua of the SPE rat model, 
while no significant difference was seen in whole placental tissue. Although this 
is in agreement with an increase in expression reported by the expression 
profiling study examining chorionic tissue blocks in severe LOPE (Hu et al., 
2009), the two other expression profiling studies reported a significant 
downregulation when sampling random sites across the placenta in both severe 
PE (Xu et al., 2014a) and SPE (Vashukova et al., 2016). Candidate studies 
similarly reported significant downregulation of miR-195-5p in third trimester 
placenta of severe LO (Gunel et al., 2020) and severe PE patients (Bai et al., 
2012). In the profiling study conducted in SPE patients reporting a 
downregulation, decidual tissue was included when collecting samples from 
maternal sites. Hence, upregulation of miR-195-5p in the SPE rat model may 
reflect processes specific to the preclinical model rather than layer-specific 
changes. Evidence from in vitro studies suggests dysregulation of miR-195-5p in 
the placenta plays a role in PE via modulating genes that may contribute to the 
genetic basis of PE. In HUVECs, miR-195-5p overexpression inhibited endothelial 
cell invasion and tube formation via suppressing VEGFA (Zhao et al., 2017). Gene 
association studies have shown VEGFA polymorphisms (Hamid et al., 2020, 
Amosco et al., 2016) and haplotypes (Gannoun et al., 2017) are associated with 
PE. With VEGFA haplotypes either reducing or enhancing risk (Gannoun et al., 
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2017), it remains unclear whether elevated placental miR-195-5p therefore 
represents a harmful or protective mechanism. In support of increased miR-195-
5p mediating normal placental development, overexpression of miR-195-5p in 
trophoblasts promoted invasion via inhibiting activin A receptor type 2A 
(ACVR2A) (Bai et al., 2012) and activin A receptor type 2B (Wu et al., 2016), 
with susceptibility loci for PE identified within the ACVR2A gene in multiple 
populations (Roten et al., 2009, Ferreira et al., 2015, Amosco et al., 2019). In 
trophoblasts exposed to acute oxidative stress, miR-195-5p overexpression 
further stimulated apoptosis and reduced mitochondrial activity in part by 
inhibiting FAD-dependent oxidoreductase domain-containing 1 (FOXRED1) and 
pyruvate dehydrogenase phosphatase regulatory subunit (PDPR) (Wang et al., 
2018a). However, chronic stimulation led to reduced miR-195-5p expression, 
coinciding with elevated levels of FOXRED1 and PDPR in placentas of 
preeclamptic patients (Wang et al., 2018a). Thus, evidence also suggests 
reduced placental miR-195-5p expression in PE may represent a defensive 
mechanism against oxidative stress. Overall, conflicting evidence regarding the 
direction of expression of placental miR-195-5p in PE likely mirrors its 
differential expression between cell types. Since miR-195-5p can target genes 
implicated in the genetic basis of PE in a range of cell types in the placenta, 
further preclinical and clinical studies should be conducted to gain a greater 
understanding of the role of miR-195-5p in the placenta in PE and its suitability 
as a therapeutic target. 
Due to inconsistencies in the reported direction of expression of placental 
miRNAs in PE, collating and comparing evidence from preclinical and clinical 
studies remains essential to identify potential factors contributing to opposing 
findings. Evaluation of candidate miRNAs in the placenta of a rat model of SPE 
contributed to the growing body of evidence that placental miRNAs differ 
between PE subtypes and placental layers. The direction of expression of 
placental miRNAs in the preclinical model repeatedly contradicted findings from 
clinical studies, indicating SPE may exhibit a distinct miRNA expression profile. 
More clinical studies examining placental miRNAs exclusively in patients with SPE 
are therefore required since only one expression profiling study has been 
conducted to date. Furthermore, the novel finding of a miRNA expressed in 
opposite directions in different placental layers highlights the importance of 
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mapping miRNA expression across the placenta, as this has implications for 
targeting miRNAs therapeutically. Finally, while differing pathological processes 
between preclinical models and patients may account for differences in 
placental miRNA expression, identifying similarities is crucial for research 




Chapter 6 Characterisation of miRNAs and 
predicted gene targets in the placentas of a rat 






Animal models are essential to studying pregnancy and its related disorders due 
to the ethical and practical limitations of conducting research in pregnant 
humans. Rodents in particular are commonly used in preclinical research due to 
the similarities between humans, rats, and mice in placental development, 
structure, and function (Rai and Cross, 2014, Georgiades et al., 2002). Moreover, 
genome-wide expression profiling studies in mouse and human placenta have 
revealed commonalities in molecular patterns across the placenta and gestation 
(Soncin et al., 2018, Cox et al., 2009). Genome-wide microarray profiling of first 
and third trimester human and mouse placenta detected 517 genes differentially 
expressed across gestation that were common to both species, representing 18% 
of mouse and 43% of human differentially expressed genes (Soncin et al., 2018). 
Furthermore, analysis of expression patterns revealed 129 genes were 
upregulated and 147 genes were downregulated in both species across gestation, 
while the remaining 231 showed differing patterns of expression between the 
species (Soncin et al., 2018). In a separate study, microarray expression analysis 
of human villous tree and mouse labyrinth samples detected 2869 transcripts 
unique to both species and 6609 transcripts common to both species, with over 
70% of all detected transcripts correlating in expression between the human and 
mouse (Cox et al., 2009). Protein analysis of the same samples detected 6970 
ortholog proteins of which 2519 were common to both species (Cox et al., 2009). 
Although these studies show species-specific patterns exist, they also highlight 
that humans and rodents display molecular similarities at both the 
transcriptional and posttranscriptional level in the placenta and across 
gestation. 
MiRNA expression profiling studies in human primary trophoblasts and placental 
tissue demonstrate significant changes also occur in miRNA expression 
throughout pregnancy, implicating miRNAs as molecular regulators of placental 
development and function (Morales-Prieto et al., 2012, Gu et al., 2013). In turn, 
dozens of miRNA expression profiling studies in human placentas from 
pregnancy-related disorders, such as PE and FGR, show placental miRNAs are 
dysregulated in disease states (Sheikh et al., 2016, Chiofalo et al., 2017). 
However, only a handful of miRNA expression profiling studies have been 
conducted in pregnant rodents (Inoue et al., 2017, Inoue et al., 2020, Su et al., 
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2020). Inoue et al. employed miRNA microarray profiling to examine expression 
of miRNAs from the rodent specific C2MC in the placenta of cluster deleted mice 
(Inoue et al., 2017). Knockdown of expression impaired placental development 
and frequently induced foetal lethality or defects (Inoue et al., 2017). Su et al. 
performed miRNA expression profiling on mouse placentas at embryonic day (E) 
12.5, 13.5, 14.5, and 18.5, reporting significant differences in the expression of 
more than 50 miRNAs at E 18.5 (Su et al., 2020). Furthermore, Su et al. 
conducted miRNA expression profiling after administration of the 
immunostimulant, poly(I:C), reporting significant differences in several placental 
miRNAs (Su et al., 2020). Expression profiling studies make it possible to study 
global changes in expression in a hypothesis-free manner compared to the 
hypothesis-driven nature of candidate studies. The aforementioned profiling 
studies in pregnant rodents demonstrate that, like in humans, global changes in 
placental miRNA expression occur throughout pregnancy and in disease states. 
No published miRNA expression profiling study could be identified that examines 
placental miRNA expression in an animal model of PE. Collectively, this 
highlights the value of and need for miRNA expression profiling studies in animal 
models of PE. Elucidating the miRNA profile of animal models of PE allows for 
comparisons with human data, thereby providing insight into the role of 
placental miRNA in PE and their therapeutic potential. 
In addition to examining placental miRNA expression, evaluating gene targets 
and the functional role of miRNAs in placental cell types are critical experiments 
to gain a greater understanding of the involvement of miRNAs in the placenta 
and in PE. A key example is miR-210-3p, the most frequently detected 
dysregulated miRNA in placentas of preeclamptic patients (Sheikh et al., 2016). 
A total of sixteen clinical studies have reported miR-210-3p is significantly 
upregulated in the placenta in PE, while one study in mild preeclamptic patients 
found it was significantly downregulated (Frazier et al., 2020). Numerous genes 
have been validated as miR-210-3p gene targets in trophoblasts through reporter 
construct assays, found to be significantly downregulated in preeclamptic 
placentas in which miR-210-3p was upregulated, and implicated in impaired 
trophoblast invasion, migration, iron metabolism, proliferation, and 
syncytialization, namely thrombospondin type I domain containing 7A (THSD7A), 
potassium channel modulatory factor 1 (KCMF1), ephrin-A3 (EFNA3), homeobox-
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A9 (HOXA9), iron-sulphur cluster scaffold homolog (ISCU), cytoplasmic 
polyadenylation element-binding 2 (CPEB2), colony stimulating factor (CSF1), 
and integrin subunit alphaM (ITGAM), (Luo et al., 2016, Luo et al., 2014, Lee et 
al., 2011, Zhang et al., 2012, Wang et al., 2020b, Awamleh and Han, 2020). 
Dysregulation of miR-210-3p and its gene target ISCU has also shown to cause 
trophoblast mitochondrial dysfunction (Muralimanoharan et al., 2012, Anton et 
al., 2019). Collectively, these preclinical and clinical findings suggest increased 
expression of miR-210-3p may contribute to trophoblast dysfunction in PE. In 
poly I:C induced PE mice compared to WT mice, miR-210-3p expression was 
significantly upregulated and its predicted gene target STAT6 was significantly 
downregulated, a mediator that promotes the expression and differentiation of 
anti-inflammatory Th2 cytokines (Kopriva et al., 2013). STAT6 has previously 
shown to be downregulated in trophoblasts overexpressing miR-210-3p (Ahn et 
al., 2017) and in the placenta of preeclamptic patients (Su, 2016, Fan et al., 
2016), suggesting miR-210-3p may also regulate the immune response of 
trophoblasts. These comparisons demonstrate the importance of examining 
evidence from patients, animal models, and in vitro studies, as each system 
enables investigations into different aspects of the role of placental miRNAs in 
health and disease. 
In the previous chapter, significant differences were detected in candidate 
placental miRNAs in our rat model of SPE. Comparisons with published data from 
clinical studies revealed both differences and similarities between the rat model 
and preeclamptic patients. In this chapter, miRNA sequencing was performed to 
identify differentially expressed placental miRNAs in our SPE rat model in a 
hypothesis-free manner. Furthermore, the dysregulation of select miRNAs and 
predicted gene targets was examined by RT-qPCR in placental tissue from the 
rat model of SPE as well as preeclamptic patients to evaluate the clinical 
relevance of the findings. Evidence from placental tissue from the rat model of 
SPE and preeclamptic patients is in agreement with published data that miR-210-
3p is upregulated in PE. In turn, the role of miR-210-3p was studied in 
trophoblasts in-vitro by knocking down and overexpressing the miRNA and 




6.2 Hypotheses and aims 
6.2.1 Hypotheses 
• An altered placental miRNA transcriptome induces changes in placental 
gene expression in a rat model of SPE, with changes mirrored in the 
placentas of patients with PE. 
• A placental miRNA dysregulated in PE affects predicted gene targets and 
the functional properties of trophoblast cells in vitro. 
6.2.2 Aims 
• Identify differentially expressed placental miRNAs in the placenta of a rat 
model of SPE using miRNA sequencing. 
• Validate differentially expressed miRNAs in whole placentas and placental 
layers of a rat model of SPE and in placentas of patients with PE. 
• Evaluate expression of predicted gene targets in placentas of a rat model 
of SPE and patients with PE. 
• Investigate the relationship between a candidate placental miRNA, 






6.3.1 SPE rat model placental tissue 
Placental tissue was obtained from a rat model of SPE previously established by 
our group (Morgan et al., 2018), as described in section 5.3.3.1. In brief, the 
model was established as follows: once pregnancy was confirmed, 12-week-old 
SHRSP rats were randomly assigned to 0.9% saline vehicle (control) or Ang II at 
1000 ng/kg/min (SPE) via ALZET® 2002 osmotic minipumps (Charles River, Kent, 
UK) implanted subcutaneously on GD 10.5. Dams were euthanised on GD 18.5 for 
collection of placental tissue. From each litter, whole placentas were excised, 
of which several were dissected into individual placental layers (decidua (dec), 
junctional zone (jx), and labyrinth (lab)), snap frozen in liquid nitrogen, and 
stored at -80C. Whole placentas from n=4 SPE rats and n=4 control rats (total n= 
8 rats) and individual placental layers from n=3 SPE rats and n=4 control rats 
(total n=7 rats) were available for evaluation of miRNA/gene expression and 
included in the study analysis. 
6.3.2 RNA extraction and quality control 
Total RNA was extracted from 50 mg of placental tissue using the miRNeasy Mini 
Kit (QIAGEN, Manchester, UK) as detailed in section 2.1.4. Once tissues were 
homogenised in QIAzol, RNA extractions were immediately carried out or tissues 
were stored at -80C until RNA extractions were performed. RNA extracted from 
whole placental tissue was analysed using the Agilent BioAnalyzer 2100 as 
detailed in section 2.1.4.2. RNA extracted from individual placental layers was 
analysed using NanoDrop ND-1000 Spectrophotometer as detailed in section 
2.1.4.1. All tissues passed the respective quality control checks. 
6.3.3 MiRNA library preparation, sequencing, and analysis 
MiRNA library preparation and sequencing were performed by Glasgow 
Polyomics. MiRNA Sequencing libraries were prepared from total RNA using the 
QIAGEN QiaSeq miRNA Library Kit. Libraries were sequenced on the Illumina 
NextSeq™ 500 platform in 75 base, single end mode. Adapter and quality 
trimming of raw sequence reads was performed using the program CutAdapt. 
The quality of the reads before and after trimming were checked using the 
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program FastQC. The quality trimmed reads were aligned to the reference 
genome (GRCH38 release 79) using the program Bowtie (version 1.0.0). The 
number of reads aligning to known small RNAs, defined by a gff3 file for human 
(GRCH38 release 79) downloaded from miRBase, was obtained using bedtools. 
Mapped reads were input into DEseq2 for differential expression analysis to 
compare samples from the SPE model rat group and control rat group. A total of 
827 reads mapped to known mature rat miRNAs listed in the miRBase database 
with a MIMAT accession number. The base mean, log2 fold change (z-scored), 
and p-value of <0.05 adjusted for a false discovery rate (FDR) <5% was 
determined for comparison of each mature miRNA. Principal component analysis 
(PCA) was performed by Glasgow Polyomics. The heatmap (including hierarchal 
analysis) and volcano plot were produced together with Simon Fisher, who 
designed the software PadPlot. 
6.3.4 Literature review for selection of candidate miRNAs 
The fifteen miRNA expression profiling studies identified in the literature review 
in the previous chapter (Table 5-2) were utilised in this chapter. In addition, 
four studies that had previously been excluded based on the time of placenta 
collection not being stated were included in this literature review (Table 6-1). 
These were included based on the assumption that placentas were collected at 
the time of delivery despite the study not explicitly stating this. The data from 
these four studies were collated with the data from the previously included 
fifteen studies (Table 5-2) to broaden the scope of miRNAs detected by 
expression profiling studies in placenta samples from preeclamptic patients. 
Candidate miRNAs were selected based on their direction of expression detected 
by miRNA sequencing in placentas of SPE model rats matching the direction of 




Table 6-1 Additional miRNA expression profiling studies conducted in third trimester placentas of patients with PE included in the literature review. 
 FC, fold change; PE, preeclampsia, EO, early onset; LO, late onset; SPE, superimposed PE, N/A, not available. 
 
Study Type of study Significance Type of PE Sample size (n) Type of delivery  Sampling area 
(Zhu et al., 2009) Microarray p<0.05 and >1.8-FC Severe PE (n=8) 
control (n=8) 
PE and controls matched for 
gestational age at delivery 
Placental villi 
(Ishibashi et al., 2012) Microarray 
and 
sequencing 




PE (term and preterm) 
control (term) 
Placenta 




Central portion of the 
placental disc 




8 maternal and 
8 foetal sites 
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6.3.5 Validation of candidate miRNAs in placentas of a rat model 
of SPE by TaqMan RT-qPCR 
TaqMan RT-qPCR was performed as detailed in section 2.2 using the primers 
listed in Table 6-2. Data were analysed as detailed in section 2.2.3, with Ct 
values normalised to housekeeper (U87). 
Table 6-2 Primer sequences of Applied Biosystems™ TaqMan™ microRNA Assays. 
Assay name Assay ID Mature miRNA sequence 
Hsa-miR-210-3p 000512  CUGUGCGUGUGACAGCGGCUGA 
Rno-miR-19b-3p 000396 UGUGCAAAUCCAUGCAAAACUGA 
Hsa-miR-214-3p 002306 ACAGCAGGCACAGACAGGCAGU 
Hsa-miR-145-5p 000467 GUCCAGUUUUCCCAGGAAUCCCUU 
U87 001712  ACAATGATGACTTATGTTTTTGCCGTTTACCCAGCTGAG
GGTTTCTTTGAAGAGAGAATCTTAAGACTGAGC 
 
6.3.6 Study participants and placental tissue collection 
Placental tissues were kindly gifted by a research group from University of 
Oxford. Placental tissues were obtained with written informed consent from 
women undergoing elective caesarean section without labour at John Radcliffe 
Hospital Maternity Centre in Oxford, UK between 2015-2019. Placental tissue 
was collected from patients with PE (n=6) and healthy pregnant women controls 
(n=4) approved by the Central Oxfordshire Research Ethics Committee C (REFS 
07/H0607/74 & 07/H0606/148). PE was defined according to the ISSHP 
recommendation; new-onset hypertension (>140 mmHg systolic or >90 mmHg 
diastolic) and presence of one or more of the following: proteinuria (spot urine 
protein/creatinine >30 mg/mmol [0.3 mg/mg] or >300 mg/day or at least 1 g/L 
[‘2 + ’] on dipstick testing), other maternal organ dysfunction, and/or 
uteroplacental dysfunction (Tranquilli et al., 2014). Healthy pregnant women in 
the control group had no current or previous history of PE or other gestational 
hypertensive disorders and no foetal abnormalities. Tissue samples, 
approximately 8 mm in width, were collected within 10 min of delivery from 
between the middle section of the placenta and the umbilical cord, capturing 
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maternal and foetal portions of the placenta. Placentas were immediately snap 
frozen in liquid nitrogen and stored in -80C until further analysis. 
6.3.7 RNA extraction and quality control 
After disrupting placental tissues with a mortar and pestle, total RNA was 
extracted from 50 mg of placental tissue using the miRNeasy Mini Kit (QIAGEN, 
Manchester, UK) as detailed in section 2.1.4. Once tissues were homogenised in 
QIAzol, RNA extractions were immediately carried out or tissues were stored at -
80C until RNA extractions were performed. RNA extracted was analysed using 
NanoDrop ND-1000 Spectrophotometer as detailed in section 2.1.4.1. All 
tissues passed quality control. 
6.3.8 Evaluation of candidate miRNAs in placentas of patients 
with PE by TaqMan RT-qPCR 
TaqMan RT-qPCR was performed as detailed in section 2.2 using the primers 
listed in Table 6-3. Data were analysed as detailed in section 2.2.3, with Ct 
values normalised to housekeeper (RNU44). 
Table 6-3 Primer sequences of Applied Biosystems™ TaqMan™ microRNA Assays. 
Assay name Assay ID Mature miRNA sequence 
Hsa-miR-210-3p 000512  CUGUGCGUGUGACAGCGGCUGA 
Hsa-miR-19b-3p 000396 UGUGCAAAUCCAUGCAAAACUGA 
Hsa-miR-214-3p 002306 ACAGCAGGCACAGACAGGCAGU 




6.3.9 Gene target prediction 
Gene target prediction of miR-210-3p was performed using two online software 
programs: TargetScan 7.2 (http://www.targetscan.org/vert_72/) and miRDB 
(http://www.mirdb.org). Gene target prediction of miR-210-3p was also 
performed using Ingenuity Pathway Analysis (IPA) software. IPA was utilised to 
identify predicted targets with high and moderate confidence. Predicted targets 
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were overlaid with genes implicated in PE as determined by the IPA database. 
Predicted gene targets were only considered as candidates if they had not yet 
been validated experimentally in trophoblast cells. 
6.3.10 Evaluation of candidate gene targets by TaqMan RT-
qPCR 
TaqMan RT-qPCR was performed as detailed in section 2.2 using the primers 
listed in Table 6-4 for human placental samples and the primers listed in Table 
6-5 for rat placental samples. Data were analysed as detailed in section 2.2.3, 
with Ct values normalised to housekeeper (RNU44 and U87). 





Assay ID Fluorescent label 
Brain-derived neurotrophic factor BDNF Hs02718934_s1 FAM 
Fibroblast growth factor receptor-like 1 FGFRL1 Hs00222484_m1 FAM 
NDUFA4, mitochondrial complex 
associated 
NDUFA4 Hs00800172_s1 FAM 
Solute carrier family 6 member 1 SLC6A1 Hs01104475_m1 FAM 
β-2-microglobulin B2M Hs99999907_m1 VIC 
 





Assay ID Fluorescent label 
Brain-derived neurotrophic factor BDNF Rn02531967_s1 FAM 
Fibroblast growth factor receptor-like 1 FGFRL1 Rn01531250_g1 FAM 
β-actin ACTB Rn00667869_m VIC 
 
6.3.11 Trophoblast cell culture 
The human BeWo trophoblast cell line (ATCC, Middlesex, UK) was kindly gifted 
by Dr Dilys Freeman and Mrs Fiona Jordan (cells frozen down at -80ºC at passage 
9). All cell culture work was carried out under sterile conditions in class II 
biological safety cabinets. Cells were maintained in complete media, DMEM/F-12 
(Gibco™, ThermoFisher, Paisley, UK) supplemented with 10% foetal bovine serum 
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(FBS) (Gibco™, ThermoFisher, Paisley, UK) and 1% penicillin/streptomycin 
(Gibco™, ThermoFisher, Paisley, UK), in a humidified incubator with 5% CO2 at 
37C. 
6.3.11.1 Cell revival 
Frozen down cells were thawed when required at 37ºC in a water bath and 
immediately transferred to a 10 mL universal containing 5 mL prewarmed 
complete media. The suspension was gently mixed by pipetting up and down 
several times and then centrifuged at 1200 RPM for 5 min. The supernatant was 
discarded, and the remaining cell pellet was resuspended in 1.5 mL of complete 
media. The cell suspension was added to a T25 flask containing 3.5 mL of 
prewarmed complete media and placed in the incubator for maintenance. 
6.3.11.2 Cell maintenance 
Cells were checked daily and media was changed every 24-72 h. Cells were 
passaged when they reached 70-80% confluency. Passaging was performed by 
removing media and washing the cells with 5 mL of 1X PBS. Cells were detached 
from the flask by adding 2 mL of 1X trypsin-EDTA (Sigma-Aldrich, Schnelldorf, 
Germany) and placing the flask in the incubator for 5 min. Cells were checked 
under the microscope to see if they had detached, and the flask was gently 
tapped until the cells were floating freely. To inactivate the trypsin, 6 mL of 
complete media was added to the flask. The total volume of cell suspension was 
transferred to a 10 mL universal and centrifuged at 1200 RPM for 5 min. The 
supernatant was discarded, and the remaining cell pellet was resuspended in 
complete media for subculturing at a 1:3 ratio or for cryopreservation. For 
cryopreservation, cells were resuspended in 95% complete media supplemented 
with 5% dimethyl sulfoxide (Fisher Scientific, Loughborough, UK) and aliquoted 
into cryovials (Alpha-laboratories, Hampshire, UK). The cryovials were placed in 
an isopropanol filled Mr. FrostyTM Freezing Container (ThermoFisher Scientific, 




6.3.11.3 Cell counting 
Cell counting was performed after trypsinisation prior to cryopreservation or for 
seeding cells at a desired density. Cells were counted using a Bright Line 
Haemocytometer (Sigma, Dorset, UK). The cell suspension (10 µL) was diluted 
1:2 with 0.4% trypan blue (10 µL) (Sigma, Dorset, UK), and 10 μL of the solution 
was pipetted onto the haemocytometer underneath a coverslip. Using a light 
microscope, the number of viable cells in each of the corner quadrants was 
counted. Blue stained cells or cells touching the bottom or right-hand line of any 
quadrant were not counted. An average of the four quadrants was calculated 
and multiplied by 104 and corrected for by the dilution factor to obtain the 
number of cells per mL in the suspension. 
6.3.11.4 Cell transfection 
Cells were trypsinized and resuspended to obtain a seeding density of 1.5x105 
cells /mL and set aside in a 37ºC water bath prior to reverse transfection. 
Reverse transcription was performed on a 12-well plate using siPORT™ NeoFX™ 
Transfection Agent (Ambion, Loughborough, UK). SiPORT™ NeoFX™ Transfection 
Agent (3 µL or 1 µL) was diluted into Opti-MEM® medium to 50 µL and incubated 
for 10 min at room temperature. MirVana™ miRNA Mimic (miR-210-3p, assay ID 
MC10516), mirVana™ miRNA Inhibitor (has-miR-210-3p, assay ID MH10516), and 
mirVana™ miRNA Inhibitor Negative Control #1 (Ambion, Loughborough, UK) (3 
µL) were diluted into Opti-MEM® medium to 50 µL. The diluted transfection 
reagent and diluted mirVana™ miRNA were mixed together at equal volumes and 
incubated at room temperature for 10 min. Transfection complexes were 
aliquoted at 100 µL per well. Cell suspensions of 900 µL containing 1.5x105 cells 
were added to each well, and the plate was gently tilted back and forth to 
evenly distribute and mix the cell suspension with the transfection complexes. 
The cells were incubated for 24, 48, or 72 h until ready to assay.  
6.3.11.5 RNA extraction and quality control 
Total RNA was extracted from cells using the miRNeasy Mini Kit (QIAGEN, 
Manchester, UK) as detailed in section 2.1.4. Once cells were lysed by adding 
QIAzol, RNA extractions were immediately carried out or cell homogenates were 
stored at -80C until RNA extractions were performed. RNA extracted was 
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analysed using NanoDrop ND-1000 Spectrophotometer as detailed in section 
2.1.4.1. All RNA extracted passed quality control. 
6.3.11.6 Evaluation of miR-210-3p and predicted gene target expression 
by TaqMan RT-qPCR 
TaqMan RT-qPCR was performed as detailed in section 2.2 using the primers 
listed in Table 6-4. Data were analysed as detailed in section 2.2.3, with Ct 
values normalised to housekeeper (RNU44). 
6.3.11.7 MTT assay 
Cell viability was measured with TACS® MTT Cell Proliferation Assay kit (R&D 
Systems, Abingdon, UK). Cells were washed with 1X PBS and transfection media 
was replaced with low serum (1% FBS) media. Cells were incubated with 100 µL 
MTT Reagent for 3 h at 37ºC. Detergent Reagent (1 mL) was added to each well, 
and cells were incubated overnight at room temperature. A ‘no cells’ control 
was used as a blank. Absorbance was measured at 560 nm using the PerkinElmir 
2030 plate reader (Perkin Elmer, Singapore, Singapore). The blank absorbance 
value was subtracted from all readings prior to analysis. 
6.3.12 Statistical analysis 
For miRNA sequencing data, a p-adjusted value <0.05 was considered significant. 
GraphPad Prism 9 was used to analyse all other data sets. TaqMan data are 
shown as mean Ct ± SEM and were analysed as follows: the SPE model group 
(Ang II) vs control group (vehicle) as well as patients with PE vs healthy controls 
were compared by unpaired t-test (with Welch’s correction as appropriate); cells 
only, scramble, mimic and inhibitor groups were compared by one-way ANOVA 
followed by Tukey’s post-hoc multiple comparisons test. Clinical characteristics 
are presented as mean ± SD or median (range). All normally distributed variables 
were compared by unpaired t-test (with Welch’s correction as appropriate) and 
non-normally/discrete variables by Mann-Whitney U test. MTT assay data were 
expressed as median cell viability % (IQR). This was calculated from absorbance 
ratios of treatment values normalised to ‘cells only’ values set to 100% and 
analysed by Kruskal-Wallis test followed by Dunn’s post-hoc multiple 




6.4.1 RNA quality control 
Rat placenta RNA quality and concentration were assessed prior to miRNA 
sequencing using the Agilent 2100 Bioanalyzer by analysing the electrophoretic 
trace. In the electrophoresis gel, bands at ~4000 and ~2000 nts across all 
placenta samples indicate detection of 28S and 18S ribosomal RNA, respectively 
(Figure 6-1A). Faint bands ~100 nts across all samples demonstrate detection of 
small RNA (Figure 6-1A). The electropherogram of a control sample shows clear 
distinct peaks of 28S and 18S ribosomal RNA at ~4000 and ~2000 nts, with low 
noise between the peaks, indicating extraction of intact RNA (Figure 6-1B). The 
electropherogram also shows a peak between 25-200 nts, indicating presence of 
small RNA such as miRNA (Figure 6-1B). The peak at 25 nts represents the DNA 
ladder (Figure 6-1B). The ratio of the 28S and 18S ribosomal RNA peaks 
determined the RIN. All RNA samples had a RIN greater than 8 (Table 6-6), 
indicating extraction of intact RNA suitable for miRNA sequencing. 
6.4.2 Quality control of miRNA sequencing samples 
A PCA plot was generated to visualise the variance between individual samples 
and groups based on their miRNA expression profiles. PCA clustering was 
observed between the control and SPE model group (PC1=46% variance and 
PC2=15% variance), indicating variation in the miRNA expression between 
samples was primarily due to treatment differences between control rats 
(vehicle) and SPE model rats (Ang II) (Figure 6-2). Samples in the SPE model 





Figure 6-1 Representative image of Agilent 2100 Bioanalyzer results. 
Representative results from Eukaryote Total RNA Nano assay run on whole placenta samples (C 
numbers) from control (vehicle-treated (V)) and SPE model (Ang II-treated (T)) SHRSP rats for 
assessment of RNA quality and concentration. (A) Electrophoresis run of the ladder, controls 
(Brownie BH, Dino Hughes, Gromit Poulton, Dinky Clews, Barney Mc, Prince Eire, and Barney R), 
and samples (C numbers). (B) Electropherogram for sample from control SHRSP rat (C9759) and 
overall results, including RNA concentration, rRNA Ratio (28S and 18S ribosomal RNA), and RIN. 
 
Table 6-6 Agilent 2100 Bioanalyzer results of RNA quality (RIN) and concentration. 
Animal  ID RIN Concentration (ng/µL) 
Control C9759 10.0 664 
 C9765 9.5 420 
 C9930 10.0 543 
 C9767 10.0 452 
SPE model C9758 9.5 524 
 C9872 10.0 514 
 C9948 9.4 356 
 C9955 9.4 382 





Figure 6-2 Principal component analysis plot of whole placental samples from control and SPE model rats. 
PCA was performed to identify the variation between samples from the control and SPE model groups based on their miRNA expression data.  
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6.4.3 Summary of differentially expressed miRNAs by miRNA 
sequencing 
In the placentas of SPE model rats, 56 miRNAs were significantly differentially 
expressed compared to control rats (adjusted p-value of<0.05) (Figure 6-3). Of 
these, 32 miRNAs were significantly upregulated and 24 miRNAs were 
significantly downregulated in the placentas of SPE model rats compared to 
control rats (adjusted p-value of<0.05) (Figure 6-3), which are listed in Table 
6-7. Due to the relatively large number of significantly differentially expressed 
miRNAs detected by miRNA sequencing, a selection of candidate miRNAs was 
chosen to investigate further. Candidate miRNAs were selected based on their 






Figure 6-3 Heatmap of significantly differentially expressed miRNAs in placentas of SPE 
model rats compared to control rats as detected by miRNA sequencing. 
Heatmap showing hierarchical cluster analysis of significantly differentially expressed miRNAs with 
expression presented as log2 fold change (z-scored) (adjusted p-value of <0.05). Red indicates 
upregulation and blue indicates downregulation in expression. Colour intensity is determined by 
log2 fold change. Each column represents a placenta sample from a single rat: control rats (C9930, 
C9759, C975, and C9767) and SPE model rats (C9955, C9758, C9872, and C9948). Dendrogram 
at the top of the heatmap represents hierarchical clustering of rats within and between groups, and 
dendrogram to the left of the heatmap represents hierarchical clustering within and between up- 















Table 6-7 List of significantly differentially expressed miRNAs in placentas of SPE model 
rats compared to control rats as detected by miRNA sequencing. 















rno-miR-20b-3p 1.14 20.20 6.21E-03 rno-miR-652-5p -1.46 47.93 3.90E-06 
rno-miR-203a-3p 0.58 4287.63 1.89E-05 rno-miR-216a-5p -0.99 22.78 4.48E-02 
rno-miR-203b-5p 0.58 4287.63 1.89E-05 rno-miR-330-3p -0.88 66.47 2.08E-04 
rno-miR-210-3p 0.58 3024.11 1.89E-05 rno-miR-24-2-5p -0.78 66.04 2.38E-03 
rno-miR-3574 0.58 3024.11 1.89E-05 rno-miR-186-3p -0.76 63.28 2.89E-03 
rno-miR-138-5p 0.49 853.90 1.14E-03 rno-miR-24-1-5p -0.63 65.60 3.35E-02 
rno-miR-203a-5p 0.39 1353.45 9.55E-04 rno-miR-375-3p -0.59 439.07 6.12E-08 
rno-miR-203b-3p 0.39 1353.45 9.55E-04 rno-miR-652-3p -0.46 431.25 2.33E-05 
rno-mir-542-5p 0.37 22981.42 7.25E-05 rno-miR-214-3p -0.45 352.06 9.24E-04 
rno-mir-542-3p 0.36 264299.80 4.76E-05 rno-miR-770-5p -0.44 274.99 6.78E-03 
rno-miR-672-5p 0.35 926.81 9.24E-04 rno-miR-33-5p -0.42 132.43 5.58E-02 
rno-miR-147 0.34 544.48 6.37E-03 rno-miR-188-5p -0.41 175.52 9.19E-03 
rno-miR-155-5p 0.33 4335.52 2.38E-03 rno-miR-181b-5p -0.40 286.37 6.21E-03 
rno-miR-182 0.33 59057.97 4.76E-05 rno-miR-222-3p -0.40 127.42 5.33E-02 
rno-miR-3556b 0.31 4655.04 3.73E-03 rno-miR-196a-5p -0.40 2287.91 1.89E-05 
rno-mir-29c-3p 0.31 9259.60 6.21E-03 rno-miR-495 -0.38 744.40 9.19E-03 
rno-miR-293-5p 0.31 72733.49 2.26E-04 rno-miR-770-3p -0.37 443.10 2.01E-03 
rno-mir-450b-3p 0.28 3831.14 7.33E-04 rno-miR-881-3p -0.31 517.58 4.08E-02 
rno-miR-322-5p 0.27 297923.00 2.89E-03 rno-miR-218b -0.28 978.31 6.21E-03 
rno-miR-291a-5p 0.27 3266.43 2.23E-03 rno-miR-425-5p -0.26 6732.42 6.29E-05 
rno-miR-463-5p 0.27 16596.91 2.95E-03 rno-miR-145-5p -0.26 4483.38 6.21E-03 
rno-miR-183-5p 0.26 37752.35 2.23E-03 rno-miR-374-5p -0.23 3794.60 1.53E-02 
rno-miR-3553 0.26 37752.35 2.23E-03 rno-mir-181a-5p -0.23 1591.92 5.13E-02 
rno-mir-19b-3p 0.26 25000.34 6.72E-05 rno-mir-218a-5p -0.21 5580.29 9.19E-03 
rno-miR-96-5p 0.25 25078.48 2.89E-03 rno-miR-652-5p -1.46 47.93 3.90E-06 
rno-mir-351-5p 0.24 59227.43 5.85E-04 rno-miR-216a-5p -0.99 22.78 4.48E-02 
rno-miR-743b-3p 0.23 18896.54 3.09E-03 rno-miR-330-3p -0.88 66.47 2.08E-04 
rno-miR-743a-3p 0.22 27050.93 3.29E-03     
rno-miR-450a-5p 0.21 21268.30 4.32E-02     
rno-miR-463-3p 0.21 15060.15 9.19E-03     
rno-miR-871-3p 0.19 9545.47 2.90E-02     
rno-miR-99b-3p 0.18 1762.04 5.58E-02     




6.4.4 Literature review for selection of candidate miRNAs 
Of the 56 significantly differentially expressed miRNAs detected by miRNA 
sequencing, a total of eleven miRNAs were identified that were detected by 
miRNA expression profiling studies in placenta samples from preeclamptic 
patients (Table 6-8). The direction of expression of four miRNAs as detected by 
miRNA sequencing matched the direction of expression reported by the 
expression profiling studies in placentas of preeclamptic patients (Table 6-8). 
MiR-210-3p and miR-19b-3p were found to be upregulated and miR-214-3p and 
miR-145-5p were found to be downregulated in miRNA sequencing in placentas 
of the SPE rat model and in expression profiling studies in placentas of 
preeclamptic patients (Table 6-8). These candidates (miR-210-3p, miR-19b-3p, 
miR-214-3p, and miR-145-5p (Figure 6-4)) were selected for validation in whole 
















(Enquobahrie et al., 2011) 
(Betoni et al., 2013) 
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Figure 6-4 Volcano plot of miRNA expression in whole placenta samples of SPE models 
compared to controls as detected by miRNA sequencing. 
Expression is presented as adjusted p-value (-log) plotted against log2 fold change, with positive 
fold change values indicating upregulation and negative values indicating downregulation of 
miRNAs in placentas of SPE model rats versus control rats. Orange denotes miRNAs significantly 
differentially expressed and blue denotes no significant difference in expression (p-value of <0.05 
























6.4.5 Validation of candidate miRNAs in a rat model of SPE 
The expression of four candidate miRNAs was evaluated by RT-qPCR in whole 
placentas and individual placental layers of SPE model rats compared to control 
rats to validate the findings from the miRNA sequencing experiment. None of the 
candidate miRNAs (miR-210-3p, miR-19b-3p, miR-214-3p, and miR-145-5p) were 
significantly differentially expressed in whole placentas of SPE model rats 
compared to controls (Figure 6-5). MiR-210-3p was significantly downregulated in 
the decidual layer (1.43±0.03 vs 0.41±0.29 Ct, p<0.05) and significantly 
upregulated in the labyrinth layer (3.04±0.05 vs 3.60±0.12 Ct, p<0.05) of SPE 
model rats compared to controls (Figure 6-6A) (as previously reported in Chapter 
5 Figure 5-4). MiR-19b-3p was significantly downregulated in the decidual layer 
(2.69±0.13 vs 2.10±0.15 Ct, p<0.05) of SPE model rats compared to controls 
(Figure 6-6B). MiR-145-5p was significantly downregulated in the labyrinth layer 
(1.38±0.03 vs 1.26±0.02 Ct, p<0.05) of SPE model rats compared to controls 
(Figure 6-6D). There was no significant difference in miR-214-3p expression 






Figure 6-5 Evaluation of candidate miRNAs in whole placentas of a rat model of SPE by 
TaqMan RT-qPCR. 
(A) MiR-210-3p, (B) miR-19b-3p, (C) miR-214-3p, and (D) miR-145-5p were not significantly 
differentially expressed in whole placental tissue of a rat model of SPE. Data are shown as mean 
Ct  SEM. Ct values were normalised to housekeeper U87, n=4 per group, analysed using Ct 





Figure 6-6 Evaluation of candidate miRNAs in individual placental layers (decidua, 
junctional zone, and labyrinth) of a rat model of SPE by TaqMan RT-qPCR. 
(A) MiR-210-3p was significantly downregulated in the decidua and significantly upregulated in the 
labyrinth of a rat model of SPE (as previously reported in Chapter 5 Figure 5-4). (B) MiR-19b-3p 
was significantly downregulated in the decidua of a rat model of SPE. (C) MiR-214-3p was not 
significantly differentially expressed in individual placental layers of a rat model of SPE. (D) MiR-
145-5p was significantly downregulated in the labyrinth of a rat model of SPE. Data are shown as 
mean Ct  SEM. Ct values were normalised to housekeeper U87, *p<0.05, n=3 in SPE group and 
n=4 in control group, analysed using Ct values by unpaired t-test or unpaired t-test with Welch’s 




6.4.6 Candidate miRNAs in patients with PE 
6.4.6.1 Clinical characteristics of study participants 
The clinical characteristics of patients with PE (n=6) and healthy pregnant 
control women (n=4) are listed in Table 6-9. Patients with PE and healthy 
controls were matched in terms of maternal age, BMI, and parity (Table 6-9). 
However, patients with PE delivered at a significantly earlier gestational age 
compared to healthy controls (p<0.05), and infants of patients with PE were 
significantly lighter than infants of healthy controls (p<0.05) (Table 6-9). In line 
with the clinical symptoms of PE, patients with PE had significantly higher 
maximum systolic and diastolic blood pressure compared to healthy controls 
(p<0.0001), and significant proteinuria was detected in patients with PE 
compared to healthy controls (p<0.01) (Table 6-9). 
6.4.6.2 Evaluation of candidate miRNAs in patients with PE 
The expression of four candidate miRNAs was evaluated by RT-qPCR in placentas 
of patients with PE compared to healthy pregnant control women. In line with a 
significant upregulation in placentas of SPE model rats as detected by miRNA 
sequencing, miR-210-3p and miR-19b-3p were significantly upregulated in 
placentas of preeclamptic patients compared to controls (2.34±0.24 vs 4.03±0.24 
Ct, p<0.01 and -0.26±0.16 vs 0.34±0.09 Ct, p<0.05, respectively) (Figure 6-7A 
and B). There was no significant difference in miR-214-3p and miR-145-5p 
expression in the placentas of preeclamptic patients compared to controls 




Table 6-9 Clinical characteristics of pregnant healthy control women and women with PE. 
Characteristic (units) Control (n=4) PE (n=6) 
Maternal age (years) 35.3 ± 4.1 37.3 ± 4.1 
Gestational age (weeks) 39.9 ± 1.2 35.7 ± 3.1* 
Maximuma systolic blood pressure 
(mm Hg) 
127.0 ± 8.7 176.0 ± 9.2 **** 
Maximuma diastolic blood pressure 
(mm Hg) 
69.0 ± 8.2 99.2 ± 3.1 **** 
Maximuma protein (mg/dL) ND/NAD 351.0 (41.0-786.0) ** 
Infant birth weight (g) 3868.8 ± 251.2 2271.0 ± 928.5 * 
Body mass index at delivery (kg/m2) 28.2 ± 6.0 25.5 ± 4.3 
Parity (number of past pregnancies 
reaching viable gestation) 
0.5 (0-1.0) 1.0 (1.0-1.0) 
amaximum refers to maximum values recorded during pregnancy. Values are presented as mean ± 
SD or median (range), *p<0.05, **p<0.01, ****p<0.0001, unpaired t-test (with Welch’s correction as 
appropriate) for age, blood pressure, weight, and body mass index and Mann-Whitney U test for 






Figure 6-7 Evaluation of candidate miRNAs in placentas of patients with PE by TaqMan RT-
qPCR. 
(A) MiR-210-3p and (B) miR-19b-3p were significantly upregulated in placentas of patients with PE. 
(C) MiR-214-3p and (D) miR-145-5p were not significantly differentially expressed in placentas of 
patients with PE. Data are shown as mean Ct  SEM. Ct values were normalised to housekeeper 
RNU44, *p<0.05 and **p<0.01, n=4 in healthy pregnant group and n=6 in PE group, analysed using 




6.4.7 Evaluation of predicted gene targets of miR-210-3p 
6.4.7.1 Selection of candidate miR-210-3p predicted gene targets 
TargetScan 7.2 and miRDB were utilised to identify predicted gene targets of 
miR-210-3p in humans. A total of 15 genes were predicted to be miR-210-3p 
targets in humans by both TargetScan and miRDB (Table 6-10). Although not 
predicted by TargetScan or miRDB to be a gene target in rats, fibroblast growth 
factor receptor-like 1 (FGFRL1) was selected as a candidate gene target since it 
has the greatest number of predicted conserved sites and has not yet been 
validated as a miR-210-3p gene target in trophoblast cells (Table 6-10). Brain-
derived neurotrophic factor (BDNF) and NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 4, 9kDa (NDUFA4) were selected as candidate genes since 
they are predicted to be miR-210-3p targets in rats by both TargetScan and 
miRDB and have not yet been validated as miR-210-3p gene targets in 
trophoblast cells (Table 6-10). 
In addition to TargetScan and miRDB, predicted gene targets of miR-210-3p were 
identified by IPA. The predicted gene targets of miR-210-3p were overlaid with 
the 707 genes IPA has listed as associated with PE. The overlap led to 
identification of a single gene, solute carrier family 6 member 1 (SLC6A1) (Figure 
6-8). SLC6A1 was selected as the final candidate gene target to investigate 










conserved sites  
in human 
Predicted  
gene target  
in rat 
Validated target in 
trophoblast cells 
 TargetScan miRDB TargetScan miRDB  
FGFRL1 8 8 No No No 
SCARA3 3 2 No No No 
ELFN2 2 1 Yes No No 
ISCU 1 1 Yes Yes Yes1 
BDNF 1 1 Yes Yes No 
NDUFA4 1 1 Yes Yes No 
GPD1L 1 1 Yes No No 
KMT2D 1 1 Yes No No 
MID1IP1 1 1 Yes No No 
KCMF1 1 1 No No Yes2 
B4GALT5 1 1 No No No 
DENND6A 1 1 No No No 
DIMT1 1 1 No No No 
E2F3 1 1 No No No 
ST3GAL3 1 1 No No No 
Selected candidate genes are highlighted in bold. (1) (Lee et al., 2011) and (2) (Luo et al., 2014). 
FGFRL1, fibroblast growth factor receptor-like 1; SCARA3, scavenger receptor class A member 3; 
ELFN2, extracellular leucine rich repeat and fibronectin type III domain containing 2; ISCU, iron-
sulphur cluster assembly scaffold; BDNF, brain-derived neurotrophic factor; NDUFA4, NDUFA4, 
mitochondrial complex associated; GPDL1, glycerophosphodiesterase-like 1; KMT2D, lysine 
methyltransferase 2D; MID1IP1, MID1 interacting protein 1; KCMF1, potassium channel 
modulatory factor 1; B4GALT5, β-1,4-galactosyltransferase 5; DENND6A, DENN domain 
containing 6A; DIMT1, DIMT1 rRNA methyltransferase and ribosome maturation factor; E2F3, E2F 





Figure 6-8 Predicted gene targets of miR-210-3p overlaid with 707 PE genes from IPA. 




6.4.7.2  Evaluation of candidate miR-210-3p predicted gene targets in a 
rat model of SPE and patients with PE 
The expression of four candidate genes (FGFRL1, BDNF, NDUFA4, and SLC6A1) 
was evaluated by RT-qPCR in placentas of patients with PE. FGFRL1 and BDNF 
were significantly downregulated in the placentas of preeclamptic patients 
compared to healthy pregnant controls (-10.56±0.30 vs -11.64±0.35 Ct, p<0.05 
and -6.72±0.18 vs -8.08±0.21 Ct, p<0.01, respectively) (Figure 6-9A and B). 
NDUFA4 and SLC6A1 were not significantly differentially expressed in the 
placentas of preeclamptic patients compared to controls (Figure 6-9C and D). 
The predicted gene targets FGFRL1 and BDNF that were significantly 
differentially expressed in patients with PE were subsequently evaluated in 
whole placentas of a rat model of SPE. FGFRL1 was significantly downregulated 
in SPE model rats compared to control rats (16.04±0.21 vs 15.28±0.18 Ct, 
p<0.05) (Figure 6-10A). BDNF was not detected in the placentas of SPE model 





Figure 6-9 Evaluation of miR-210-3p predicted gene targets in placentas of patients with PE 
by TaqMan RT-qPCR. 
(A) FGFRL1 and (B) BDNF were significantly downregulated in placentas of PE patients. (C) 
NDUFA4 and (D) SLC6A1 were not significantly differentially expressed in the placentas of PE 
patients. Data are shown as mean Ct  SEM. Ct values were normalised to housekeeper B2M, 
*p<0.05 and **p<0.01, n=4 in healthy pregnant group and n=6 in PE group, analysed using Ct 
values by unpaired t-test. 
 
 
Figure 6-10 Evaluation of miR-210-3p predicted gene targets in whole placentas of a rat 
model of SPE by TaqMan RT-qPCR. 
(A) FGFRL1 was significantly downregulated in whole placentas of a rat model of SPE. (B) BDNF 
was not detected in whole placentas of rats. Data are shown as mean Ct  SEM. Ct values were 
normalised to housekeeper ACTB, n=4 per group, analysed using Ct values by unpaired t-test.  
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6.4.7.3 Evaluation of candidate miR-210-3p predicted gene targets in 
trophoblastic BeWo cells 
Trophoblastic BeWo cells were transfected with a miR-210-3p mimic and miR-
210-3p inhibitor to evaluate the effect of overexpressing and knocking down 
miR-210-3p on predicted gene targets: FGFRL1, BDNF, NDUFA4, and SLC6A1. In 
addition, BeWo cells were assayed for viability to determine if miR-210-3p 
overexpression and knockdown (and potentially dysregulation of predicted gene 
targets) influenced this property of trophoblast cells. 
MiR-210-3p expression was significantly increased following transfection with a 
miR-210-3p mimic compared to untransfected cells (cells only) at 24 h (-6.63 
±0.09 vs 6.05±0.09 Ct, p<0.0001) and at 48 h (-7.26±0.04 vs 6.50±0.04 Ct, 
p<0.0001) (Figure 6-11A and C, respectively). MiR-210-3p expression was also 
significantly increased with the miR-210-3p mimic when compared to the 
negative control scramble (p<0.0001) and miR-210-3p inhibitor (p<0.0001) at 
both 24 and 48 h (Figure 6-11A and C). MiR-210-3p expression was significantly 
decreased following transfection with a miR-210-3p inhibitor compared to 
untransfected cells (cells only) at 24 h (7.59±0.22 vs 6.05±0.09 Ct, p<0.0001) 
and at 48 h (9.27±0.33 vs 6.50±0.04 Ct, p<0.0001) (Figure 6-11A and C, 
respectively). MiR-210-3p expression was also significantly decreased with the 
miR-210-3p inhibitor when compared to the negative control scramble 
(p<0.0001) and miR-210-3p mimic (p<0.0001) at both 24 and 48 h (Figure 6-11A 
and C, respectively). 
Transfection of BeWo cells with miR-210-3p inhibitor led to a significant increase 
in cell viability compared to untransfected cells (cells only) at 24 h (p<0.0001) 
(Figure 6-11B) with no significant difference when compared to the negative 
control scramble and miR-210-3p mimic, suggesting transfection reagents were 
affecting cell viability. There was no significant difference in cell viability 
between transfection with the negative control scramble, miR-210-3p mimic, 
and miR-210-3p inhibitor at both 24 and 48 h (Figure 6-11B and D, respectively), 
further suggesting changes in miR-210-3p expression had no effect on cell 
viability. Due to the influence of transfection on cell viability, miRNA and gene 
target RT-qPCR data were reanalysed to compare mimic and inhibitor 




Figure 6-11 Evaluation of miR-210-3p expression by TaqMan RT-qPCR and cell viability by 
MTT assay in trophoblastic BeWo cells transfected with miR-210-3p mimic and inhibitor for 
(A) and (B) 24 hours and (C) and (D) 48 hours.  
BeWo cells were transfected with 30 nM miRNA scramble/mimic/inhibitor and 3 µL siPORT™ 
NeoFX™ Transfection Agent for 24 and 48 hours and assayed for gene expression and cell 
viability. (A) MiR-210-3p was significantly increased after 24 hours with miR-210-3p mimic 
treatment compared to cells only, scramble, and miR-210-3p inhibitor treatment. MiR-210-3p was 
significantly decreased after 24 hours with miR-210-3p inhibitor treatment compared to cells only, 
scramble, and miR-210-3p mimic treatment. (B) Cell viability was significantly increased following 
24-hour transfection with a scramble, mimic, and inhibitor compared to untransfected cells (cells 
only). (C) MiR-210-3p was significantly increased after 48 hours with miR-210-3p mimic treatment 
compared to cells only, scramble, and miR-210-3p inhibitor treatment. MiR-210-3p was significantly 
decreased after 48 hours with miR-210-3p inhibitor treatment compared to cells only, scramble, 
and miR-210-3p mimic treatment. (D) Cell viability was significantly increased following 48-hour 
transfection with a scramble, mimic, and inhibitor compared to untransfected cells (cells only). For 
(A) and (C), data are shown as mean Ct  SEM. Ct values were normalised to housekeeper 
RNU44, ***p<0.0001, n=3 technical replicates per group, analysed using Ct values by one-way 
ANOVA followed by Tukey’s post-hoc multiple comparisons test. For (B) and (D), data are shown 
as median (IQR). Values were expressed relative to untransfected cells only control (considered 
100%), ****p<0.0001, n=3 technical replicates per group, analysed by analysed by Kruskal-Wallis 




6.4.7.3.1 MiR-210-3p and candidate predicted gene targets expression in 
BeWo cells transfected for 24 hours 
After 24 h transfection, the miR-210-3p mimic led to a significant increase in 
miR-210-3p expression compared to the negative control scramble (-6.63±0.09 vs 
6.02±0.10 Ct, p<0.0001) and miR-210-3p inhibitor (-6.63±0.09 vs 7.59±0.22 Ct, 
p<0.0001) (Figure 6-12A). The miR-210-3p inhibitor led to a significant decrease 
in miR-210-3p expression compared to the negative control scramble (7.59±0.22 
vs 6.02±0.10 Ct, p<0.0001) and miR-210-3p mimic (7.59±0.22 vs -6.63±0.09 Ct, 
p<0.0001) (Figure 6-12A). 
FGFRL1 was significantly downregulated following transfection with the miR-210-
3p mimic compared to the negative control scramble (11.35±0.64 vs 9.44±0.15 
Ct, p<0.05), while there was no significant difference in FGFRL1 expression 
following transfection with the miR-210-3p inhibitor (Figure 6-12B). BDNF was 
not significantly differentially expressed following transfection with the miR-
210-3p mimic or inhibitor compared to the scramble (Figure 6-12C). NDUFA4 and 
SLC6A1 were not detected in BeWo cells following transfection with the negative 





Figure 6-12 Evaluation by TaqMan RT-qPCR of miR-210-3p and predicted gene targets in 
trophoblastic BeWo cells transfected with miR-210-3p mimic and inhibitor for 24 hours. 
BeWo cells were transfected with 30 nM miRNA scramble/mimic/inhibitor and 3 µL siPORT™ 
NeoFX™ Transfection Agent for 24 hours and assayed for gene expression. (A) MiR-210-3p was 
significantly increased after 24 hours with miR-210-3p mimic treatment compared to scramble and 
miR-210-3p inhibitor treatment. MiR-210-3p was significantly decreased after 24 hours with miR-
210-3p inhibitor treatment compared to scramble and miR-210-3p mimic treatment. (B) FGFRL1 
was significantly downregulated following miR-210-3p mimic treatment compared to scramble. (C) 
BDNF was not significantly differentially expressed following miR-210-3p mimic and inhibitor 
treatment compared to scramble. (D) NDUFA4 and (E) SLC6A1 were undetected in BeWo cells 
across all transfections. Data are shown as mean Ct  SEM. Ct values were normalised to 
housekeeper RNU44 (A) and B2M (B) and (C), *p<0.05 and ***p<0.0001, n=3 technical replicates 
per group, analysed using Ct values by one-way ANOVA followed by Tukey’s post-hoc multiple 
comparisons test.  
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6.4.7.3.2 MiR-210-3p and candidate predicted gene targets expression in 
BeWo cells transfected for 48 hours 
After 48 h transfection, the miR-210-3p mimic led to a significant increase in 
miR-210-3p expression compared to the negative control scramble (-7.16±0.04 vs 
6.24±0.16 Ct, p<0.0001) and miR-210-3p inhibitor (-7.16±0.04 vs 9.27±0.33 Ct, 
p<0.0001) (Figure 6-13A). The miR-210-3p inhibitor led to a significant decrease 
in miR-210-3p expression compared to the negative control scramble (9.27±0.33 
vs 6.24±0.16 Ct, p<0.0001) and miR-210-3p mimic (9.27±0.33 vs -7.16±0.04 Ct, 
p<0.0001) (Figure 6-13A).  
FGFRL1 was significantly downregulated following transfection with the miR-210-
3p mimic compared to the negative control scramble (11.58±0.43 vs 9.66±0.23 
Ct, p<0.05) and miR-210-3p inhibitor (11.58±0.43 vs 9.61±0.46 Ct p<0.05) 
(Figure 6-13B). There was no significant difference in FGFRL1 expression 
between transfection with the negative control scramble and miR-210-3p 
inhibitor (Figure 6-13B). BDNF was not significantly differentially expressed 
following transfection with the miR-210-3p mimic or inhibitor compared to the 
scramble (Figure 6-13C). NDUFA4 and SLC6A1 were not detected in BeWo cells 
following transfection with the negative control scramble, mimic, and inhibitor 
(Figure 6-13D and E). 
Due to the miR-210-3p mimic inducing supraphysiological overexpression of miR-
210-3p, the transfection experiment was repeated with the lowest 
recommended volume of transfection agent (1 µL). MiR-210-3p mimic led to a 
significant increase in miR-210-3p expression compared to the negative control 
scramble (-3.73±0.12 vs 5.65±0.11 Ct, p<0.0001) and miR-210-3p inhibitor       
(-3.73±0.12 vs 6.98±0.06 Ct, p<0.0001) (Figure 6-14A). Transfection with 1 µL 
of transfection reagent still induced supraphysiological expression levels of miR-
210-3p, but this was lower than with 3 µL of transfection reagent (-3.73 vs -7.16, 
respectively). While FGFRL1 was significantly reduced with the miR-210-3p 
mimic compared to the negative control scramble (4.56±0.01 vs 4.39±0.05 Ct, 
p<0.05), this was no longer significant when compared to the miR-210-3p 
inhibitor (Figure 6-14B). As was seen with 3 µL of transfection reagent, BDNF was 
not significantly differentially expressed (Figure 6-14C), and SLC6A1 was not 
detected (Figure 6-14E). However, NDUFA4 was detected following transfection 
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with 1 µL of transfection reagent with the negative control scramble, mimic, and 
inhibitor, although there was no significant difference between the treatments 
(Figure 6-14D). Additional 72 h transfections were run, but no significant 




Figure 6-13 Evaluation by TaqMan RT-qPCR of miR-210-3p and predicted gene targets in 
trophoblastic BeWo cells transfected with miR-210-3p mimic and inhibitor for 48 hours. 
BeWo cells were transfected with 30 nM miRNA scramble/mimic/inhibitor and 3 µL siPORT™ 
NeoFX™ Transfection Agent for 48 hours and assayed for gene expression. (A) MiR-210-3p was 
significantly increased after 48 hours with miR-210-3p mimic treatment compared to scramble and 
miR-210-3p inhibitor treatment. MiR-210-3p-3p was significantly decreased after 48 hours with 
miR-210-3p inhibitor treatment compared to scramble and miR-210-3p mimic treatment. (B) 
FGFRL1 was significantly downregulated following miR-210-3p mimic treatment compared to 
scramble and miR-210-3p inhibitor treatment. (C) BDNF was not significantly differentially 
expressed following miR-210-3p mimic and inhibitor treatment compared to scramble. (D) NDUFA4 
and (E) SLC6A1 were undetected in BeWo cells across all transfections. Data are shown as mean 
Ct  SEM. Ct values were normalised to housekeeper RNU44 (A) and B2M (B) and (C), *p<0.05 
and ***p<0.0001, n=3 technical replicates per group, analysed using Ct values by one-way 




Figure 6-14 Evaluation by TaqMan RT-qPCR of miR-210-3p and predicted gene targets in 
trophoblastic BeWo cells transfected with miR-210-3p mimic and inhibitor for 48 hours. 
BeWo cells were transfected with 30 nM miRNA scramble/mimic/inhibitor and 1 µL siPORT™ 
NeoFX™ Transfection Agent for 48 hours and assayed for gene expression. (A) MiR-210-3p was 
significantly increased after 24 hours with miR-210-3p mimic treatment compared to scramble and 
miR-210-3p inhibitor treatment. MiR-210-3p was significantly decreased after 24 hours with miR-
210-3p inhibitor treatment compared to scramble and miR-210-3p mimic treatment. (B) FGFRL1 
was significantly downregulated following miR-210-3p mimic treatment compared to scramble and 
miR-210-3p inhibitor treatment. (C) BDNF and (D) NDUFA4 were not significantly differentially 
expressed following miR-210-3p mimic and inhibitor treatment compared to scramble. (E) SLC6A1 
were undetected in BeWo cells across all transfections. Data are shown as mean Ct  SEM. Ct 
values were normalised to housekeeper RNU44 (A) and B2M (B), (C), and (D), *p<0.05 and 
***p<0.0001, n=3 technical replicates per group, analysed using Ct values by one-way ANOVA 




In this chapter, significantly differentially expressed placental miRNAs were 
identified in a rat model of SPE, representing the first study to conduct miRNA 
sequencing in the placenta of an animal model of PE. Furthermore, significant 
differences in the direction of expression of miRNAs (specifically, miR-210-3p, 
miR-19b-3p, and miR-145-5p) were found within placental layers of the SPE rat 
model, a finding previously only shown in human placentas. MiR-210-3p was 
shown to be significantly differentially expressed in the placentas of patients 
with PE. Expression of miR-210-3p and its predicted gene target, FGFRL1, 
demonstrated an inverse relationship in the placentas of the SPE rat model and 
preeclamptic patients as well as in placental trophoblast cells. This provides 
novel evidence of altered FGFRL1 expression in the placenta in PE, which may 
be linked to dysregulated placental miR-210-3p, adding to the existing literature 
that suggests miR-210-3p plays a pathological role in PE. 
Comparing these findings with other PE animal models and clinical studies 
highlights the importance of investigating the role of placental miRNAs in 
subtypes of PE and in the different layers of the placenta. In a mouse model of 
PE, induced by activation of the maternal immune system with poly I:C, miR-
210-3p was significantly upregulated in the placenta (Kopriva et al., 2013), 
corresponding with the increased expression detected by miRNA sequencing in 
our rat model of SPE and by RT-qPCR in patients with PE. An upregulation of 
placental miR-210-3p across PE subtypes is supported by the large number of 
clinical studies reporting increased miR-210-3p in the placentas of patients with 
mild (Adel et al., 2017), severe (Muralimanoharan et al., 2012), EO (Ishibashi et 
al., 2012), LO (Chen et al., 2019), diagnosed (Wang et al., 2019a), and SPE 
(Vashukova et al., 2016). In contrast, one study observed a significant 
downregulation of miR-210-3p in patients with mild PE (Zhu et al., 2009). It is 
unlikely this represents a miRNA signature specific to the mild PE subtype since 
another study in mild preeclamptic patients reported a significant increase in 
expression (Adel et al., 2017). Rather, a decrease in miR-210-3p expression may 
reflect differences in placental hypoxia and in turn underlying pathological 
processes. In a study of pregnant mice exposed to moderate hypoxia, a 
significant downregulation of placental miR-210-3p was noted (Krawczynski et 
al., 2016). Hence, miR-210-3p expression may only be induced in more severe 
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hypoxic conditions as previously discussed (Chapter 5 Discussion). However, 
hypoxia-independent stimuli also regulate placental miR-210-3p expression, 
supported by the significant downregulation of miR-210-3p observed in the 
maternal decidual layer as previously discussed (Chapter 5 Discussion). In further 
support of hypoxia-independent mechanisms driving miR-210-3p, the key 
mediator of the cellular response to hypoxia, HIF-1 α, was not significantly 
differentially expressed in any of the placental layers of this SPE model rat 
(Morgan et al., 2018). It should be noted though that expression levels of its 
isoform, HIF-2 α, were not measured, which has previously shown to drive miR-
210-3p expression in trophoblasts in vitro (Lalevée et al., 2014). In terms of 
expression differences between layers, three clinical studies have shown 
elevated miR-210-3p levels in the basal plate (comprising of maternal and foetal 
tissue) (Luo et al., 2014, Xu et al., 2014a, Zhang et al., 2015a), and two of these 
found no significant difference in expression in the chorionic plate (comprising 
of foetal tissue) (Luo et al., 2014, Xu et al., 2014a). Investigating miR-210-3p 
expression between placental layers, and in particular the decidua of patients 
with SPE remains crucial, as it may provide insight into whether SPE shows a 
unique placental miR-210-3p signature. 
In addition to the candidate miRNA miR-210-3p, expression profiling studies in 
the placentas of patients with PE reported dysregulation of the other 
candidates, miR-19b-3p (Ishibashi et al., 2012, Zhang et al., 2015b, Zhang et al., 
2015a), miR-214-3p (Zhao et al., 2014, Xu et al., 2014a, Hu et al., 2009), and 
miR-145-5p (Ishibashi et al., 2012), with results matching the direction of 
expression seen in the miRNA sequencing conducted in rats with SPE. However, 
validation studies by RT-qPCR of these miRNAs in the placental layers of the SPE 
rat model produced conflicting results. Although a significant downregulation of 
miR-145-5p in the labyrinth matches the results from the miRNA sequencing 
experiment and clinical studies, a significant downregulation of miR-19b-3p in 
the decidua is in contrast to the increased expression observed in the miRNA 
sequencing experiments and in clinical studies. Furthermore, a number of 
significantly differentially expressed placental miRNAs detected by the miRNA 
sequencing experiment showed the opposite direction of expression as reported 
by sequencing or microarray experiments in patients with PE, including miR-
181a-5p (Zhu et al., 2009, Jiang et al., 2015, Hu et al., 2009, Xu et al., 2014a, 
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Zhang et al., 2015a), miR-542-3p (Lykoudi et al., 2018, Xu et al., 2014a, Betoni 
et al., 2013, Zhu et al., 2009), and miR-222-3p (Hu et al., 2009), and in patients 
with SPE, namely miR-542-5p and miR-495 (Ishibashi et al., 2012). Finally, 
placental miRNAs (miR-126-3p (Yan et al., 2014), miR-148a/152 (Yang et al., 
2016a), and miR-576-5p (Wang et al., 2020c)) previously investigated in other 
animal models of PE, specifically L-NAME-induced PE rats, were not detected by 
miRNA sequencing as significantly differentially expressed in our rat model of 
SPE. Collectively, these findings further highlight the importance of examining 
placental miRNA expression in individual layers both within animal models of PE 
and patients with PE.  
Of the four candidate predicted gene targets of miR-210-3p, FGFRL1 and BDNF 
were significantly downregulated in the placentas of PE patients. FGFRL1 was 
also significantly downregulated in the placentas of SPE model rats, matching 
the upregulation of miR-210-3p seen in whole placental tissue from the SPE 
model rats as detected by miRNA sequencing and in the placentas of PE patients. 
FGFRL1 belongs to the fibroblast growth factor receptor (FGFR) family, which 
bind FGFs to regulate an array of cellular processes, including proliferation, 
differentiation, migration, and apoptosis (Trueb, 2011). Unlike other family 
members, FGFRL1 lacks an intracellular protein kinase domain required for 
signalling, contributing to evidence supporting its function as a decoy receptor 
(Trueb, 2011). Relatively few studies have investigated the role of FGFRs in the 
placenta. FGFRs are expressed in placental trophoblasts, macrophages, and 
blood vessel walls (Anteby et al., 2005) and have shown to regulate trophoblast 
characteristics (Baczyk et al., 2006). They have found to be dysregulated in 
trophoblasts in patients with PE (Loichinger et al., 2016) and upregulated in 
endothelial cells in patients with placental vascular disease (Wang et al., 2006). 
However, no study could be identified that has investigated FGFRL1 expression 
and/or function in the placenta. In the current study, overexpressing miR-210-3p 
in placental trophoblasts downregulated FGFRL1 expression levels, although this 
had no effect on trophoblast viability. Previous studies have shown increasing 
miR-210-3p, and in turn inhibiting FGFRL1, stimulates angiogenesis in 
endothelial cells (Cui et al., 2015) and cancer cells (Yang et al., 2016d), inhibits 
cancer cell proliferation (Yang et al., 2017b), and promotes (Liu et al., 2018d) or 
inhibits (Yang et al., 2017b) cell migration and invasion depending on cancer cell 
264 
 
type under study. Future studies may therefore seek to elucidate other 
trophoblast characteristics which may be altered, including migration and 
invasion, and the role of miR-210-3p and FGFRL1 in other placental cell types, 
such as macrophages. 
BDNF belongs to a family of proteins known as neurotrophins, which play a key 
role in regulating differentiation, structure, and function of neurons 
(Hempstead, 2015). In pregnancy, evidence suggests BDNF supports placental 
growth and development by stimulating trophoblast cell growth and survival 
(Kawamura et al., 2009), protecting trophoblasts against oxidative stress (Fujita 
et al., 2011, Sahay et al., 2015), and potentially inducing angiogenesis (Sun et 
al., 2009) as well as promoting foetal growth and development via placental 
signalling (Mayeur et al., 2010, Kodomari et al., 2009). It has therefore been 
postulated that downregulation of placental BDNF may reflect pathological 
conditions while an upregulation may represent a protective role (Sahay et al., 
2020). Previous studies in PE patients have reported lower levels of BDNF in 
placental cotyledons (D'souza et al., 2014) and the basal region of the placenta 
(Sahay et al., 2020) and higher levels in the central foetal region (Sahay et al., 
2015), suggesting the role of BDNF differs across the placenta. In the current 
study, BDNF was significantly downregulated in the placentas of PE patients, 
which comprised of both maternal and foetal tissue. Although BDNF is a 
predicted target of miR-210-3p and an experimentally validated gene target in 
other cell types, overexpressing miR-210-3p in trophoblast cells had no 
significant effect on BDNF expression, indicating other factors influence BDNF 
expression to a greater extent in trophoblasts. 
Investigating dysregulated placental miRNAs in a subtype of PE as well as within 
individual placental layers represents the major strength of the current study. 
However, a major limitation is that findings from an SPE rat model were 
evaluated in patients diagnosed with PE rather than patients with SPE. This was 
due to the limited availability of samples, which in turn accounts for the small 
sample size. Another limitation of the current study is that there were 
significant differences in foetal weight and gestational age at delivery between 
patients with PE and the healthy control group. These differences may have 
influenced miRNA and gene expression findings since placental miRNAs have 
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shown to differ depending on foetal weight (Awamleh et al., 2019, Pineles et 
al., 2007, Weedon-Fekjær et al., 2014) as well as between term and preterm 
deliveries (Mayor-Lynn et al., 2011, Hromadnikova et al., 2017) and term and 
preterm PE (Anton et al., 2015, Yang et al., 2019b). Controlling for preterm 
deliveries however is a double-edged sword. While controlling for the variable 
may account for its effects on placental miRNA expression, preterm deliveries 
are by definition not normal pregnancies and may therefore introduce other 
confounding effects when used as a control. Preclinical and clinical studies in PE 
subtypes remain cornerstone experiments for investigating the role of placental 
miRNAs in this heterogenous disorder. 
Another weakness of this study was a lack of significance in miRNA expression in 
whole rat placentas when examined by RT-qPCR in comparison to miRNA 
sequencing. Selection of candidate miRNAs for validation was based on 
significance in miRNA sequencing and supporting literature from patients with PE 
rather than considering an arbitrary log2 fold change cut-off value. MiRNA 
expression levels have shown to exhibit a positive relationship with their activity 
(Kozomara et al., 2014), suggesting larger differences in miRNA expression may 
lead to greater changes in expression of target mRNA. This supports the use of a 
log2 fold change cut-off value in sequencing data in order to select candidate 
miRNAs for further investigation that are potentially more biologically relevant. 
However, other evidence suggests miRNA expression levels are a poor indicator 
of activity (Plotnikova et al., 2019, Kozomara et al., 2014). This underpinned the 
choice to select candidate miRNAs based on previous identification in patients, 
with the aim of validating clinically relevant miRNAs. As a result, candidate 
miRNAs exhibited log2 fold changes less than -0.5 and 1 in miRNA sequencing 
data. Hence, small changes in expression therefore arguably failed to reach 
significance when examined by RT-qPCR. In addition, a small sample size likely 
contributed to a lack of significance. Despite a small sample size, greater 
differences in expression were seen in individual placental layers, which reached 
significance with RT-qPCR. Finally, although the relationship between miR-210-
3p and predicted gene targets FGFRL1, BDNF, NDUFA4, and SLC6A1 was explored 
in-vitro, in a preclinical PE model, and in patients with PE, validation with 
reporter constructs is required to confirm direct regulation of the miRNA and its 
gene targets. Nonetheless, the findings in this chapter provide novel evidence 
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and build on the growing number of studies that suggest miR-210-3p plays a key 
pathological role in PE by modulating gene expression and therefore represents a 




Chapter 7 General discussion 
Gene therapy holds potential as a treatment strategy for PE, a complex disorder 
involving multiple genetic and environmental factors, with ineffective 
management. Although placental gene therapy for FGR has undergone 
considerable clinical progress, non-invasive and non-viral techniques that target 
the placenta are needed to address the safety concerns of the current gene 
therapy strategy for FGR. Furthermore, suitable targets for gene therapy for PE 
have yet to be found. This work sought to demonstrate that UMGD can achieve 
tissue-specific transfer of an expression vector in a non-invasive and non-viral 
manner and is therefore suitable for targeting placenta. Investigations into 
miRNA expression and predicted gene targets in placental tissue from a 
preclinical model of SPE as well as preeclamptic patients and in a trophoblast 
cell line sought to show miRNAs play a role in the pathology of PE by 
demonstrating their dysregulation and to identify potentially suitable 
therapeutic targets for gene therapy applications. 
UMGD in conjunction with a plasmid vector represents a non-viral and non-
invasive delivery system in gene therapy. Prior to this work, a single published 
study applied the technique to targeting the placenta in vivo (Babischkin et al., 
2019). In the study, UMGD of VEGF to the placenta in a baboon model of 
impaired uterine artery remodelling restored EVT invasion of the uterine arteries 
(Babischkin et al., 2019). However, non-targeted tissues were not evaluated for 
gene transfer, an important preclinical measure to provide supporting evidence 
of safety of the technique. Furthermore, as mice are more practical and more 
frequently used as models of PE, establishment of a UMGD protocol for tissue-
specific transfer of an expression vector that could be applied to mouse 
placentas was required. Following optimisation of an in vivo UMGD protocol in 
Chapter 3, a UMGD proof-of-concept study was conducted which demonstrated 
tissue-specific gene transfer of a luciferase plasmid to mouse hearts in Chapter 
4. The protocol was then applied to mouse placentas, showing evidence of 
limited gene transfer. Non-target tissues were not evaluated for gene transfer 
due to time constraints, meaning this aspect of safety could not be confirmed in 
the study targeting the placenta. Placental-specific delivery of an expression 
vector with UMGD therefore remains to be demonstrated in order to support the 
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clinical translatability of this technique. Targeted delivery to the placenta 
evidenced by lack of gene transfer in non-target tissues is currently lacking in 
preclinical studies of gene therapy in pregnancy disorders. This is critical to the 
development of placental gene therapy since the lives of both mother and foetus 
are at risk. 
In addition to the non-viral, non-invasive, and targeted aspects of UMGD, several 
other factors contribute to the potential of UMGD as a strategy for placental 
gene therapy. Diagnostic US is routinely used in pregnancy, and its safety record 
spans decades, supporting clinical translation of UMGD (Torloni et al., 2009). 
MBs as US contrast agents are not currently indicated in obstetrics due to limited 
research into possible harmful effects and lack of knowledge of their ability to 
pass through the placenta (Sidhu et al., 2018). Nonetheless, several studies 
investigating the diagnostic utility of MBs in pregnant patients support their safe 
use in pregnancy (Ordén et al., 2000, Windrim et al., 2016, Xiong et al., 2016). A 
study reporting on safety parameters following administration of Levovist found 
no harmful foetal or maternal effects relating to birthweight, placental weight 
and morphology, prenatal haemorrhage, cord arterial and venous blood pH, and 
umbilical artery resistance index (Ordén et al., 2000). A significant increase was 
observed in the number of foetal heart rate accelerations, movements, and 
short-term variations in heart rate, although this was attributed to the maternal 
stress response to US (Ordén et al., 2000). Preclinical studies investigating the 
effects of MBs on placental permeability provide evidence that MBs do not cross 
the placental barrier (Hua et al., 2009, Arthuis et al., 2013). Pregnant rats were 
administered the tracer compound Evan’s blue followed by a bolus dose of 1 
mL/kg SonoVue and subject to intermittent or continuous US at an MI of 0.13, 
1.0, or 1.4 for 5 min (Hua et al., 2009). Evaluation by naked eye and 
fluorescence microscopy revealed Evan’s blue was detectable in the placenta 
but none in the foetus across all groups (Hua et al., 2009). Post-sacrifice 
examination of tissue with lanthanum, a stain that cannot penetrate through the 
cell membrane, showed lanthanum particles were present in the intercellular 
space between syncytiotrophoblasts but not cytotrophoblasts, suggesting MBs 
may affect placental cells but do not disrupt the placental barrier (Hua et al., 
2009). Another study in pregnant rats administered Vevo MicroMarker® found 
MBs did not alter perfusion in the umbilical cord or foetus, providing indirect 
269 
 
evidence that MBs do not disrupt the placental barrier (Arthuis et al., 2013). 
Furthermore, histological analysis revealed no foetal or placental abnormalities, 
although it should be noted the study was conducted at a relatively low MI of 
0.43 (Arthuis et al., 2013). Although only a handful of studies have investigated 
the safety of MBs in pregnancy at MIs below 1.4, they suggest safety risks are low 
and thereby support utilizing UMGD for targeting the placenta. Nonetheless, 
investigating the effect of UMGD on placental permeability is pertinent to 
establishing foetal gene transfer does not occur. Foetal gene transfer was not 
assessed in the published UMGD study targeting the placenta and also not 
examined in the UMGD placenta study in Chapter 4 due to time constraints. Even 
if low, the risk of foetal gene transfer with UMGD to the placenta needs to be 
evaluated due to the serious ethical implications of this occurring. 
The low levels of placental gene transfer in Chapter 4 highlight important 
factors that must be addressed for UMGD to be considered an efficient placental 
delivery system, namely optimal MB, vector, and US conditions. The plasmid 
DNA:MB ratio can significantly influence transfer efficiency. However, as 
previously discussed in Chapter 3 and 4, injection volume restrictions, safe MB 
concentrations, and technical challenges limit the adjustments that can be made 
to the concentration and volume of plasmid DNA and MBs. Custom-made MBs 
that protect plasmid DNA from degradation or display targeting abilities are 
therefore commonly used to enhance transfer efficiency. Despite this apparent 
advantage, a major benefit of using commercially available MBs is the data 
available from preclinical safety assessments relating to pregnancy. Preclinical 
studies of SonoVue and Luminity revealed ‘no special hazard for humans based 
on conventional studies of genotoxicity, fertility, embryo/foetal development, 
parturition or post-natal development, and local tolerance’ (EMA, 2008b, EMA, 
2009). In contrast, in pregnant rabbits exposed to Optison, maternal and 
embryo/foetal toxicity was observed (EMA, 2008a). In addition to the preclinical 
safety data, SonoVue was selected for this work due to its availability and ease 
of preparation. SonoVue and Luminity can be prepared within under 2 min, with 
the approved medicinal products manufactured to government safety and quality 
standards ensuring minimal batch variation. This highlights the convenience and 
clinical translatability of commercially available MBs is an important advantage 
to consider for their use in UMGD studies. Altering plasmid DNA characteristics 
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may therefore be an alternative strategy to improve transfer efficiency rather 
than employing custom made MBS. Polymers complexed with plasmid DNA with 
trophoblast-specific promoters (Cyp19a or PLAC1) have previously shown to 
exhibit targeted placental delivery, with no evidence of inflammation or immune 
infiltration seen following intraplacental delivery of PLAC1 complexes (Ellah et 
al., 2015). Plasmid DNA with placental-specific promoters could therefore be 
adopted by future UMGD studies. Adjusting plasmid DNA characteristics to 
improve transfer efficiency is further supported by the high doses of MBs used in 
preclinical studies. The work in Chapter 3 and 4 utilised SonoVue doses at 
approximately 150 times the approved clinical dose, so increasing MB 
concentration and volume in future studies should be avoided to improve clinical 
translatability. Finally, future work should seek to optimise US parameters since 
different output modes and frequencies will likely improve transfer efficiency as 
previously discussed. 
For the work in Chapter 3 and 4, plasmid vectors carrying reporter genes were 
utilised since the aim of the UMGD studies was to demonstrate proof-of-concept. 
The overarching concept was to establish the technique for targeting placental 
miRNAs. In the future, this could be achieved using miRNA expression plasmids 
or agomirs/antagomirs in conjunction with UMGD. Several UMGD studies have 
delivered miRNA expression plasmids via peripheral IV injections to the kidney 
(Zhong et al., 2011), liver (Yang et al., 2013), and heart (Liu et al., 2015), and 
provided evidence of targeted delivery as well as therapeutic benefit. An 
alternative approach is to use agomirs/antagomirs since their longer half-life 
and smaller size compared with plasmid DNA could enhance transfer efficiency. 
However, off-target effects remain a prevailing concern (Beards et al., 2017, 
Krützfeldt et al., 2005). An in vivo study investigating UMGD of 
agomirs/antagomirs showed delivery of the compounds complexed to cationic 
MBs to mouse hind limbs following tail vein administration (Kwekkeboom et al., 
2015). The effect on miRNA expression in the target as well as non-target organs 
was not fully assessed. Hence, further studies are required to determine if UMGD 
of agomirs/antagomirs can localise delivery and stimulate efficient transfer. 
Given previous studies showing targeted delivery with miRNA expression 
plasmids and the targeting ability of plasmids to the placenta, future work may 
benefit from focussing on plasmid DNA delivery rather than agomirs/antagomirs. 
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Although the UMGD protocol established in Chapter 4 requires optimisation, 
application of the technique to pregnant mice is important for preclinical 
development of the delivery system. 
In Chapter 5, a literature review was conducted of published expression profiling 
studies in placentas of preeclamptic patients which identified 22 significantly 
differentially expressed placental miRNAs consistently detected as dysregulated 
after collating data from fifteen studies. These findings build on a previous 
systematic review from 2016 that examined profiling studies of differentially 
expressed miRNAs in PE in any sample type (tissue, fluids, or otherwise) (Sheikh 
et al., 2016). Sub analysis identified twelve miRNAs dysregulated in PE in 
profiling studies examining placental tissue (Sheikh et al., 2016). Since the 
previous systematic review was performed, an additional four profiling studies 
examining preeclamptic placental tissue have been conducted. In addition to 
including more recent publications, more stringent criteria were applied to the 
literature review in Chapter 5 (examination of placental tissue from the third 
trimester with time of collection stated) than the sub analysis of the systematic 
literature review. The current work focussed on placental tissue since one of the 
overarching aims of this thesis was to evaluate the therapeutic potential of 
dysregulated miRNAs in the placenta. Furthermore, the literature review 
focussed on third trimester placental tissue since the aim of Chapter 5 was to 
evaluate candidate miRNAs in third trimester placental tissue that was available 
from a rat model of SPE. As a result of including newly published studies and 
excluding more studies compared with the systematic review, only three miRNAs 
(miR-210-3p, miR-223-3p, and miR-181a-5p) overlapped between the published 
systematic review and literature review in Chapter 5 in terms of the 
dysregulated placental miRNAs detected by at least three profiling studies. Of 
note, more recent publications included in the literature review also detected 
miR-210-3p and miR-223-3p as differentially expressed and the reported 
direction of expression agreed with findings from studies conducted prior to 
2016. This highlights how the work in Chapter 5 builds on existing literature and 
the importance of conducting the up-to-date literature review given the growing 
number of expression profiling studies being conducted in preeclamptic patients. 
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Of the 22 differentially expressed placental miRNAs identified by the literature 
review in Chapter 5, ten miRNAs were reported by studies as being dysregulated 
in the same direction of expression. Studies concurred despite differences in 
terms of the type of experiment performed, type of PE under study, gestational 
age at the time of delivery, and sampling area. This suggests that some 
dysregulated placental miRNAs may be uniformly differentially expressed across 
the placenta and common to preeclamptic patients in the third trimester 
regardless of disease presentation. However, no miRNA was detected as 
significantly differentially expressed by all profiling studies. MiR-210-3p and miR-
223-3p were the most frequently detected miRNAs, detected by seven and five 
studies respectively, all of which agreed in the direction of expression. Lack of 
detection by other studies may be attributed to methodological and biological 
factors as previously discussed. All studies included in the literature review 
examined third trimester placenta samples to account for differences in 
placental miRNA expression between trimesters, which has previously been 
reported (Morales-Prieto et al., 2012, Gu et al., 2013). However, even within the 
third trimester, studies have shown significant differences in placental miRNA 
expression (Mayor-Lynn et al., 2011, Hromadnikova et al., 2017, Anton et al., 
2015, Yang et al., 2019b). With several of the clinical studies included in the 
literature review noting significant differences in gestational age between PE 
and control groups as well as examining term and preterm deliveries, this may 
account for inconsistent findings between clinical studies. Validation and 
replication in larger independent cohorts and across the placenta is therefore 
required to confirm whether some miRNAs are differentially expressed across 
the placenta and amongst all preeclamptic subtypes. On the other hand, the 
literature review provided evidence of placental miRNA expression differing 
between types of PE, adding to the existing literature that shows differences 
between subtypes (Lykoudi et al., 2018, Weedon-Fekjær et al., 2014) as well as 
presenting symptoms (Pineles et al., 2007, Awamleh et al., 2019). Finally, the 
literature review highlighted that a single miRNA expression profiling study has 
been conducted in patients with SPE. Since SPE exhibits overlapping but also 
distinct molecular, pathological, and clinical features compared with PE (Stanek, 
2018, Barbosa et al., 2015, Chang et al., 2011), further miRNA expression 
profiling studies in this subset of patients are warranted. 
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One criterion for selecting candidate miRNAs from the literature review in 
Chapter 5 was published in vitro studies providing supporting evidence of a role 
for the miRNA in the pathology of PE. This was chosen as one of the criteria so 
that evidence from clinical through to in vitro studies could be referred to when 
discussing the potential role and therapeutic value of the miRNA in PE. However, 
this meant that fourteen miRNAs which may potentially contribute to abnormal 
placental development in PE were not investigated further. MiR-214-3p and miR-
542-3p may be of particular interest to investigate in future preclinical studies 
given the agreement between clinical studies of their direction of expression in 
PE and the existence of a rat ortholog. Of the eight candidate miRNAs selected, 
five were significantly differentially expressed in whole placental tissue or 
individual placental layers of a rat model of SPE. This provides novel evidence of 
dysregulation of miRNAs within placental layers in rats, a finding previously only 
shown in humans. RNA expression profiling studies in rat and human placenta 
have shown distinct gene expression patterns exist between zonal layers relating 
to the functional compartmentalization of the placenta (Shankar et al., 2012, 
Sood et al., 2006). Hence, layer-specific patterns in miRNA expression would be 
expected. Another study conducted laser microdissection followed by RNA 
profiling on trophoblast subpopulations (syncytiotrophoblasts, invasive 
cytotrophoblasts, and endovascular cytotrophoblasts) from patients with severe 
PE and women who had a preterm birth (Gormley et al., 2017). Genes were 
significantly differentially expressed between the patient groups in a cell-
specific manner and related to pathways known to be dysregulated in PE, such 
as vascular development; immune functions; responses to VEGF, TGF-ß, and 
oxygen; and cellular movement (Gormley et al., 2017). Transcriptional analysis 
also found five miRNAs (miR-20b, miR-181a-1, miR-339, miR-520-e, and miR-561) 
that were significantly differentially expressed between the patient groups 
(Gormley et al., 2017). In addition to layer-specific differences, miRNAs 
therefore also likely show significant differences between placental cell types in 
animal models of PE, although this requires experimental evidence. 
In Chapter 5, comparisons between placental miRNA expression in the SPE rat 
model with published clinical studies of preeclamptic patients identified several 
miRNAs potentially suitable as therapeutic targets in PE. MiR-223-3p and miR-
181a-5p were significantly differentially expressed in the placentas of the SPE 
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rat model, although in the opposite direction to that reported by clinical studies 
from the literature review as well as other candidate studies. MiR-181a-5p was 
significantly upregulated in the rat model of SPE, while significantly 
downregulated in profiling and candidate studies in preeclamptic patients. 
Although miR-223-3p was significantly upregulated in the rat model of SPE, it 
was significantly downregulated across clinical profiling studies, including in the 
study of patients with SPE. This suggests the opposing finding may reflect 
processes specific to the preclinical model and highlights the limitations of 
animal models in recapitulating a ‘human’ disease. It should be noted though 
that comparisons were made between an animal model of a specific subtype of 
PE with data from patients encompassing all PE subtypes, in terms of severity, 
disease onset, and timing of delivery, all factors which may have influenced the 
findings of clinical studies. Profiling studies of preeclamptic patients were 
included in the literature review regardless of the type of PE under study since 
only a single profiling study has been performed in pateints with SPE. Despite 
these opposing findings between the animal model and patient data, the 
consistency amongst clinical studies in the reported direction of expression of 
miR-223-3p and miR-181a-5p underpin their potential as therapeutic targets. 
However, future studies would need to employ other animal models of PE to 
investigate this further. Although no significant difference was seen in whole 
placental tissue, miR-363-3p was significantly downregulated in the decidua of 
the SPE rat model and across profiling and candidate studies. The miRNA 
therefore represents another potential therapeutic candidate and targeting the 
miRNA in the placenta could be investigated further in the rat model of SPE. 
MiR-195-5p was significantly upregulated in the decidua of the SPE rat model, 
which is in agreement with a profiling study conducted in severe LOPE patients 
but in disagreement with studies in patients with severe PE and SPE. The 
inconsistency between clinical studies as well as with the rat model of SPE, 
suggest miR-195-5p expression likely differs between subtypes. Nonetheless, in 
vitro studies have demonstrated miR-195-5p modulates genes (VEGFA and 
ACVR2A) in which polymorphisms have been shown to be associated with PE risk. 
Further preclinical and clinical studies should therefore be conducted to gain a 
greater understanding of the role of the miRNA in PE. Finally, miR-210-3p was 
significantly downregulated in the decidua but upregulated in the labyrinth of 
the SPE rat model. This is the first work that could be identified that shows 
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miRNAs can be differentially expressed in the opposite direction in different 
placental layers. The upregulation of miR-210-3p in the labyrinth is in line with 
the sixteen human profiling studies and candidate studies that show miR-210-3p 
is increased in preeclamptic patients. The downregulation of miR-210-3p in the 
decidua is in line with one clinical study that found miR-210-3p was 
downregulated in patients with mild PE. As previously discussed, downregulation 
of miR-210-3p may relate to low levels of hypoxia, with preclinical and clinical 
evidence supporting miR-210-3p as the master ‘hypoxamir’. Differences in the 
direction of miR-210-3p expression in placental layers may account for the lack 
of significance of miR-210-3p expression in whole placental tissue of the SPE rat 
model. The labyrinth encompasses the largest area and may therefore have 
underpinned the trend towards an increased expression of miR-210-3p in whole 
placental tissue. Downregulation of miR-210-3p in the decidua however may 
have reduced relative expression levels when the placenta was examined as a 
whole. Despite the differences between layers, miR-210-3p remains a 
therapeutic target of interest and targeting the miRNA could be investigated 
further in the rat model of SPE. It remains unclear what layer or cell of the 
placenta would or could be targeted with gene therapy strategies. However, 
inhibiting miR-210-3p across the placenta could provide insight into 
whether/how the role of miR-210-3p differs between layers and in turn the 
physiological implications of further blocking its effects in the decidua. 
The work in Chapter 6 was the first to conduct miRNA expression profiling in the 
placenta of an animal model of PE, detecting a total of 56 differentially 
expressed miRNAs in the rat model of SPE compared to controls. A literature 
review was conducted to select candidate miRNAs for validation with RT-qPCR in 
whole placental tissue and individual placental layers of the SPE rat model as 
well as in placentas from preeclamptic patients. Four studies that had previously 
been excluded from the literature review in Chapter 5 (based on the time of 
placenta collection not being stated) were included in the literature review in 
Chapter 6. After consideration, it was decided that it was reasonable to assume 
that the placentas were collected at the time of delivery despite the time of 
collected not explicitly being stated. This highlights a limitation of the literature 
review in Chapter 5, namely that an additional four studies could have been 
included to broaden its scope. The literature review in Chapter 6 showed that, 
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of the 56 dysregulated miRNAs, eleven had previously been detected in 
expression profiling studies in preeclamptic patients. This means the majority of 
dysregulated placental miRNAs may be specific to the animal model or species. 
It should be noted though that only one clinical profiling study has been 
conducted in patients with SPE, suggesting that a lack of congruity with clinical 
data could be attributed to the subtype under study. These factors may 
contribute to the number of significantly differentially expressed placental 
miRNAs detected by the sequencing experiment in the rat model of SPE that 
showed the opposite direction of expression as reported by sequencing or 
microarray experiments in patients with PE, including miR-181a-5p, miR-542-3p, 
and miR-222-3p, and in patients with SPE, namely miR-542-5p and miR-495. 
Candidate miRNAs for further investigation were selected based on their 
direction of expression in the SPE model matching the direction of expression 
reported in clinical studies to support future studies seeking to target a 
placental miRNA in the rat model of SPE. None of the candidate miRNAs were 
validated by RT-qPCR in whole placental tissue, highlighting a major limitation 
of this work. 
Rather than utilizing an arbitrary log2 fold change cut-off (most commonly >2 or 
1.5), the selection of candidate miRNAs was based on significance in miRNA 
sequencing and potential clinical relevance. MiRNA expression levels have shown 
to exhibit a positive relationship with their activity (Kozomara et al., 2014), 
suggesting larger differences in miRNA expression may lead to greater changes in 
expression of target mRNA. This supports the use of a log2 fold change cut-off 
value in sequencing data in order to select candidate miRNAs for further 
investigation that are potentially more biologically relevant. However, other 
evidence suggests miRNA expression levels are a poor indicator of activity 
(Plotnikova et al., 2019, Kozomara et al., 2014). Since the aim was to evaluate 
clinically relevant miRNAs, candidate miRNAs were selected based on published 
literature from preeclamptic patients reporting dysregulation of the miRNA 
rather than a log2 fold change cut-off. In turn, the four candidate miRNAs had a 
fold change less than +/-0.6. Hence, the differences in expression may not have 
been large enough to confer significance when measured by RT-qPCR. Within 
placental layers, three of the four candidate miRNAs showed significant 
differences in expression. Although a significant downregulation of miR-145-5p in 
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the labyrinth matched the results from the sequencing experiment and clinical 
studies, a significant downregulation of miR-19b-3p in the decidua contrasted 
with the increased expression observed in the sequencing experiments and in 
clinical studies. These findings support the concept that miRNA expression in 
whole placental tissue is largely determined by expression in the labyrinth, likely 
due to its large surface area. Since only one clinical study has detected 
dysregulation of placental miR-145-5p expression and only two clinical studies 
for miR-19b-3p, further clinical studies are required to draw any inferences 
concerning their suitability as therapeutic targets. Finally, as previously 
discussed miR-210-3p was dysregulated in the labyrinth and decidua in the SPE 
rat model. 
Validation of the candidate miRNAs in placentas from preeclamptic patients 
found miR-210-3p and miR-19b-3p were significantly upregulated by 3-fold and 
1.5-fold respectively, concurring with the increased expression detected by the 
sequencing experiment in the SPE rat model. A drawback of these findings is 
that validation was performed in patients diagnosed with PE rather than patients 
with SPE, the subtype modelled in the rat. This was due to the limited 
availability of samples, which in turn underpins the small sample size. In the 
current work, validation was performed in n=4 healthy controls and n=6 
preeclamptic patients. In addition, it is important to consider that significant 
differences in foetal weight and gestational age at delivery between patients 
with PE and healthy controls may have had an impact of miRNA and gene 
expression findings since these factors have previously shown to affect placental 
miRNA expression (Awamleh et al., 2019, Pineles et al., 2007, Weedon-Fekjær et 
al., 2014, Mayor-Lynn et al., 2011, Hromadnikova et al., 2017, Anton et al., 
2015, Yang et al., 2019b). Nonetheless, as findings from the current work on the 
preclinical PE model and preeclamptic patients supported the existing literature 
that miR-210-3p is dysregulated in PE, this miRNA was selected for further 
investigations into predicted gene targets and in vitro characterisation. 
Of the four predicted gene targets (FGFRL1, BDNF, NDUFA4, and SLC6A1), 
FGFRL1 and BDNF were significantly downregulated in placentas from 
preeclamptic patients. Examination of these two genes in the placentas of the 
rat model of SPE found only FGFRL1 was significantly downregulated and BDNF 
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was undetected. Evaluation of all four genes in trophoblasts following miR-210-
3p overexpression found only FGFRL1 was significantly downregulated. NDUFA4 
and SLC6A1 were either undetected or detected at high Ct values, suggesting 
they unlikely play a role in cytotrophoblasts. As they showed no significant 
difference in expression in preeclamptic patients compared to healthy controls, 
this also suggests they are unlikely to play a role in PE. Overexpressing or 
knocking down miR-210-3p expression also had no significant effect on BDNF 
expression, indicating other factors beside the miRNA regulate BDNF expression 
or that it is not a direct target. Evidence from the preeclamptic patients, 
preclinical model, and in vitro studies suggest that FGFRL1 is a target of miR-
210-3p and upregulation of the miRNA in PE coincides with downregulation of 
the gene. However, reporter construct assays are required to validate FGFRL1 as 
a gene target of miR-210-3p. Furthermore, a major limitation of these findings is 
that protein expression of the predicted gene target was not assessed, a key 
piece of evidence required to confirm inhibition of the mRNA at the 
posttranscriptional level. Nonetheless, studies have shown miRNAs can degrade 
the mRNA of gene targets (Ruike et al., 2008). The current findings provide 
indirect evidence that FGFRL1 is dysregulated in PE due to increased miR-210-3p 
expression, but further studies are required to confirm this. MiR-210-3p 
overexpression and knockdown had no effect on cell viability. A previous study 
showed miR-210-3p overexpression inhibited invasion and promoted iron 
accumulation in Swan 71 but not BeWo trophoblasts (Lee et al., 2011). Swan 71 
cells are a model of extravillous cytotrophoblasts while BeWo cells are a model 
of villous cytotrophoblasts. Another study found miR-210-3p overexpression 
inhibited syncytialization of BeWo cells (Wang et al., 2020a), suggesting that 
miR-210-3p may modulate differentiation rather than proliferation of villous 
cytotrophoblasts. Hence, miR-210-3p may regulate different properties in 
distinct subpopulations of trophoblasts. Finally, several clinical studies have 
reported dysregulation of miR-210-3p in placentas from patients with cases of 
FGR and SGA (Awamleh and Han, 2020, Lee et al., 2011, Awamleh et al., 2019). 
This provides further evidence that miR-210-3p may regulate trophoblasts since 
impaired trophoblast function is a pathological feature common to these 
pregnancy complications (Khong et al., 1986, Kaufmann et al., 2003). 
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The work from Chapter 5 and 6 provides preclinical and clinical evidence that 
contributes to the existing literature implicating dysregulation of placental miR-
210-3p expression in the pathology of PE. The majority of evidence suggests an 
upregulation of miR-210-3p in the placenta leads to downregulation of target 
genes contributing to the pathological processes underlying PE, primarily by 
modulating the properties of trophoblasts. In turn, miR-210-3p represents a 
prominent therapeutic target of interest, and future studies in animal models of 
PE should seek to evaluate whether inhibiting placental miR-210-3p expression 
confers therapeutic benefit. Given the in vitro evidence of miR-210-3p 
regulating trophoblasts and the availability of plasmids with trophoblast specific 
promoters, targeted inhibition of miR-210-3p in trophoblasts remains an 
intriguing therapeutic strategy to be explored. Due to lack of availability of 
placental tissue, miR-210-3p expression was not evaluated in the placentas of 
the SPE rat model at an earlier time point. This should be considered for future 
studies since it would provide insight into whether miR-210-3p dysregulation is a 
cause or consequence of PE pathology. Of note, several profiling and candidate 
clinical studies found miR-210-3p was significantly differentially expressed in the 
blood of preeclamptic patients between 11 and 20 weeks of pregnancy (Ura et 
al., 2014, Xu et al., 2014a, Anton et al., 2013). This indicates dysregulation may 
occur prior to PE diagnosis and therefore that miR-210-3p may contribute to 
early pathological processes. Whether this dysregulation occurs in the placenta 
however remains to be shown, with animal models providing the unique 
opportunity to study this given the ethical constraints in humans. One clinical 
study reported that miR-423-5p expression in first trimester plasma samples 
could predict the development of EOPE at a sensitivity of 87.5% and specificity 
of 80% (Timofeeva et al., 2018). Furthermore, miR-423-5p was significantly 
differentially expressed in term placenta of EOPE patients (Timofeeva et al., 
2018). Dysregulation of a circulating miRNA prior to the onset of PE 
corresponding with dysregulation of the miRNA in the placenta would represent 
an ideal scenario for therapeutic targeting in the placenta. Therapy could be 
administered prior to disease onset as a preventative treatment following a 
precision medicine approach. Biro et al. found exosomal and Ago-bound miR-
210-3p was significantly increased in preeclamptic patients (Biró et al., 2017, 
Biro et al., 2019). In vitro, the group showed hypoxia stimulated intracellular, 
exosomal, and Ago-bound miR-210-3p expression (Biro et al., 2019), suggesting 
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trophoblasts contribute to the elevated circulating levels of miR-210-3p in 
patients with PE. Although validation of placental and circulating miRNA 
expression profiles in larger cohorts is still required, this thesis contributes to 
the growing body of evidence that miR-210-3p represents a particular miRNA of 
interest to target therapeutically in PE. 
This thesis has provided information on a gene therapy technique for targeting 
the placenta as well as miRNAs dysregulated in the placenta in PE. The 
development of safe and effective delivery systems that target the placenta 
remains key to establishing placental gene therapy as a strategy for pregnancy 
disorders arising from abnormal placental development, such as PE. A growing 
number of studies suggest placental miRNAs play a key role in the pathology of 
PE, and one study has shown therapeutic benefit to the foetus after targeting 
placental miRNAs in animal model of PE. Identifying suitable placental miRNAs to 
target therefore remains essential to establishing gene therapy as a therapeutic 
strategy in PE. The work in this thesis has provided means to further investigate 
UMGD for targeting the placenta in pregnant mice, important animal models in 
pregnancy research. In addition, the work in this thesis has highlighted 
attributes of miRNAs that should be considered in future work seeking to 
evaluate the role of placental miRNAs in PE and/or target placental miRNAs as 
well as led to the identification of several miRNAs in the placenta that are 








8.1 RT-qPCR raw data 
8.1.1 Study 2 
Table 8-1 Raw data of SYBR RT-qPCR run with primers, LGFP1 and LGFP2, on left and right 
kidneys of the three UMGD treatment rats and a negative control rat.  
LGFP1 
Sample Well Gene Ct Tm1 Tm2 Tm3 
Treatment rat 1 right kidney 
A1 LGFP1 32.754 78.385   
B1 LGFP1 32.175 78.385   
C1 LGFP1 33.429 78.385   
Treatment rat 1 left kidney 
A3 LGFP1 31.305 78.253   
B3 LGFP1 38.143 70.779   
C3 LGFP1 32.625 78.253 72.877  
Treatment rat 2 right kidney 
A5 LGFP1 32.776 78.253 74.188  
B5 LGFP1 32.712 78.385   
C5 LGFP1 37.617 73.795 78.909 87.695 
Treatment rat 2 left kidney 
A7 LGFP1 32.867 78.385   
B7 LGFP1 37.609 72.877   
C7 LGFP1 37.496 72.877 78.909 87.564 
Treatment rat 3 right kidney 
A9 LGFP1 35.497 72.746   
B9 LGFP1 32.847 78.253   
C9 LGFP1 32.876 78.253 65.402  
Treatment rat 3 left kidney 
A11 LGFP1 38.874 70.516   
B11 LGFP1 32.793 78.385   
C11 LGFP1 Undetermined 61.074   
Negative control right kidney 
A13 LGFP1 Undetermined 61.337   
B13 LGFP1 35.844 73.139   
C13 LGFP1 34.670 73.139   
Negative control left kidney 
A15 LGFP1 38.428 78.909 70.516 87.433 
B15 LGFP1 37.527 73.139   
C15 LGFP1 39.343 73.664 82.319 87.433 
Plasmid A24 LGFP1 Undetermined 78.516   
NFW A17 LGFP1 Undetermined 61.337   
LGFP2 
Sample Well Gene Ct Tm1 Tm2 Tm3 
Treatment rat 1 right kidney 
E1 LGFP2 33.680 76.811   
F1 LGFP2 32.395 76.811   
G1 LGFP2 Undetermined 71.959   
Treatment rat 1 left kidney 
E3 LGFP2 31.982 76.811   
F3 LGFP2 Undetermined 61.337   
G3 LGFP2 Undetermined 70.779   
Treatment rat 2 right kidney 
E5 LGFP2 31.736 76.811   
F5 LGFP2 32.213 76.942   
G5 LGFP2 Undetermined 61.337   
Treatment rat 2 left kidney 
E7 LGFP2 33.895 76.942   
F7 LGFP2 Undetermined 61.205   
G7 LGFP2 Undetermined 61.205   
Treatment rat 3 right kidney 
E9 LGFP2 32.179 76.942   
F9 LGFP2 33.866 76.942   
G9 LGFP2 33.748 76.942   
Treatment rat 3 left kidney 
E11 LGFP2 Undetermined 61.205   
F11 LGFP2 37.244 72.352   
G11 LGFP2 33.540 76.942   
Negative control right kidney 
E13 LGFP2 33.496 76.942   
F13 LGFP2 33.787 76.942   
G13 LGFP2 Undetermined 61.074   
Negative control left kidney 
E15 LGFP2 Undetermined 87.564 61.337 76.155 
F15 LGFP2 31.869 76.942   
G15 LGFP2 Undetermined 61.337   
Plasmid E24 LGFP2 4.311 77.073   
NFW E17 LGFP2 Undetermined 61.468   
Highlighted in bold: multiple melting temperatures, outlier melting temperatures, or undetermined Ct values 
and in red: samples selected to run on a gel and for sequencing. TM, melting temperature; Ct, cycle threshold; 
NFW, nuclease free water.  
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Table 8-2 Raw data of SYBR RT-qPCR run with the β-actin housekeeper on left and right 
kidneys of the three UMGD treatment rats and a negative control rat. 
β-actin 





Tm1 Tm2 Tm3 
Treatment rat 1 right kidney 
I1 ACTB 19.896 19.928 0.034 77.073   
J1 ACTB 19.963   76.942   
K1 ACTB 19.925   77.073   
Treatment rat 1 left kidney 
I3 ACTB 19.019 19.013 0.038 77.073   
J3 ACTB 18.973   77.073   
K3 ACTB 19.048   77.073   
Treatment rat 2 right kidney 
I5 ACTB 18.637 18.872 0.205 77.204   
J5 ACTB 18.962   77.073   
K5 ACTB 19.016   77.073   
Treatment rat 2 left kidney 
I7 ACTB 18.877 18.926 0.065 77.073   
J7 ACTB 19.000   77.073   
K7 ACTB 18.902   76.942   
Treatment rat 3 right kidney 
I9 ACTB 19.790 19.562 0.263 77.204   
J9 ACTB 19.275   77.073   
K9 ACTB 19.621   77.073   
Treatment rat 3 left kidney 
I11 ACTB 19.880 19.861 0.049 77.073   
J11 ACTB 19.806   77.073   
K11 ACTB 19.898   77.073   
Negative control right kidney 
I13 ACTB 19.712 19.691 0.020 77.073   
J13 ACTB 19.689   77.073   
K13 ACTB 19.673   77.073   
Negative control left kidney 
I15 ACTB 19.472 19.572 0.089 77.204   
J15 ACTB 19.643   77.204   
K15 ACTB 19.602   77.204   
all samples 19.428 0.427    
Plasmid I24 ACTB 34.682   73.532 79.303  
NFW I17 ACTB 36.751   74.188   
Highlighted in bold: multiple melting temperatures or outlier melting temperatures. ‘All samples’ designates Ct 
mean and SD of Ct means of all kidney samples. TM, melting temperature; Ct, cycle threshold; SD, standard 




8.1.2 Study 3 
Table 8-3 Raw data of TaqMan RT-qPCR run with primers, Luc2 and β-actin, on controls. 
Controls 
Sample Well Gene Ct Gene Ct 
MM 
B21 Luc2 Undetermined ACTB Undetermined 
B22 Luc2 Undetermined ACTB Undetermined 
B23 Luc2 Undetermined ACTB Undetermined 
NFW 
D21 Luc2 Undetermined ACTB Undetermined 
D22 Luc2 Undetermined ACTB Undetermined 
D23 Luc2 Undetermined ACTB Undetermined 
MM from  
cDNA plate 
H21 Luc2 Undetermined ACTB Undetermined 
H22 Luc2 Undetermined ACTB Undetermined 
H23 Luc2 Undetermined ACTB Undetermined 
NFW from 
cDNA plate 
J21 Luc2 Undetermined ACTB Undetermined 
J22 Luc2 Undetermined ACTB Undetermined 
J23 Luc2 Undetermined ACTB Undetermined 
MM and NFW from  
cDNA plate 
N21 Luc2 Undetermined ACTB Undetermined 
N22 Luc2 33.964 ACTB Undetermined 
N23 Luc2 Undetermined ACTB Undetermined 
No RT  
L21 Luc2 32.969 ACTB Undetermined 
L22 Luc2 33.662 ACTB Undetermined 
L23 Luc2 33.745 ACTB Undetermined 
Highlighted in bold: undetermined Ct values. Ct, cycle threshold; SD, standard deviation; MM, 
master mix; NFW, nuclease free water; RT, reverse transcriptase; ACTB, β-actin; Luc2, luciferase. 
 
Table 8-4 Raw data of TaqMan RT-qPCR run with primers, Luc2 and β-actin, on controls. 
Controls 
Sample Well Gene Ct Gene Ct 
MM 
I18 Luc2 35.451 ACTB Undetermined 
I19 Luc2 34.198 ACTB Undetermined 
I20 Luc2 35.329 ACTB Undetermined 
NFW 
L18 Luc2 21.969 ACTB Undetermined 
L19 Luc2 8.780 ACTB Undetermined 
L20 Luc2 Undetermined ACTB 29.710 
MM from  
cDNA plate 
I2 Luc2 Undetermined ACTB Undetermined 
I3 Luc2 33.064 ACTB Undetermined 
I4 Luc2 33.603 ACTB Undetermined 
NFW from 
cDNA plate 
L2 Luc2 37.580 ACTB Undetermined 
L3 Luc2 39.991 ACTB Undetermined 
L4 Luc2 Undetermined ACTB Undetermined 
No RT 
L10 Luc2 Undetermined ACTB Undetermined 
L11 Luc2 32.942 ACTB Undetermined 
L12 Luc2 34.692 ACTB Undetermined 
Highlighted in bold: undetermined Ct or >35 Ct values. Ct, cycle threshold; SD, standard deviation; 





8.1.3 Study 4 
Table 8-5 Raw data of TaqMan RT-qPCR run with primers, Luc and β-actin, on left and right 
kidneys and skeletal muscles of the three UMGD treatment rats and a positive control rat 
and negative control rat. 
Left kidney 





Treatment rat 1 
left kidney  
D2 Luc Undetermined N/A N/A ACTB 19.862 19.566 0.260 
D3 Luc Undetermined   ACTB 19.376   
D4 Luc Undetermined   ACTB 19.460   
Treatment rat 2 
left kidney  
D6 Luc Undetermined N/A N/A ACTB 18.736 18.815 0.170 
D7 Luc Undetermined   ACTB 18.699   
D8 Luc Undetermined   ACTB 19.010   
Treatment rat 3 
left kidney  
D10 Luc Undetermined N/A N/A ACTB 19.783 19.843 0.054 
D11 Luc Undetermined   ACTB 19.886   
D12 Luc Undetermined   ACTB 19.860   
Positive control 
left kidney  
D14 Luc Undetermined N/A N/A ACTB 19.152 19.192 0.035 
D15 Luc Undetermined   ACTB 19.206   
D16 Luc Undetermined   ACTB 19.218   
Negative control 
left kidney  
D18 Luc Undetermined N/A N/A ACTB 19.584 19.704 0.106 
D19 Luc Undetermined   ACTB 19.786   
D20 Luc Undetermined   ACTB 19.741   
all samples 19.424 0.418 
Right kidney 





Treatment rat 1 
right kidney  
B2 Luc Undetermined N/A N/A ACTB 19.528 19.384 0.165 
B3 Luc Undetermined   ACTB 19.204   
B4 Luc 39.733   ACTB 19.420   
Treatment rat 2 
right kidney  
B6 Luc Undetermined N/A N/A ACTB 20.023 19.889 0.229 
B7 Luc Undetermined   ACTB 19.624   
B8 Luc Undetermined   ACTB 20.019   
Treatment rat 3 
right kidney  
B10 Luc Undetermined N/A N/A ACTB 19.803 19.917 0.100 
B11 Luc Undetermined   ACTB 19.990   
B12 Luc Undetermined   ACTB 19.959   
Positive control 
right kidney  
B14 Luc Undetermined N/A N/A ACTB 19.399 19.300 0.096 
B15 Luc Undetermined   ACTB 19.292   
B16 Luc Undetermined   ACTB 19.208   
Negative control 
right kidney  
B18 Luc Undetermined N/A N/A ACTB 19.084 19.169 0.076 
B19 Luc Undetermined   ACTB 19.192   
B20 Luc Undetermined   ACTB 19.230   
all samples 19.532 0.348 
Skeletal muscle 





Treatment rat 1 
skeletal muscle  
F2 Luc Undetermined N/A N/A ACTB 22.621 22.670 0.216 
F3 Luc Undetermined   ACTB 22.483   
F4 Luc Undetermined   ACTB 22.906   
Treatment rat 2 
skeletal muscle  
F6 Luc Undetermined N/A N/A ACTB 21.481 21.553 0.076 
F7 Luc Undetermined   ACTB 21.545   
F8 Luc Undetermined   ACTB 21.632   
Treatment rat 3 
skeletal muscle  
F10 Luc Undetermined N/A N/A ACTB 21.979 22.167 0.292 
F11 Luc 38.416   ACTB 22.504   
F12 Luc Undetermined   ACTB 22.019   
Positive control 
skeletal muscle  
F14 Luc Undetermined N/A N/A ACTB 16.483 16.665 0.184 
F15 Luc Undetermined   ACTB 16.663   
F16 Luc Undetermined   ACTB 16.850   
Negative control 
skeletal muscle  
F18 Luc Undetermined N/A N/A ACTB 21.248 21.181 0.081 
F19 Luc Undetermined   ACTB 21.091   
F20 Luc Undetermined   ACTB 21.204   
all samples 20.847 2.406 
Highlighted in bold: undetermined CT or >35 Ct values. ‘All samples’ designates Ct mean and SD 
of Ct means of all tissue samples. Ct, cycle threshold; SD, standard deviation; ACTB, β-actin; Luc, 
luciferase; N/A, not available.  
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Table 8-6 Raw data of TaqMan RT-qPCR run with primers, Luc and β-actin, on controls. 
Controls 
Sample Well Gene Ct Gene Ct 
MM 
J2 Luc Undetermined ACTB Undetermined 
J3 Luc Undetermined ACTB Undetermined 
J4 Luc 37.922 ACTB Undetermined 
NFW 
H2 Luc Undetermined ACTB Undetermined 
H3 Luc Undetermined ACTB Undetermined 
H4 Luc Undetermined ACTB Undetermined 
MM from  
cDNA plate 
J6 Luc Undetermined ACTB Undetermined 
J7 Luc Undetermined ACTB Undetermined 
J8 Luc Undetermined ACTB Undetermined 
NFW from 
cDNA plate 
H6 Luc Undetermined ACTB Undetermined 
H7 Luc Undetermined ACTB Undetermined 
H8 Luc Undetermined ACTB Undetermined 
No RT 
H10 Luc Undetermined ACTB Undetermined 
H11 Luc Undetermined ACTB Undetermined 
H12 Luc Undetermined ACTB Undetermined 
Highlighted in bold: undetermined Ct or >35 Ct values. Ct, cycle threshold; SD, standard deviation; 




8.1.4 Study 5 
Table 8-7 Raw data of TaqMan RT-qPCR run with primers, Luc and β-actin, on heart and 
skeletal muscle of the three UMGD treatment mice, a positive controls mouse, a negative 
control mouse, and controls 
Heart 






mouse 1 heart 
B1 Luc 30.258 31.016 0.664 ACTB 15.999 15.858 0.124 
B2 Luc 31.299   ACTB 15.766   
B3 Luc 31.492   ACTB 15.810   
Treatment 
mouse 2 heart 
B5 Luc 31.945 32.402 0.398 ACTB 16.031 16.048 0.035 
B6 Luc 32.584   ACTB 16.088   
B7 Luc 32.677   ACTB 16.024   
Treatment 
mouse 3 heart 
B9 Luc 33.340 34.419 0.946 ACTB 14.887 14.932 0.099 
B10 Luc 34.816   ACTB 15.045   
B11 Luc 35.102   ACTB 14.863   
Positive control 
heart 
B13 Luc 33.106 33.758 0.605 ACTB 15.744 15.736 0.012 
B14 Luc 33.866   ACTB 15.722   
B15 Luc 34.301   ACTB 15.742   
Negative control 
heart 
B17 Luc 37.756 32.724 0.302 ACTB 16.161 16.207 0.059 
B18 Luc 32.407   ACTB 16.187   
B19 Luc 33.009   ACTB 16.274   
all samples 15.756 0.494 
Skeletal muscle 








F1 Luc Undetermined 39.266 0.464 ACTB 16.238 16.289 0.057 
F2 Luc 38.938   ACTB 16.280   




F5 Luc Undetermined N/A N/A ACTB 17.111 17.192 0.071 
F6 Luc 39.236   ACTB 17.230   




F9 Luc 30.258 31.067 0.706 ACTB 16.474 16.415 0.056 
F10 Luc 31.384   ACTB 16.363   
F11 Luc 31.559   ACTB 16.407   
Positive control 
skeletal muscle 
F13 Luc 28.783 28.885 0.275 ACTB 15.042 15.070 0.032 
F14 Luc 29.196   ACTB 15.105   
F15 Luc 28.676   ACTB 15.064   
Negative control 
skeletal muscle 
F17 Luc Undetermined N/A N/A ACTB 16.668 16.681 0.031 
F18 Luc Undetermined   ACTB 16.716   
F19 Luc Undetermined   ACTB 16.659   
all samples 16.329 0.785 
Highlighted in bold: undetermined Ct or >35 Ct values. ‘All samples’ designates Ct mean and SD of 
Ct means of all tissue samples. Ct, cycle threshold; SD, standard deviation; ACTB, β-actin; Luc, 




Table 8-8 Raw data of TaqMan RT-qPCR run with primers, Luc2 and β-actin, on controls. 
Controls 






B21 Luc Undetermined N/A N/A ACTB Undetermined N/A N/A 
B22 Luc Undetermined   ACTB Undetermined    
B23 Luc Undetermined   ACTB Undetermined     
MM 
D21 Luc Undetermined N/A N/A ACTB Undetermined N/A N/A 
D22 Luc Undetermined   ACTB Undetermined    
D23 Luc Undetermined   ACTB Undetermined     
NFW from  
cDNA plate 
H24 Luc 37.688 N/A N/A ACTB Undetermined N/A N/A 
I24 Luc Undetermined   ACTB Undetermined    
J24 Luc Undetermined   ACTB Undetermined     
MM from 
cDNA plate 
K24 Luc Undetermined N/A N/A ACTB Undetermined N/A N/A 
L24 Luc Undetermined   ACTB Undetermined    
M24 Luc Undetermined   ACTB Undetermined     
No RT (SM) 
K22 Luc Undetermined N/A N/A ACTB Undetermined N/A N/A 
L22 Luc Undetermined   ACTB Undetermined    
M22 Luc Undetermined   ACTB Undetermined     
No RT (Heart) 
H22 Luc Undetermined N/A N/A ACTB Undetermined N/A N/A 
I22 Luc Undetermined   ACTB Undetermined    
J22 Luc Undetermined   ACTB Undetermined     
Highlighted in bold: undetermined Ct or >35 Ct values. Ct, cycle threshold; SD, standard deviation; 
MM, master mix; NFW, nuclease free water; RT, reverse transcriptase; ACTB, β-actin; Luc, 
luciferase; SM, skeletal muscle; N/A, not available. 
 
Table 8-9 Raw data of TaqMan RT-qPCR run with primers, Luc and β-actin, on tissue 
samples and controls. 
Tissue (duplex) 






mouse 1 heart 
 Luc 30.953 31.041 0.160 ACTB 19.048 18.990 0.051 
 Luc 31.226   ACTB 18.970   
 Luc 30.945   ACTB 18.953   
Positive control 
skeletal muscle 
 Luc 29.633 29.771 0.154 ACTB 18.776 18.822 0.049 
 Luc 29.937   ACTB 18.873   
 Luc 29.744   ACTB 18.817   
Negative control 
skeletal muscle 
 Luc 32.300 32.029 0.235 ACTB 20.228 20.418 0.164 
 Luc 31.881   ACTB 20.512   
 Luc 31.907   ACTB 20.513   
MM only  
 Luc 31.986 32.053 0.102 ACTB Undetermined N/A N/A 
 Luc 32.170   ACTB Undetermined    
 Luc 32.002   ACTB Undetermined     
Tissue (singleplex) 
Treatment 
mouse 1 heart 
 Luc 30.121 30.163 0.037 ACTB 18.790 18.566 0.211 
 Luc 30.174   ACTB 18.536   
 Luc 30.193   ACTB 18.372   
Positive control 
skeletal muscle 
 Luc 29.258 29.222 0.080 ACTB 18.599 18.442 0.140 
 Luc 29.278   ACTB 18.331   
 Luc 29.130   ACTB 18.396   
Negative control 
skeletal muscle 
 Luc 30.709 30.893 0.227 ACTB 19.973 20.555 0.512 
 Luc 31.147   ACTB 20.937   
 Luc 30.822   ACTB 20.754   
MM only  
 Luc 30.951 30.858 0.167 ACTB Undetermined N/A N/A 
 Luc 30.958   ACTB Undetermined   
 Luc 30.665   ACTB Undetermined   
Highlighted in bold: undetermined Ct or >35 Ct values. Ct, cycle threshold; SD, standard deviation; 
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